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Abstract
The Knight group has for some time been utilising the acid-catalysed hydroamination to synthesise 
pyrrolidines 140. This method was also utilised to produce poly-cyclic systems, of either a spiro- 
220 or a fused-nature 12, through cascade reactions using a sulfonamide as a terminator. This was 
examined further to establish some scope and limitation. In particular, we have shown that the 
reaction is not limited to the formation of tertiary carbenium ions but could be implemented for 
cyclisations via secondary carbenium ions 155. The hydroamination was also shown to be most 
successful at forming highly hindered, bridged compounds 194, which would be difficult to 
synthesise through other means.
The hydroamination reaction was then investigated in terms of its potential as a variant of the 
classical Pictet-Spengler reaction towards dihydroisoindoles 363 and tetrahydroisoquinolines 361. 
This was briefly explored in terms of the type of remote functional groups that would be 
compatible with this method. The formation of the isoindoles and isoquinolines was successful and 
further investigations of compatible functional groups need to be performed.
The synthesis of the trisubstituted piperidine 447 was attempted using the acid-catalysed 
hydroamination method, believing that this would be a simple extension of the pyrrolidine 
synthesis. Unfortunately, this was not successful; instead the corresponding pyrrolidine 449 was 
isolated. This led us to further investigate the sensitivity of sterically crowded piperidines towards 
acid. Successful synthesis of trisubstituted piperidine 501 was achieved by changing the 
JV-protecting group.
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Abbreviations in this text are:
Ac Acetyl
APCI Atmospheric Pressure Chemical Ionisation
Aq. Aqueous
Ar Aromatic
Boc Butoxycarbonyl
9-BBN 9-Borabicyclo[3.3.1]nonane
Cone. Concentrated
Cbz Benxyl carbamate
DBU 1,8-Diazobicyclo[5.4.0]undec-7-ene
DCM Dichloromethane
d.e. Diastereomeric excess
DIAD Diisopropyl azodicarboxylate
DMAP Dimethylaminopyridine
DMF A^A-Dimethylformamide
dtbpf Di-fer/-butyl phosphine ferrocene
e.e. Enantiomeric excess
Eq. Equivalents
El Electro Ionisation
ES Electro Spray
hr Hour
hrs Hours
HRMS High Resolution Mass Spectrometry
IR Infra red
LDA Lithium diisopropylamine
LRMS Low Resolution Mass Spectrometry
m.p. Melting point
M Molar (moles L'1)
mins Minutes
MsCl Mesyl chloride/ methanesulfonyl chloride
NMR Nuclear Magnetic Resonance
Ns / nosyl para-N itrobenzenesulfonyl
z-Pr fro-Propyl
Ppm Parts per million
Py Pyridine
r.t. Room temperature
Sat. Saturated
TBAF tetra-H-Butylammonium fluoride
TBS tert-Butylsilyl
THF Tetrahydrofiiran
TLC Thin Layer Chromatography
TfOH Trifluoromethane sulfonic acid
PCy3 Tricyclohexylphosphine
TsNHBoc iV-(fer/-Butoxycarbonyl)-/?-toluenesulfonamide
Ts / tosyl p -T oluenesulfonyl
TsCl p-T  oluenesulfonyl chloride
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Chapter 1
Introduction to Acid-Catalysed Hydroamination
“Hydroamination is a highly atom-economical process in which an amine N-Hfunctionality is 
added to an unsaturated carbon-carbon linkage."1
1.1. Hydroamination Development
Nitrogen-containing saturated heterocyclic systems are important core structures in organic 
chemistry because of their presence in many natural products; making the development of simple 
procedures for the formation of heterocycles, such as pyrrolidines and piperidines, highly 
desirable. Other nitrogen containing compounds including amines, enamines and imines, are 
valuable and commercially important bulk chemicals, speciality chemicals and pharmaceuticals.4 
Amongst various synthetic routes, hydroamination, the direct formation of a new carbon-nitrogen 
bond by addition of an amine to an unsaturated carbon-carbon bond, is of particular significance.5 
The reaction offers a potentially atom-efficient pathway starting from readily accessible alkenes 
and alkynes. 6'7'w °
The hydroamination of alkenes is more difficult compared to that of alkynes because of the lower 
reactivity and electron density of carbon-carbon double bonds.11 A particular challenge is the 
reversal of stereochemistry to obtain the anti-Markovnikov product.12 During recent years, 
hydroamination became a widely explored operation in the synthesis of nitrogen heterocycles and 
complex nitrogenous molecules in general. The Markovnikov addition of protected amines to 
alkynes is also now an established synthetic strategy. In early studies, hydroaminations were 
mostly triggered by alkali and lanthanide metals, followed by a shift in focus to the use of 
zirconium, titanium5,13 and late transition metal catalysts.14 Most of these are employed as 
homogenous catalysts, though new strategies for the immobilisation of these have gained and will 
undoubtedly continue to gain increased importance.103
Acid-catalysed hydroaminations have been developed from related, well studied methods of 
carbon-oxygen bond formation using acid catalysts. Alkenes undergo hydration in moderately 
concentrated aqueous sulfuric acid to generate saturated alcohols .15
2
1.2. Bronsted Acid-Catalyzed Hydroamination of Alkenes and Alkynes
Except for solid acids, Bronsted acids had not been used extensively as catalysts in 
hydroamination processes involving alkenes and alkynes because of the more basic character of 
the nitrogen compared with the ^-system of unsaturated compounds. This resulted in the 
preferential formation of ammonium salts instead of the carbenium ions, which result from proton 
addition to carbon-carbon double or triple bonds. In this way, the nucleophilic character of the 
nitrogen is removed and thus attack of the nucleophile on the ^--system cannot occur. Despite these 
general considerations, it was found that catalytic amounts of Bronsted acids favoured the 
inter- and intramolecular hydroamination of alkenes and alkynes with homogeneous and
1A 17 IQheterogeneous catalysts. * * A reaction pathway via intermediate protonation of styrenes was 
proposed by Hii for copper-catalysed hydroaminations.19 In nearly all hydroamination reactions, 
the basicity of the amine or amine derivative plays a key role: more basic amines lead to lower 
rates of reaction.20
1.2.1. Intermolecular Brensted Acid-Catalyzed Hydroamination o f Alkenes
Hydroamination/hydroarylation of olefins 1 with anilines 2 was performed using 
PhNH3B(C6F5)4.Et20  (Scheme 1.1). 21
H HN— ^
R1 R2
H
)— \  
R 1 R2
3 Y = -B(C6F5)4
Scheme 1.1. a) PhNH3B(C6F5)4.Et20  (5 mol%) b) C6D6
The addition reactions tolerate substitution on the nitrogen as well as in the aromatic ring of the 
aniline 2. Electron-withdrawing substituents on the aniline ring increase the overall yield of the 
reaction and favour the formation of the hydroamination product. Stabilized carbocations 3 were 
postulated to act as a reaction intermediate, and either the nitrogen or the aromatic ring could act 
as the nucleophile to give, after proton loss, the hydroamination or hydroarylation products 4 or 5,
71respectively. Dupont found that intermolecular hydroamination or hydroarylation reactions of 
norbomene and cyclohexadiene performed with catalytic amounts of Bronsted acids in ionic 
liquids provided higher selectivity and yields than those obtained in classical organic solvents.22
3
He and co-workers reported the hydroamination of simple olefins 6 with tosylamide 7 under 
relatively mild conditions mediated by trifluoromethanesulfonic acid at low concentrations to give 
compounds 8 (Scheme 1.2 and Table 1.1). Under the same reaction conditions, CbzMU could be 
added to 1,3-dienes to afford allylamines in good yields.23 Hartwig reported a very similar result, 
at almost the same time.24
  H NHTsRr \  t s n h 2    w
R1 R2
6 7 7
Scheme 1.2. a) 5% TfOH, PhMe
Table 1.1. Examples of hydroamination of simple olefins with 5% trifluomethanesulfonic acid
Olefin 6 Temperature / °C Time / hrs Yield / %
Vh 85 15 70
0
85 15 85
^ ^  ^ —OMe 60 15 8 8
Marcsekova and Doye found that substituted anilines 2 reacted with styrenes 1 in the presence of 
catalytic amounts of aqueous hydrogen iodide to give a mixture of the corresponding 
hydroamination and hydroarylation products, 4 and 5, respectively (Scheme 1.3 and Table 1.2).25
n h 2
r 1 Rz
1 2 
Scheme 1.3. a) 5 mol% HI, PhMe
X
\ HN
H . n h 2
4 5
4
Table 1.2. Examples of hydroamination/hydroarylation of simple olefins with hydrogen iodide
Olefin 1 Anilines 2 Temperature / °C Time / hrs Ratio of 4 : 5 Yield / %
" b
135 4 3 :2 98
~ b H2N—^  Cl
135 24 2:3 86
- o
135 24 5 :4 80
F
135 24 7 :3 82
The hydroamination reaction is the predominant process; however, the hydroarylation reaction 
becomes more important in the case of aryl-substituted olefins. The electronic properties of the 
amine and the olefin play important roles in the selectivity of the reaction. The proposed 
mechanism for this reaction involved an initial addition of hydrogen iodide to the olefin followed 
by a nucleophilic substitution.
1.2.2. Intramolecular Bronsted Acid-Catalyzed Hydroamination o f Alkenes
Intramolecular hydroamination is of great interest, because nitrogen-containing heterocycles are 
synthesized from amino olefins. The first example of a Bronsted acid-catalyzed intramolecular 
hydroamination was reported by Schlummer and Hartwig.2 Aminoalkenes 9 bearing an electron 
withdrawing group at the nitrogen atom led to pyrrolidines and piperidines 10 in excellent yields 
in the presence of a substoichiometric amount of triflic acid in hot toluene (Scheme 1.4). Lactams 
(9, X = O) were also prepared under the same reaction conditions starting from amides.
n = 1 or 2
9 10
Scheme 1.4. a) 20 mol% TfOH, Toluene, 100 °C
During studies on palladium-catalyzed hydroamination26 of tosylamides,27 they discovered from 
control experiments that this Bronsted acid catalyzed cyclisation generates five- and six-membered 
heterocycles in good yield. The initial experiments showed that tosyl-protected aminoalkene 9
5
cyclised in the presence of catalytic Pd(PPh3 ) 4  and triflic acid. However, this reaction, in contrast 
to reactions of free amines, occurred in the absence of palladium to give heterocycles 10 in good 
yield. In the absence of acid, no product was observed, even upon prolonged heating at 100 °C in 
toluene.2
In the case of using sulfuric acid as catalyst, yields were generally lower. In a proposed 
mechanism, the alkenyl tosylamide is protonated first at the tosylamide group, the proton then 
transferred intramolecularly to the double bond, and finally, the resulting carbenium ion is trapped 
by the sulfonamide, which regenerates a protond rendering the process catalytic in acid. The 
regiochemistry of the process is determined mostly by the stability of the carbenium ion 
intermediate, thus, most of these transformations are overall unfavourable 5-endo-tng cyclisations, 
according to Baldwin’s rules.28 Yin and Zhao applied the former methodology to the synthesis of 
indolines and quinolines using iV-arylsulfonyl-2-allylanilines as starting materials, the process 
being carried out in toluene at 80 °C in the presence of a catalytic amount of triflic acid.29 
Contemporaneously to the study of Schlummer and Hartwig, Haskins and Knight demonstrated 
that triflic acid was an excellent catalyst for inducing overall 5-endo-trig cyclisation of homoallylic 
sulfonamides to give pyrrolidines. They applied this methodology to the synthesis of polycyclic 
compounds through a cationic cascade terminated by a sulfonamide group. For instance, geranyl 
derivative 11 underwent rapid cyclisation at 0 °C to give 90% isolated yields of the 
frvms-annulated pyrrolidine 12, as a 3:2 epimeric mixture at the amino ester stereogenic centre 
(Scheme 1.5). This assignment of structure was confirmed by a single crystal X-ray 
crystallographic determination of a separated sample of the major isomer of the glycine derivative 
12a.
O C k* -
11a R = H 12a R = H
11b R = Me 12b R = Me
Scheme 1.5. a) 0.4 eq. TfOH, CHC13, 0 °C
Intramolecular hydroamination reactions of non-activated alkenes with basic alkylamines using 
Bronsted acid catalysis were unknown until Ackermann et al. found that ammonium salts of 
weakly coordinating anions enabled efficient catalysis but at elevated temperatures. The reaction 
conditions allowed the use of substrates bearing a variety of valuable functional groups, so
'■y i
Zus-homoallyl amines 13 were converted into pyrrolidines 14 in high yields (Scheme 1.6).
C 0 2Me
6
Scheme 1.6. a) 20 mol% R3NHX, 1,4-dioxane, 120- 130 °C, 24 hrs
This protocol is not restricted to gem-disubstituted substrates and can be applied to primary 
alkylamines.
1.3. Development o f Acid-Catalysed Hydroamination in the Knight 
Group
The development in acid-catalysed hydroaminations in the Knight group resulted directly from
9^research into iodocyclisations. Sharland of the Knight group discovered that iodopyrrole- 
2-carboxylates 17 could readily be obtained by base-induced elimination of the elements of 
/?-toluenesulfinic acid upon exposure of the initial iodocyclisation product 16 to two equivalents of 
l,8-diazobicyclo[5.4.0]undec-7-ene (DBU) in DMF at ambient temperature (Scheme 1.7).
NHTs
17
N- COzEt 
Ts
Scheme 1.7. a) 3 eq. I2, K2C03, MeCN b) 2 eq. DBU, DMF, 20 °C, ~2 hrs
However, in their initial investigations of this elimination reaction, they found that heating the 
iodo-dihydropyrrole 18 with one equivalent of DBU in DMF at 90 °C led to the formation of a 
mixture of the desired iodopyrrole 19 together with the deiodinated pyrrole 20 (Scheme 1.8).
18
Ph
jr\i ^ s' N/ ^C02Me 
H
20
Scheme 1.8. a) 1 eq. DBU, DMF, 90 °C, ~2 hrs
It was reasoned that the dehalogenation was probably a result of protonation of the 
iodo-dihydropyrrole 18 at the nitrogen to give cation 21, followed by ring opening with loss of an 
iodonium ion and subsequent acid-catalysed cyclisation of the starting material 22 to give the
observed deiodopyrrole 20 (Scheme 1.9). Initially, it was thought that some kind of radical 
chemistry was involved in this deiodination. However, extensive experimentation showed this not 
to be the case. Independent proton sources were shown to induce the same reaction, so it was 
concluded that protonated DBU was acting as such a proton source.
Another possibility is that the mechanism could involve a [l,5]-hydride shift of the initial 
elimination product 23 to the isomeric structure 24, where the iodine could be removed by a 
nucleophile to give deprotonated 20 (Scheme 1.9).
■CC>2Me
C 0 2Me
C02Me C02Me
23 24
Scheme 1.9.
These observations suggested that it might be possible to trigger 5-endo-d\g cyclisations using a 
proton source.
Sharland then found that treatment of representative y-alkynyl-p-hydroxy-a-amino esters 27 with 
/7-toluenesulfonic acid could be used to achieve the synthesis of highly substituted pyrroles. The 
precursors 27 were obtained from condensation of the corresponding ynals 25 with tin(II) enolates 
(Scheme 1.10).32
NHTs
25 26 27
Scheme 1.10.
These precursors 27 were treated with 0.5 equivalents of /?-toluenesulfinic acid resulting in 
excellent yields of about 70 - 90 % of N-tosyl derivative of the pyrroles 28 (Scheme 1.11).
8
OH
C 0 2Et
a  / /  \ \
C 0 2EtX L
NHTS j s
27 28
R = Bu, Ph, Propen-2-yl
Scheme 1.11. a) 0.5 eq. TolSOH, toluene, reflux, 6 hrs
It was also shown that /?-toluenesulfonic acid could be used with equal efficiency, which is a 
further support for an acid-catalysed mechanism (Scheme 1.9).
Amjad33, also of the Knight group, showed that in pyrrolidine syntheses from (£)-homoallylic 
sulfonamides 29 using iodocyclisations in the presence of a proton source, the thermodynamically 
more stable 2,5-cis diastereoisomers 32 were formed, whereas exposure to excess iodine in the 
presence of potassium carbonate showed a distinct preference for the formation of the 2,5-trans 
isomers 31. These results were thought to be due to an initial cyclisation via a chair-like transition 
state conformation 30, which leads to the 2,5-trans isomers 31, and which can then be followed by 
proton-induced cyclo-reversion and re-closure and hence equilibrium towards, and eventually 
only, the more thermodynamically stable 2,5-cis isomers 32 (Scheme 1.12).
‘V—
r 1 _ —r2 —-— "■— - Ri\ rJ O ^
HN ^ ^ N H T s  R N R R N R
I R2  Ts Ts
Ts
29 30 31 32
I________________ [no b a se ]_______________  f
Scheme 1.12. a) I2, K2C03
The stereochemical outcomes appear to follow largely the chair-like conformation 30, wherein the 
sp3-bonded group (R2) adopts an equatorial position during the initial cyclisation, under basic 
conditions, hence leading to kinetic products, the 2,5-trans isomers 31. Omission of the base leads 
to only the 2,5-cis isomers 32. The pathways were proven by exposing a 2,5-/r<ms-pyrrolidine 31 
to a mixture of hydrogen iodine and iodine, when conversion into the c/s-isomer 32 occurred 
rapidly. Acid-catalysed cyclo-reversion and equilibration to the thermodynamically more stable 
c/s-isomers 32 then follows (Scheme 1.13).
9
R2 kinetic 2,5-trans product
R1— —R2 
HN I
Ts
29
Scheme 1.13. a) I2, K2C 03 b) I2, H+ c) I2, HI
Developing this theme, which clearly shows that a tosylamide group remains sufficiently 
nucleophilic in the presence of a strong acid (HI), Haskins30 of the Knight group then later 
discovered that trifluoromethanesulfonic acid is an excellent catalyst for inducing such overall 
5-endo cyclisations of homoallylic sulfonamides to give pyrrolidines in excellent yields (usually 
over 90%). Motivated by the prospects for discovering a rapid approach to highly substituted 
proline-derivatives, attempts were made to cyclise more highly substituted examples.
1.4. Conclusion
From the results shown, in particular those reported by Hartwig and Haskins, the acid-catalysed 
hydroamination has a great potential to be a powerful method for the synthesis of nitrogen 
containing heterocycles. This potential is explored in the following chapters.
r1*',C 3 '* ,r:nTs
thermodynamic 2,5-cis  product
32
NTs
31
10
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Chapter 2
Acid-Catalysed Hydroaminations -  Model Studies
2.1. Introduction
Pyrrolidines are important compounds, as their motif often appears in natural products, such as 
alkaloids: hygrine, nicotine, tropine, or cocaine (Figure 2.1), which showed significant biological
activities. 34,35,36,37,38
NI
Me
hygrine nicotine
Figure 2.1. Structures of alkaloids containing pyrrolidine
HO
tropine
Yo Ph
cocaine
Other compounds having this moiety include the amino acids and related derivatives, such as 
kainic acid or proline. In addition, prolinol derivatives, such as the (S)/(R)~ 1 -amino-2- 
(methoxymethyl)-pyrrolidines (SAMP/RAMP), have found important applications as chiral
auxiliaries, mainly in asymmetric alkylations (Figure 2.2).39
HOoC
H02C
NH2
(+)-a-kainic acid proline RAMP
Figure 2.2. Structures of amino acid pyrrolidines and chiral auxiliaries
NH:
SAMP
Due to their importance, many different strategies towards the synthesis of pyrrolidines have been 
developed. The methods to construct the pyrrolidine ring can be divided into intermolecular and 
intramolecular reactions.3b’40'41'42-43
2.1.1. Intermolecular Methods for Pyrrolidine Formation
Some of the oldest methods for pyrrolidine formation rely upon the disconnection of the two 
bonds alpha to the nitrogen in the final product, meaning that the nitrogen can be introduced as a 
primary amine.
12
The reductive amination of 1,4-diketones 33 is one of the oldest methods for the preparation of
2,5-disubstituted pyrrolidines 34 (Scheme 2.1); this method has been used for the preparation of 
natural non-symmetrical 2,5-dialkyl-pyrrolidines.44
0 /—v
II D1 red u c tiv e  am in a tio n  /  \
O H
33 34
Scheme 2.1.
This method is not stereoselective, since a 1:1 mixture of cis and trans isomers is obtained. Further 
optimisation showed that treatment of 1,4-diketones 33 with an excess of ammonium carbonate 
allowed the formation of the not isolated pyrrole intermediates 35, which were hydrogenated to 
give the trans isomers of the major compound (d.r. = 85 : 15) (Scheme 2.2). 45
X ^ ~ Y R' ------------------- ^     ► R ^ v ^ R 1
O H H
33 35 36
a: R = (CH2 )6 CH3 , R1 = (CH2 )3 CH3  
b: R = (CH2 )4 CH3, R1 = (CH2 )3 CH3  
c: R = (CH2 )5 CH3i R1 = (CH2 )4 CH3
Scheme 2.2. a) (NH4)C03 b) H2, Rh/Al2C03
Several factors, such as the size of the ring formed (i.e. pyrrolidine or piperidine), the nature of the 
substituents as well as the nature of the reducing agent, influences the c is : trans diastereomer 
ratio.46
The nucleophilic attack of primary amines upon 1,4-dihydroxy derivatives, results in direct 
cyclisation to form trans 2,5-disubstituted pyrrolidines (Scheme 2.3). This is a well known 
reaction directly derived from the studies on the aminocyclisations of 2,5-dibromoadipic acid 
esters, where trans : cis stereoselectivity can be improved by chiral auxiliaries.47,48,49,50
° X a /  \
'R 2  R1 | , \ / ^ R 2
OX R
3 7  X = Ts, Ms, Tf 3 8
Scheme 2.3. a) R-NH2
Usually the stereoselectivity and the stereospecificity of these reactions are excellent when 
non-racemic starting materials are used. Chirality may be introduced in non-racemic cases by two 
methods: i) use of enantiomerically pure diols - both stereogenic centres are inverted, due to the 
cyclisation occurring through stereospecific SN2-type reactions; ii) stereoselective formation of
enantiomerically pure pyrrolidines from racemic mixtures of 1,4-dihydroxy derivatives can be 
achieved through the implementation of chiral auxiliaries.51,52,53,54,55,56,57,58
In another approach, chiral allylsilanes 39 were treated with A-acylimines 40, generated in situ 
from arylacetals or aldehydes to form cis JV-acylpyrrolidines 41 as the major isomers at 
temperatures between -100 °C and -78 °C, whereas at temperatures between -78 °C and -20 °C, 
AT-acylhomoallylic amines 42 were obtained (Scheme 2.4).59
©
F3 Bv © ^C 0 2Me 
N
'C 0 2Me 
SiMe2Ph
39
Scheme 2.4. a) -78 °C
rA h
40
R = aryl 
X = H, OMe
NSiMe2Ph 
C 0 2Me
H , H k  
O^OMe
NHC02Me X
~ ^C02Me
Me
41 42
Arylamines were generally more reactive and gave higher yields of pyrrolidines in comparison to 
acetals; aliphatic aldehydes, on the other hand, did not give rise to the corresponding pyrrolidines.
[l,3]-Dipolar cycloadditions are amongst the most efficient methods for the preparation of 
pyrrolidines and pyrrolines.60,61 The reactions are usually concerted, regioselective and highly 
stereoselective. Imines of a-amino esters 43 are known for reacting with electron deficient alkenes 
44 in the presence of a Lewis acid to give polysubstituted pyrrolidines (Scheme 2.5).
riX% i
R2
^ co2r3
43
/
44
R® R4
R|^ N/ ^ C02r3
H 
45
R1 = Ph R2  = Ph R2  = Me R4  = H R5  = Me Lewis acid = LiBr Yield = 100%
R1 = Ph R2  = Me R3  = Me R4  = H R5  = C 0 2Me Lewis acid = AgOTs Yield = 81%
R1 = naphth R2  = Me R3  = Me R4  = H R5  = C 0 2Me Lewis acid = AgOAc Yield = 100%
R1 = Ph R2  = Me R3  = Me R4  = C 0 2Me R5  = C 0 2Me Lewis acid = AgOAc Yield = 90%
R1 = Ph R2  = Ph R3  = Me R4  = C 0 2Ph R5  = C 0 2Ph Lewis acid = LiBr Yield = 85%
Scheme 2.5. a) NEt3, Lewis acid
AgOAc appeared to be the most efficient catalyst, for the stereospecific preparation of
2,5-disubstituted pyrrolidines.62 It has been shown that the use of LiBr as a Lewis acid reverses the 
exo-endo selectivity of the reaction, compared with those achieved with AgOTf.63 Three main 
strategies for asymmetric [1,3]-dipolar cycloadditions of azomethine ylides have been exemplified 
by Grigg: i) use of chiral dipolarophiles,64,65,66,67 ii) use of chiral azomethine ylides,68,69,70 iii) use 
of chiral catalysts.61,71
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Highly diastereoselective [3 + 2] cycloadditions of azomethine ylides linked to planar arene 
chromium complex 46 and methyl acrylates have been found where only one diastereomer 47 was 
detected in the products. These were then oxidatively decomplexed to yield pyrrolidines 48
(Scheme 2.6). The use of a titanium Lewis acid resulted in reverse product regiochemistry.72
R1
^  r2
Cr(CO ) 3  N C 0 2Me 5 2 ' 85%
a, b
46
rC 0 2Me 84 - 95%
48
Scheme 2.6. a) LiBr, NEt3 b) CH2=C(R2)C02Me c) hv, air, MeCN
Nucleophilic opening of aziridines by phenylthiolate ions or azides, followed by cyclisation into 
pyrrolidines, usually gives a mixture of polysubstituted pyrrolidines and piperidines, mostly 
forming pyrrolidines as the major product, with yields ranging from 51 to 84%.73 This was 
improved upon by the reaction of enantiopure aziridines, 50 with an allylsilyllithium species 49 
and has been used in the chiral synthesis of 2,3,5,5-tetrasubstituted pyrrolidines 52, via the 
predominant ^-intermediates 51 (Scheme 2.7).74 Silypyrrolidine 52 can easily be converted to 
the corresponding alcohol 53, as the silyl is essentially a masked hydroxyl group.
©
49
TsI
N R 2z_vK
R 1
50
PhMe2Si
57 - 74%
‘  I  ini-i i s
v U s
NHTs
2
PhMe2SL NHTs
syn
51
R1 = Me, /-Pr, /'-Bu, Bn 
R2  = H, Me
anti
syn: anti 
67 :33 to 79 : 21
a 74 - 92%
Ri,- j c S -
R2  N 
Ts 
52
SiMe2Ph OH
Me R2  N 
Ts 
53
Me
Scheme 2.7. a) p-TsOU, CH2C12
One-pot tandem Michael addition-cyclisation reactions of protected propargylamines 54 and 
Michael acceptors, catalysed by copper iodide, have successfully yielded pyrrolidines 56 in good 
yields, ranging from 19 -  89% with good stereoselectivity (Scheme 2.8).75
15
RX .R3
+
V R2  3
T  — — - V -*^ r 4 1 9 - 8 9 %  ¥
NHR1 R1
54 55 56
d.r. = 8 5 : 15 to 1 0 0 :0
R 1 = Me, Bn, Ts
R2, R3  = C 0 2 Et, CN, N 02, Me
R4  = Ph, Me, c-hex
Scheme 2.8. a) «-BuLi (10 mol%), Cul (3 mol%), THF
A formal [5 + 2] cycloaddition between chromium complex 57 and a bulky terminal alkyne 58, 
proceeded via cycloadduct 60. This decomplexed in pyridine to diones 61. Cyclisation and 
elimination of water then yielded pyrrolidines 59 (Scheme 2.9).76
_ y 0 E t a ) — \  ^
(OC)5 C r = < , / - P r  + = = — r     ^  , ^ / S - P r
N (  R = f-Bu, 60% N
NMe2  R = CMe2NMe2, 58% Me
5 7  5 5  R = adamantyl, 50% 5 0
OEt
R - / ^
Py, H2Q
J j ^ Cr(CO ) 5  -Cr(CO ) 3
O -H
P
NHMe V-Pr
‘NI
Me
60
/-Pr
NH /-PrI
Me
61
Scheihe 2.9. a) Pyridine, 80 °C
Silver acetate has been used as a catalyst for the cycloaddition of methyl isocyanoacetate 62 with 
activated alkenes 63, yielding pyrrolidines 64 (Scheme 2.10). A stepwise mechanism was 
proposed, explaining the partial loss of stereochemistry observed when disubstituted alkenes were 
used.77
R
,R© ©
C = N -C H 2 C 0 2Me +
62
67 - 82%
\ N^ C 0 2Me
H
63 64
Scheme 2.10. a) cat. AgOAc, MeCN
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2.1.2. Intramolecular Methods to Afford Pyrrolidines
The reactions of amino-alcohol 65 derivatives are usually stereospecific and very little 
epimerisation occurs (Scheme 2.11).78,79,80
OX = leaving group 66
Scheme 2.11.
The reaction of different vV-(3-chloropropyl) imines 69 with an excess of lithium powder and a 
catalytic amount of 4,4-di-terf-butylbiphenyl (DTBB) gave the expected pyrrolidines 70 
(Scheme 2.12).
ci
f  ,  a , R’ S  b , * \J ~ \
R 2 " V  hcih2n^ - ^ ci L I R2^ V
R2 N H
67 68 69 70
Scheme 2.12. a) H20  (or MeOH), Na2C03 b) LiDTBB (5%) c) H20
From a mechanistic point of view, it is hypothesised that a chlorine-lithium exchange takes place 
(without affecting the imine) giving an organolithium intermediate 71 (Figure 2.3), in which an 
intramolecular addition occurs via an 5-endo-trig process, generating the expected pyrrolidines 
after work-up.
71
Figure 2.3. Proposed intermediate for endo-trig cyclisation to occur
In the case of imines derived from aliphatic ketones and aldehydes, this method gave significantly 
lower yields.3b
Samarium iodide has been used in two procedures to facilitate pyrrolidine formation by the 
addition of a-aminoalkyl radicals to alkenes. Radicals 73 generated from a-amino-benzotriazoles
O 1
72 exist in equilibrium with cyclised radicals 74 (Scheme 2.13).
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Sml2
72 73 74
R = Pr, i-Pr, c i s : trans = 1.5 :1 .0  to 5.8 :1 .0  (Yield: 37 - 71%) 
R = t-Bu, c i s : trans = 1 :100  to 1.0 :19 .7  (Yield: 34 - 36%)
E+ = H2 O, MeOD, l2l /-PrNCO, aldehydes, ketones
Sml2
NI
Bn
75
E+
E
NI
Bn
76
Scheme 2.13. a) Sml2, THF-HMPA
Modest diastereoselectivity was generally observed in radical pyrrolidine cyclisations, induced by
a chiral perhydro-l,3-benzoxazine moiety (Scheme 2.14)
3 steps
82
V-NH2
77
H
78 SePh
49 - 60% b - d 51 - 62%
N
H
81
Scheme 2.14. a) Bu3SnH, C6H6, AIBN b) A1H3, THF c) PCC d) KOH
The major diastereomer from the reaction shown was product 79. Cleavage of the N, O-acetal 
moiety and two step removal of the chiral auxiliary, resulted in enantiopure 3-substituted 
pyrrolidines 81 and 82.
A synthesis of kainic acid 86 involved a nickel-catalysed allene cyclisation yielding product 85 in 
good yield and excellent stereoselectivity (d.r. = 98:2) (Scheme 2.15). The reaction mechanism 
was proposed to be identical to the extensively studied nickel-catalysed cyclisation of alkenes.83
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o'V-O
cv oMe ° y  > •
Me
h o 2 c — \  / =
4 steps I * a  2 step s <** xe  L •  ** ^ step s / \
\N NH ------- —  %      —  . /  \
f  N ^S^C 3
^  ---- . ^
28% I  o x'v ^
u .
Me
85
CH 57% \ _ J ' 24% h° 2C' H’^ c h 2 o —\  H
o
83 84  86
Scheme 2.15. a) MeLi/ZnCl2, Ni(COD)2 (10mol%), Ti(0-/-Pr)4
Ring-closing metathesis has often been employed for the synthesis of pyrrolidines. Recent 
substrates have included phenyl-substituted dienes84 and the products from enantioselective allylic 
aminations of allylic carbonates.85,86 Pyrrolidines prepared as part of a study on the rhodium- 
catalysed domino silylformylation of enynes showed that the nature of the N-substituent greatly 
affects the outcome of the reaction (i.e. 90 showed no incorporation of carbon monoxide) 
(Scheme 2.16).87
a ^ V ^ SiMe2Ph
T s - N       T s -N
N— ^  74% V - ^ C H 2OH
87 88
/ — =  a / ^ ^ SiMe2ph
B n -N   ► B n -N  I
78% Me
89 90
Scheme 2.16. a) Me2PhSiH, CO (20 kg cm'2), Rh(CO)2(acac) (0.5 mol%), C6H8, 90 °C
Buchwald and Sturla reported an asymmetric cyclocarbonylation of enynes, catalysed by an 
enantiomerically pure titanocene complex 93. For the best enantioselectivity, an electron-rich 
nitrogen centre was required in the starting enyne 91 (Scheme 2.17).88
R2
I    ► R1- N ^ f ) = 0
\ - ^  76 - 93%
e.e. = 4 - 95% \ ’y
91 92 /Ti
R1 = n-octyl, allyl, Bn, Ts, Ph, f-BuCO 
R2  = Me, Ph
Scheme 2.17. a) 107 (10 -  15 mol%), CO (14 psig), toluene, 95 °C
c P
93
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During the course of these studies, Buchwald and co-workers also discovered a titanocene-
O Q
catalysed cycloisomerisation of dienes 94, one example of which yielded a pyrrolidine. This 
method was used for the stereoselective preparation of ^-3,4-disubstitited 95 and 
5y»,5y«-2,3,4-trisubstituted pyrrolidine 96, which was exploited in a new total synthesis of 
(-)-a-kainic acid (Scheme 2.18).90
PhO
✓__
o
R = H 85% (6:1 s y n : anti) N
R = Me 84% (syn  only) g n
94 95
PhO,
" j j  -Ti(0-/-Pr) 2  /
74%
Bn 4
N
:1
96 97
Scheme 2.18.
The Knight group employed a reverse-Cope elimination in the synthesis of (-)-hygroline 102 and 
(+)-pseudohygroline 101 (Scheme 2.19).91
TBDPSO TBDPSO TBDPSO
N inno/ N ‘  N -. .  /  v , . .  1u07o ,• v H ► H
Me OH Me O O Me
98 99® 3 1 0  100
HO HO
O S ' *I H 
Me
101
(+)-pseudohydroline
U
Me
102
(-)-hygroline
Scheme 2.19. a) CHC13, 60 °C
Contrary to earlier studies, which suggested that substituents at the distal end of the participating 
alkene greatly inhibited reaction, allylic oxygen groups were found to facilitate the cyclisation, 
though the stereoselectivity was found to be low.
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2.1.3. Reaction of Amino Alkenes
Numerous syntheses of substituted pyrrolidines by intramolecular cyclisation of 5-alkenyl amines
O'*) Qlvia the aminyl radical have been reported: photolysis, thermolysis of iV-chloroamines and 
anodic oxidation of lithium amides and hydroxylamines9 4 ,9 5  are among the most encountered 
methods. Two procedures to note involve: i) the anodic oxidation of y,5-unsaturated lithium 
amides leading stereospecifically to cis 2,5-disubstituted pyrrolidines 104,96 and ii) the 
intramolecular cyclization of JV-chloroalkenylamine in the presence of tributyltin hydride and 
azoisobutyronitrile («-Bu3 SnH-AIBN) giving rise almost exclusively to trans-2,5-disubstituted 
pyrrolidines 106 (Scheme 2.20) . 9 7
NHMe
103
NHMe
105
R3
R2
R3  
R2
a
2 - 85%
- C V
Me
104
Yields = 2 to 52% d.e. = 100% cis
R1 = H, CH3) C2 H5i C6 H5i p-CH 3 C6 H4l p-CH3 OC6 H4
R2  = CH3l C3 H7i C4 H9
r 3  = h
Yields = 6 6  to 85% d.e. = 100% cis  
R1 = H, CH3l C6 H5  
R2  = Me 
R3  = H
1 9 -6 3 % • WMe
106
Yields = 19 to 63% 
R1 = H, CH3, C6 H5  
R2  = H, CH3) C6 H5  
R3  = H, CH3
d.e. = 1 0 0 % trans
Scheme 2.20. a) BuLi, e' b) NCS, «-Bu3SnH, AIBN
Tokuda reported the stereoselective synthesis of cw-2,5-disubstituted N-methyl-pyrrolidines 108 
as single diastereomers by treating ^-alkenyl amines 107 with a catalytic amount of «-BuLi (i.e. 
0.1 equivalents of w-BuLi) (Scheme 2.21) . 9 6
R = Ph, H
NLiI
Me
fast
fast
Me
108
Me
Scheme 2.21.
Aminomercuration (with HgCb) of 8 -alkenylamines 109 resulted in a mixture of 2,5-disubstituted 
pyrrolidines 110 and piperidines 111 being obtained. 9 7 The regio- and stereoselectivities were 
better for the amidomercuration than for the aminomercuration and the trans isomer was always 
the major isomer formed (cis : trans 2 : 98) (Scheme 2.22) . 98
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a  - c
N
H
110
Yield > 70%  
d .e . = 96%
a  - c
NI
/-Pr 
110
NI
/-P r
111
overall yield ( 1 1 0  & 1 1 1 ) = 60%  
c is  & trans
Scheme 2.22. a) HgCl2 b) NaBRt c) HC1
Harding also showed that 5-alkenylamines, when treated by Hg(OAc)2 , led to 2,6-disubstituted 
piperidines; and observed an equilibrium between the trans and cis products." Takahata used this 
to synthesise *r<ms-2,5-dialkylpyrrolidines 115 from L-norleucine 112 (with d.r. cis : trans = 1 : 25 
and e.e. = 98%) and has since then been used toward the synthesis of numerous 2,5-disubstituted 
pyrrolidines (Scheme 2.23).100’101’102
c o 2h
1
nC4H9'^TvNH2H
112
A7C4 H9  1  NHCbz H
113
nC4 H9'
HgBr
N 
Cbz
114
A7C4H9jr > -N
Cbz
115
Scheme 2.23.
Diastereoselective iodoamination of 3-acetyloxybut-l-enylamine 116 and 118 have been
1 mperformed, yielding pyrrolidines 117 and 119. The biphasic conditions shown in Scheme 2.24 
were essential for the high yields and short reaction times, as was the very large Af-substituent.
OAc
O r * !MU Of ItNHPf
116
OAc
NHPf
118
R = p-tolyl, 92% (cis  only)
R = Ph, 90% (cis:trans = 62:1)
AcO, A 
l
Pf
R Yield cis:trans
p-tolyl 90 25:1
Ph 90 5:1
OMOM 6 6  21:1
117
I
Pf
Pf =
119
Scheme 2.24. a) I2, NaHC03 (aq ): THF : Et20  (2 :1 :1)
A strategy related to the preparation of tetrahydrofurans was used in the stereoselective formation 
of /nms-pyrrolidines (Scheme 2.25).104
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NHCOPh
It
120
H
OBn OBn
121 122
OBn
Ph |-
123
H
7 v - <  O B n>HQJph
124
Bz0N ^ SO ^ /°Bn
125
Scheme 2.25. a) I2, MeCN b) H20
Selenocyclisations have largely been used for the synthesis of 2,5-disubstituted 
tetrahydrofurans, 105 though Clive used this method for the preparation of pyrrolidines substituted 
at C-2. 106 Selenocyclisations of homoallylic sulfonamides 126 have also been reported, but 
stereochemical outcome of the pyrrolidine products 127 were somewhat unpredictable 
(Scheme 2.26).107’108
.SePh
a, b
NHTs
126
NHTs
126
N
Ts
127
.SePh
a, c
R ^ V ^ R 1
Ts
127
Scheme 2.26. a) PhSeCl, CH2C12, -78 °C, 0.5 -  1 hr b) K2C03, 5 mol% H20  c) cat. 10 M HC1
Yoshikoshi described the synthesis of 2,5-dialkylated pyrrolidines 131 by hydrogenation of acetyl- 
nitronates 130 prepared from enolates 128 and nitroalkenes 129. Unfortunately, 
diastereoselectivity is low: 64 to 72% in favour of the cis isomer (Scheme 2.27).1 
© . ^  -R2
109
cR1' S )  
128
Scheme 2.27. a) H2, Pt02
Y R2  
N 0 2
129
i '\\ N-R1 _6  -OAc 
130 131
This was improved by synthesising the pyrrolidines via cyclic and chiral nitrones obtained by 
electrophilic a-hydroxyamination of a chiral sultam. The pyrrolidines obtained were 
enantiomerically pure with overall yields ranging from 48 to 60%, depending on the nature of the 
substituents and with d.e. = 87 to 99% in favour of the trans isomers. 110
23
The hydrogenation of y-nitroketones to give cw-2,5-disubstituted pyrrolidines, 1 1 1 ’112 was achieved 
through the syw-addition of hydrogen on the intermediate pyrroline, resulting in the formation of 
cis pyrrolidines. 1 1 3 ,1 1 4
Most syntheses of 2,3,4,5-tetrasubstituted pyrrolidines 135 proceed via an azidoketone 134 to give 
enantiomerically pure pyrrolidines 135 (Scheme 2.28).115,116,117
n 3 o h  h o - -o h
FT * CHO 
132
Scheme 2.28.
N3 O
-"^cho* ho^^A /O P O s
133
*
OH O 
134
OH
135
Aminoketones 136 can be hydrogenated in the same way as nitroketones and azidoketones 
Hydrogenation of aminoketone 136 in the presence of 10% palladium on charcoal in methanol 
cleaved the protecting group from the amino function as well as reduction of the ketone and the 
cyclisation leading to 2,5-disubstituted pyrrolidines 137 of exclusive cis configuration, whereas 
treatment of aminoketones 138 with ammonium formate in the presence of 10% palladium on 
charcoal in methanol under reflux, gave a mixture of cis- and fr*<ms-2,5-disubstituted pyrrolidines 
138 (3: 2) (Scheme 2.29).118
Hi 
BnNv'
Z O
136
87%
n-CyHis
a 72%
137
AJ-C7H15 + n-C 7H15
trans
Scheme 2.29. a) H2, 10% Pd/C b)HC02NH4,10% Pd/C
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2.2 Background to Current Work
The synthesis of pyrrolidines through acid-catalysed hydroaminations has previously been 
developed within the Knight group. Pyrrolidines, such as 140 and 142 had been successfully 
isolated through cyclisation of homoallylic sulfonamide 139 and 141 with triflic acid 
(Scheme 2.30).30
139
NHTs 
R C 0 2Me
.NHTs
> c y
R R = H 95%
N- C 0 2Me R = Me 97% 
Ts 
140
R1" ^ A
R C 0 2Me
141
R 1 = Ph, R* = H 95%
1 -  Dh d 2 _
j2 _J~Y 2i1- ^ \ N/ ^ C 0 2Me R1 = Ph, R* = Me 96%
Ts
142
R1 = Me, R2  = H 91% 
R1 = Me, R2  = Me 94%
Scheme 2.30. a) 0.4 eq. TfOH, CHC13, 0 °C, 2.5 hrs b) 0.4 eq. TfOH, CHC13, 25 °C, 4.5 hrs
This cyclisation has also been used in the implementation of cascade reactions, where a multitude 
of rings can be formed, with the sulfonamide acting as the terminator (Scheme 2.31).
  JMHTs
R
C 0 2Me
NHTs
143
H+
Scheme 2.31. a) 0.4 eq. TfOH, CHC13, 0 °C, 0.25 hrs
144R = H (95%)
R = Me (97%)
This all developed from previous work conducted in the Knight group on iodocyclisations (see 
Chapter 1).
The acid-catalysed hydroamination follow an overall 5-endo-trig process, but this does not mean 
that they are subject to Baldwin’s rules. Because the cyclisation involves the formation of a 
carbocation, which is the driving force for the cyclisation, ring formations that are disfavoured 
according to Baldwin’s rules are still possible under these conditions. Baldwin’s rules are relevant 
to iodocylisations that are not driven by the formation of carbocations (Scheme 2.32).
a
-H-
HO
O
147
5-endo -trig  HO
HO.
5-exo-trig 0 ‘
146
Scheme 2.32. a) 3 eq. I2
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2.3 Results and Discussion
2.3.1 Simple Pyrrolidines
To further expand the work performed by Haskins, simple pyrrolidines were to be synthesised 
where the substitution patterns and the type of substituent are varied. This would give a good
that needs to be answered is whether the presence of the ester group actually necessary for the 
cyclisation to occur.
As a general limitation, a synthetic route was to be no more than five steps to the pyrrolidines (v). 
This generally involved the synthesis or purchase of either an alcohol (i) or the amines (iii). The 
alcohols (i) were reacted under Mitsunobu conditions (PPI13, DIAD, THF, 0 °C, 24 hours) with the 
Weinreb reagent (TsNHBoc) to give the desired precursors (ii). The amines (iii) were tosylated to 
sulfonamides (iv) and then both precursors were reacted under acidic conditions to afford the 
pyrrolidines (v) (Scheme 2.33).
Scheme 2.33. a) PPh3, DIAD, TsNHBoc, THF, 0 °C, overnight b) /?-TsCl, NEt3, DMAP, DCM, -78 °C, overnight c) 
0.5 eq. TfOH, DCM 0 -  40 °C
The first pyrrolidine synthesised was synthetically straightforward: 4-methyl-3-penten-l-ol 148 
was converted into the corresponding sulfonamide 149 followed by cyclisation to 
dimethylpyrrolidine 150 (Scheme 2.34).
Scheme 2.34. a) PPh3, DIAD, TsNHBoc, THF, 0 °C, overnight b) 0.5 eq. TfOH, DCM 0 °C, 2.5 hrs
An unexpected bonus was the observation that both the Boc deprotection and cyclisation occurred 
in a single step. In hindsight, this was a reasonable observation, as standard removal of a Boc
indication as to the scope of these hydroaminations. Previous work by Haskins always included an 
ester group, used in precursor synthesis, adjacent to the amine for synthetic ease. 3 0 ,1 1 9  A question
NTsBoc
Ts
ii v
NHTs
Ts
iii iv v
R
R = Ts 150a Yield: 95% 
R = Ns 150b Yield: 97%148
R = Ts 149a Yield: 42% 
R = Ns 149b Yield: 40%
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i ongroup employs the use of trifluoroacetic acid (TFA) (pKa 0.3). Since the hydroaminations are 
acid-catalysed, it is reasonable to expect that the triflic acid (pKa -13) would indeed be successful 
in removing the Boc group. The removal of the Boc group was achieved successfully with full 
conversion to pyrrolidines 150. Another advantage of this cyclisation is that provided pure 
precursor (ii) is used and the reaction reaches completion, no purification of the produced 
pyrrolidine (iii) is required.
It seemed prudent to see whether this method could be expanded beyond the use of tertiary 
carbenium ion formation. Haskins had performed cyclisations on secondary and tertiary carbenium 
ions, though all of these had an ester adjacent to the nitrogen. 3 0 ,1 1 9  The result above (Scheme 2.34) 
shows that an ester is unnecessary for the cyclisation of tertiary carbenium ions to occur.
A simple example was sought that would be easily comparable to 150. 2-Methyl-1- 
tosylpyrrolidine 155 is a viable and comparable target and was synthesised from commercial 
toms'-3-pentenenitrile 151 (Scheme 2.35).
a  ^ — ,oh ,_b.„
49%
153
/ ^ ^ N T s B o c  -J-*.
50%  91%  Ts
154 155
Scheme 2.35. a) 30% H20 2, 3 M NaOH, 80 °C for 1 hr then 20 °C for 1 hr b) LiAlH4 Et20 , 0 °C, 1 hr c) PPh3, DIAD, 
TsNHBoc, THF, 0 °C, overnight d) 0.5 eq. TfOH, DCM, 40 °C, 48 hrs
The cyclisation was successfully completed with an excellent yield of 91%. Heating was needed to 
reach full conversion to the pyrrolidine 155, as well as a longer reaction time of 48 hours 
compared with that required for formation of pyrrolidine 150. The requirement for moderate 
heating and the longer reaction time could be a symptom of the secondary carbenium ion 
generated from 154. Could the inclusion of a charge stabilising group, such as a phenyl, help 
reduce the reaction time? Sulfonamide 158 was synthesised in a similar fashion to sulfonamide 
154, from commercial /raws-styrylacetic acid 153 (Scheme 2.36).121
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24%
158
c
N
Ts
159
59%
Scheme 2.36. a) LiAlH*, Et20 , 0 °C, 1 hr b) PPh3, DIAD, TsNHBoc, THF, 0 °C, overnight c) 0.5 eq. TfOH, DCM, 20
°C, 48 hrs
The cyclisation was successful for the formation of 2-phenylpyrrolidine 159 and occurred at lower 
temperature than the cyclisation to 155. This appears to reflect the relative carbenium ion 
stabilities.
Secondary carbenium ions are more challenging to form than tertiary examples. There are two 
possible secondary carbenium ions that can form from sulfonamide 154; these are both equally 
likely to form (Scheme 2.37). Trapping the secondary carbenium ion 154a will form the observed 
pyrrolidine 155 through a formally disfavoured overall 5-endo-Xng process. Carbenium ion 154b 
would form the severely strained 4-membered ring 160, though an overall 4-exo-trig process.
154a
Ts
155
154
©
154b 160
Scheme 2.37.
Two possible carbenium ions can form from 158; however the benzylic carbenium ion 158a is 
much more likely to form than 158b due to the stabilisation afforded by the phenyl group, 
resulting in the exclusive formation of pyrrolidine 159 (Scheme 2.38).
158
Ph/ ^ i ^ / NTsBoc — h-
©
158b
Ph
NTs
161
Scheme 2.38.
Hence, cyclisations can occur without an ester in examples of both secondary and tertiary 
carbenium ions; though cyclisations involving secondary carbenium ions require higher 
temperatures and longer reaction times than tertiary carbenium ions. As reasonably expected, the 
presence of the ester was not necessary for the key cyclisation.
The next stage was to increase the substitution around the pyrrolidine ring by including a methyl 
group in the 5-position of the anticipated products to hopefully give 2,2,5-trisubstituted pyrrolidine 
162 and 2,5-disubstituted pyrrolidine 163 (Figure 2.3).
Figure 2.3. Structures of pyrrolidines with increased substitution
2,2,5-Trimethylpyrrolidine 162 was synthesised successfully via alcohol 166, resulting from 
opening of propylene oxide 164 with 2-methyl-propenylmagnesium bromide 165 
(Scheme 2.39) . 122
purification of the product. Extra substitution had slightly increased the time required for the
Ts Ts
162 163
100%
164 165 166
I 7ROZ Ts
167 162
Scheme 2.39. a) Cul, THF, -35 °C, 1.5 hrs b) PPh3, DIAD, TsNHBoc, THF, 0 °C, overnight c) 0.5 eq. TfOH, DCM, 
0 °C, 4 hrs
The cyclisation was high yielding and complete conversion was achieved without the need for
production of 2,2,5-trimethylpyrrolidine 162 compared with 2,2-dimethylpyrrolidine 150 
(Scheme 2.34), although both reactions proceeded relatively rapidly at 0 °C.
The same synthetic approach was used for the synthesis of 2-methyl-5-phenyl-l-tosylpyrrolidine 
163122 using styrylmagnesium bromide 168 to open propylene oxide 164 (Scheme 2.40).
B r M g ^ Ph Ph^ ^ Y 0H
48% '
164 168 169
NTsBoc
170 163
Scheme 2.40. a) Cul, THF, -35 °C, 1.5 hrs b) PPh3, DIAD, TsNHBoc, THF, 0 °C, overnight c) 0.5 eq. TfOH, DCM, 
0 °C, 24 hrs
The ring opening of the epoxide 164 was successful, though not as high yielding as for the 
previous example 166. The cyclisation was achieved in 100% yield, an improvement on the 
synthesis of 2-phenylpyrrolidine 159. The reaction was performed at a lower temperature (0 °C 
rather than 20 °C) and had a shorter reaction time of 24 hours.
2.3.2 Terminal Double Bonds -  Secondary vs. Primary Carbenium Ions
Formations of primary carbenium ions are expected to be so unfavourable that they would be most 
unlikely to participate in this type of hydroamination. This was a relatively easy concept to 
investigate, involving the movement of the double bond to a terminal position (172) 
(Figure 2.4) . 123
BocTsN BocTsN
171 172
Figure 2.4. Structure of homoallylic sulfonamide 171 and ftw-homoallylic sulfonamide 172
If the primary carbenium ion was formed and underwent cyclisation via a favoured 6-endo-trig 
process, then the corresponding piperidine would be observed. If, as was expected, the primary 
carbenium ion was not formed, and instead the secondary was formed, then pyrrolidines 174 
would be formed via a favoured 5-exo-trig process.
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The terminal alkene sulfonamide 172 was synthesised from 5-hexen-2-ol 173124 using a Mitsunobu 
reaction (Scheme 2.41).
67%
173
BocTsN
172
J 3 -N
Ts
174a
Ts
174b
Scheme 2.41. a) PPh3, DIAD, TsNHBoc, THF, 0 °C overnight b) 0.5 eq. TfOH, DCM, 40 °C, 24 -  72 hrs
The results for the cyclisation of 172 are depicted in Table 2.1 below, along with the cis : trans 
ratios observed, which were estimated from *H NMR.
Table 2.1. Table showing cis : trans ratio for cyclisation of terminal alkene 172
Acid8 Temperature / °C Time / hrs trans :cis ratio Yield / %
TfOH 20 24 Boc removal 0
TfOH 40 24 3.0 : 1.0 99
TfOH 40 72
©©CO 88
h 2so 4 40 72 1.0: 1.0 88
8 either 0.5 eq. TfOH in DCM or 2 drops of sulfuric acid in DCM
The cyclisation of (R)-tert-butyl hex-5-en-2-yl(tosyl)carbamate 172 at 40 °C overnight, showed 
successful formation of the desired products 174, with a diastereomer ratio of 3.0 : 1.0. Leaving 
the cyclisation with triflic acid for 72 hours showed no change in the diastereomer ratio. Treating 
sulfonamide 172 with concentrated sulfuric acid at 40 °C for 72 hours resulted in a diastereomer 
ratio of 1 . 0  : 1 .0 .
The two diastereomer were separated by recrystallisation from dichloromethane, where the major 
isomer 174b crystallised as a colourless solid and the minor isomer 174a remained as a viscous 
oil. X-ray diffraction confirmed that the major diastereomer was fra/w-pyrrolidine 174b 
(Figure 2.5).
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cu
C12.
CL3
CIO
C14
Figure 2.5. X-ray structure of major ftvms'-pyrrolidine 174b. Full crystallographic data is included in the appendix.
The structure in Figure 2.5 showed bond lengths and angles consistent with the five membered 
ring structure depicted in Figure 2.5.
The trans diastereomer was formed in greater abundance than the cis diastereomer when using 
triflic acid to catalyse the cyclisation. Sulfuric acid on the other hand showed an equal mixture of 
the two diastereomers, which may be due to the reaction having reached equilibrium.
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3.5 1.03.0 7.0 5.0 5.0 4.5 4.0 3.0 2.0 1.5
Figure 2.6. *NMR spectrum showing diastereomers 174a and 174b as a mixture
The CHs either side of the nitrogen for pyrrolidines 174a and 174b, were observed at 3.98 -  3.93 
ppm for the trans and 3.62 -  3.59 ppm for the czs-diastereomer, respectively. The two tosyl Me 
groups were observed at 2.35 ppm and 2.34 ppm, respectively (Figure 2.6 and 2.7).
4.4 4.043 43 4.1 3.9 3.8 3.7 3.6 3.5 3.33.4 3.2
" ~ i r "
Figure 2.7. Expanded section of 'H NMR spectrum for diastereomers 174a and 174b
Determination of the identity of each diastereomer was also possible by comparison with NMR 
data amassed on similar examples synthesised by Jones (Figure 2.8) . 125 He had synthesised 
diastereomers 175 and 176 by iodocyclysation, followed by removal of the iodine (Figure 2.8). 
When the reactions had been performed under basic conditions then the major diastereomer 
isolated were the trans 2,5-disubstituted pyrrolidines 175, however, when the reactions were 
conducted under acidic conditions then the major diastereomers isolated were the cis 2 ,5 - 
disubstituted pyrrolidines, as was observed for 174 (Scheme 2.41).
33
r1 r2
Et Bu
Et Pent
Me Bu
Et Ph
R1^ R2
Ts Ts
175 176
Figure 2.8. Structure of diastereomers synthesised by Jones125
Jones stated that for the 2,5-disubstituted pyrrolidines in Figure 2.7 “the resonance corresponding 
to the 2-CH and the 5-CH (i.e. the CHs alpha to the nitrogen) for the /raws-pyrrolidines have a 
downfield shift of ca. 0.3 ppm by !H NMR relative to the corresponding c/s-2,5-disubstituted 
pyrrolidine”. This same phenomenon was observed for 174a and 174b.
2.3.3. Investigation intoRing Opening and Re-closure
Work previously carried out by Haskins showed the possibility of ring opening and re-closure. 
This is most obvious when there are groups either side of the nitrogen, as these can either be in cis 
or trans with respect to one another (Figure 2.9) . 3 0 ,1 1 9
J  WR1 Jl V r1 r1=H-Me
R* ^ N^ C 0 2Me R* ^ N^ ' 'C 0 2Me 
Ts Ts
cis trans
R = Ph 177 
R = Me 178
Figure 2.9. Structures of pyrrolidines used by Haskins to investigate ring-opening and re-closure
This observation was investigated further, using the forgoing examples and, in addition, an 
example where R1 = z-Pr. These compounds are amino acid derivatives, which were synthesised 
from glycine, alanine or valine.
Amino acids 179 were converted into the corresponding methyl esters 180, followed by formation
of the benzyl imines 181 (Scheme 2.42). The imine acts as a protecting group for the next step of
the synthesis. 3 0 ' 119 ' 126
r 1  r 1  r 1  
T a ,  T b ,  T
H2N C 0 2H H2N C 0 2Me P h ^ N  C 0 2Me R = H, M e,/-Pr
179 180 181
Scheme 2.42. a) SOCl2, MeOH, 20 °C, overnight b) Benzaldehyde, MgS04, NEt3, DCM, 20 °C, 30 hrs
Imines 181 were deprotonated with in situ generated LDA and then reacted with either cinnamyl 
or crotyl bromide (Scheme 2.43).
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r \    p i
P h ^ ^ -NX ^s 'C 0 2Me R y ~ C 0 2Me R1 = H, Me, /'-Pr
/=M
Ph
181 R = Ph 182
R = Me 183
Scheme 2.43. c) LDA, crotyl or cinnamyl bromide, THF, -78 °C, 1 hr, then r.t., 1 hr
iV-Protecting group exchange was carried out, where imines 182 and 183 were hydrolysed to the 
corresponding amines, followed by immediate tosylation to give sulfonamides 184 and 185 
(Scheme 2.44).
r 1 p1
R— $  ) ^ - C 0 2Me d ’ e  R— V  C 0 2Me R 1 = H, M e,/-P r
/ = N  TsHN
Ph
R = Ph 182 R = Ph 184
R = Me 183 R = Me 185
Scheme 2.44. d) 1 M HC1, Et20 , 2 hrs e) /?-TsCl, NEt3, DCM, -78 °C, overnight
Sulfonamides 184 and 185 were cyclised with varying amounts of triflic acid to determine the 
effect this would have on the diastereomer ratio (Scheme 2.45).
J T Y 'PhJ' ' ' ^ N^ " C 0 2Me 
Ts
177 1R1 = H, Me, /-Pr
J D £ '
Ts
178
Scheme 2.45. f) 0.5 eq. TfOH, DCM, 0 °C
The standard conditions for the cyclisation with triflic acid involve the use of 0.5 equivalents of 
acid. 11 9 The amount of acid was then increased to 1, 2 and 5 equivalents. The data shown in the 
Tables 2.2 to 2.4 below have been calculated from !H NMR spectra.
The major isomer should be the 2,5-cis isomer. Due to what is known about energetic stability, the 
large substituents should be in the “pseudo-equatorial” position meaning that they would be cis to 
one another (Figure 2.10).
R1
Ph— / - C 0 2Me f
TsHN
184
Rl r
C 0 2Me ------
TsHN
185
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= =
Ph n c° 2Me —  
Ts
C0 2 Me 
* NTs
177a
Figure 2.10. Structural explanation of possible favourable cis diastereomer formation
The cinnamyl derivatives were cyclised and the diastereomer ratios evaluated (Table 2.2) . 127
j r v
Ph^ sHN/ ^ C° 2Me
j r yPhJ^ \ N/ ' ' /C0 2Me
Ts
184
R1 = H, Me, /-Pr
177
Scheme 2.46. a) 0.5 eq. TfOH, DCM, 0 °C 
Table 2.2. Isomer ratios for the cinnamyl derivatives
R1 Equivalents Isomer Ratios after 1 hr 
trans: cis
Isomer ratio after 24 hrs 
trans: cis
H 0.5 1.0: 1.2 1.0 : 1.1
H 1 1.0 :2.4 a 1.0: 4.0
H 2 1.0: 1.3 1.0: 1. 1
H 5 1.0: 1.0 1.0: 1.0
Me 0.5 1.0: 3.0a 1.0: 3.0 8
Me 1 1.0: 3.18 1.0: 2.2
Me 2 1.5 : 1.0 1.0: 1.8
Me 5 1.6: 1.0 1.0: 2.2
/-Pr 0.5 1.0:38 1.0: 4.3
/-Pr 1 1.0: 5.5 8 1.0: 3.6
/-Pr 2 1.0: 4.0 1.0: 4.0
/-Pr 5 5.0: 1.0 : 5.0b 2.0 : 1.8 : 1.0b
Starting material observed second ring opened product observed
The glycine derivative overall, showed little change in diastereomer ratio when increasing the 
equivalents of acid added, stirring for either 1 hour or 24 hours. The reaction using 1 equivalent of 
acid for 24 hours had a diastereomer ratio of 1.0 : 4.0, the largest ratio observed for 177.
It was difficult to compare the three amino acid derivatives to one another. No apparent correlation 
seemed obvious between the use of the same equivalents or times exposed to the acid.
In comparison to Haskins’ observations, the results obtained were rather different (Table 2.3) . 119
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Table 2.3. Comparison with the isomer ratios observed by Haskins
Haskins New
Derivative Equivalents Isomer ratio after 1 h 
cis ; trans
Equivalents Isomer ratio after 1 h 
c is ; trans
Glycine 2 >20: 1.0 2 1.3 : 1.0
Glycine 5 >20: 1.0 5 1.0: 1.0
Alanine 0.5 2.9: 1.0 0.5 1.3 : 1.0
Alanine 1 3.5 : 1.0 1 1.3 : 1.0
Alanine 5 9.0 : 1.0 5 1.6: 1.0
Haskins obtained isomer ratios of 20.0: 1.0 with the glycine derivative when using 2 and 5 
equivalents of TfOH. This could not be repeated; instead an isomer ration of 1.3 : 1.0 was 
observed for all the equivalents used apart from 1 equivalent of TfOH where a ratio of 1 : 4 was 
observed. For the alanine derivative, Haskins observed a 9.0 : 1.0 ratio for 5 equivalents, which 
again could not be repeated. Instead, a diastereomer ratio of 1.6 : 1.0 was observed. This difference 
in isomer ratio is difficult to explain but highlights the inherent difficulty associated with this 
method. The difference in diastereomer ratio observed by Haskins and those reported in Table 2.2 
could possibly be due to varying levels of water present in the reaction.
The valine derivative had not been cyclised previously. Unfortunately, no significant differences in 
the isomer ratios were observed. This changed when using 5 equivalents; a third compound 
appeared. This new compound was tentatively identified as a ring opening product 186a or 186b 
by NMR, as essentially a single isomer (Figure 2.11).
CC^ Me CC^ Me
NHTs NHTs
186a 186b
Figure 2.11. Possible structure for ring opening of valine derivative 177c
The !H NMR showed a distinct NH peak as a doublet, suggesting that it must be adjacent to 
another proton. This was not the case in the synthesised starting material 184c wherein the NH 
appeared as a broad singlet. To confirm that this doublet was in fact the NH, a D2 O shake was 
performed, resulting in the disappearance of the doublet and a change in the multiplicity of the CH 
adjacent to the NH, from a double double doublet (ddd) to a double doublet (dd). The lack of /-Pr 
and alkene protons in the NMR spectra also suggesting that ring opened product 186b had been 
isolated and not 186a. The methyl groups of the z-Pr group also show significant difference in
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chemical shift than observed for the starting alkene 184c and those expected for ring opened by­
product 186a. The methyl groups appeared as doublets at 1.05 and 0.89 ppm for alkene 184c; a 
similar value and splitting would be expected for 186a. The resonance observed, however, were 
two singlets at 2.37 and 1.96 ppm, giving further supporting the deduction that the minor ring 
opened byproduct observed is indeed 186b.
Investigations into the cis/trans diastereomer ratios for the crotyl derivatives were also performed.
JTV''J^ N^ ' /C0 2Me 
Ts
185 178
Scheme 2.47. a) 0.5 eq. TfOH, DCM, 0 °C
As for the cinnamyl derivative, the cis isomer was expected to be the major isomer observed, at 
least for R1 = H, due to steric interactions (see Figure 2.9); and the results are depicted in 
Table 2.4.
Table 2.4. Isomer ratios for crotyl derivatives
R1 Equivalents Isomer ratio 
after 1 hour
trans: cis
Isomer ratio 
after 2 hours
trans: cis
Isomer ratio 
after 3 hours
trans: cis
Isomer ratio 
after 24 hours
trans: cis
H 0.5 1.0: 2.0 1.0 1.3 1.6 1.0 1.0 2.1
H 1 - 1.0 3.0 1.0 2.6 1.0 2.6
H 2 1.0: 2.7 1.0 2.7 1.0 2.6 1.0 3.9
H 5 1.0: 2.3 1.0 2.3 1.0 3.6 1.0 2.8
Me 0.5 2.0: 1.0 1.4 1.0 2.0 1.0 1.9 1.0
Me 1 1.6: 1.0 1.6 1.0 1.3 1.0 1.1 1.0
Me 2 1.7: 1.0 1.5 1.0 1.7 1.0 1.5: 1.0
Me 5 1.1 : 1.0 1.1 1.0 1.6 1.0 1.1 1.0
The glycine derivative showed inversion of ratios after 3 hours, which reverted back to the ratio 
observed after 1 hour using 0.5 equivalents of acid. This inversion was not observed for 1, 2 and 5 
equivalents of acid added. The alanine derivative showed a gradual decline in diastereomer ratio 
over 24 hours although this could be due to experimental error. The valine derivative did not 
cyclise under any of the cyclisation conditions shown in Table 2.2. Presumably, the cyclisation 
could not occur because the short lived carbenium ion is difficult for the bulky sulfonamide to 
approach. The cyclisation for the valine cinnamyl derivative can occur, due to the generated
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CO^Me
carbenium ion being stabilised by the phenyl group adjacent to it, meaning it will have a longer 
life time, thus giving the bulky sulfonamide a chance to approach it.
2 .3 3 ,1  Investigations o f  th e  M echanism
Investigating the reaction mechanism was performed with a deuterium study. This involved the 
implementation of deuterated triflic acid to perform the reaction with (Scheme 2.48). Deuterated 
triflic acid was diluted in dry DCM to give a 0.695 M stock solution to be used for the cyclisation.
Cyclo-reversion is believed to occur from the beginning of the reaction, so double deuterium 
incorporation should be observed. Carbon-deuterium bonds are generally much stronger than 
carbon-hydrogen bonds; meaning that hydrogen would be preferentially lost over a deuterium
Unfortunately, there was no evidence of deuterium incorporation at all. This was rather unexpected 
as deuterated triflic acid was the only source of protonation and the cyclisations still occurred. The 
lack of deuterium incorporation was possibly due to the deuterium exchanging with hydrogen of 
DCM, thus meaning that the cyclisations were conducted with non-deuterated triflic acid.
These deuteration experiments should be repeated with a solution of deuterated triflic acid in 
deuterated chloroform. A saturated solution of K2 CO3 in D2 O should be used in the quenching of 
the reaction, to prevent further exchange. The strength of the nitrogen-deuterium bonds must also
CO2M6C0 2 Me CC>2Me
TsHN
Ts
184 187 188
Scheme 2.48,
(Scheme 2.49).
C0 2 Me CC>2Me
TsDN
189 188
CC^ Me C0 2 Me
Ts
190 191
Scheme 2.49.
be taken into consideration, as these are stronger than nitrogen-hydrogen bonds. The difference in 
bond strength could slow the removal of this and thus slow the rate of reaction. If this is still not 
observed, than one could conclude that N-H cleavage is not a rate determining step.
2.3.4 Transannular Cyclisations
The synthesis of pyrrolidines and other cyclic systems that have been discussed employed a planar 
mode of addition. Does this always have to be the case? Can the synthesis of bridged compounds 
through transannular hydroaminations be achieved?
194 (Scheme 2.50); there is no evidence of formation of the alternative secondary carbocation, 
which would have resulted in the less hindered product.
isoquinuclidine, which are very important precursors to natural products, such as ibogaine, 
dioscorine and (+)-catharanthine (Figure 2.12) . 1 2 9 ’1 3 0 ’131
Figure 2.12. Structures of natural products containing an isoquinuclidine moiety
Since they are important, a new synthetic method of forming these hindered compounds using the 
hydroamination technique was investigated. The incorporation of different R groups, in place of 
the methyl group shown in 194 (Scheme 2.50) was desired. Ideally, the synthesis should allow 
access to different isoquinuclidines in as few steps as possible, meaning incorporation of these 
different functional groups should occur late on in the synthesis. This new methodology would be 
most suited for the elaboration of non-natural analogues substituted at a bridgehead carbon 
adjacent to the nitrogen, thus giving access to many new types of potentially bioactive derivatives.
Commercially available (4-methylcyclohex-3-enyl)methanol 192128 was converted into 
sulfonamide 193, followed by cyclisation to give only the sterically crowded bridged piperidine
NTsBoc b
192 193 194
Scheme 2.50. a) PPh3, DIAD, TsNHBoc, THF, 0 °C, overnight b) 0.5 eq. TfOH, DCM, 20 °C, 48 hrs
This is an example of /r<ms-annular cyclisation and the compound formed 194 is an example of an
CO2M©
ibogaine d isco rine (+ )-ca tharin th ine
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The proposed synthetic approach to the desired isoquinuclidine derivatives 201 is outlined in 
Scheme 2.51.
o o
X ^  - 7 -M eaSiO ^^ 79% Me3S i O ' ^ ^  42%
195 196 197 198
NTs^ j ^ J ^ N T s B o c  d ^  hq^ ^ | ^ ^ N T sBoc e
199 200 R = E t, Ph, Bz 201
Scheme 2.51. a) Hydroquinone, toluene, 110 °C, 24 hrs b) i) LiAlH4, THF ii) 15% NaOH, MeOH, 30 min c) PPh3, 
DIAD, TsNHBoc, THF, 0 °C, overnight d) RMgBr, THF, 0 °C e) 0.5 eq. TfOH, DCM 20 °C
1 29The synthetic route up to keto-alcohol 198 followed literature procedure by Borden; 
unfortunately the Mitsunobu reaction leading to sulfonamide 199 was not successful. An 
alternative route was sought starting from keto-alcohol 198 and is outlined in Scheme 2.52.
OMs NHTs NHTsOH
96%
R
 d r /  NTs
p  — pf Ph Rz
198 202 203 204 "  "  r-". 201
Scheme 2.52. a) MsCl, NEt3, DCM, 20 °C, 2 hrs133 b) p-TsNH2, KOH, DMF, 100 °C, 24 hrs c) RMgBr, THF, 0 °C
d) 0.5 eq. TfOH, DCM 20 °C
Conversion of the hydroxyl group of 198 into mesylate 202 was successful, though the subsequent 
reaction with /?-toluenesulfonamide was not. The synthesis of isoquinuclidines 201 was abandoned 
and a new synthetic route towards 200 or 204 needs to be devised. The syntheses above 
(Schemes 2.51 and 2.52) could possibly be successful if the probable interference from the ketone 
was overcome through implementation of a protecting group, such as a dithiane. Alternatively, a 
completely different synthetic approach could be taken. Formation of the amine 211 through ring 
closing metathesis, where the substitution was incorporated prior to the ring closure 
(Scheme 2.53).
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205 206 207
XT
210
C02Me
R 208
X T *
211
Scheme 2.53.
The synthetic approach shown in Scheme 2.53 could allow for additional substitution around the 
ring.
2.3.5 Cascades & Fused Systems
Cascade reactions, where multiple ring systems were formed in one step (Scheme 2.31) result in 
formation of compounds with interesting structural scaffolds, such as spiro- and fused systems. 
These are compounds that can be difficult to synthesise in just a few steps through means other 
than a hydroamination. 134
Targeting a 4,6-fiised system, lavandulol 212 was converted to sulfonamide 213 via a Mitsunobu 
reaction, followed by cyclisation (Scheme 2.54).
H O - a  BocTs N-
41%
212 213 214
Scheme 2.54. a) PPh3, DIAD, TsNHBoc, THF, 0 °C, overnight b) 0.5 eq. TfOH, DCM, 40 °C, 24 hrs
It was hoped that a four membered ring would be formed, despite the overall 4-exo-trig 
cyclisations being disfavoured by Baldwin’s rules (Scheme 2.55). Cyclisations have already been 
proven to be possible despite being disfavoured by Baldwin’s rules, such as 152 in Scheme 2.35.
BocTsN-
213
-H- TsN
214
Scheme 2.55.
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The synthesis of 214 was unsuccessful, which was not particularly surprising, as the four 
membered ring formed would have been under considerable strain.
Formation of a 5,5-fused system was attempted next, through formation of the pyrrolidine ring 
upon an already present cyclopentane (Scheme 2.56).
216a being formed at the ring junction rather than the isopropyl as expected. Also protonation at 
the isopropenyl would result in formation of two isomers 216b and 216c; where 216b would
Figure 2.13. Three possible carbenium ions formed from 216
If the carbenium ion at the ring junction 216a and 216c were favoured, then this would explain the 
lack of cyclisation occurring. The resulting 4-membered ring formed from carbenium ion 216a 
would be too strained to make its formation feasible.
A study was undertaken on the cyclisation of geranyl derivatives of glycine and valine 
(Scheme 2.57). These were synthesised by the same method as the cinnamyl and crotyl derivatives 
in Figure 2.8, employing geranyl bromide in the substitution reaction. 135
NTsBoc
215 216 217
Scheme 2.56. a) PPh3, DIAD, TsNHBoc, THF, 0 °C, ovemigbt b) 0.5 eq. TfOH, DCM, 40 °C, 48 hrs
The cyclisation was not successful, possibly due to steric crowding or due to the carbenium ion
favour cyclisation due to its proximity to the nitrogen required for the cyclisation to occur 
(Figure 2.13).
NTsBocNTsBoc NTsBoc
216a 261b 216c
CC^ Me
C0 2 Me
NHTs
218 R = H or /-Pr 219
Scheme 2.57. a) 0.5 eq. TfOH, DCM
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Table 2.5. Comparison o f genaryl glycinate and valinate derivatives
R Equivalents Isomer ratio after 1 hour 
trans: cis
Isomer ratio after 24 hours 
trans: cis
H 2 1.0 : 10.0 1.0: 2.5
z'-Pr 2 1.0 : 10.0 1.0 : 5.0
The diastereomer ratios observed for the fused-cycle 219 were higher than those for the 
pyrrolidines 177 & 178; reminiscent of the ratios observed by Haskins for the cinnamyl glycinate 
177a and alaninate 178a derivatives. 119 The glycinate derivative 219 diastereomer ratio decreased 
from 1.0 : 10.0 after 1 hour to 1.0 : 2.5 after 24 hours. A similar but less marked decrease was 
observed for the alanine derivative, where the ratio decreased from 1.0 : 10.0 to 1.0: 5.0. It is 
believed that the ratio shifts in favour of the fr*<ms-diastereomer, the thermodynamic product, after 
prolonged exposure to acid. 136
2.3.6. Indene
As well as synthesising simple pyrrolidines, previous work by Haskins has shown that spiro-cyclcs 
can be formed through acid-catalysed hydroaminations. These had ester functionality adjacent to 
the formed hindered amine (Scheme 2.58).30
TsHN c ° 2 Me
219
:> R
“N
Ts
C 0 2Me R = H 9 2 % 
R = M e 96%
220
Scheme 2.58. a) 0.5 eq. TfOH, CHC13, 0 °C, 0.25 hrs
The ester adjacent to the sulfonamide is not needed for acid-catalysed hydroamination to occur. Is 
this also the case for spiro-cycles, such as 2 2 1 , which would also represent an extension to the 
present methods (Figure 2.14)?
''N T s
221
Figure 2.14. Indanone derived spiro-cycle
This was to be tested in the synthesis of indene-derived spiro-cycle 221. The original synthetic 
route is outlined in Scheme 2.59.
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OH
225
99%
O
224223
'"N T s
221
over 2 steps  
11% NTsBoc
226
Scheme 2.59. a) CeCl3, allylMgBr, MsCl, NEt3, conc. HC1, 20 °C, 3 hrs b) 9-BBN, aq. NaOH, H20 2, 80 °C, 2 hrs 
c) PPh3, DIAD, TsNHBoc, THF, 0 °C, overnight d) 0.5 eq. TfOH, DCM, 0 °C
The synthesis of alcohol 225 followed a known literature procedure. 137 The cerium chloride- 
mediated Grignard reaction was successful, but problems were encountered with the 9-BBN 
hydroboration/oxidation reaction. Alcohol 225 proved difficult to isolate, which is not something 
observed by Pearson. The problem of isolating alcohol 225 was eventually overcome by omitting 
its purification and instead carrying it forward to the Mitsunobu reaction to give sulfonamide 226. 
Unfortunately, the cyclisation to the desired sp/Vo-pyrrolidine 221 could not be achieved.
An alternative synthetic approach from indanone 223 involved the formation of an ethyl ester
129through a Homer-Wadsworth-Emmons reaction was attempted, as outlined in Scheme 2.60.
13%
223 227 228 229
"N TsNHTs
230 231 221
Scheme 2.60. a) triethyl phosponoacetate, NaH, THF b) LiAlH4, THF, 0 °C c) TsCl, pyridine, 0 °C d) NaCN, DMSO
e) p-TsCl, NEt3, DMAP, DCM, -78 °C f) 0.5 eq. TfOH, DCM, 0 °C
Reduction to the alcohol 228 resulted in isolation of a residue that was deemed beyond 
purification.
An alternative Homer-Wadsworth-Emmons reaction, to give acid 232, which would negate the 
need for a cyanide reaction was attempted (Scheme 2.61).139’140
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.  0 0  V^COOH
223 225
NTs" ■ " *  CQ NTsBoc
226
Scheme 2.61. a) 2-carboxyethyltriphenylphosphonium bromide, NaH, THF:DMSO (1:1) 0 °C, overnight b) LiAlH4, 
THF, 0 °C c) PPh3, DIAD, TsNHBoc, THF, 0 °C, overnight d) 0.5 eq. TfOH, DCM, 0 °C
The Homer-Wadsworth-Emmons reaction was unsuccessful, with no discemable amount of 232 
visible in the proton spectra.
l-Chloro-3-iodopropane was reacted with indene 234.141 Chloride 235 was treated with potassium 
phthalimide through a Gabriel synthesis, 142 and converted to sulfonamide 237 (Scheme 2.62).
75%
233 234 235
c. d
44%
NHTs
237236
NTs
221
Scheme 2.62. a) «-BuLi, THF, 0 °C b) K+ phthalimide c) H2NNH2, EtOH, 60 °C d) /?-TsCl, NEt3, DMAP, DCM, -78 
°C e) 0.5 eq. TfOH, DCM, 0 °C
Sulfonamide 237 was not successfully cyclised to the desired sp/ro-pyrrolidine 221, as had been 
observed for sulfonamide 226 (Scheme 2.59). Why the cyclisation did not occur is still unknown. 
Possibly harsher conditions are needed for the reaction to occur. There is also the distinct 
possibility that the sulfonamide is unable to approach the reaction site due it being too hindered. If 
this is the case then the cyclisation should be attempted with a smaller 7V-protecting group, such as 
a mesylate or methoxycarbonyl.
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2.5.7. 0-N Compounds
2.3.7.1 Isoxazolid ine vs. M orpholine
Proctor investigated whether suitably protected hydroxylamines could be used to trap an acid- 
generated carbenium ion. The first substrates that Proctor synthesised were isoxazolidines, such as 
241 in Scheme 2.63.143
Scheme 2.63. a) PPh3, DIAD, jV-hydroxyphthalimide, THF, 0 °C b) MeNH2, Et20  c) p-TsCl, DMAP, pyridine, DCM, 
-78 °C, overnight d) 0.5 eq. TfOH, DCM, 0 °C, 10 min,
Complete conversion of the starting material was observed, though a minor product was also 
observed. The structure of the isoxazolidine 241 was confirmed by X-ray crystallography and the 
minor product was identified as a regioisomer of product 241, isoxazolidine 242.
The structure of this regioisomer was further confirmed by synthesis of 246; the actual regioisomer 
was not synthesised, due to the possibility of the same kind of rearrangement occurring, especially 
during [l,3]-dipolar addition. Instead a derivative was synthesised, the corresponding amino- 
alcohol 246 resulting from nitrogen-oxygen bond cleavage, as laid out in Scheme 2.64.
OH
96%
a b, c
O 89%
238 239
96% Ts
240 241 242
3.5
O 0
95%
243 244
O
NHTsNHTs
91%
245 246
Scheme 2.64. a) SOCl2, MeOH b) /?-TsCl, NEt3, DMAP, DCM c) MeMgCl, THF, 0 °C
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The cleavage of the nitrogen-oxygen bond was then attempted through hydrogenation; 144 this 
proved difficult, as after 7 days, proton spectrum of the crude product revealed only 40% 
conversion to the amino alcohol 246 (Scheme 2.65).
OH
'O' ' -^NHTs
242 246
Scheme 2.65. a) H2, Pd/C. MeOH, 48 hrs
Although a pure sample of the hydrogenolysed product was not isolated, the correlation of the new 
resonance in the proton NMR spectrum of this mixture of compound with the those found in the 
authentic sample of the amino alcohol 246, showed an exact match. This provided excellent 
support for the structural assignment of the minor product and the hypothesis that the products of 
the cyclisation reaction were the isoxazolidine 241 and regioisomer 242 (Scheme 2.63).
Previous observations suggested that the major cyclisation product resulted from trapping of a 
carbenium ion generated by the protonation of an alkene bond in the tertiary position 240a, under 
acidic conditions. 143 Protonation may also occur at the nitrogen nucleophile; however, although 
this would initially block its ability to act as a nucleophile, this may also assist in protonation of 
the alkene by allowing for intramolecular proton transfer. In the case of the O-allylic 
hydroxylamines, the hydroxylamine oxygen is a further potential site for protonation. Protonation 
at the oxygen 240b would result in the hydroxylamine becoming a considerably better leaving 
group, generating iV-tosyl hydroxylamine 248 and a relatively stabilised, allylic carbenium ion 247 
(Scheme 2.66).
©.NHTs NHTs NHTs
X >
249a 242
Scheme 2.66.
The loss of the hydroxylamine 248 was hypothesised to be a reversible process, with this portion 
of the molecule able to reattach through the nucleophilic oxygen and regenerate the starting
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material 240, which could then cyclise to give the expected product 241. The hydroxylamine could 
also reattach to the carbenium ion through the nitrogen instead, resulting in the rearranged starting 
material 249. This compound could then cyclise through generation of a tertiary carbenium ion 
249a followed by attack of the oxygen, yielding the minor product 242 (Scheme 2.66).
Studies into acid-catalysed cyclisations of sulphonamides, conducted by Haskins, showed a 
limitation in an apparent inability to synthesise piperidines via overall 6-endo-thg cyclisations. In 
one notable example, the sulfonamide 250, designed for the synthesis of piperidine 251, instead 
cyclised to yield pyrrolidine 252, an overall 5-exo-trig cyclisation, presumably occurring via 
rearrangement to a secondary carbenium ion intermediate and cyclisation through this species
(Scheme 2.67). 119
CCbMe
CO2M6
TsHN
C 0 2Me
Ts
252
Scheme 2.67. Cyclisation of sulfonamide 250 resulting in unexpected 5-exo-trig product 252
In order to test whether a similar phenomenon would be observed in the cyclisation of 
hydroxylamines, suitable tosyl-protected hydroxylamine 254 was synthesised from the homo­
prenyl alcohol 148, which is commercially available (Scheme 2.68) . 143
91%
148 253
- a
b, c
83%
'NHTs
254
93% N' Ts
255
Scheme 2.68. a) PPh3, DIAD, JV-hydroxyphthalimide, THF, 0 °C, overnight b)MeNH2, Et20, 40 °C, 2 hrs c) jo-TsCl, 
DMAP, pyridine, DCM, -78 °C, overnight d) 0.5 eq. TfOH, DCM, 0 °C, 10 min
Application of the standard cyclisation conditions returned not only the desired six-membered
cyclic product 255, but delivered it as a single product and with no need for farther purification.
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In the case of the homoprenyl analogue 254, loss of the hydroxylamine portion of the molecule 
would leave a primary carbenium ion, which is far less stable than the allylic carbenium ions 
shown in Scheme 2.67, thus resulting in none of the regioisomer being produced.
These findings suggested that if the hydroxylamine is not in an allylic (or perhaps similary 
stabilised) position, the rearrangement process does not occur and a single product is obtained. 
This effect was examined in the synthesis of isoxazolidine 241, where the alkene bond was 
repositioned so that the hydroxylamine oxygen was no longer in an allylic position, taking care 
that the same tertiary carbenium ion was generated.
From commercially available, zso-prenyl alcohol 256, the tosyl-protected hydroxylamine 258 was 
synthesised (Scheme 2.69). Exposure to triflic acid delivered the desired isoxazolidine 241, as a 
single product and with no further purification required.
Scheme 2.69. a) PPh3, DIAD, A-hydroxyphthalimide, THF, 0 °C, overnight b) NeNH2, Et20 , 2 hrs c) pyridine, 
DMAP9 jp-TsCl, DCM, -78 °C, overnight d) 0.5 eq. TfOH, DCM, 0 °C, 10 min
Proctor had attempted the synthesis of the isoxazolidine 262 with a phenyl substituent, from 
(is)-cinnamyl alcohol 259 (Scheme 2.70).
Scheme 2.70. a) PPh3, DIAD, N-hydroxyphthalimide, THF, 0 °C, overnight b) MeNH2, Et20, 2 hrs c) pyridine, 
DMAP,/>-TsCl, DCM, -78 °C, overnight d) 0.5 eq. TfOH, DCM, 0 °C
256 257
98% Ts
258 241
O
78%
261
NHTs
Ts
262
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Unfortunately treatment with triflic acid resulted in the decomposition of the substrate. The 
decomposition could be attributed to the sensitivity of either the starting material or the reaction 
products to the acidic conditions. It was possible that the same kind of regioisomerisation was 
occurring for 261 as had been observed previously with allylic hydroxylamine 240 (Scheme 2.66). 
In this case an unstable intermediate carbenium species may have been generated; unfortunately, 
the possibility of synthesising an alternative non-allylic isomer did not exist.
Thus, in order to complete these model studies, some additional experiments were carried out at 
the outset of the present project. Homoallylic analogue 264 was synthesised, as this was not 
expected to participate in the isomerisation and could potentially deliver a 6 -membered product by 
addition to a benzylic carbenium ion. This idea was vindicated by the isolation of the morpholine 
265 in a very successful yield (Scheme 2.71).
0
1/ ^ - Y oh Ph/ ^ v ^ ' ° HPh"
99% 20%
156 157
c, d e
62%
264
NHTs ^0™>/ Ph N 70% Ts
265
Scheme 2.71. a) LiAlH4, Et2 0, 20 °C, 1 hr b) PPh3, DIAD, iV-hydroxyphthalimide, THF, 0 °C, overnight c) H2NNH2, 
EtOH, 60 °C, 2 hrs d) p-TsCl, NEt3, DMAP, DCM, -78 °C, overnight e) 0.5 eq.TfOH, DCM, 20 °C, 24 hrs
The successful isolation of morpholine 265 prompted the investigation into whether its formation 
was due to the stability of the benzylic carbenium ion generated or if this outcome would be true 
for all possible morpholine syntheses involving a secondary carbenium ion. The analogue of 
sulfonamide 254 (Scheme 2.68) was therefore synthesised from commercially available trans- 
3-pentenitrile 151 as shown in Scheme 2.72.
43%
151
OH
152
78%
153
41%
266
d, e
51%
'NHTs
267
Scheme 2.72. a) 30% H20 2, 3 M NaOH, 80 °C, 2 hrs then 20 °C, 1 hr b) LiAlH4 Et20, 20 °C, 1 hr c) PPh3, DIAD, 
A-hydroxyphthalimide, THF, 0 °C, overnight d) H2NNH2, EtOH, 60 °C, 2 hrs e) /?-TsCl, DMAP, NEt3, DCM, -78 °C, 
overnight
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Unfortunately, the anticipated morpholine 268 was not isolated; instead isoxazolidine 269 was 
formed as a single product (Scheme 2.73).
f  NI Ts
269
Scheme 2.73. 0.5 eq. TfOH, 24 hrs, 0 °C
Both the morpholine and isoxazolidine would have been formed through a secondary carbenium 
ion. The formation of isoxazolidine 269 was due to the 5-exo-trig cyclisation being favoured over 
the 6-endo-trig formation of morpholine 268. Again, although not strictly a Baldwin-type 
cyclisation as it is cationic, when the formation of the two possible carbenium ions is equally 
likely, the reaction will follow the pattern set out by Baldwin. Presumably morpholine 268 would 
be made from the 4-hexenyl analogue. Hence, despite the sensitivity and weakness of an N-0 
bond, with the exception of the cinamyl (and possibly crotyl) examples, they all worked well with 
secondary carbenium cations.
This needs to be expanded further to see if other groups, such as electron donating and 
withdrawing, would favour the formation of a morpholines or isoxazolidines; as well as 
investigating the effect of substitution pattern.
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2.3.7.2 Transannular C yclisations
As transannular cyclisations were successful for sulfonamide 193 (Scheme 2.50), the possibility of 
this occurring with hydroxylamines derivatives was investigated (Scheme 2.74).
OH a
96%
270192
NHTs
64%
270
NTs
86%
272
Scheme 2.74. a) PPh3, DIAD, N-hydroxphthalimide, THF, 0 °C, overnight b) H2NNH2, EtOH, 60 °C 2 hrs c) p-TsCl, 
NEt3, DMAP, DCM, -78 °C, overnight d) 0.5 eq.TfOH, DCM, 0 °C, 2 hrs
The cyclisation to oxazepane 272 was successfully achieved in a good yield without further need 
for purification. No evidence of the alternative product, resulting from trapping of a secondary 
carbenium ion, was observed.
Examples of bridged-morpholines 276, through trans-annular cyclisation were achieved from 
3-methylcyclohex-2-enol 273a and 3,5,5-trimethylcyclohex-2-enol 273b, as shown in 
Scheme 2.75.
273 274
TsNR
NHTs
a R = H 8 6 % 
b R = Me 90%
275 276
Scheme 2.75. a) PPh3, DIAD, N-hydroxphthalimide, THF, 0 °C, overnight b) H2NNH2, EtOH, 60 °C, 2 hrs c) /?-TsCl, 
NEt3, DMAP, DCM, -78 °C, overnight d) 0.5 eq.TfOH, DCM, 0 °C, 24 hrs
Both cyclisations were successful and high yielding. This was unexpected for isoxazolidine 276b, 
as it was feared that the methyl groups may cause steric hindrance and therefore prevent the 
cyclisation from occurring. Both examples would be extremely difficult to synthesise in such a 
short sequence with excellent yields.
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2,3,7,3 Spiro-Isoxazolidines
Haskins demonstrated the stability of the sulfonamides to trap acid-generated carbenium ions 
could be extended to the synthesis of fused ring systems via acid catalysed poly-ene cascade 
reactions (Scheme 2.31), with sulfonamides acting as terminators. 3 0 ,1 1 9  Both Bronsted and Lewis 
acid-catalysed cascade reactions had recently received considerable interest and have found 
applications in numerous total syntheses. 145 Proctor investigated this further and achieved the 
synthesis of a suitable cascade precursor, starting from commercially available geraniol 277 
(Scheme 2.76).143
Y G
277 278
63% O
88%
.NHTs
279
Scheme 2.76. a) PPh3, DIAD, iV-hydroxyphthalimide, DCM, 0 °C, overnight b) H2NNH2, EtOH, 60 °C, 2 hrs 
c) /?-TsCl, NEt3, DMAP, DCM, -78 °C, overnight
Exposure to a catalytic amount of triflic acid leads to rapid consumption of the starting material 
279 and the formation of two products 280a and 280b, in the ratio ~ 4 : 1 (as judged by integration 
of resonance in the proton NMR of crude product), which were separated by silica gel 
chromatography (Scheme 2.77).
NHTs
279
NTs+
280b
4% isolated yields
Scheme 2.77. f) 0.5 eq. TfOH, DCM, 40 °C, 48 hrs
Working on the assessment that, in each of the cascade reactions described, the minor product 
resulted from isomerisation of the allylic TV-tosyl hydroxylamine subunit, it seemed a logical 
approach to attempt the same tactic for preventing this isomerisation (see Scheme 2.66 on p.46) as 
had proved successful previously, i.e. repositioning of the double bond so that the hydroxylamine 
was no longer in the allylic position. The geraniol isomer 283 was synthesised using the method of 
Chong and elaborated in the standard manner. 146 Application of triflic acid resulted in an initially
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surprising, yet in retrospect predictable result: synthesis of the spiro-cyclic isoxazolidine 286 
(Scheme 2.78).
Vp> 
-° 'NY56%
281 282 283
84%
284
c, d
30%
.NHTs
70%
285 286
Scheme 2.78. a) TMEDA, 2 eq. »-BuLi, Et20, 0 °C for 6  hrs, then -78 °C overnight b) PPh3, DIAD, N- 
hydroxphthalimide, THF, 0 °C, overnight c) H2NNH2, EtOH, 60 °C, 2 hrs d) /?-TsCl, NEt3, DMAP, DCM, -78 °C, 
overnight e) 0.5 eq. TfOH, DCM, 0 °C, 1 hr
For formation of the carbocyclic ring to occur, this must take place prior to the formation of the 
isoxazolidine ring. Protonation of the double bond furthest from the hydroxylamine moiety, 
followed by attack by the second double bond, leaves a tertiary carbenium species 285a that can be 
attacked by the hydroxylamine nucleophile to form the spirocyclic isoxazolidine 286 
(Scheme 2.79).
NHTs .NHTs
285 285a
L  ^NHTsn/  ''a'
285b 286
Scheme 2.79.
The protonation seems unlikely to be so regiospecific that a series of rapid equilibria may be 
present to give the presumably thermodynamic product 286.
Next the spiro-cyclic bridged isoxazolidine of homolimonenol was synthesised, through a cascade 
reaction to form both the bridge and the isoxazolidine. Homolimonenol 288 was first synthesised 
from (K)-limonene 287 utilising the method described by Blomquist, 147 using paraformaldehyde 
in an inefficient ene reaction. The original stereochemistry was destroyed in the cyclisation to 
bridge spiro-cycle 291 (Scheme 2.80).
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Scheme 2.80. a) paraformaldehyde, Sn(IV)Cl4 , DCM, 20 °C, 3 days b) PPh3, DIAD, TV-hydroxphthalimide, THF, 
0 °C, overnight c) H2NNH2, EtOH, 60 °C, 2 hrs d) /j-TsC1, NEt3, DMAP, DCM, -78 °C, overnight e) 0.5 eq. TfOH, 
DCM, 0 °C, 1 hr
The spirocyclic bridged isoxazolidine 291 was isolated as a single isomer. The cyclisation could 
have occurred in either an endo- or exo-manner to give either 291a or 291b, respectively 
(Figure 2.15).
TsN \ \  i
O
291a 291b
endo exo
Figure 2.15. Two possible isomers of xl30
According to NMR analysis it would appear that the single isomer is in fact the exo-product 291b, 
which is sensible considering the reaction mechanism as shown in Scheme 2.81.
H+
: NHTs
NTs
290 291a
Scheme 2.81.
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2.4. Conclusion and Future Work
From the eclectic mixture of reactions that have been performed in this chapter some conclusions 
can be drawn. First and foremost, it has been shown that an ester adjacent to the nitrogen involved 
in the cyclisation is not required. The acid-catalysed hydroamination cyclisations as a whole have 
been achieved in good yields without any need for purification. In those cases where the 
sulfonamide nitrogen is further protected with a Boc group; this can be removed in situ in the 
cyclisation step, thus negating a deprotection reaction.
The hydroamination hag also been shown to be applicable to the formation of bridged compounds 
through a trans-annular cyclisation, such as isoquinuclidine 194. Unfortunately, the designed 
synthetic approach to give a wider variety of isoquinuclidine derivatives was unsuccessful due to 
difficulties in forming sulfonamides 200 and 204. An alternative approach for these is needed to 
allow cyclisation to isoquinuclidines 201 (Scheme 2.52 and 2.53).
The cyclisation has also been used in the synthesis of isoxazolidines as well as morpholines, as a 
continuation of work started by Proctor. This also allowed the synthesis of 5/ 7/>o-isoxazolidines 
286 and 291, which were isolated cleanly and as single isomers.
Though as a whole, the syntheses of the targeted compounds in this chapter have been successful, 
more still needs to be accomplished with this acid-catalysed hydroamination method. The 
synthesis of 3,4-disubstituted 292 and 2,3,4,5-tetrasubstituted 293 pyrrolidines still needs to be 
investigated (Figure 2.16).
Ts Ts
292 293
Figure 2.16. 3,4-Disubstituted and 2,3,4,5-tetrasubstitued pyrrolidines
Difficulties with the use of triflic acid, in terms of its shelf-life and ease of use, resulted in the use 
of concentrated sulfuric acid in some syntheses, which have been successful. Further investigation 
into the use of sulfuric acid needs to be made, especially in terms of accuracy of measurement of 
the acid; and insolubility in dichloromethane. This will most likely evolve into testing of other 
acids, most likely chiral super-acids, which would hopefully allow control of stereochemistry in 
the synthesised pyrrolidines.
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Chapter 3
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Chapter 3
A Hydroamination Variant of the Pictet-Spengler 
Reaction
3.1. Introduction
3.1.1. Development o f the Pictet-Spengler Reaction
The condensation of /?-phenethylamine 300 with carbonyl compounds in the presence of an acid 
catalyst to give 1,2,3,4-tetrahydroisoquinolines 301 (Scheme 3.1) is known as the Pictet-Spengler 
reaction and is a special case of the Mannich reaction. 1 4 8 ,1 4 9 ,1 5 0 ,1 5 1 ,1 5 2
CH2(OCH3)2
NH2
HCI
300 301
Scheme 3.1. a) CH2 (OCH3)2, HCI
The reaction was extended by Decker and Becker to the condensation of substituted
1 SIphenethylamines 302 with various aliphatic and aromatic aldehydes 303.
MeOv ys.
T i  I V i  A  7 i  i  H  i i  ^ |  |XJ  H2  r A h    J U   ^ ~  O  hMeO R H MeO HC* MeO
302 303 304 305R
Scheme 3.2.
3.1.2. Tetrahydroisoquinolines
The Pictet-Spengler reaction has been used widely for the synthesis of a variety of 
1,2,3,4-tetrahydroisoquinolines 309 because of the generally mild reaction conditions. 1 5 1 ,1 5 4 ,1 5 5  
The proposed mechanism shown in Scheme 3.3, is believed to involve formation of a Schiff s base 
308. This intermediate Schiff s base 308 has in some cases been isolated and subsequently 
cyclised to the isoquinoline derivative 309 by exposure to acid. 155
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R20
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N+-H
NH
309
-H+
RnO
R20
Scheme 3.3.
The electrophilic ring closure is induced by electron-donating substituents; this is illustrated by the 
cyclisation of phenylalanine 310a and its meta hydroxyl derivative 310b to the corresponding 
tetrahydroisoquinoline 312a and 312b by treatment with formaldehyde 311 and hydrochloric acid 
(Scheme 3.4). The fact that even unactivated phenethylamines can be cyclised under these 
conditions suggests that only a low activation energy is required for this cyclisation to occur.
:Y = Y V c ° 2H 0
kJ N H 2 A
HCI
C 0 2H
NH
a R = H 37% 
b R = OH 70%
310 311 312
Scheme 3.4.
In general, alkoxyl groups direct the cyclisation to the para position. Thus the reaction of 
3-methoxyphenethylamine 313 with formaldehyde yields only 1,2,3,4-tetrahydroisoquinoline 314 
and none of the 8 -methoxy compound 315; the same observation is made in the related 
Bischler-Napieralski reaction. 1 5 2 ,1 5 6
MeO
-H-
MeO
NH2 NH
OMe
315 313 314
Scheme 3.5.
If the alkoxy groups are replaced by hydroxyl groups, the orientation rule becomes invalid and the 
ring closure proceeds to both ortho and para positions, such as for the treatment of phenolic 
compound 316 with acetaldehyde afforded a mixture of 317 and 318, which are derivatives of 
xylopinine, in equal amounts (Scheme 3.6). 1 5 7 ,1 5 8
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Scheme 3.6.
Hydrochloric acid has been the most commonly employed dehydrating agent, but sulfuric acid and 
acetic acid have found occasional use. 159 For preparation of isoquinolines sensitive to strong acid, 
a modification of the Pictet-Spengler reaction has been reported using formic acid and 
formaldehyde, conditions of the Eschweiler-Clarke reaction. 1 5 9 ,1 6 0 However, undesired N- 
methylisoquinolines are formed as minor products if primary amines are used. Preparation of acid- 
sensitive isoquinolines with a Pictet-Spengler reaction, employing a base (e.g. pyridine or 
triethylamine), have been reported. For example the condensation of TV-methyl-3’- 
hydroxyphenethylamine 319 with benzaldehyde 320 in the presence of pyridine or triethylamine 
gives tetrahydroisoquinoline 321 (Scheme 3.7). 1 6 1 ,1 6 2
HO
MeO
319
NHR Ph H
OX
320 321
Scheme 3.7.
Formaldehyde, most frequently employed as the carbonyl compound in the Pictet-Spengler
reaction, 155 generally gives the product in excellent yield and is used preferably to methylal or
sodium hydroxymethanesulfonate. 163 However, pyruvic acid 323 reacts much more easily than 
aldehydes (Scheme 3.8) . 164
Me°YV^i
n h 2
MeO
OX,c o 2h
OMe
322 323
Scheme 3.8.
Meom /Nh 
MeO y  Y
OMe ' C 0 2H 
324
A biogenetically patterned asymmetric synthesis of (+)-laudanosine 326 from (-)-dopa 325 has 
been reported by Yamada. 165 Similar results were reported by Brossi, 166 and a stereospecific 
isoquinoline synthesis has also been achieved from amino acids. 167
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HO.
NH
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Scheme 3.9.
Stereopecificity in the Pictet-Spengler reaction was achieved for the synthesis of 7,8-dioxygenated 
isoquinoline; one of the cyclisation position was blocked with bromine (see Scheme 3.6), and the 
methoxy group replaced by a hydroxyl group to offset the inactivation of the nucleus caused by the 
- I  effect of the bromine atom. These manipulations were anticipated to promote ring closure ortho 
to the hydroxyl group and the reaction of bromophenethylamine 327 with aldehyde 328 and 
hydrochloric acid gave the expected l,2,3,4-tetrahydro-8-hydroxy-7-methoxyisoquinoline 329
(Scheme 3.10) . 16 8 This tactic is now widely used for protoberberine alkaloid syntheses. 169
MeO
O
NH2 r h 2c ^ h
328
NH
MeO'
OH
329
Br OCH2Ph 
— ( /  y — OMe
OCH2Ph
OMe
Yield / % 25 49
Scheme 3.10.
Asymmetric syntheses, where the chirality transfer occurs from a chiral auxiliary introduced to 
either the P-arylethylamine or the aldehyde component were continued from earlier studies on the
1 70Pictet-Spengler asymmetric synthesis of isoquinoline alkaloids. Comins investigated the 
influence of a chiral auxiliary, e.g. (+)-toms-2 -(a-cumyl)cyclohexyl, appended to the amine 
nitrogen in 330 as well as in the aldehyde equivalent 331, which was substituted with a bromine at
171 179C-2, on the degree of stereoselectivity in the cyclisation step (Scheme 15). ’ The C-2 bromine
not only caused an increase in stereoselectivity during the cyclisation step (tetrahydroisoquinoline 
332 was formed as a mixture of diastereomers with 77% d.e.) but was helpful for separation of the 
diastereomeric products. The major (+)-332 was converted into aporphine alkaloid (+)-glaucine 
333.
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Scheme 3.11.
The diastereoselective Pictet-Spengler reaction has also been applied to the construction of various 
tetrahydroisoquinoline moieties of ecteinascidine and saframycine types of antitumor alkaloids. 173
, 174,175, 176,177,178,179,180
A number of asymmetric syntheses of isoquinoline alkaloids mediated by sulfur containing 
auxiliaries have been reported. The efficient synthesis of tetrahydroisoquinoline 337 carried out 
under very mild conditions has been developed from chiral A-p-tolylsulfmylphenylethylamine 335 
and aliphatic aldehydes with excellent selectivity (e.e. = 93% and e.e. = 92% for 336a and 336b,
respectively) (Scheme 3.12) 181
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Scheme 3.12.
The synthesis of 1-trifluoromethyl tetrahydroisoquinoline alkaloids 340 and 341, based on the
Pictet-Spengler cyclisation using a sulfinyl auxiliary to generate C-l quaternary stereogenic centre,
was reported by Bravo (Scheme 3.13).182 The stereoselectivity achieved during the cyclisation of
the sulfoxide 338 to give the tetrahydro derivative 339 was as a 6:1 mixture of (IS/R)/(\R/R)
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diastereomers which were postulated to result from a cis geometry of the C=N double bond in 338, 
with the two aromatic rings on the same side of this bond, thus minimising the dipole-dipole 
interactions between the S=0 and C=N bonds, and hindering the si face of the molecule.
H2  / Raney-Ni
MeO
c h 2o
NaBH3CN
1. Pumm erer
2. K2 C 0 3, HgCI
3. NaBH4
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MeO
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Scheme 3.13.
3.1.3. Pictet-Spengler Reaction of Indoles
The reaction was originally utilised exclusively to prepare tetrahydroisoquinolines and became the 
standard method for their formation. 154 The use of an indole base was first shown by Tatsui in 
1928 during the preparation of carboline 343 (Scheme 3.14).183,184,185
342
H Me 
343 
Scheme 3.14.
The development of the enantioselective Pictet-Spengler reaction in recent years has rendered this 
condensation an important synthetic method for formation of macroline/sarpagine/ajmaline indole
1 fiA 187alkaloids. ’ The interest in the total synthesis of indole alkaloid natural products stems from 
their complex structures and diverse medicinal properties. For example, vincristine and vinblastine 
from Catharanthus roseusm  have long been established as antitumor alkaloids189 of clinical 
significance, while reserpine190 as well as ajmaline191 exhibit very important cardiovascular effects 
(Figure 3.1) . 192
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Figure 3.1.
Research on the stereospecific Pictet-Spengler condensation has lead to enantioselective
1intermediates, such as Cook’s tetracyclic ketone 345 (Figure 3.2).
Me
345
Figure 3.2. Cook’s tetracyclic ketone intermediate
Work in this area was preceded by the discovery that the Pictet-Spengler reaction could be effected 
in non-acidic aprotic media as well as under the classical conditions of acid catalysis.
The synthesis of TV^-benzyltryptophan methyl ester 347 was achieved from tryptophan methyl ester 
345 and benzaldehyde at room temperature, followed by reduction of the imine 346.194 To improve 
conversion of ester 345 into imine 346, benzaldehyde and amine 345 were heated at reflux. 
Although the imine 346 was initially observed, after prolonged heating the products were the cis 
and trans diastereomers of 1 -phenyl-3-(methoxycarbonyl)-1,2,3,4-tetrahydro-/?-carboline 348 in 
95% yield (Scheme 3.15).
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Scheme 3.15.
This result was surprising, for generally the Pictet-Spengler reaction had been carried out in a
tryptophan methyl ester 345 had occurred without the aid of acid catalysts, and detailed studies 
were carried out.
Excellent yields of tetrahydro-/?-carbolines were obtained from tryptophan methyl ester 345 and a 
variety of aldehydes. It was apparent from examination of the data that yields of the Pictet- 
Spengler reaction could be improved in non-acidic aprotic media, which was even more apparent 
when acid-labile aldehydes were used as substrates, having substituents such as acetals, esters, 
amides and acetonides, heretofore too labile to be used in this condensation. 196 )197 The yields for 
cyclisations carried out under non-acidic aprotic conditions were generally two or three times 
better than in aqueous acidic conditions.
There are two pathways for the Pictet-Spengler reaction between tryptamine derivatives 349 and
1052carbonyl compounds (Scheme 3.16). The Pictet-Spengler reaction (see 349 - 354) has generally 
been thought to proceed via a spiroindolenine intermediate 352 as shown in Scheme 3.16 (path A), 
although Casnatiso has shown that cyclization can occur by direct attack at position 2 of the indole 
(path B) when very reactive electrophiles are employed. 19 9 No matter which path occurs, it is the 
electrophilic nature of the carbon double bond in 351 that is the driving force of the cyclisation. 2 0 0  
Performing the reaction in non-acidic, aprotic media permitted the study of the correlation between 
the electron density on the aliphatic nitrogen atom with the ease of cyclisation, since protonation 
of the nitrogen atom by solvent was no longer a complicating factor. 201
protic solvent with acid catalysts. 195 It was presumed that the Pictet-Spengler reaction with the
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Scheme 3.16.
Several groups had investigated the cis/trans isomer ratios in the Pictet-Spengler reaction, all of 
which showed mixtures of cis and toms-isomers. 2 0 2  Ungemach discovered that the reaction of 
A^-benzyltryptophan methyl ester 347 with salicylaldehyde 355 provided a single diastereomer 
356 in 97% yield (Scheme 3.17). Steric interactions in this 1,2,3-trisubstituted /?-carboline were 
too complex to permit an unequivocal assignment using C NMR spectroscopy. Removal of 
the A^-benzyl function of this indole permitted comparison of the properties with authentic 
cis- and trans-1,3,-disubstituted /?-carbolines prepared by an independent route. 2 0 0  In this case, the 
A^-benzyl group clearly directed this condensation in a trans stereospecific manner. 2 0 4  This 
represented the first completely stereoselective result in the A^-H tetrahydro- /?-carboline methyl 
ester series.
CO2M6
347 355
OH
356
Scheme 3.17.
The possibility that hydrogen bonding through the hydroxyl group of the salicylaldehyde 355 
could have played a role in the stereoselectivity of this reaction led to the use of aldehydes devoid 
of the hydroxyl group. Examination of the 13C NMR spectrum indicated the presence of only the 
trans-isomer in the reaction mixture, demonstrating that the hydroxyl group played no role in 
directing the stereochemical outcome of the condensation. In previous examples of this reaction
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when performed in the absence of the A^-benzyl function, formation of the cis and trans-isomer 
resulted. 2 0 0
Previous studies have shown that strain between position 1 of the tetrahydro-/?-carboline and the 
TVa-substituent could be the dominant factor in determining the cis/trans ratio in the Pictet- 
Spengler reaction in the A^-series. 2 0 5  Smaller aldehydes were condensed with amine 347 and the 
cis/trans ratio examined, but no evidence of the cis isomer was seen.
3.1.4. Conclusion
Tetrahydroquinoline alkaloids, due to their widespread occurrence in nature, diverse biological 
activity (including the unnatural congeneres) , 2 0 6  and useful chemical properties, have become 
attractive targets for organic synthesis. In the past decade, a wide range of synthetic methods have 
been reported for the synthesis of chiral non-racemic alkaloids.
Most of these methods have been based on diastereoselective syntheses using chiral auxiliaries, 
usually derived from natural products, appended either to or around the nitrogen of isoquinoline 
(or its precursor) or in the C-l substituent (or its equivalent). In this context, the traditional 
Bischler-Napieralski cyclisation/reduction and Pictet-Spengler syntheses, as well as the addition of 
carbon nucleophiles to the C=N double bond have been the most explored strategies. 2 0 7  
The major limitation of the classic Pictet-Spengler reaction towards tetrahydroisoquinolines is that 
only a small number of phenylamines can successfully be used in the reaction (Figure 3.3) . 15 1 ,2 0 8
357 358 359
Figure 3.3. Phenylamines used in the classic Pictet-Spengler reaction
The detailed study of the Pictet-Spengler reaction has progressed from the discovery of improved 
non-acidic aprotic reaction conditions to probing the mechanistic phenomena involved. It is clear 
that enantiomerically pure A^-benzyltryptophan alkyl esters can be condensed with aldehydes (acid 
labile or otherwise) to provide trans-1,3-disubstituted l,2,3,4-tetrahydro-/?-carbolines in 
stereospecific fashion. Pictet-Spengler reaction of these same aldehydes and esters under acidic 
conditions should also provide the trans isomer with 1 0 0 % diastereoselectivity, albeit with slightly 
lower yields. 154
Although the 1-substituted tetrahydroisoquinoline alkaloids are readily synthesised in an
asymmetric manner, there is no one general method that would secure preparation o f all types o f
isoquinoline alkaloids with high optical purity employing simple procedures. Usually the applied
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methodologies suffer from various limitations, such as, e.g. moderate to poor yields, unsatisfactory 
regio- and stereoselectivity, non-availability or cost o f starting materials or reagents, multistep
3.2. Hypothesis
Due to the limitations seen with the Pictet-Spengler reaction for the production of 
tetrahydroisoquinolines 361, a new synthetic approach was needed, preferably one that did not 
require the involvement of a directing group. It was hypothesised that if the appropriate precursors 
360 could be synthesised, then a hydroamination variant of the Pictet-Spengler reaction should be 
possible (Scheme 3.18).30
This method could potentially also be used to form dihydroisoindoles 363, through the same 
chemistry, with an appropriate precursor 362. This is especially interesting, since formation of 
dihydroisoindoles 363 utilising a Pictet-Spengler reaction are not noted in the literature 
(Scheme 3.19).
procedures, etc. Therefore, the question o f finding a more efficient and/or simpler synthetic
*)(Y1strategy that also has greater functional group compatibility is still open.
360 361
Scheme 3.18.
362 363
Scheme 3.19.
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3.3. Results and Discussion
3.3.1. Proposed Synthetic Route
To arrive at the desired precursors needed for the cyclisation to give dihydroisoindoles and 
tetrahydroisoquinolines, a synthetic route was proposed that started from 2 -bromobenzylamine 
364 and 2-bromophenethylamine 365, respectively (Figure 3.4).
nh 2
n h 2
365
Figure 3.4.
These amines would be TV-protected by tosyl groups to give sulfonamides 366 and 367, which 
would then be treated with vinylboronic acids 369 to give the desired precursors. These were then 
hopefully to be cyclised using the hydroamination method developed by the Knight group to give 
either the dihydroisoindoles 363 or the tetrahydroisoquinolines 361 (Scheme 3.20).
n NH2 Tosylation nNHTs Suzuki
n NHTs
Hydroamination
362 n a 1 363 n = 1
360 n = 2 361 n = 2
Scheme 3.20.
2-Bromobenzylamine 364 was readily available through commercial sources and converted into 
the corresponding sulfonamide 366 in excellent yield by reaction with p-toluenesulfonyl chloride. 
Commercial alcohol 368 was reacted under standard Mitsunobu conditions (see Chapter 1) to give 
the corresponding Boc-protected sulfonamide; the Boc group was removed to give sulfonamide 
367 in excellent yield (Scheme 3.21)
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Scheme 3.21. a) p-TsCl, DMAP, NEt3, DCM, 0 °C b) PPh3, DIAD, TsNHBoc, THF, -78 °C c) TFA, DCM
3.3.2. Suzuki Reaction
The sulfonamides were required to undergo Suzuki reactions with various vinylboronic acids to 
give the precursors needed for the cyclisations. The Suzuki reaction of sulfonamide 366 with 
/ra/w-2-phenylvinylboronic acid 369a was first tried with [PPh3]4Pd and NaHCC>3 in DMF 20 9  
however, this reaction yielded none of the desired product 362a even when heated at reflux for 72 
hours or when the reaction was performed in a microwave oven (Scheme 3.22).
reactions. These pre-mixes consist of different combinations of catalyst, ligand and base and are 
designed to aid in the weighing of the small quantities of catalyst and ligand actually used in each 
reaction, especially when performed on a small scale. A selection of “pre-mixes” were screened 
on the reaction between sulfonamide 366 and frvms-2 -phenylboronic acid 369a (Scheme 3.22) and 
the results are shown in Table 3.1. These reactions were all carried out in a microwave oven, as 
recent literature had showed this to be very successful for triggering Suzuki reactions. 2 4 6 *1’2 1 0
(HO)2B
NHTs NHTs
366 369a 362a
Scheme 3.22.
The failure of the Suzuki reaction may have been due to the electron rich nature of sulfonamide 
366 and possibly also due to the steric hindrance that would be present at the reaction site as it is 
ortho to the sulfonamide.
The Eli Lilly Catalyst Laboratory provided a range of “pre-mixes” to trial for these Suzuki
Table 3.1. Results for a variety of catalyst, ligand and base mixtures for the Suzuki reaction
Catalyst / ligand / base mixture3 Solvent Crude Yield of 362a /%
Pd(PPh3 ) 4  / NaHC03 2 1 1 DMF 0 b
Pd(OAc) 2 / PCy3 / K3PO4 DMF / H2 Od 61c
Pd(OAc) 2 / dtbpf*12 / K3P0 4 DMF / H2 Od 63°
Pd(dba) 2  / dtbpf / K3P0 4 DMF / H2Od 43a,b
Pd(Quinoline-8 -carboxylate) 2  / K2C0 3 2 1 3 DMF / H2Od 58b
Pd(PPh3 ) 4 / NaOH DMF / H2Od 47b
Pd(0Ac)2 /K 2C0 3 H20 37b
a 100 °C, 100W, 30 min;b starting material visible;c clean product isolated, no purification required,d 1 :1 mixture
Though all reactions apart from the one involving Pd(PPh3 ) 4  gave some moderate yields of the 
desired product, the best conditions for this transformation was the reaction using a combination 
ofPd(OAc)2, 1,1 ’-bis(di-tert-butylphosphine)-ferrocene (dtbpf) and K3PO4 , though the yield was 
far from ideal. It was reasoned that a change of solvent system could possibly improve this; 2 1 4  the 
results of this investigation are shown in Table 3.2.
Table 3.2. Effect of Solvent upon the Suzuki reaction
Catalyst / ligand / base mixture3 Solvent Crude Yield / %
Pd(OAc)2/ dtbpf/ K3P0 4 Dioxane / H20 92b
Pd(OAc)2 /d tbpf/K 3P0 4 Toluene /H 20 89b
Pd(OAc)2 /d tbpf/K 3P0 4 Ethanol / H20 90c
Pd(OAc)2 /d tbpf/K 3P0 4 H20 72b
a 100 °C, 100W, 30 min; starting material visible,c clean product isolated, no purification required
All of the new solvent combinations resulted in improved yields; however, all but one of these 
contained starting material. The reaction performed in ethanol and water gave an excellent yield, 
and most importantly none of the starting materials were visible by NMR.
This optimised Suzuki reaction was then applied to the synthesis of more dihydroisoindole and 
tetrahydroisoquinoline precursors 362 and 360 respectively (Scheme 3.23).
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Scheme 3.23. b) Pd(OAc)2, dtbpf, K3P 04, EtOH/Water, 100 W, 100 °C, 30 min
The boronic acids chosen for these reactions were a selection of styrylboronic acids with electron 
withdrawing and electron donating groups 369a - e (Figure 3.5).
(HO)2B (HO)2B (HO)2B (HO)2B /m ip
369a 369b 369c 369d 369e
Figure 3.5. Styrylboronic acids for the Suzuki reaction
This allowed the assessment as to whether the electron withdrawing or donating nature of the 
substituents would have an effect upon the rate of cyclisation.
Another set of boronic acids to be used in the Suzuki reaction were the alkylboronic acids 
369f - h, including a cyclohexenyl boronic acid 369g, which upon cyclisation, if successful, would 
result in formation of a spzro-compound (Figure 3.6).
(HO)2B (HO)2B
369f
Figure 3.6. Alkyboronic acids for the Suzuki reaction
369g 369h
The difference in the rates of cyclisation of the aryl and alkyl derivatives, if any, can be 
determined by comparing these two sets of compounds.
The boronic acids 369a - h were reacted with sulfonamides 366 and 367, to give the precursors 
362 and 360 for the cyclisation hopefully to give the various dihydroisoindoles 363 and 
tetrahydroisoquinolines 361. The yields for the Suzuki reactions are shown in Table 3.3.
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Table 3.3. Yields of the Suzuki reaction for dihydroisoindol and tetrahydroisoquinoline precursors
Boronic Acida Yield / % (n = 1) 362 Yield / % (n = 2) 360
369a 90 99
369b 81 85
369c 91 60
369d 99 99
369e 95 96
369f 83 69
369g 97 94
369h 95 8 6
a Pd(OAc)2, dtbpf, K3PO4 , EtOH/H2 0 , 1 0 0  °C, 100W, 30 min
The Suzuki couplings for both the dihydroisoindole 362 and tetrahydroisoquinoline 360 
precursors were all achieved in excellent yield. No purification was required and they were able to 
be taken directly onto the new cyclisation step. Not much difference was observed in the yields 
between the dihydroisoindole precursors 362 and the tetrahydroisoquinoline precursors 360; 
indeed, any difference observed may simply be due to experimental error.
3.3.3. Cyclisations
3.3.3.1. D ihydroisoindols
The successful synthesis of precursor 362a - h meant that cyclisation to the dihydroisoindols 363 
could be tested. This was expected to proceed through benzylic carbenium ions 370a, which are 
then attacked by the lone pair of the sulfonamide nitrogen to give the desired product 363 via an 
overall 5-exo-trig process (Scheme 3.24).
NHTs
362
NHTs
370a 363 
Scheme 3.24.
Of course, there is no guarantee that the carbenium ion formed is that depicted in Scheme 3.24: 
the protonation could occur at the other end of the double bond. In precursors 362a -  e this would 
also form a benzylic carbenium ion, 370b, which would result in the formation of a 
tetrahydroisoquinoline 371, through an overall 6-endo-trig process (Scheme 3.25).
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362a - e
NHTs
370b 371
Scheme 3.25.
There was also the distinct possibility that this cyclisation would not occur, due to iV-protonation 
to 372, followed by loss of tosylamine and cyclisation to indene 375 (Scheme 3.26).
372 R 373 374 375
Scheme 3.26.
Compounds 362f - h (Scheme 3.23) would most likely form carbenium ion 370a as this would be 
the more stable carbenium ion, as they do not include the benzyl functionality that 362a-e  
possess. It was believed that the overall 5-exo-trig cyclisation would be the favoured process, 
resulting in formation of the dihydroisoindols shown in Figure 3.7.
NTs NTs NTs NTs
363a 363b 363c 363d
NTs
363e
Figure 3.7.
NTs
363f
NTs
363g
NTs
363h
Compounds 363a - h  were cyclised with triflic acid, the standard method for cyclisations 
performed by the Knight group3 0  and the results are shown in Table 3.4.
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Table 3.4. Yields and conditions for cyclisation to afford dihydroisoindols with TfOH
Starting
Material
Product Acida Temperature / °C Time / hrs Yield / %
362a 363a TfOH 0 24 98
362b 363b TfOH 40 24 81
362c 363c TfOH 40 24 84
362d 363d TfOH 40 24 71
362e 363e TfOH 40 24 8 6
362f 363f TfOH 40 2 93
362g 363g TfOH 0 6 70
362h 363h TfOH 40 3 1 0 0
a 0.5 eq. TfOH, DCM
In general, the cyclisations occurred in excellent yields and no starting material was visible. Some 
of the lower yields may be due to loss in the work up of the reaction, a relatively standard hazard 
when working on a small scale. All but two of the reactions needed heating to reflux; these were 
the phenyl and pentenyl derivatives 363a and 363h. All of the aryl derivatives 363a -  e required 
reaction times of 24 hours, whereas the alkyl substituted precursors all required less time to react. 
From the reaction of aryl derivatives, it can be deduced that the electron donating and 
withdrawing nature of the substituents have little overall effect equally, as these all required 
heating in comparison to the “neutral” phenyl derivative 363a.
Some difficulties were encountered with the use of triflic acid as the catalyst for the 
hydroamination in these reactions. Triflic acid is very water sensitive, so the stock solution used 
would become less efficient over time as water contamination occurred. This was frustrating as it 
removed the certainty that what was being added to all the reactions over time was of the same 
concentration. It was observed in cyclisations in Chapter 1, in reactions that involved Boc removal 
as well as cyclisation in the same step, that “old” stock solutions would achieve the Boc removal 
but then stall at the cyclisation stage. The cyclisation could be achieved if more acid was added. If 
the reaction of the Boc compound was then carried out with a freshly made up stock solution of 
triflic acid, then the Boc deprotection and cyclisation would occur in one pot. One approach to 
solving this problem was to replace triflic acid with an acid that was not so water sensitive, such 
as sulfuric acid. Sulfuric acid is cheap and readily available in any organic laboratory, it is easier 
to handle that triflic acid and the reactions seemed less sensitive to the presence of water. To 
determine the effectiveness of sulfuric acid in comparison to triflic acid, the cyclisations were
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repeated using concentrated sulfuric acid as the catalyst for the hydroaminations to give the 
desired dihydroisoindols (Table 3.5).
Table 3.5. Yields and conditions for cyclisation to afford dihydroisoindols with concentrated H2 S04
Starting
Material
Product Acid3 Temperature / °C Time / hrs Yield / %
362a 363a h 2 s o 4 2 0 48 92
362b 363b h 2 s o 4 40 48 70
362c 363c h 2 s o 4 40 24 73
362d 363d h 2 s o 4 40 24 67
362e 363e h 2 s o 4 40 24 67
362f 363f h 2 s o 4 40 4 1 0 0
362g 363g h 2 s o 4 0 24 78
362h 363h h 2 s o 4 40 3 98
a 2 drops of sulfuric acid, DCM
When comparing the cyclisations using triflic acid and sulfuric acid, not much difference in the 
reaction conditions can be seen. Some of the reaction times have increased but the reactions still 
proceeded cleanly, without any by-product formation. This was very encouraging as this showed 
that sulfuric acid was just as potent for these cyclisations as triflic acid, despite its insolubility in 
dichloromethane.
Showing that the products isolated are in fact the dihydroisoindoles 363 as expected and not the 
tetrahydroisoquinolines 371 is difficult to do. The indene 375 alternatives (Scheme 3.26) were 
quick to eliminate as the spectra would lack the tosyl group attached to the nitrogen; these were 
clearly present in all of the isolated compounds. But how can the dihydroisoindoles 363 and their 
isomers tetrahydroisoquinoline 371 be distinguished? As they are isomers, they have the same 
mass, though there is the possibility of a difference in fragmentation between the two isomers, it 
could be difficult to empirically assign the two. Unfortunately, none of the compounds are solids 
so X-ray crystallography was ruled out. One crude method involves analysis of the NMR spectra, 
looking at the likely resonances and coupling patterns for the isomers.
The simplest isomers to distinguish are those of s/?/ro-dihydroisoindole 363g and fused bicyclic 
tetrahydroisoquinoline 371g (Figure 3.8). The most obvious distinction would be visible in the 13C 
spectrum; the dihydroisoindole 363g would have a quaternary for the spiro-center that would not 
be present in the fused compound 371g. This quaternary is very clearly present in the 13C 
spectrum at 74 ppm.
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363g 371g
Figure 3.8. Relevant resonances for s/uro-dihydroisoindole 363g and bicyclic tetrahydroisoquinoline 371g
From this structure we can also extrapolate the possible resonances for the CH2 adjacent to the 
nitrogen and benzene ring; which resonated as a singlet at 4.53 ppm for 363g.
The next compound that was examined was 363h. If the tetrahydroisoquinoline 371h had been 
isolated instead of the desired isoindole derivative 363h, then four benzylic protons would be 
visible, the four proton at positions 3 and 5 (Figure 3.9), rather than the three expected for 363h, 
potions at positions 1 and 2 (Figure 3.9). This is true for all the of the dihydroisoindole derivatives 
363, apart from s/?z>o-dihydroisoindole 363g. The proton spectrum showed that only three 
benzylic protons were present; the two protons at position 2 were observed at 4.58 and 4.51 ppm 
as doublets with a spliting of 14.8 Hz. The proton adjacent to the nitrogen resonated at 4.92 as an 
apparent singlet. The resonance for the CH alpha to the nitrogen would also shift significantly
upfield to around 3 ppm, if it were the tetrahydroisoquinoline 371.
5
363h 371h
Figure 3.9. Relevant 'H resonance for dihydroisoindole 363h and tetrahydroisoquinoline 371h
A more challenging structure to assign was that of phenyl derivative 363a (Figure 3.10). No 
significant difference in the resonances would be apparent between the two isomers. The 
assignment as to which isomer had been isolated was based purely on comparison to the 
resonances and splitting patterns observed for compounds that have been positively identified as 
dihydroisoindoles. The two protons at position 2, alpha to the nitrogen, resonated at 4.53 and 
4.12 ppm as doublets with a coupling constant of 15.9 Hz, which is consistent with the coupling 
constant measured for dihydroisoindole 363h and others.
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x61a x71a
Figure 3.10. Relevant resonaces for dihydroisoindole 363a and tetrahydroisoquinoline 371a
3.3.3.2. Tetrahydroisoquinolines
The success of the cyclisations towards the dihydroisoindole derivatives 363 gave hope that these 
cyclisations would also be successful for the tetrahydroisoquinoline derivatives 361 
(Scheme 3.18).
As for the dihydroisoindole precursors 362, two carbenium ions could be formed, after 
protonation of the double bond of 360 (Scheme 3.27). Carbenium ion 376a would give the desired 
tetrahydroisoquinoline product 361 through an overall 6 -exo-trig process, which is favoured 
according to Baldwin’s rules; whereas carbenium ion 376b would give the 7-membered ring 377, 
which would occur through an overall 1-endo-trig process, which is also favoured by Baldwin’s 
rules (Scheme 3.27).
NHTs NHTs NTs
360 376a 361
c o
R
376b 377
Scheme 3.27.
For precursors 360 there was little concern that A-protonation could lead to the loss of tosylamine 
and thus give rise to alternative cyclisation products 380a and/or 380b. The carbenium ion 379 
generated (Scheme 3.28) would not be stabilised as would have been the case for the 
dihydroisoindole precursors 362 as shown in Scheme 3.25.
NHTs
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Scheme 3.28.
Due to 6 -membered rings generally being formed preferentially over 7-membered rings, the 
synthesis of the tetrahydroisoquinolines 361 (Figure 3.11) was believed to possible.
NTs
361a
N T s
361b
NTs
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NTs
361 d
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N Ts
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361 h
Figure 3.11.
The results for the cyclisation of 360 with triflic acid to give tetrahydroisoquinolines 361 are 
shown in Table 3.6.
Table 3.6. Yields and conditions for cyclisation to afford tetrahydroisoquinolines with TfOH
Starting
Material
Product Acid8 Temperature / °C Time / hrs Yield / %
360a 361a TfOH 0 24 100
360b 361b TfOH 40 24 87
360c 361c TfOH 40 24 72
360d 361d TfOH 40 24 75
360e 361e TfOH 40 24 54
360f 361f TfOH 40 24 90
360g 361g TfOH 0 24 83
360h 361h TfOH 0 24 92
a 0.5 eq. TfOH, DCM
As with the dihydroisoindoles 363, the cyclisations were successful, high yielding and produced 
no discemable by-products. The reaction conditions, in terms of temperatures for the cyclisations 
to give both 363 and 361 were, overall, much the same, although the alkyl derivatives of the 
dihydroisoindoles 363f - g were formed considerably faster than those of the 
tetrahydroisoquinolines 361f - g. Again the aryl compounds showed no difference in reaction 
conditions when comparing the electron withdrawing and donating nature of the substituents. The 
alkyl derivatives 361f -  h reacted under milder conditions that the aryl derivatives 361a -  e, with 
the notable exception of 361f, which requires heating, unlike the equivalent dihydroisoindole 
363f.
Some of the cyclisations were repeated with concentrated sulfuric acid, as with the 
dihydroisoindole 363; the results are shown in Table 3.7.
Table 3.7. Yields and conditions for cyclisation to afford tetrahydroisoquinolines with concentrated H2S04
Starting
Material
Product Acida Temperature / °C Time / hrs Yield / %
360a 361a h 2so 4 20 48 99
360b 361b h 2so 4 - - -
360c 361c h 2so 4 - - -
360d 361d h 2so 4 40 48 56
360e 361e h 2so 4 40 48 80
360f 361f h 2so 4 - - -
360g 361g h 2so 4 20 24 81
360h 361h h 2so 4 40 4 89
a 2 drops of sulfuric acid, DCM
Again, when comparing the cyclisations with TfOH to those using concentrated sulfuric acid, the 
reactions are comparable except that the reaction times have again doubled in length, as was 
observed with the dihydroisoindols 363.
Evidence for the formation of the desired tetrahydroisoquinolines 361 over the 7-membered 
system 377 and the carbocycles 380, relied solely upon NMR data, as for the dihydroisoindoles 
363 (Scheme 3.7). The carbocycles 380 could be eliminated quickly as the tosyl groups were 
clearly visible in the spectra. This was not unsurprising as the formation of carbocycles 380 would 
be mechanistically unreasonable. Formation of the 7-membered systems 377 also seems 
unfeasible, as generally six-membered ring formation is favoured over 7-membered rings.
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For spiro-cyclic compound 361g, the obvious difference to that of the fused 7-ring system 377g 
would be the absence of the quaternary in the carbon spectra (Figure 3.12). The quaternary carbon 
is quite clearly present in the spectrum (50.0 ppm) and thus confirming the successful synthesis of 
361g. The splitting pattern for the two protons adjacent to the nitrogen was expected to show a 
double double doublet for each proton in this type of system. The protons would have excibited 
large axial-axial couplings (ca. 14 Hz), two axial-equatorial interactions {ca. 4-10 Hz) and two 
equatorial-equatorial interactions (1 -4  Hz). However, the two protons resonated at similar 
chemical shift to give the appearance of an apparent double double with / =  13.6 and 7.0 Hz.
NTsNTs CH
CH
361g 377g
Figure 3.12 Relevant resonance for tetrahydroisoquinoline 361g and the 7-membered derivative 377g
Analysis of the NMR data of the reaction to give tetrahydroisoquinoline 361 h showed that there 
were only three benzylic protons present, positions 1 and 3, rather than the four that would have 
been expected if the 7-membered ring 377h had been isolated, position 4 and 7. Another important 
piece of evidence is the splitting for the CH adjacent to the nitrogen; a triplet was observed at 
4.88 ppm with coupling constants of 6.5 Hz, which fits with the data that was expected for 
tetrahydroisoquinoline 361h. A more complicated splitting pattern would have been present if 
377h had been isolated for this proton, position 4, as it is adjacent to two CH2  groups. The two 
protons adjacent to the nitrogen, position 2, showed resonances between 3.81 and 3.35 ppm as 
multiplets.
NTs
361 h
Figure 3.13. Relevant resonance for tetrahydroisoquinoline 361h and the 7-membered derivative 377h
As for dihydroisoindoles 363, the phenyl derivative of the tetrahydroisoquinolines was the most
challenging to assign, due to the similarity in shifts between the two isomers 361a and 3 7 7 a
(Figure 3.14). The triplet at 5.12 ppm with a coupling constant of 6 . 6  Hz, was attributed to the
proton adjacent to the nitrogen of tetrahydroisoquinoline, position 1 as a more complicated
splitting pattern would have been observed if 377a had been isolated.
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Figure 3.14. Relevant resonance for tetrahydroisoquinoline 361a and the 7-membered derivative 377a
3.4. Remote Functional Groups
Though the derivatives of the dihydroisoindols 363 and tetrahydroisoquinolines 361 demonstrated 
the successful application of the acid-catalysed cyclisation from vinyl-precursors 362 and 360, the 
functional groups were not overly inspiring and the scope of the reaction needed to be investigated 
further. This was to be done by determining if remote functional groups would successfully 
survive the acidic reaction conditions and not interfere where possible. Commercially available 
boronic acids 369i- n (Figure 3.15) were reacted under the conditions used for the Suzuki 
reactions with boronic acids 369a - h with sulfonamides 366 and 367. Unfortunately the reactions 
were unsuccessful for boronic acids 369i -  m.
Figure 3.15. Boronic acids containg usefull remote functional groups
Some interest was seen in having a remote alcohol group present during the cyclisation to give the 
dihydroisoindols 363 and tetrahydroisoquinolines 361. The Knight group has not performed any
seemed an ideal candidate to test this out. First of all, a method for the introduction of this remote
allylboronates 382 using either a rhodium catalysed hydroboration2 1 5  or a zirconium- mediated
(HO)2B(HO)2B(HO)2B
(HO)2B(HO)2B (HO)2B
3691 369m 369n
model cyclisations with an alcohol group present in the molecule. The Pictet-Spengler reaction
alcohol group had to be devised. Recent literature discussed the conversion of alkynes 381 into
hydroboration; 2 1 6  both were tried and the rhodium-catalysed reaction was successful 
(Scheme 3.29).
-oh 7•o
381 382
Scheme 3.29. a) RhHCl(CO)(PPh3)3, pinacol borane, toluene, 20 °C, 4 hrs
Unfortunately, the reaction of boronic acid pinacol ester 382 with sulfonamide 366 was 
unsuccessful. This could possibly have been due to the alcohol group interfering with the reaction. 
To avoid this, the alcohol was protected with a silyl group and then transformed into the 
corresponding pinacol ester 382a (Scheme 3.30).216
H—= — v a B C k / ^ / - \ ^ O T B D M S
'— OTBDMS /
^ r °381a 7 382a
Scheme 3.30. a) carbonchlorohydridotris(triphenylph6spahen)Rh, pinacol borane
Unfortunately, the Suzuki reaction with the TBDMS protected alcohol 382a was again 
unsuccessful (Scheme 3.31).
NHTs _  ^  r>TDn»*e a . " "NHTs(TY"  o.r/*^ ^otbdms
366 382b 383
OTBDMS
Scheme 3.31. Pd(OAc)2, dtbpf, K3P04, EtOH/Water, 100 W, 100 °C, 30 min
An alternative method for the synthesis of 383 is through the utilisation of a Wittig reaction and 
will be discussed later.
3.4.1. Alternatives to Suzuki
The difficulties encountered with the Suzuki reaction and its subsequent optimisation highlights 
the need to look at alternate methods for the formation of these vinyl precursors. The most 
obvious alternatives are other palladium-catalysed cross-coupling reactions, such as the Hiyama, 
Kumada, Negishi, Sonogashira, Stille and Heck reactions, which all belong to the same category 
of Pd-catalysed cross-coupling reactions of organic halides, triflates or other electrophiles with 
organometallic reagents and follow a general mechanistic cycle. There are slight variations for the 
Hiyama and Suzuki reactions, for which an additional activation step is required for the 
transmetallation to occur. 2 1 7  The Kumada and Negishi reaction have shown some incompatibility
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with amines, therefore these reactions would require further protection of the amines 364 and 365. 
Another viable reaction is the Wittig reaction
Kumada
The Kumada coupling was developed in 1972 and was the first Pd or Ni-catalyzed cross coupling 
reaction. It involves the coupling of Grignard reagents 385 with alkyl, vinyl or aryl halides (or 
triflates) 384 under Ni-catalysis provides an economic transformation, but the reaction was limited 
to halide partners that do not react with organomagnesium compounds. The advantage of this 
reaction is the direct coupling of Grignard reagents, which avoids additional reaction steps such as 
the conversion of Grignard reagents into zinc compounds, as for the starting materials in the 
Negishi coupling. 2 1 8 ,2 1 9
n 1  . .  .  PM nV  Ni(dppb)CI2  or R = Aryl, Vinyl, Alkyl
R X + RM gX -------------------- ► R R R1 = Aryl, Vinyl
384 385 pd<pph3>« 386 X = CI>Br>l
Scheme 3.33.
The ready availability and low cost of Grignard reagents make the Kumada coupling a valuable 
reaction for the formation of carbon-carbon bonds. Iron-catalysed Kumada coupling reactions of 
secondary alkyl halides encompass nearly entire reaction spectrum through bond formation with 
aryl, alkenyl, and alkyl Grignard reagents. The successful coupling of secondary alkyl halides 
with aryl Grignard reagents under iron catalysis were demonstrated by Nakamura, to produce 
excellent yields. 2 2 0  The iron-catalysed activation of the alkyl bromide out competes the 
nucleophilic attack of the Grignard reagent on functional groups such as keto, ester, chloride, and 
nitrile groups, which makes this method extremely powerful. 221
Cobalt-catalysis has a great deal of potential with regard to the cross-coupling of alkyl halides. 
The coupling of primary, secondary and even tertiary alkyl electrophiles with Grignard reagents 
was developed, 2 2 2  though functional groups, such as amides, esters, and carbamates did not 
survive the reaction conditions. The scope of the cobalt-catalysed coupling of secondary alkyl 
halides and aryl Grignard reagents is limited when a phosphine ligand is used, 2 2 3 but with a 
diamine ligand2 2 4  the reaction is quite efficient. 221
Negishi
The Negishi coupling, published in 1977, was the first reaction that allowed the preparation of 
unsymmetrical biaryls in good yields. The versatile nickel- or palladium-catalyzed coupling of 
organozinc compounds with various halides (aryl, vinyl, benzyl, or allyl) has broad scope. 2 1 8 ,2 2 5  It 
is compatible with many functional groups including ketones, ester, amides, and nitriles. 2 2 6
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Scheme 3.34.
RZnX
Ni(PPh3 ) 4  or
CI2 Pd(PPh3 ) 2  + 2 ('Bu)2AIH
R 1- R  R = Alkenyl, Aryl, Allyl, Benzyl, Propargyl
R1 = Alkenyl, Aryl, Alkynyl, Alkyl, Benzyl, Allyl
The reaction of a variety of secondary alkyl electrophiles with organozinc reagents at room 
temperature using [Ni(cod)2]/sBu-pybox, 2 2 7  proceeds in the presence of various functional groups, 
such as sulfonamides, ethers, acetals, esters, and amides. Alkyl chlorides, alkyl tosylates, and 
tertiary alkyl bromides do not react under these conditions. 2 2 8
Hiyama
The Hiyama coupling is a palladium-catalyzed C-C bond formation between aryl, alkenyl, or alkyl 
halides or pseudohalides (e.g. triflates) 390 and organosilanes 391; an activating agent such as 
fluoride ion or a base is required. The transmetallation step is reluctant to occur without the effect 
of an activating agent and lead to a pentavalent silicon compound 394 (Scheme 3.33). For the 
transmetallation to occur in the Hiyama coupling, fluoride activation and the formation of
018 OOQpentavalent silicon is essential. ’
Me0 2 C
390
Pd(PPh3)4 
oxidative addition
F3Si 
Bu4N+ F:
r r X
391
jnMe0 2C ^ \0- 
392
O-
- Pd(PPh3 ) 4  
reductive elimination
Pd-B rM e02C -q  
393
F4Si
transmetallation
, - 0 ~
,C 0 2Me
394
M e02 C ' 'q '  
395
Pd
Scheme 3.35.
Organosilane reagents have many of the attractions of organoborane reagents, including 
availability, low toxicity, and high functional group compatibility. To further increase the scope of 
the reaction with secondary alkyl electrophiles, a nickel(II)-catalsyed coupling of aryl 
trifluorsilanes was developed. 2 3 0  A variety of cyclic and acyclic secondary bromides and cyclic
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iodides can be used, and the substrates can contain ether, imide, ketone, and carbamate functional
221groups.
The Hiyama-Denmark coupling is a modification of the Hiyama Coupling, in which the
cross-coupled products 400. Fluoride is not needed as activator, so the reaction is compatible with 
substrates bearing silyl-protecting groups and can be performed in large-scale reactors. The
and electronic properties of the silicon centre. It was proposed that the mechanism for the 
transmetallation involves the formation of a pentavalent silicon species, suggesting that the in situ- 
generated silanolate forms an organopalladium complex, which is activated by a second
O  1 O O 'J  1
equivalent of the silanolate prior to transmetallation.
Scheme 3.36.
Sonogashira
The Sonogashira reaction is a Pd/Cu-catalysed cross-coupling reaction of organohalides with
reaction; In contrast to the Castro-Stephens coupling, which uses stoichiometric copper, the 
Sonogashira variant uses catalytic palladium and copper. 2 2 5 ,2 3 2 ,2 3 3 ,2 3 4
In 2006, the first Sonogashira coupling of unactivated secondary alkyl bromides was reported. 2 3 5  
The reaction proceeded well in the presence of a palladium complex with a iV-heterocyclic carbene 
(NHC) ligand at elevated temperatures in polar solvents. 221
The Sonogashira reaction could be a possibility for the synthesis of the /nms-2-(4-methoxy)- 
phenyl derivative 362n. 2 3 6 ,2 3 7 ,2 3 8  fra«s-2-(4-Methoxy)phenylboronic acid 369n is expensive to, 
whereas the corresponding alkyne is relatively inexpensive. The produces alkyne could then be 
selectively reduced to the trans-alkene (Scheme 3.31).
palladium-catalyzed coupling of deprotonated silanols 397 with vinyl and aryl halides leads to
Hiyama-Denmark Coupling occurs in the presence of a base and strongly depends on the steric
Me\ ,Me MH 
nC5 H11x ' ^ Sl "OH
Mex ,Me 
n C s H n ^ ^ ^ 'O -  M+
ArylPdL2X
O -P d -A ry l
396 397 MX 398
transmetallation LI
Me Me
C7Hi3Me2Siv.^Si
0  OK
399 400
terminal alkynes. This is closely related to the Cadiot-Chodkiewicz coupling and Castro-Stephens
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NHTsNHTsa
OMe401 362n OMe
C C " *
364
Scheme 3.37. a) (Ph3P)2PdCl2 , Cul, Et3N b) Lindlar catalyst, H2 
Stille
The Stille coupling was first reported in the 1970s and is a versatile C-C bond forming reaction
between stannanes 403 and halides or pseudohalides (e.g. triflates) 402, with very few limitations
on the R-groups (Scheme 3.38). 2 3 9  Well-elaborated methods allow the preparation of different
products from all of the combinations of halides and stannanes depicted below (Scheme 3.38).
The main drawback is the toxicity of the tin compounds used, and their low polarity, which makes
them poorly soluble in water. Stannanes are stable, but boronic acids and their derivatives undergo
018much the same chemistry in what is known as the Suzuki coupling. The triflates are more 
widely used, as they are readily prepared from phenols or enolisable aldehydes or ketones. In 
these reactions, the presence of a source of halide is needed, such as LiCl. 2 4 0 ’241
R -X  + R1—Sn(R 2 ) 3   ► R -R 1  + X—Sn(R 2 ) 3
402 403 405 405
Scheme 3.38.
Nickel-catalysed processes with secondary electrophiles were also extended to the Still reaction by 
using monoorganotin reagents. 2 4 2  Monoorganotin reagents are especially useful, as they are not as 
toxic as triorganotin reagents and do not make product purification as difficult. 221 
There are many known side-reactions for the Stille reaction, which include homocoupling, 
transfer of “non-transferable” ligands, destannylation, cine substitution and aryl migration. The 
most common side-products are those involving a homocoupling event. 2 4 3 *2 4 4 >2 4 5 >2 4 6 >2 4 7 >2 4 8 >2 4 9 when 
electron-rich aryl- or heteroarylstannanes are used, destannylation can be a problem; 2 5 0 ,2 5 1  
however, usually the volatile side-products can be removed during work-up. Some scattered 
examples of cine substitution have been reported in the case of 1 -substituted 1 -stannylethylenes.
’ ’ A proposed mechanism involves insertion of the Pd -aryl species across the double bond 
of the alkene followed by P-elimination and protodestannylation. 225
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Heck
The palladium-catalyzed C-C coupling between aryl or vinyl halides and activated alkenes in the 
presence of a base is referred to as the Heck Reaction. The Heck reaction involves the reaction of 
an aryl or alkenyl halide or triflate with an alkene, resulting in an alkene product, whereby one of 
the C-H bonds has been substituted; 2 5 5 ,2 5 6  formally, this represents a direct functionalisation 
reaction 2 2 5  Recent developments in the catalysts and reaction conditions have resulted in a much 
broader range of donors and acceptors being amenable to the Heck Reaction. One of the benefits 
of the Heck Reaction is its outstanding trans selectivity. 2 4 1 ,2 5 7
R-X Pd(°> .  R ^ z 
406 407
Scheme 3.39.
Oshima et al developed a cobalt-catalysed version for the coupling of secondary alkyl bromides 
with styrene derivatives. 2 5 8  Secondary alkyl chlorides also participated in the coupling reaction, as 
well as a variety of styrene derivatives. A tert-butoxybarbonyl group and a carbamate group were 
tolerated. 221
Wittig
The Wittig Reaction allows a completely different disconnection approach compared to that used 
in the cross-coupling reactions (Figure 3.16).
cross-coupling NHTs
NHTs
366
*362 NHTs
Wittig
408
Figure 3.16. Disconnection for both the cross-coupling approach and the Wittig reaction
Alkenes are prepared by the reaction of an aldehyde or ketone with the ylide generated from a 
phosphonium salt. For the synthesis towards the cyclisation precursors 362 and 360 this means 
that the Wittig reaction could be performed with either the aldehyde (R = H) or the ketone 
(R = Me), thus allowing the inclusion of greater steric hindrance (Scheme 3.40).259
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NHTs ______ ^  f| NHTs
R1 R1 = H, Me
|| n = 1 or 2O ^  ,
4 0 9  4 1 0  R2
Scheme 3.40.
The geometry of the resulting alkene depends on the reactivity of the ylide. Stabilized ylides give 
(£)-alkenes whereas non-stabilized ylides lead to (Z)-alkenes, but it seems unlikely that this 
feature affects the outcome of the present acid-catalysed conditions. 2 1 7 ,2 4 1
Any potential difficulties that could be encountered are most likely to be possible to overcome by 
using the Wittig modifications, such as the Julia and Peterson Olefinations.
3.5. Conclusion and Future Work
The hydroamination variant of the Pictet-Spengler reaction has been successful for the synthesis of 
both the dihydroisoindoles 363 and tetrahydroisoquinolines 361. Some problems were encountered 
with the Suzuki reaction but overcome by the use of a ferrocene bi-phosphine ligand (dtbpf) and 
heating in a microwave in an equal measure of ethanol and water. The inclusion of remote 
functional groups through a Suzuki cross-coupling failed (369i -  m) and needs to be addressed. 
Further investigations into determining whether remote functional groups can survive the 
cyclisation reaction conditions will need to be performed.
A viable synthetic route towards precursors 362i -  m and 360i - m needs to be developed allowing 
an assessment of which groups will be able to withstand the cyclisation conditions. This will most 
likely involve the use of one of the alternatives to the Suzuki reaction, discussed above. Ideally, a 
reaction starting from sulfonamides 366 and 367, such as other cross-coupling reactions, would be 
preferred. The chances are that more than one of these cross-coupling will need to be used to 
arrive at the various remote functional groups, due to commercial availability and synthetic ease. 
Most likely, any reaction chosen will involve more steps towards 362 and 360, in comparison to 
the Suzuki.
Functional groups that are known to survive the cyclisations include esters, sulfones not connected 
to the reaction site, and remote allyl groups (see Chapter 2). One particular remote functional 
group of interest is the hydroxyl group. Can this survive the acidic cyclisation conditions? It is also 
of interest to see which alcohol protecting groups would be able to survive (Scheme 3.41).
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NHTs
NTs n = 1 or 2
4 1 2
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Scheme 3.41.
As discussed in the introduction to this chapter, Pictet-Spengler reactions towards 
tetrahydroisoquinolines contain a directing methoxy group. This is not necessary for the 
hydroamination variant of the Pictet-Spengler reaction to occur, as the reaction proceeds through a 
carbenium ion, which dictates the reaction site. The plan is to include this methoxy group, not as a 
directing group, but instead to possibly allow further substitution after the cyclisation has been 
achieved (Scheme 3-42).
MeO. MeO.
NHTs
NTs
MeO' MeO'
4 1 3 4 1 4
Scheme 3.42.
This could then also be expanded to the inclusion of other functionalities, which are incompatible 
with the classic Pictet-Spengler reaction, such as a nitro group 415a or a methyl ester 415b 
(Scheme 3.43).
a r 1 = n o 2
b R1 = C 0 2MeNTsNHTs
4 1 64 1 5
Scheme 3.43.
Another area to investigate is the possibility of performing these reactions with nitrogen protecting 
groups that are easier to remove than the tosyl group that has been used for both the 
dihydroisoindols 363 and tetrahydroisoquinolines 361. The tosyl group could easily be substituted 
with a nosyl group or a carbamate, both of which are fairly simple to remove (Scheme 3.44).
91
MeO. MeO.
NHPG
NPG n = 1 or 2
MeO' MeO'
417 418
PG = Ns or C02Me
Scheme 3.44.
If the hydroamination variant of the Pictet-Spengler reaction can be shown to not only be 
successful in the classic Pictet-Spengler constraints but to also be able to overcome these 
limitations, then this could be a real alternative of the Pictet-Spengler reaction.
In the future, natural product synthesis may also be on the cards using the hydroamination variant 
of the Pictet-Spengler reaction.
The stereochemical implications of the acid-catalysed hydroamination variant of the Pictet- 
Spengler reaction need to be investigate (Figure 3.17). Would the inclusion of a substituent 
adjacent to the sulfonamide affect the cyclisation? Would the predominant isomer have the 
substituents either side of the nitrogen be syn to one another as has, on the most part, been 
observed for the pyrrolidines (see Chapter 2)?
NHTs
419
NHTs
420
Figure 3.17. Inclusion of substituents adjacent to the nitrogen
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Chapter 4
Ring-Contraction of Piperidines
4.1. Introduction
The synthesis of piperidines was deemed an important addition to the acid-catalysed 
hydroamination method, due to the synthetic importance of such compounds. Functionalised 
piperidines are among the most common building blocks in natural products, and, more 
interestingly, in many biologically active compounds such as pergoline, scopolamine and 
morphine (Figure 4.1) . 2 6 0
SMe
HN
Ph
O.,
r N H
'o hHO
pergoline scopolamine
Figure 4.1. Natural products containing a piperidine moitey
morphine
In Chapters 2 and 3, the acid-catalysed hydroamination had successfully been used in the 
formation of pyrrolidines and morpholines, as well as in the synthesis of dihydroisoindoles and 
tetrahydroisoquinolines. Surely this synthetic method should also be applicable to the synthesis of 
piperidines, especially if the distal terminus of the alkenes were fully substituted (Scheme 4.1).
: g r >>1 uw/  'd5
R
R2.
R1 HN'I
Ts
440
N
Ts
441
Scheme 4.1.
The anticipated synthesis of 2,2,6-trimethylpiperidine 447 from 6-methylhept-5-en-2-one 442, via 
the oxime 4432 61 and amine 4442 6 2  to sulphonamide 445 was used to test this (Scheme 4.2).
NHTs
100% 50%
442 443 444 445
Scheme 4.2. a) Hydroxylamine.HCl, NaOAc, EtOH, 60 °C, 2 hrs b) LiAlH4, THF, 70 °C, 3 hrs c) p-TsCl, NEt3, 
DMAP, DCM, -78 °C, overnight
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This particular example was chosen due to the tertiary carbenium ion 446 expected to form, which 
would facilitate an overall 6-endo-Xng cyclisation, to hopefully give piperidine 447 (Scheme 4.3).
NHTs NHTs
Scheme 4.3.
Most surprisingly, little of the desired 447 was isolated; instead the corresponding isopropyl 
pyrrolidine 449 was formed, which would have involved formation of a secondary carbenium ion 
448 and an overall 5-exo-trig cyclisation (Scheme 4.4)
NHTs NHTs
H+ 445 448 449
Scheme 4.4.
Though both cyclisations are favoured by Baldwin’s rules, it was thought that formation of tertiary 
carbenium ion 446 would be favoured over secondary carbenium ion 448. However, it would 
appear that this is not the case.
This was unexpected as this very principle had in fact been used by Hartwig to produce 
piperidines, as well as pyrrolidines. Due to the small quantity of 447 formed in the reaction 
further investigations were needed. Was piperidine 447 formed initially and then converted to 449 
during the course of the cyclisation reaction? The small quantity of 447 produced during the 
reaction was separated from pyrrolidine 449 and was exposed to the cyclisation conditions again 
(Scheme 4.5).
447 449
Scheme 4.5. a) 0.5 eq. TfOH, DCM, 20 °C
If pyrrolidine 449 was isolated, then this would suggest that piperidine 447 must ring open and 
re-close to give pyrrolidine 449. The reaction was sampled at regular intervals (Table 4.1) and 
analysed by proton NMR. 2 6 3
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Table 4.1. Exposure of 2-methylpiperidine 447 to acidic conditions8
Time / mins Major product 445 : 447 : 449 ratio / % b
5 Piperidine 447 ~ 10 : 85 : 5
15 Pyrrolidine 449 ~ 0 : 25 : 75
45 Pyrrolidine 449 0: 7: >93
75 Pyrrolidine 449 0 :0 :  100
a 0.5 eq. TfOH, dichloromethane, 20 °C as approximated from H NMR spectra
As can be seen in Table 4.1, piperidine 447 was still present after 5 minutes at 20 °C but after just 
15 minutes pyrrolidine 449 was the major product present in the reaction mixture. During the 
subsequent hour, piperidine 447 was fully converted into the pyrrolidine 449. This conversion 
could possibly occur though a series of equilibria, where piperidine 447 is the kinetic product and 
pyrrolidine 449 the thermodynamic product (Scheme 4.6).
447 449
kinetic therm odynam ic
Scheme 4.6.
This is very similar to the ring opening and re-closure mechanism proposed for the pyrrolidine 
formation from amino acids discussed in Chapter 2.
In hindsight, this had already been seen in work produced by the Knight group. Haskins had 
attempted the synthesis of piperidine 450 and sp/ro-piperidine 451 (Figure 4.2); in both cases the 
corresponding pyrrolidines were isolated cleanly. This was surprising as both pyrrolidines were 
again formed via a less stable secondary carbenium ion intermediate.
451450
Figure 4.2. Piperidines 450 and 451
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The pyrrolidine 453 was isolated instead of 450, with a cis : trans ratio of ca. 3 :2  (from !H NMR) 
(Scheme 4.7) . 119
~ ba-H-
N C 0 2Me 
Ts
450
TsHN C 0 2Me 
452
N^ C 0 2Me
Ts
453
Scheme 4.7. (a) 0.4 eq. TfOH at 0 °C no cyclisation (b) 0.6 eq. TfOH, 20 °C 1 hr
Due to this unexpected result, confirmation of the pyrrolidine structure 453 was sought; the 
compound 453 was synthesised through an alternative method featuring an iodocyclisation 
(Scheme 4.8).
C 0 2Me 
NHTs
w <
C 0 2Me
454
Ts
455
N^ ^C 0 2Me
Ts
453
Scheme 4.8. a) I2, K2C03, MeCN b) H2j Pd/C, MeOH, Et3N
Iodopyrrolidine 455 was isolated (cis : trans ratio of ca. 1 : 4) and was deiodinated to give 
pyrrolidine 453 and showed the same spectroscopic data as that generated by the acid-catalysed 
cyclisation, although the diastereomeric isomer ratios differed.
The cyclohexenyl derivative 456 also failed to give the desired sp/ro-piperidine 451 when treated 
with triflic acid; instead pyrrolidine 457 was formed essentially as a single isomer (Scheme 4.9).
>r C 0 2Me
451
-H-
HNI
Ts
C 0 2Me
^ \ ^ \ N/ ' C 0 2Me
U  Ts
456 457
Scheme 4.9.
11The lack of piperidine formation was evident from the C data, as the quaternary carbon expected 
for the spiro-CQntrQ was not discemable. In addition two CH signals were present at 64.8 and 
40.5 ppm. Originally, the possibility of a 6/7 fused system 459 was considered which would have 
formed via secondary carbocation 458 (Scheme 4.10).
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Scheme 4.10.
The pyrrolidine structure was, however, confirmed by X-ray crystallography. Pyrrolidine 457 was 
isolated as a single isomer, where the cyclohexyl and methyl ester substituents were cis to one 
another, as would be expected from this type of reaction and a result that was observed in the 
cinnamyl and crotyl derivatives 177 and 178 described in Chapter 2 (p. 35 and 37).
e t aC2
0 1
[Cl
c?
ca
ClQCll
119Figure 4.3. X-ray structure of 457
Haskin’s observations, as well as the failure to cleanly synthesise trimethylpiperidine 447 from 
sulfonamide 445, prompted further inspections of Hartwig’s results. These showed a successful, 
high yielding synthesis of 2-phenylpiperidine 460; however, for the synthesis of 
2-benzylpiperidine 461, a very low yield was noted (Table 4.2).
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Table 4.2. Hartwig’s yields for the synthesis of piperidines;2
Starting Material Product Acid Time Yieldc
TfOH8 2 83
NHtW ^ i Ts J^ 4 6 0
H2S04b 24 80
QU51 CuO
ts 461
TfOH8
H2S04b
2
24
51
0
a 20 mol% TfOH, 100 °C 20 mol% H2S04, 100 °C c Isolated yield after column chromatography
The yields for the production of 2-phenylpiperidine 460 were high for the reactions with both 
acids, however, the 2-benzylpiperidine 461 yield was relatively low for the cyclisation with triflic 
acid and none of this product 461 was isolated when using sulfuric acid. No mention was made as 
to what was isolated for the sulfuric acid-catalysed reaction, or the nature of other product, which 
was formed during the reaction with triflic acid. All that was noted was that neither any starting 
material nor the alternate 7-membered product related to piperidine 461, was recovered.
4.2. Results and Discussion
4.2.1. Ring Contraction o f Piperidines
Since it has been observed that 2,2,6-trimethylpiperidine 447 was rapidly converted into the 
corresponding isopropyl pyrrolidine 449 under hydroamination conditions, it was felt that it would 
be worthwhile investigating if other piperidines would undergo the same transformation 
(Scheme 4.11).
441 462 463
Scheme 4.11.
A variety of piperidines were chosen to see what effect substitution type and pattern would have 
on the putative ring contraction under acidic conditions (Figure 4.4).
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Figure 4.4. Piperidines proposed for rearrangement to pyrrolidines
Most of these piperidines 472 are commercially available and were treated with p-toluenesulfonyl 
chloride to give the corresponding tosylpiperidines 441 (Scheme 4.12).
Scheme 4.12. a) p-TsCl, NEt3, DMAP, DCM
Tetramethylpiperidine 468 was unfortunately not successfully tosylated. Even a strong base, such 
as H-BuLi (pKa 51), was not able to successfully affect tosylation (Scheme 4.12). This was most 
likely due to the steric hindrance presented by the four methyl groups surounding the nitrogen. 
This is consistent with the literature. 2 6 4
Scheme 4.12. a) w-BuLi, p-TsCl, THF, 65 °C, 72 hrs
The failure in the tosylation of piperidine 468 gave the indication that crowding due to 
a-substituents may have played a role in the ring-contraction of piperidine 447 to pyrrolidine 449 
(Scheme 4.5).
2-Methyl-1-tosylpiperidine 474 was believed to be the very unlikely to rearrange to the related 
pyrrolidine 475. 2-Methylpiperidine 465 is commercially available and was tosylated and then 
exposed to acid at a variety of temperatures (Scheme 4.13).
H
472
Ts
441
H
468
Ts
473
100
N
H
465
90% NTs
474
N
Ts
475
Scheme 4.13. a) p-TsCl, DMAP, NEt3, DCM, -78 °C b) TfOH, DCM 0 - 40 °C or conc. H2S04, toluene, 20 -110 °C
As Hartwig had synthesised piperidines with both triflic acid and sulfuric acid, both of these were 
used for the attempted rearrangement of piperidines to pyrrolidines. The results for
2-methylpiperidine 474 at a variety of temperatures and times, are shown in Table 4.3.
Table 4.3. Exposure of 2-methylpiperidine to acid at different temperatures
Acid8 Solvent Temperature / °C Time / hrs Conversion / % c
TfOH DCM 20 3 0
h 2so4 DCM 20 3 0
TfOH DCM 40 3 0
h 2so4 DCM 40 3 0
TfOH Toluene 110 24 0
H2S04 Toluene 110 72 9
TfOH Toluene 110 72 5
H2S04b Toluene 110 24 21
H2S04b Toluene 110 72 6
- Toluene 110 24 0
formed from piperidine
At relatively low temperatures, none of piperidine 474 was ring contracted to the corresponding 
pyrrolidine 475. However with increasing temperatures and the length of reaction time, then some 
conversion into pyrrolidine 475 was observed, the most pronounced example of which was a 21% 
conversion 475 with sulfuric acid when heated to 110 °C for 24 hours. Oddly, when the reaction 
was left for 72 hours the amount of pyrrolidine 475 seen was lower, almost a quarter less. What is 
important to note is the fact that this piperidine 474 was not expected to ring contract at all; 
nevertheless it had, and under fairly standard acidic conditions to which piperidines are often 
exposed. A control reaction was performed which omitted both acids to show that the contraction 
was not thermally induced.
The appearance of the pyrrolidine 475 peaks can clearly be seen between 3.0 and 3.5 ppm in the 
proton NMR spectra shown below (Figure 4.5). There is also clear evidence of doubling of the 
tosyl peaks both in the aromatic region as well as of the tosyl methyl, which appears at 2.33 ppm 
for the pyrrolidine 475 and 2.32 ppm for piperidine 474.
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Figure 4.5. Appearance of pyrrolidine 475 peaks
Since 2-methylpiperidne 474 was partly converted into pyrrolidine 475, would moving the methyl 
group to the 3-position improve or hinder this conversion (Scheme 4.14)?
T ) 84% ■ T )N'
Ts
X 3N
Ts
466 476 477
Scheme 4.14. a) p-TsCl, DMAP, NEt3, DCM, -78 °C b) TfOH, DCM 0 -  40 °C or conc. H2S04, toluene, 20 -110 °C 
Table 4.4. Exposure of 3-methylpiperidine to acid at different temperatures
Acida Solvent Temperature / °C Time / h Conversion / % b
TfOH DCM 20 3 0
h 2so4 DCM 20 3 0
TfOH Toluene 110 24 0
h 2so4 Toluene 110 24 0
TfOH Toluene 110 72 0
a 0.5 eq. Of TfOH or 2 drops of conc. H2S04; b amount of pyrrolidine formed from piperidine
As can be seen in Table 4.4, none of piperidine 476 was ring contracted to pyrrolidine 477. This 
was surprising, as it had been surmised that as a tertiary carbenium ion 479 could be formed in the
3-position of the piperidine at the methyl substitution this would then favour the formation of the 
pyrrolidine 477 (Scheme 4.15).
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476 478 479 477
Scheme 4.15.
The ring contraction could not even be persuaded to occur when heating the reaction mixture at 
110 °C for 72 hours. As this was felt to be the most extreme conditions that a piperidine is likely to 
be exposed to under acidic conditions, it was conceded that the rearrangement was unlikely to 
occur when a piperidine is substituted in the 3-position, rather than at its 2-position. Inital and 
presumably necessary carbon-nitrogen rupture by A-protonation to give secondary carbenium ion 
478 would not be particularly favourable as there was no special steric inducement. From this it 
was concluded that it may not be possible to ring contract piperidines substituted at the 3-position. 
This is something that needs to be investigated further; unfortunately for this study no other 
piperidines substituted in the 3-position were available.
Returning to piperidines substituted at the 2-position, the ring contraction was then attempted on 
2-phenylpiperidine 460. This was synthesised by the reduction of 2-phenylpyrridine 480 with the 
aid of Adam’s catalyst, 2 6 5  followed by conversion into the sulfonamide 460 (Scheme 4.16).2
H Ts
480 469 460
Scheme 4.16. a) Pt02, H2, EtOH, latm b) /?-TsCl, DMAP, NEt3, DCM, -78 °C
Compound 460 was of particular interest, as it had been synthesised by Hartwig using 
hydroamination with an 83% yield using TfOH and 80% using sulfuric acid, meaning that in 
theory, the piperidine 460 should not rearrange to pyrrolidine 481, or if it does, then only to a very 
small extent (Scheme 4.17).
460 480
Scheme 4.17. c) TfOH, DCM 0 - 40 °C or conc. H2S04, to luene  20 -110 °C
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Table 4.5. Exposure of 2-phenylpiperidine to acids at a variety of temperatures
Acid8 Solvent Temperature / °C Time / h Conversion / % b
TfOH DCM 20 3 0
h 2so4 DCM 20 3 0
TfOH DCM 20 24 0
TfOH DCM 40 24 0
TfOH Toluene 110 72 decomposed
H2S04 Toluene 110 72 decomposed
piperidine detected
Exposure of piperidine 460 at low temperatures resulted in no conversion into pyrrolidine 481, as 
was also observed when heating to 100 °C for 24 hours. An unexpected result occurred when 
piperidine 460 was heated at 100 °C for 72 hours with either acid: all of piperidine 460 had 
disappeared according to *H NMR analysis. At first it was though that pyrrolidine 481 had been 
formed, however upon closer inspection of the NMR data, it became apparent that this was not the 
case. 2-Benzylpyrrolidine 481 had recently been synthesised by Zhang and co workers2 6 6  and 
comparing their spectroscopic data to that observed for the products obtained after 72 hours 
confirmed that the pyrrolidine 481 had definitely not been formed. This now left the issue of trying 
to determine what had been produced in the reaction. None of the starting piperidine 460 was
ofnevident in the spectra nor was any of the TV-protected piperidine present. In fact tosyl groups 
were clearly visible in the spectra, which could not be the tosylate salts due to the basic work up 
used. The piperidine had clearly changed and the only hypothesis that seemed reasonable was that 
the piperidine either ring opened in some fashion, or that the tosyl group may have come off the 
nitrogen and then added to the phenyl. This latter theory would fit best with the observations made 
in the NMR spectra, as there was clearly more than one tosyl group present; which could be 
explained by the phenyl have ortho- and para-tosyl substitution, and possible some meta-tosyl 
substitution, 482a-c (Scheme 4.18).
460
Ts
482a 482b 482c
Scheme 4.18.
The failure in the ring contraction of 460 was most curious, considering that 2-methylpiperidine 
474 had rearranged and led to a further investigation of its structure to find an explanation of this. 
When searching the literature a NMR study on the conformational aspects of the acyl derivatives
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of c*s-2,6-dimethylpiperidines by Chow came to light. They found that the interaction between the 
oxygen of the acyl group and the a-equatorial methyl in 483a was severe and thus the favoured 
structure was 483b, where the acyl and a-methyl groups were in an axial orientation to one another 
(Figure 4.6) . 2 6 8
483a 483b
Figure 4.6. Structures of axial and equatorial a-methyl of cis-2,6-dimethylpiperidine 483
Comparison of the chemical shifts of the a-protons for acylpiperidine 483 with the corresponding 
data of 7V-benzoyl-4-/-butylpiperidine left no doubt that the a-protons were equatorially orientated 
in the former compound. The coupling patterns of the a-protons also agreed fully with this, 
showing coupling constants of ca. 8 . 8  Hz.
Examination of the proton NMR data for 460 showed that the phenyl group had not adopted an 
axial orientation towards the 7V-tosyl group 460b but rather an equatorial orientation 460a. This 
was confirmed by the coupling patterns, which showed that the a-proton at 3.84 ppm had a 
coupling constant of 15.4 Hz, very characteristic of an axial interaction (Figure 4.7).
Ph
460a 460b
Figure 4.7. Structures showing axial and equatorial a-phenyl of 2-phenyl piperdine 460
This equatorial orientation of the phenyl group was a little surprising due to the steric crowding 
that must be present. When considered this further, however, it seemed logical to presume that this 
structure may be favoured due to the possible 7c-stacking of the phenyl and tosyl groups 
(Figure 4.8).
460a
Figure 4.8. Possible 7t-stacking between the phneyl and tosyl group
During the synthesis of 2 -phenylpiperidine 469, using the conditions described by Overberger and 
Herin, 2 6 5  2-phenylpyridine 480 over reduced to give 2-cyclohexylpiperidine 470. Though not a
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compound that it had originally been planned to use in the testing of the ring contraction theory, 
484 was also an appropriate compound to use and would be analogous to using an /so-propyl 
substituted piperidine.
480 470 484
Scheme 4.19. a) Pt02, H2, Etanol, 2 -  3 atm. b) p-TsCl, DMAP, NEt3, DCM, -78 °C
After piperidine 470 was tosylated, it was exposed to both triflic and sulfuric acid (Scheme 4.20), 
the results of which are shown in Table 4.6.
484 485
Scheme 4.20. c) TfOH, DCM 0 - 40 °C or conc. H2S04 in toluene 20 -110 °C 
Table 4.6. 2-cyclohexylpiperidine exposed to acid at different temperatures
Acid8 Solvent Temperature / °C Time / h Conversion / % b
TfOH DCM 20 3 0
TfOH Toluene 110 24 32%
TfOH Toluene 110 72 48%
h 2so4 Toluene 110 72 23%
a 0.5 eq. Of TfOH or 2 drops of conc. H2S04; b amount of pyrrolidine formed from piperidine
When the cyclohexyl piperidine 484 was heated to 110 °C with both triflic and sulfuric acid, 
conversion into the pyrrolidine 485 was observed. In the case of triflic acid, longer exposure 
resulted in more pyrrolidine 485 being formed, 48% after 72 hours, however, when the compound 
484 was refluxed with sulfuric acid for 72 hours only half that amount of pyrrolidine 484 was 
observed. From this it can be concluded that for this type of system, triflic acid appears to be more 
effective at inducing ring contraction, perhaps due to it being much more soluble in toluene.
Hartwig had also synthesised the 2-benzylpiperidine 461 using a hydroamination, although only in 
disappointing yields (see Table 4.2). He was unable to account for alternative products other than 
the lack of starting material present, so compound 461 was also exposed to the acids at different 
temperatures (Scheme 4.21) and the results are shown in Table 4.7.
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471 461 486
Scheme 4.21. a) p-TsCl, DMAP, NEt3, DCM, -78 °C b) TfDH, DCM 0 - 40 °C or conc. H2S04, toluene, 20 -110 °C
Table 4.7. Exposure of 2-benzylpiperidine to acid at different temperatures
Acid8 Solvent Temperature / °C Time / h Conversion / %
TfDH DCM 20 24 0
h 2so4 DCM 20 24 0
TfOH DCM 40 24 0
h 2so4 DCM 40 24 0
h 2so4 Toluene 110 3 0
h 2so4 Toluene 110 24 27
TfDH Toluene 110 72 44
TfOHb Toluene 110 24 30
TfDHc Toluene 110 24 57
a 0.5 eq. Of TfOH or 2 drops of conc. H2S04 unless otherwise stated; 1.0 eq. Of TfOH;c 2.0 eq. Of TfOH; amount 
of pyrrolidine formed from piperidine
As expected, ring contraction occurred when the reaction was heated to 110 °C for 24 hours with 
sulfuric acid, giving a 27% conversion to pyrrolidine 486. Triflic acid gave a 44% conversion 
when heated for 72 hours in toluene; increasing the amount of triflic acid but with shortened 
reaction time also resulted in conversion, the largest overall yield of 57% being seen for 2 
equivalents of triflic acid for 24 hours at 110 °C
Piperidine 487 was exposed to the acidic hydroamination conditions in order to investigate the 
stereochemical aspects of the contraction. The pure czs-piperidine 467 was purchased and 
converted into the tosylated piperidine 487. Would the stereochemistry be retained when the ring 
contraction occurred or would a mixture of products be seen? From previous experience with 
pyrrolidine ring formation (Chapter 2), it is known that the ds-pyrrolidine is usually favoured, 
though both the cis- and /raws-diastereomers can easily be formed. The ratio of these 
diastereomers can also be affected by length of reaction time and the amount of acid used in the 
reaction. This same phenomenon was expected for ds-2,6 -dimethyl-1 -tosylpiperidine 487 
(Scheme 4.22); the results shown in Table 4.8.
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467 487 488a 488b
Scheme 4.22. a) p-TsCl, DMAP, NEt3, DCM, -78 °C b) TfDH, DCM 0 - 40 °C or conc. H2S04, Toluene, 20 -110 ° C
Table 4.8. Exposure of 2,6-dimethylpiperine to acid at different temperatures
Acid8 Solvent Temperature / °C Time / h Conversion / % b 487 : 488a : 488b
TfOH DCM 20 3 0
h 2so4 DCM 20 3 0
h 2so4 DCM 40 3 0
TfOH DCM 20 24 0
h 2so4 DCM 20 24 0
TfOH DCM 40 24 0
h 2so4 Toluene 110 3 46 : 28 : 26
h 2so4 Toluene 110 24 28 : 50 : 22
h2so4 Toluene 110 72 43 : 43 : 14
TfOH Toluene 110 72 62 : 15 : 23
- Toluene 110 24 0
1 1 ■ I i ii . i—iii i » in 1 i
a 0.5 eq. Of TfOH or 2 drops of conc. H2S04; amount of pyrrolidine formed from piperidine
As expected, 487 ring contracted to give two pyrrolidines, which were diastereomers of one 
another. From observations made by Haskins and those discussed in Chapter 2, the major 
pyrrolidine diastereomer was expected to be the c/s-isomer 488a. The major pyrrolidine isomer 
when the piperidine was reacted with concentrated sulfuric acid was pyrrolidine 488a, however 
when using trifilic acid and refluxing in toluene for 72 hours this ratio was inverted. A control 
reaction was performed which omitted both acids to show that the contraction was not thermally 
induced.
The full assignment of these pyrrolidines cannot be made due to the difficulty in separating them 
from the remaining piperidine, however, from work carried out by Jones (Figure 4.9) 2 6 9 and 
comparison with pyrrolidine 174a and 174b synthesised in Chapter 2 (Figure 4.10), a provisional 
assignment was made. Jones had been able to separate the two diastereomers (Figure 4.9) and
OAQ • • • •assign relevant NMR resonances, which assisted in the assignment of diastereomer peaks for 
174 (p. 31).
175 176
Figure 4.9. Structure of diastereomers synthesised by Jones269
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The two methine groups alpha to the nitrogen in the pyrrolidine ring, were determined through 
careful integration. For the czs-isomer these appeared at 3.55 -  3.45 ppm, whereas in the 
trans-isomer, the corresponding values were 3.84 -  3.70 ppm. There was also a minor difference 
in the shift of tosyl methyl peaks for the two diastereomers. The cis isomer methyl resonates at 
2.42 ppm whereas the fnms-isomer methyl appeared at 2.40 ppm. This concurred with trend in 
data exhibited by pyrrolidines 174a and 174b in Chapter 2 (Figure 4.10).
....
Ts Ts
174a 174b
Figure 4.10. Diastereomers 174a and 174b
From this it was concluded that major diastereomer is c/s-pyrrolidine 488a and the minor 
diastereomer is /raws-pyrrolidine 488b.
Was substitution even necessary for this type of ring contraction to occur? Evidence that changing 
the substitution pattern had an effect upon the ring contraction was seen, but did that really mean 
that it was necessary? Therefore, the ring contraction on the parent piperidine 489 with both acids 
at varying temperatures was examined (Scheme 4.23). The resulting pyrrolidine 155 (p. 26) was 
synthesised in Chapter 2, and therefore its characteristic NMR spectroscopic data were known.
O  —  QN N NTsH Ts
464 489 155
Scheme 4.23. a) p-TsCl, DIAD, NEt3, DCM, -78 °C b) TfDH, DCM 0 - 4 0  °C or conc. H2S04, toluene 110 °C
Table 4.9. Exposure of piperidine to acid at different temperatures
Acid8 Solvent Temperature / °C Time / h Conversion / % b
TfOH DCM 20 3 0
h2so4 DCM 20 3 0
TfOH DCM 20 24 0
h 2so4 DCM 20 24 0
TfOH DCM 40 24 0
h2so4 DCM 40 24 0
TfOH Toluene 110 24 0
h 2so4 Toluene 110 24 0
TfOH Toluene 110 72 0
- Toluene 110 24 0
a 0.5 eq. Of TfDH or 2 drops of conc. H2S04; b amount of pyrrolidine formed from piperidine
A pattern appeared to be emerging: as substitution a to the tosyl protected nitrogen increased and 
as the substitution increased in size, the contraction to the corresponding pyrrolidines appears to 
occur more readily. Thus the failure to contract the parent piperidine 489 to the corresponding 
pyrrolidine 155 was perhaps unsurprising. Could the ring-contraction of piperidines be mostly due 
to steric crowding a to the bulky tosyl group?
4.2.2. Synthesis towards Piperidines
As discussed in Schemes 4.3 and 4.4, the synthesis of piperidines 447 from fo's-homoallylic 
sulfonamides 445 was unsuccessful, as the piperidine 447 ring contracted to give the 
corresponding pyrrolidine 449 (Scheme 4.24).
NHTs
442 445 449
Scheme 4.24. a) Hydroxylamine, NaOAc, EtOH b) LiAlH4, THF c) /?-TsCl, DMAP, NEt3, DCM, -78 °C d) TfOH, 
DCM, 0 °C, 1 hr
We have shown that this ring contraction can occur for other piperidines as well. The original 
purpose of the work described in this Chapter, however, was the synthesis of piperidines from 
&/s-homoallylic sulfonamides. Steric factors seem key as the tosyl group is a fairly large group. It 
seemed reasonable that if the steric bulk of the tosyl group was playing a role in the favoured 
synthesis of pyrrolidines over the piperidines then surely changing the nitrogen protecting group 
could improve the chances of synthesising a piperidine. Returning to the proposed synthesis of 
2,2,6-trimethylpiperidine (Scheme 4.3), two alternate protecting groups were tried. The first, a 
mesylate, was chosen due to its similarity to the tosyl protecting group. The mesylate belongs to 
the sulfonamide family of protecting groups but has less steric bulk and is less electron 
withdrawing than the tosyl. The mesyl sulfonamide 490 was to be prepared in the same manner as 
the tosyl sulfonamide 445 (Scheme 4.25).
NHMs
60% 49%
442 444 490
Scheme 4.25. a) Hydroxylamine, NaOAc, EtOH, 60° C, 2 hrs b) LiAlH4, THF, 70° C, 3 hrs c) MsCl, DMAP, NEt3, 
DCM, -78 °C
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As the tosylpiperidine 447 had been isolated after 5 minutes under the acidic cyclisation conditions 
but had then fully converted to the corresponding pyrrolidine 449 after 1 hour (Scheme 4.26), 
these two times were chosen to test the performance of the mesylate as a protecting/activating 
group.
d i r s - v
  *   V V ^
a ; "  1 ms
491 490 492
Scheme 4.26. d) H2S04, DCM, 0 °C, 5 m in  &  1 h r
Unfortunately, mesylate 490 gave neither clean piperidine 491 nor pyrrolidine 492. In fact all that 
was observed was starting sulfonamide 490 and some of amine 444, where the mesyl group had 
been removed, thus making it a totally inappropriate protecting/activating group for this type of 
reaction.
The second protecting group, a carbamate group (Moc group), was then tried, as this is a very 
versatile protecting group. Haskins had investigated the possibility of using the Moc group for the 
acid-catalysed hydroamination of homoallylic amides to give pyrrolidines, with disappointing 
results. When the cyclisation involved the formation of a tertiary carbenium ion, such as that 
generated from the prenyl derivative 493, the cyclisation to pyrrolidine 494 occurred with a 
moderate yield of 69%. However, when the crotyl and cinammyl derivatives 495 were subjected to 
the acidic-conditions, no cyclisation occurred (Scheme 4.27).119
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C 0 2Me C 0 2Me
493 494
R—f  y^-C02Me --------$/— C 0 2Me
C 0 2Me a R = Me C° 2Me
495 b R = Ph 496
Scheme 4.27. a) 2 eq. TfOH, CHC13, 25 °C, 2 hrs b) 5 eq. TfOH, CHC13, 62 °C, 48 hrs
In the enantioselective cyclisation towards 5,5-dimethylproline 499 from TV-protected 
prenylglycines 497, Jackson encountered a similar protecting group issue. 2 7 0  Only the cyclisation 
of TV-acetyl protected prenylglycine 497a give 5,5-dimethyproline methy ester 498a, which was 
successful deprotected to give enantiomerically pure proline analogue 499 (Scheme 4.28).
I l l
OH
497
O ^ R
5 90% M o
e.e. = 98%
498 499
a  R = Me R 1 = Me Yield = 96% 
b R = Me R 1 = H Yield = 0% 
c R = (Me)3CO R 1 = Me Yield = 0% 
d R = (Me)3CO R 1 = H Yield = 0%
Scheme 4.28. a) 20% TfDH, Toluene, 110 °C, 4 hrs b) 1 M HC1, reflux, 90 min
Since cyclisations of TV-carbamate protected, highly substituted homoallylic amines had been
11 0 970successful for both Haskins and Jackson, piperidine 501 was believed to be accessible with 
this type of protecting group. Carbamate 500 was synthesised in a similar manner to 445 and 490 
(Scheme 4.29).
NHC02Me
a, b 1 1 1 1
60% 29%
442 444 500
Scheme 4.29. a) Hydroxylamine, NaOAc, EtOH, 60° C, 2 hrs b) LiAlH4, THF, 65° C c) Methyl chloroformate, 
NaHC03, 1:1 THF/H20, 20 °C, 24 hrs
The carbamate 500 was exposed to sulfuric acid for 5 minutes and 1 hour at 0 °C. The reaction 
after 5 minutes showed the appearance of piperidine 501 and starting carbamate 500 
(Scheme 4.30).
NHC02Me d
 H------►
72% I C02Me
C02Me 2
501 500 502
Scheme 4.30. d) H2S04, DCM, 0° C, 1 hr
Piperidine 501 was successfully isolated after 1 hour and no rearrangement to pyrrolidine 502 nor 
the starting sulfonamide 500 were observed. The reactions did not require any chromatography as 
the reaction proceeded cleanly without any by-products visible in the NMR spectra (see Figures 
4.11 to 4.13). Both and 13C NMR spectra support the successful synthesis of piperidine 501; as 
can be seen from Figures 4.11 through to 4.13, carbamate 500 is clearly disappearing and 
piperdine 501 peaks are appearing. Most obvious is the disappearance of the allylic CH of 500 at
4.41 ppm and the appearance of the CHN of piperidine 501 at 4.14 ppm. Tantalisingly, Figure 4.12 
shows the possible transient intermediate.
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Figure 4.11. !NMR spectrum of carbamate 500
3.5 3.0 2.5 2.05.0 4.5 4.0 1.5 1.0
w
Figure 4.12. Reaction of carbamate 500 in acid after 5 minutes
3.5 3.0 2.55.0 2.04.5 1.5 1.0
W
Figure 4.13. Reaction of carbamate 500 in acid after 1 hour, showing that only piperidine 501 was visible.
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The 13C NMR spectra in particular, showed that the characteristic quaternary carbon next to the 
nitrogen present in piperidine 501, was visible at 54.3 ppm, as was the CH next to the nitrogen at 
48.3 ppm (Figure 4.14).
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Figure 4.14.13C NMR spectrum of piperidine 501
The quaternary carbon at 54.3 would not have been present at all if the pyrrolidine 502 had been 
isolated instead.
114
4.3. Conclusion and Future Work
From the work carried out in this chapter it can be concluded that piperidines will easily rearrange
to the corresponding pyrrolidine under fairly standard acidic conditions, when contending with 
steric interference from large groups such as the tosyl group present in 464 - 471. This should be 
taken as a synthetic warning when treating crowded piperidines to acidic conditions. More work 
need to be carried out on the ring-contraction of piperidines, especially piperidines substituted in 
the 3-position, and more highly substituted piperidines.
It has also been shown that the synthesis of 2,2,6-trimethylpiperidine 501 was achieved by 
changing from JV-protecting group from a sulfonamide 445 to a carbamate 500. This allowed 
piperidine 501 to be isolated cleanly without any visible traces of pyrrolidine 502. This had 
directly lead from observations made by Haskins where a carbamate had successfully been used as 
a N-protecting group to effect the cyclisation of a prenyl derivative 493 to pyrrolidine 494, through 
a tertiary carbenium ion. However, when a cyclisation was to be initiated through a secondary 
carbenium ion, as for derivatives 495, none of the desired pyrrolidines 496 were observed 
(Scheme 4.27). This seems to indicate that the synthesis of piperidines through this method may be 
limited to highly substituted piperidines (Figure 4.15).
Scheme 4.31. a) 0.5 eq. TfOH, DCM, 0 °C
If the synthesis of highly hindered piperidines 504 can be successfully accomplished, then the 
synthesis of sp/ra-piperidines 505 should also be attempted. The synthesis of these sp/ro-cycles 
should also include cyclohexanes that contain heteroatoms (Figure 4.15).
N H C 0 2M e
5 0 3
R = alkyl, Ph
R1 = H, M e, Ph, alkyl
C 0 2M e
5 0 4
s '  C 0 2Me
505
Figure 4.15. Possible .sp/ro-piperidines
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If this can all be conducted successfully, as has been suggested by Jackson2 7 0 ,2 7 1 then the synthesis 
of a natural product should be attempted, such as the spzVo-piperidine histrionicotoxin 
(Figure 4.16).
HO'
histrionicotoxin
Figure 4.16. Structure of histrionicotoxin
Retrosynthetic analysis of this compound shows that the spiro-piperidine core of the compound 
could be generated by acid-catalysed hydroamination. The location of the double bond is 
ambigous as either regioismer 507a or 507b would hopefully give the desired spz'ropiperidine 506 
(Scheme 4.32). The nature of the protecting group would need further investigations.
.0
RC
RO'
OR
507a
HO RO'
histrionicotoxin 506
507b
Scheme 4.32. Retrosynthetic analysis of histrionicotoxin
116
Chapter 5
117
Chapter 5
Experimental
6.1. General Details
All non-aqueous reactions were, unless otherwise stated, conducted using oven or flame-dried 
glassware and under an atmosphere of dry nitrogen. Reactions conducted at “-78°C” were cooled 
using an acetone-solid carbon dioxide bath. The triflic acid (TFOH) used in all cyclisation reaction 
was made as 0.695 M stock solution in dichloromethane. Reactions conducted at “0°C” were 
cooled using an ice-water bath. Heated reactions were conducted in a stirred oil bath heated on a 
hotplate. Unless otherwise stated, reactions were stirred magnetically. Dry tetrahydrofuran was 
obtained by fresh distillation from sodium wire and a benzophenone indicator. Dry 
dichloromethane was obtained by fresh distillation from calcium hydride. All other dry solvents 
were obtained commercially from Fisher Scientific Ltd. Silica gel chromatography and filtration 
was performed using Matrex Silica (35-70 pm). All reactions were monitored by tic, using Merck 
silica gel 60 F254 pre-coated aluminium-backed plates and were visualised using ultraviolet light, 
potassium permanganate or ammonium molybdate. All melting points (mp °C) were determined 
on a Kofler hot-stage apparatus and are uncorrected. Infrared spectra were obtained using a Perkin 
Elmer 1600 series Fourier Transform Infrared Spectrometer, as nujol mulls on sodium chloride 
plates [nujol], as liquid films on sodium chloride plates [film] or as a solution in dichloromethane 
[DCM]. Unless otherwise stated, NMR spectra were recorded on a Bruker DPX 400 instrument 
with proton (!H) NMR spectra recorded at 400 MHz and 13C spectra recorded at 100 MHz. Proton 
(!H) NMR spectra recorded at 500 MHz and 13C spectra recorded at 125 MHz were obtained using 
a Bruker DRX500 instrument. Unless otherwise stated, spectra were obtained from dilute solutions 
in deuteriochloroform and at 298 K. Abbreviations used for the multiplicities are: singlet (s), 
doublet (d), triplet (t), quartet (q), pentet (pent.), septet (sept.), unresolved multiplet (m) or 
combinations thereof. Apparent (app.) refers to overlapping peaks appearing to display a given 
multiplicity. Chemical shifts are reported relative to residual, undeuterated solvent {e.g. residual 
chloroform, 7.27 ppm in proton NMR). Mass spectra were recorded on a Fisons VG Platform II 
Mass Spectrometer using atmosphere pressure chemical ionisation [APCI]. Accurate high 
resolution mass spectral data were obtained at Cardiff University, using a Micromass Q-ToF 
Micromass Mass Spectrometer. “Evaporated” refers to solvent removal using a Buchi rotary 
evaporator with water pump vacuum and water bath at 25°C. Reactions performed in a microwave, 
were performed in a CEM Discover Microwave.
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6.2. General Procedures
General Procedure A: Mitsunobu Reaction
Triphenylphosphine (1.2 eq.) was added to tetrahydrofuran (50 ml per mmol), cooled to 0 °C 
under N2  and stirred for 10 min. Diisopropyl azodicarboxylate (1.01 eq.) was added and the 
solution stirred for 15 minutes after which it turned milky-white. Alcohol (1.0 eq.) was added and 
stirred for 20 min, followed by 7V-(ter/-butoxycarbonyl)-p-toluenesulfonamide or 
A-hydroxyphthalimide (1.01 eq.). The reaction mixture was allowed to warm slowly to room 
temperature over night; and the solvent was then evaporated.
777Work up 1: The residue was dissolved in a minimum amount of dichloromethane (5 ml), filtered
through silica and the silica, washed with dichloromethane (500 ml). The solution was reduced in 
volume to 200 ml and washed the solution with 15 wt. % hydrogen peroxide in water (40 ml). The 
two layers were separated and the organic layer washed with saturated aqueous sodium sulphite 
(30 ml) to neutralise excess hydrogen peroxide. The organic layer was dried over Na2 SC>4 and the 
solvent was evaporated.
Work up 2: The residue was dissolved in dichloromethane (15 ml) and washed with 15 wt. % 
hydrogen peroxide in water (40 ml). The two layers were separated and the organic layer washed 
with saturated aqueous sodium sulphite (30 ml) to neutralise excess hydrogen peroxide. The 
organic layer was dried over Na2 SC>4 and the solvent was evaporated.
General Procedure B: Preparation of Sulfonamides from Phthalimide
Phthalimide (1.0 eq.) was dissolved in ethanol (lOmlmml'1), to which was added hydrazine 
monohydrate (1 eq.) and the mixture was heated at 60 °C for 2 hours. The reaction mixture was 
cooled to room temperature, dried over MgSC>4 and evaporated to give the hydroxylamine, which 
was used in the next step without purification.
The hydroxylamine (1.0 eq.) was dissolved in dichloromethane (1 ml mml'1) and cooled to -78 °C. 
Triethylamine (1.01 eq.) was added, followed by DMAP (a few crystals) and p-toluenesulphonyl 
chloride (1.0 eq.). The reaction was allowed to warm to room temperature over night. The reaction 
mixture was extracted with water (3 x 30 ml) and the combined organic layers washed with copper 
sulfate (30 ml), water ( 2  x 30 ml), dried over NaS04  and evaporated.
Genreal Procedure C: Tosylation of Amines
The amine (1.0 eq.) was dissolved in dichloromethane (1 ml mmol*1) and cooled to -78 °C. 
Triethylamine (1.01 eq.) was added, followed by DMAP (a few crystals) and /?-toluenesulphonyl 
chloride (1.0 eq.). The reaction was allowed to warm to room temperature over night. The reaction
119
mixture was extracted with water (3 x 30 ml), 2M HC1 (2 x 30 ml) and 2M NaOH (2 x 30 ml), 
then dried over Na2 SC>4 and evaporated.
General Procedure D: Suzuki Reaction
Sulfonamide (1.0 eq.) and vinylboronic acid or pinacol ester (1.3 eq.) were suspended in a 1:1 
mixture of water and ethanol (3 ml per 100 mg of sulfonamide). To this suspension was then 
added the Suzuki premix (0.544 wt% Pd(OAc)2 , 1.11 wt% dtbpf and 98.4 wt% K3PO4) (0.425 g 
per 100 mg of sulfonamide) and the reaction placed in the microwave at 100W, 100 °C for 30 
minutes. The cooled mixture was then extracted with diethyl ether (3x15 ml), and the combined 
organic layers were washed with brine (30 ml), dried over MgSC>4 and evaporated.
6.3. Experimental Data
ferf-Butyl 4-methylpent-3-enyl(tosyl)carbamate 149a
148 149a
4-Methyl-3-penten-l-ol 148 (0.58 ml, 4.99 mmol, 1.0 eq.) was reacted with N-(tert-
butoxycarbonyl)-p-toluenesulfonamide (1.37 g, 5.04 mmol, 1.01 eq.) following general procedure 
A using work up 1. The crude product was recrystallised from diethyl ether to give the title 
compound 149a as a white solid (741 mg, Yield: 42%). ‘H NMR (400 MHz / CDC13) <5 7.71 
(d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.22 (d, 2H, J  = 8.3 Hz, 2  * Ts CH), 5.10 - 5.04 (m, 1H, CH),
3.74 - 3.68 (m, 2H, C//2N), 2.38 - 2.35 (m, 5H, Ts CH} & CH2), 1.65 (s, 3H, CH3), 1.60 (s, 3H, 
CH3), 1.27 (s, 9H, Boc C(CH3)3). 13C NMR (400 MHz / CDClj) 6 151.3 (C,), 143.9 (Cq), 137.6 
(C9), 135.0 (Cg), 129.2 (2 x Ts CH), 127.8 (2 x Ts CH), 119.8 (CH), 84.0 (Q), 46.7 (CH2N), 29.0 
(CH2), 27.9 (Boc C(CH3)3), 25.8 (CH3), 21.6 (Ts CH3), 17.8 (CH3). IR (neat) u/cm'1: 2981, 1717, 
1456,1380, 1132, 986, 864. HRMS (El) m/z calcd. for C14H19NO4 S [M-C4 H8f  = 297.1035; found 
297.1042.
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2,2-Dimethyl-l-tosylpyrrolidine 150a
.NTsBoc ------------------------------- N
Ts
149a 150a
A solution of /er/-butyl 4-methyl-3-enyl(tosyl)carbamate 149a (741 mg, 20.90 mmol, 1.0 eq.) in 
dichloromethane (20 ml) was cooled to 0 °C for 5 minutes, after which triflic acid (1.50 ml, 
10.45 mmol, 0.5 eq.) was added and the resulting solution stirred for 2.5 hours. The solution was 
quenched with saturated aqueous NaHCC>3 solution (10 ml), and the products extracted into 
dichloromethane (3x10 ml). The organic extracts were washed with water (3 x 30 ml), then dried 
over MgSC>4 and evaporated to give the title compound 150a as a colourless solid (0.504 g, 
Yield: 95%). All data obtained was in accordance with that previously reported in the literature, 
m.p.: 6 8  - 70 °C. 'H NMR (400 MHz / CDCI3) S 7.67 (d, 2H, 7  = 8.3 Hz, 2 x Ts CH), 7.20 (d, 2H, 
7 = 8 . 3  Hz, 2  x Ts CH), 3.31 (t, 2H, 7 =  6.5 Hz, CH2N), 2.34 (s, 3H, Ts CH3), 1.76 - 1.67 (m, 4H, 
2 x CH2), 1.36 (s, 6 H, 2 x CH3). 13C NMR (400 MHz / CDCI3) 3 132.2 (Q), 132.0 (Q), 129.4 
(2 x Ts CH), 127.1 (2 x Ts CH), 65.1 (C,), 49.3 (CH2), 42.9 (CH2), 28.3 (2 x C H 3), 22.5 (CH2), 
21.5(Ts CHi). IR (nujol) u/cm'1: 2926, 1331, 1151, 1093, 1010, 871, 811, 711, 677, 643. HRMS 
(El) m/z calcd. for Ci3Hi,N02S [M]+ = 253.1136; found 253.1134.
tert-Butyl4-methylpent-3-enyl(2-mtrophenylsulfonyl)carbamate 149b
148 149b
4-Methyl-3-penten-l-ol 148 (0.58 ml, 4.99 mmol, 1.0 eq.) was reacted with tert-butyl-2- 
nitrophenylsulfonylcarbamate (1.53 g, 5.04 mmol, 1.01 eq.) following general procedure A using 
work up 1. The crude product was recrystallised from diethyl ether to give the title compound 
149b as a yellow oil (0.762 g, Yield: 40%). 'H NMR (400 MHz / CDC13) <5 8.25 - 8.22 (m, 1H, Ns, 
CH), 7.68-7.64 (m, 3H, 3 x N s  CH), 5.11-5.06 (m, 1H, CH), 3.69-3.64 (m, 2H, C/fcN), 
2.38-2.32 (m,2H, CH2), 1.66 (s, 3H, CH}), 1.59 (s, 3H, CH3), 1.32 (s, 9H, Boc C(CH3)3). 
13C NMR (400 MHz / CDC13) 3 150.5 (Cq), 135.2 (C?), 134.0 (Ns CH) 133.3 (2 x Ns CH), 131.7 
(C,), 124.3 (Ns CH), 119.6 (CH), 84.9 (C?), 47.7 (CH2N), 29.0 (CH2), 27.8 (Boc C(CH3)3), 25.8 
(CH3), 17.8 (CH3). IR (neat) u/cm'1: 2981, 1717, 1456, 1380, 1350, 1132, 986, 750. HRMS (El) 
m/z calcd. for Ci3Hi6N2 0 6S [M-C4 H8]+ = 328.0729; found 328.0736.
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2,2-DimethyM-(2-mtrophenylsulfonyl)pyrrolidme 150b
X^n^\/NNsBoc ------- ► >^  V  N
Ns
14 9 b  150b
A solution of tert-butyl 4-methylpent-3-enyl(2-nitrophenylsulfonyl)carbamate 149b (50 mg, 
0.013 mmol, 1.0 eq.) in dichloromethane (5 ml) was cooled to 0 °C for 5 minutes, after which 
triflic acid (1.50 ml, 10.45 mmol, 0.5 eq.) was added and the resulting solution stirred for
1.75 hours. The reaction was quenched with saturated aqueous K2 CO3 solution (10 ml), and the 
products extracted into dichloromethane (3 x 30 ml). The organic extracts were washed with water 
(3 x 30 ml), dried over MgSC>4 and evaporated to give the title compound 150b as a colourless 
solid (36 mg Yield: 97%).
A solution of tert-butyl 4-methylpent-3-enyl(2-nitrophenylsulfonyl)carbamate 149b (50 mg 
0.013 mmol, 1.0 eq.) in dry dichloromethane (5 ml) was cooled to 0 °C for 5 minutes, after which 
concentrated sulfuric acid (2 drops) was added and the resulting solution stirred 1.75 hours. The 
reaction was quenched with saturated aqueous K 2 C O 3  solution (10 ml), and the products extracted 
into dichloromethane (3 x 30 ml). The organic extracts were washed with water (3 x 30 ml), then 
dried over MgSC>4 and evaporated to give the title compound 150b as a colourless solid (22 mg 
Yield: 60%).
Both samples showed identical spectroscopic and analytical data: NMR (500 MHz / C D C I 3 )
5 7.97 - 7.94 (m, 1H, Ns CH), 7.61 - 7.57 (m, 1H, 2 x Ns CH), 7.52 - 7.48 (m, 1H, Ns CH), 3.45 
(t, 2H, J  = 6 . 8  Hz, CH2N), 1.87 - 1.75 (m, 4H, 2 x CH2), 1.36 (s, 6 H, 2  x CH3). 13C NMR 
(400 MHz / CDCI3 ) S 148.5 (C„), 135.0 (C,), 133.2 (Ns CH), 131.4 (Ns CH), 130.2 (Ns CH),
123.8 (Ns CH), 66.2 (C,), 50.0 (CH2N), 42.7 (CH2), 27.6 (2 x CH3), 22.0 (CH2). IR (neat) Wcm'1: 
2970, 1545, 1456, 1380, 1350, 750. HRMS (APCI) m/z calcd. for Ci2 H,7N2 0 4S
[M+H]+ = 285.0909; found 285.0897.
(£)-Pent-3-enoic acid 152 121
151 152 OH
30 wt. % hydrogen peroxide (13.00 ml, 125 mmol, 2.6 eq.) was added dropwise over 20 minutes 
to a stirred solution of trans-3-pentenitrile 151 (5.00 ml, 48.6 mmol, 1.0 eq.) in 3 M aqueous 
NaOH (41.60 ml, 125 mmol, 2.6 eq.). The reaction mixture was heated to 80 °C for 2 hours and
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then stirred for a further hour at room temperature. The solution was washed with diethyl ether 
(30 ml), which was discarded. The aqueous solution was cooled to 0 °C and the pH adjusted to
4 -5  with 6  M HC1. The suspension was extracted with diethyl ether (3 x 30 ml) and the combined 
organic layers were washed with brine (30 ml), dried over MgS04  and concentrated to give the 
title compound 152 as a yellow oil (2.075 g, Yield: 43%). All data obtained was in accordance 
with that previously reported in the literature. 121 !H NMR (400 MHz / C D C I 3 )  S 5.68 - 5.50 
(m, 2H, 2 x CH), 3.09 (d, 2H, J  = 6 . 8  Hz, CH2), 1.64 (d, 3H, J  = 2.9 Hz, CH3).
152 OH 153
A solution of (£)-pent-3-enoic acid 152 (2.08 g, 2.08 mmol, 1.0 eq.) in diethyl ether (30 ml) was 
added dropwise to a stirred ice-cooled suspension of IIAIH4  (945 mg, 2.49 mmol, 1.3 eq.) in 
diethyl ether (30 ml) over 20 minutes and then stirred at room temperature for 1 hour. Water 
(10 ml) was added carefully and the mixture was poured into ice-diluted H2 SO4 . The solution was 
extracted with diethyl ether (3 x 30 ml), the ether extracts were washed with water (30 ml) and 
brine (30 ml), then dried over MgS04  and concentrated in vacuo to give the title compound 153 as 
an orange oil (1.40 g, Yield: 78%). All data obtained was in accordance with that previously 
reported in the literature. 121 ‘H NMR (400 MHz / CDC13) 3 5.62 - 5.53 (m, 2H, 2 * CH), 3.63 
(t, 2H, J=  6.3 Hz, CH2O), 2.29 - 2.23 (m, 2H, CH2), 1.69 (d, 3H, J = 6.3 Hz, CH3).
{E)-tert- Butyl pent-3-enyl(tosyl)carbamate 154
^  ^ ^ ^ ^ ^ .N T s B o c
153 154
(2s)-Pent-3-en-l-ol 153 (990 mg, 11.4 mmol, 1.0 eq.) was reacted with Y-(fert-butoxycarbonyl)-/?- 
toluenesulfonamide (3.14 g, 11.6 mmol, 1.01 eq.) according to general procedure A using work up 
2. The crude product was purification by flash column chromatography (eluting silica gel with 
dichloromethane) to give the title compound 154 as a white solid (1.95 g, Yield 50%). All data 
obtained was in accordance with that previously reported in the literature. 2 7 4  m.p.: 45 - 48 °C. *H 
NMR (400 MHz / CDC13) S 7.72 (d, 2H, J  = 8.3 Hz, 2 x Ts CH), 7.23 (d, 2H, J=  8.3 Hz, 2 x Ts 
CH), 5.51 - 5.43 (m, 1H, CH), 5.38 - 5.29 (m, 1H, CH), 3.73 - 3.69 (m, 2H, C/72N), 2.37 (s, 3H, Ts
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CH3), 1.59 (dd, 2H, J=  1.2Hz , 6.3 Hz, CH2), 1.27 (s, 9H, Boc C(Cft)3). 13C NMR (400 MHz / 
CDCI3) 5 153.8 (C9), 141.4 (C,), 139.6 (C9), 129.4 (2 x Ts CH), 127.8 (CH), 127.0 (CH), 126.0 
(2 x Ts CH), 82.0 (C,), 42.0 (CH2N), 28.9 (CH2), 21.8 (Boc C(CH3)3), 21.4 (Ts CH3), 14.2 (CH3). 
IR (neat) u/cm'1: 2979, 2935, 2361, 1729, 1452, 1356, 1288, 1258, 1160, 1089, 971. HRMS (ES) 
m/z calcd. for C17H2 9N2 O4 S [M+NH4 ]+= 357.1848; found 357.1833.
2-Methyl-l-tosylpyrrolidine 155
/ V V  N TsB oc
T s
154 155
{E)-tert-Butyl pent-3-enyl(tosyl)carbamate 154 (64 mg 0.19 mmol, 1.0 eq.) was dissolved in 
dichloromethane (5 ml), to which was added triflic acid (0.10 ml, 0.09 mmol, 0.5 eq.). The 
resultant solution was heated to 40 °C for 48 hours, cooled to room temperature and quenched 
with saturated aqueous K 2 C O 3  (15 ml). The two layers were separated, the aqueous layer was 
extracted with dichloromethane (2x15  ml), the combined organic layers were dried over K 2 C O 3  
and concentrated to give the title compound 155 as a white solid (41 mg Yield: 91%). All data 
obtained was in accordance with that previously reported in the literature. 2 7 5 m.p.: 84 - 87 °C.1H 
NMR (400 MHz / CDC13) S 7.65 (d, 2H, J  = 8.2 Hz, 2 x Ts C77), 7.24 (d, 2H, J  = 8.2 Hz, 2 x Ts 
CH), 3.67 - 3.60 (m, 1H, CflN), 3.42 - 3.32 (m, 1H, Ci^HBN), 3.11 - 3.04 (m, CHAi/ 5 N), 2.36 
(s, 3H, Ts CH3), 1.85 - 1.69 (m, 1 H, Ci/cHD), 1.68 - 1.56 (m, 1H, CHcHD\  1.52 - 1.35 (m, 2H, 
CH2\  1.25 (d, 3H, J  = 6.3 Hz, CH3), 13C NMR (400 MHz / CDC13) 8 143.2 (Cq), 134.8 (Q), 129.6 
(2 x Ts CH), 127.4 (2 x Ts CH), 56.1 (CH), 49.1 (CH2N), 33.5 (CH2), 23.9 (CH2), 22.9 (CH3),
21.6 (Ts CH3). HRMS (APCI) m/z calcd. For Ci2 H 18N 02S [M+H]+ = 240.1058; found 240.1070.
157
frvms-Styrylacetic acid 156 (1.50 g, 9.25 mmol, 1.0 eq.) was dissolved in dry diethyl ether (20 ml),
added to a suspension of LiAlfLj (460 mg, 12.2 mmol, 1.3 eq.) in diethyl ether (40 ml) and stirred
at room temperature for 1 hour. The reaction was then quenched by the slow addition of water
(20 ml). The mixture was then poured into ice-diluted H 2 S O 4  (20 ml), which was extracted with
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(£)-4-Phenylbut-3-en-l-ol 157276
o
156
J O
diethyl ether (3 x 30 ml). The combined organic fractions were washed with water (30 ml) and 
brine (30 ml), dried over MgSC>4 and concentrated to give the alcohol 157 as a yellow oil (1.36 g, 
Yield: 99%). All data obtained was in accordance with that previously reported in the literature.2 7 7  
'H NMR (500 MHz / CDCI3 ) S 7.32 - 7.11 (m, 5H, 5 x Ar CH), 6.43 (d, 1H, J  = 15.9 Hz, CH),
6.14 (td, 1 H J  = 7.2,15.9 Hz, CH), 3.76 (app. t, 2H ,J =  6.3 Hz, CH2), 2.50 - 2.35 (m, 2H, CH2 O), 
1.77 (br. s, 1H, OH). 13C NMR (500 MHz / CDC13) S 137.7 (C?), 132.9 (Ar CH), 128.6 (2 * Ar 
CH), 127.3 (CH), 126.4 (CH), 126.1 (2 x Ar CH), 62.0 (CH2 0), 36.5 (CH2). IR (neat) o/cm'1: 
3375, 3026, 2934, 1721, 1598, 1462, 1115, 965, 750, 690. HRMS (El) m/z calcd. for Ci0H10O 
[M-H2]+= 146.0732; found 146.0731.
(E)-tert-Buty\ 4-phenylbut-3-enyl(tosyl)carbamate 158
NTsBoc
Ph
157 158
(J£)-4-Phenylbut-3-en-1 -ol 157 (1.37 g, 9.25 mmol, 1.0 eq.) was reacted with N-{tert- 
butoxycarbonyl)-/?-toluenesulfonamide (2.50 g, 9.34 mmol, 1.01 eq.) according to general 
procedure A using work up 2. The crude product was purification by flash column 
chromatography (elitung silica gel with dichloromethane) to give the sulfonamide 158 as a 
colourless oil (889 mg, Yield: 24%). *H NMR (400 MHz / CDClj) <5 7.79 (d, 2H, J  = 8.3 Hz, 
2 x Ts CH), 7.38 - 7.18 (m, 7H, 2 x Ts CH & 5 x Ar CH), 6.51 - 6.43 (m, 1H, CH), 6.24 - 6.14 
(m, 1H, CH), 4.01 - 3.91 (m, 2H, Ctf2N), 2.69 - 2.63 (m, 2H, CH2), 2.42 (s, 3H Ts CH}), 1.30 
(s, 9H, Boc C(CHsh). 13C NMR (400 MHz / CDClj) <5 151.0 (C?), 144.1 (Cq), 137.4 (C,), 137.3 
(C,), 132.6 (Ar CH), 129.3 (2 x Ts CH), 128.5 (2 x Ar CH), 127.9 (2 x Ts CH), 127.3 (CH), 126.1 
(2 x Ar CH), 126.0 (CH), 84.3 (C?), 46.6 (CH2N), 34.0 (CH2), 27.9 (Boc C(CH3)3), 21.6 (Ts CH3). 
IR (neat) u/cm'1: 2980, 1733, 1597, 1462, 1152, 1100, 965, 845, 750, 690. HRMS (El) m/z calcd. 
for C2 2 H2 7N0 4Na23S [M+Na]+ = 424.1559; found 424.1542.
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2-Phenyl-l-tosylpyrrolidine 159
P b ^ ^ - v / N T s B o c  —  » - Q
Ts
158 159
(E)-tert-Butyl 4-phenylbut-3-enyl(tosyl)carbamate 158 (100 mg 0.25 mmol, 1.0 eq.) was dissolved 
in dichloromethane (10 ml), to which was added triflic acid (0.20 ml, 0.13 mmol, 0.5 eq.) and the 
resultant solution stirred at room temperature for 48 hours. The reaction was quenched with 
saturated aqueous K 2 C O 3 .  The two layers were separated and the aqueous layer extracted with 
dichloromethane (3x10 ml), the combined organic layers dried over K 2 C O 3  and evaporated to 
give the title compound 159 as a yellow solid (53 mg Yield: 70%). All data obtained was in 
accordance with that previously reported in the literature. 2 7 8  m.p: 77 - 82 °C. 1H NMR (400 MHz / 
C D C I 3 )  d 7.61 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.14 - 7.25 (m, 7H, 2 x Ts CH & 5 x Ar CH), 4.72 
(dd, 1H, J  = 7.9, 3.6 Hz, GHN), 3.59 - 3.52 (m, 1H, C i^HBN), 3.39 - 3.31 (m, 1H, CHAC%N), 
2.36 (s, 3H, Ts CH3), 1.94 - 1 . 8 6  (m, 1 H, CHaCHb), 1.83 - 1.71 (m, 2 H, CH2\  1.63 - 1.54 (m, 1 H, 
CHaC//«). 13C NMR (400 MHz / CDC13) S 143.3 (C9), 129.6 (2 x Ts CH), 129.3 (Cq), 128.4 
(2 x Ar CH), 127.5 (2 x Ts CH), 127.1 (C,), 127.0 (Ar CH), 126.2 (2 x Ar CH), 63.3 (CHN), 49.4 
(CH2N), 31.4 (CH2), 24.0 (CH2), 21.6 (Ts CH3). IR (neat) u/cm'1: 2961, 1598, 1462, 1152, 845, 
750,690. HRMS (APCI) m/z calcd. for Ci7H2 0NO2S [M+H]+ = 302.1215; found 302.1228.
5-Methylhex-4-en-2-ol 166122
164 165 166
A 0.5 M solution of 2 -methyl-1 -propenylmagnesium bromide 165 (35.0 ml, 17.4 mmol, 1.01 eq.) 
in tetrahydrofuran was cooled to -35 °C. Copper iodide (170 mg 0.86 mmol, 0.05 eq.) was 
introduced followed 15 minutes later by propylene oxide 164, which was added dropwise. The 
resulting solution was stirred for 30 minutes, the flask was then removed from the cold bath and 
allowed to warm to room temperature and stirred for 45 minutes. The reaction was quenched by 
adding the reaction mixture into a separating funnel containing brine (100 ml) and 12 N HC1. After 
extracting with ethyl acetate (3 x 30 ml) the combined organic phases were dried over Na2 SC>4 to 
give alcohol 166 as a colourless oil (1.97 g, Yield: 100%). All data obtained was in accordance 
with that previously reported in the literature. 122 ]H NMR (400 MHz / C D C I 3 )  S 5.23 - 5.17
126
(m, 1H, CH), 4.14-4.07 (m, 1H, CHO), 3.67-3.59 (m, 1H, CHARB), 3.47-3.43 (m, 1H, 
CHaHb), 1.72 (d, 3H, J=  1.7 Hz, CH3), 1.62 (s, 3H, CH3), 1.07 (d, 3H, J=  6.1 Hz, CH3).
terf-Butyl 5-methylhex-4-en-2-yl(tosyl)carbamate 167
OH _________
166 167
5-Methylhex-4-en-2-ol 166 (1.97 g, 17.3 mmol, 1.0 eq.) was treated with Af-(ter/-butoxycarbonyl)- 
/>-toluenesulfonamide (3.52 g, 17.4 mmol, 1.01 eq.) according to general method A using work up 
2. The crude product was purified by flash column chromatography (eluting silica gel with 40% 
ethyl acetate in hexanes) to give the title compound 167 as a yellow oil (3.53 g, Yield: 56%). 
*H NMR (400 MHz / CDC13) d 7.78 (d, 2H, J  = 8.4 Hz, 2  x Ts CH), 7.28 (d, 2H, J=  8.4 Hz, 
2 x Ts CH), 5.09 - 5.04 (m, 1H, CH), 4.52 - 4.43 (m, 1H, Ci7N), 2.71 - 2.63 (m, 1H, Ci^HB), 2.43 
(s, 3H, Ts CH3), 2.34 - 2.36 (m, 1H, CKAHB), 1.67 (s, 3H, CH3), 1.61 (s, 3H, CH3), 1.46 (d, 3H, 
J=  6.9 Hz, CH3), 1.36 (Boc C(CH3)3). 13C NMR (400 MHz / CDC13) S 150.7 (Cq), 143.6 (Q ,  
138.2 (C9), 134.2 (Cq), 129.1 (2 x Ts CH), 127.7 (2 x Ts CH), 121.3 (CH), 83.8 (C9), 55.6 (CH),
29.6 (CH2), 28.0 (Boc C(CH3)3), 25.8 (CH3),19.7 (CH3), 17.9 (CH3). IR (neat) u/cm’1: 2977, 1733, 
1598, 1462, 1152, 1100, 965, 845. HRMS (El) m/z calcd. for Ci9H3 0NO4S [M+H]+= 368.1896; 
found 368.1905.
2,2,5-Trimethyl-l-tosylpyrrolidine 162
NTsBoc _________
N
Ts
167 162
The sulfonamide 167 (100 mg 0.27 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added triflic acid (0.20 ml, 0.17 mmol, 0.5 eq.) and stirred at 0 °C for 3.5 hours. The 
reaction was quenched by the addition of saturated aqueous K2 C0 3 (15 ml). The two layers were 
separated and the aqueous layer was extracted with dichloromethane (2 x 30 ml), the combined 
organic layers dried over K2 C 0 3 and evaporated to give the title compound 162 as a colourless oil 
(48 mg Yield: 6 6 %).
The sulfonamide 167 (125 mg 0.34 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to
which was added concentrated sulfuric acid (2 drops) and stirred at 0 °C for 4 hours. The reaction
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was quenched by the addition of saturated aqueous K 2 C O 3  (15 ml). The two layers were separated, 
the aqueous layer extracted with dichloromethane (2 x 30 ml), the combined organic layers dried 
over K 2 C O 3  and concentrated to give the title compound 162  as a colourless oil (71 mg 
Yield: 78%).
Both samples show identical spectroscopic and analytical data. All data obtained was in 
accordance with that previously reported in the literature. 2 7 9  NMR (400 MHz / CDC13) S 7.76 
(d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.26 (d, 2H, J  = 8.3 Hz, 2 x Ts CH), 3.97 - 3.91 (m, 1H, CHN),
2.41 (s, 3H, Ts CH3), 2.04 - 1.87 (m, 2H, CH2), 1.71 - 1.67 (m, 1H, CHaCHq), 1.58 (s, 3H, CH3), 
1.48- 1.43 (m, 1H, CHAHB), 1.33 (s, 3H, CH3), 1.21 (d, 3H, .7=6.4 Hz, CH3). 13CNMR 
(400 MHz / CDCI3) S 142.5 (Q ), 139.9 (Cq), 129.3 (2 x Ts CH), 127.3 (2 x Ts CH), 66.2 (Cq),
57.6 (CHN), 40.6 (CH2), 31.4 (CH3), 30.3 (CH2), 26.8 (CH3), 22.7 (CH3), 21.5 (Ts CH3). IR (neat) 
u/cm'1: 2968, 1728, 1599, 1462, 1152, 845. HRMS (El) m/z calcd. for Ci4H2 iN02S 
[M]+ = 267.1293; found 267.1296.
(7s)-5-Phenylpent-4-en-2-ol 169122
B rM g ^ ^ Ph ---------
164 168
A 0.5 M solution of (jE)-styrylmagnesium bromide 168 was formed by the following method:
Magnesium fillings (400 mg, 16.4 mmol, 1.0 eq.) were stirred under nitrogen for 24 hours and
then suspended in tetrahydrofuran (33 ml). This suspension was treated with a crystal of iodine
and /?-bromostyrene (2.10 ml, 16.4 mmol, 1.0 eq.) and the suspension was stirred vigorously until
decolourisation was observed. Copper iodide (160 mg 0.81 mmol, 0.05 eq.) was added to the
freshly prepared grignard reagent 168 (1.01 eq.) at -30 °C, followed 15 minutes later by the
dropwise addition of propylene oxide 164 (1.10 ml, 16.2 mmol, 1.0 eq.). After 30 minutes the
reaction was allowed to warm to room temperature and stirred for a further 45 minutes. The
reaction was quenched by pouring the reaction mixture into a separating funnel containing brine
(100 ml) and 12 N HC1. After extracting with ethyl acetate (3 x 30 ml) the combined organic
phases were dried over Na2 S0 4. The crude product was purified by flash column chromatography
(eluting silica gel with 40% ethyl acetate in hexanes) to give the title compound 169 as a yellow oil
(1.32 g, Yield: 48%). All data obtained was in accordance with that previously reported in the
literature. 2 8 0  ‘H NMR (500 MHz / CDCI3 ) S 7.38 - 7.20 (m, 5H, 5 x Ar CH), 6.48 (d, 1H, J = 15.8,
CH), 6.23 (app. dd, 1H, J  = 6.2, 15.8 Hz, CH), 3.96-3.89 (m, 1H, CHO), 2.45-2.30 (m, 2H,
CH2), 1.25 (d, 3 H ,J  = 6.2 Hz, CH3). 13C NMR (500 MHz / CDCI3) S 137.3 (C?), 133.3 (Ar CH),
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128.6 (2 x Ar CH), 127.3 (CH), 126.3 (CH), 126.1 (2 x Ar CH), 67.4 (CHO), 43.0 (CH2), 22.9 
(CH3). IR (neat) u/cnT1: 3054, 1719, 1446, 1380, 965, 750, 690. HRMS (El) m/z calcd. for 
C11H14O [M]+= 162.1045; found 162.1041.
(E)-tert-BxiXy\ 5-phenylpent-4-en-2-yl(tosyl)carbamate 170
P h
.OH NTsBoc
P h ‘
169 170
(E)-5-Phenylpent-4-en-2-ol 169 (1.32 g, 8.2 mmol, 1.0 eq.) was treated with N-{tert- 
butoxycarbonyl)-/?-toluenesulfonamide (1.70 g, 8.25 mmol, 1.01 eq.) according to general method 
A using work up 2. The crude product was purified by flash column chromatography (eluting 
silica gel with 20% ethyl acetate in hexanes) to give the title compound 170 as a colourless oil 
(1.39 g, Yield: 41%). ‘HNMR (400 MHz / CDCI3 ) <5 7.73 (d, 2H, J  = 8.4 Hz, 2 xTs CH),
7.35 - 7.20 (m, 5H, 5 x Ar CH), 7.07 (d, 2H, J  = 8.4 Hz, 2 x Ts CH), 6.39 (d, 1H, J  = 15.6 Hz, 
CH), 6.05 (app. dd, 1H, 7 =  6.2, 15.6 Hz, CH), 4.75-4.66 (m, 1H, CHN), 2.96-2.87 (m, 1H, 
CHMn), 2.60- 2.52 (m, 1H, CH^Hb), 2.34 (s, 3H, Ts CH3), 1.53 (d, 3H,J =  6.2 Hz, CH3), 1.36 
(s, 9H, Boc C(CH,)3). 13C NMR (400 MHz / CDCI3) <5 157.2 (Cq), 143.7 (C„), 137.7 (C„), 136.8 
(C,), 129.7 (2 x Ts CH), 129.1 (2 x Ar CH), 128.5 (2 x Ar CH), 127.8 (2 x Ts CH), 127.2 (CH),
127.1 (Ar CH), 124.9 (CH), 84.0 (C9), 40.6 (CH), 38.3 (CH2), 28.0 (Boc C(CH3)3), 21.8 (Ts CH3),
20.0 (CH3). IR (neat) u/cm'1: 2979, 1786, 1725,1598, 1446,1380, 1135, 1112, 965, 827, 750, 690. 
LRMS (ES) 433.16 (M+NlV, 47%), 438.18 (M+Na+, 90%), 479.20 (M+MeCNNa+, 100%).
2-Methyl-5-phenyI-l-tosylpyrrolidine 163
The sulfonamide 170 (100 mg 0.24 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added triflic acid (0.20 ml, 0.12 mmol, 0.5 eq.) and stirred at 0 °C for 4 hours. The 
reaction was quenched by the addition of saturated aqueous K2 CO3 (15 ml). The two layers were 
separated, the aqueous layer was extracted with dichloromethane ( 2  x 30 ml), the combined 
organic layers dried over K 2 C O 3  and evaporated to give the title compound 163 as a colourless oil 
(50 mg Yield: 6 6 %).
NTsBoc
Ts
163170
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The sulfonamide 170 (100 mg 0.24 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added concentrated sulfuric acid (2 drops) and stirred at 0 °C for overnight. The 
reaction was quenched by the addition of saturated aqueous K 2 C O 3  (15 ml). The two layers were 
separated, the aqueous layer was extracted with dichloromethane (2 x 30 ml), the combined 
organic layers were dried over K 2 C O 3  and evaporated to give the title compound 163 as a 
colourless oil (75 mg Yield: 99%).
Both samples show identical spectroscopic and analytical data: lK NMR (400 MHz / CDCI3) 
3 7.73 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.39 - 7.23 (m, 7H, 5 x Ar CH & 2 x Ts CH), 4.74 - 4.68 
(m, 1H, CHN), 3.96 - 3.89 (m, 1H, CHN), 2.43 (s, 3H, Ts CH3), 1.90 - 1.65 (m, 4H, 2 x CH2), 1.26 
(d, 3H, J=  6.4 Hz, CH}). I3C NMR (400 MHz / CDCI3) <5141.7 (Cq), 140.7 (C,), 137.8 (C„), 129.7 
(2 x Ts CH), 128.5 (2 x Ar CH), 127.1 (2 x Ts CH), 126.2 (2 x Ar CH), 124.9 (Ar CH), 50.1 
(CH), 49.6 (CH), 40.6 (CH2), 31.7 (CH2), 21.8 (CH3), 21.6 (Ts CH3). IR (neat) u/cm'1: 2966,1785, 
1599, 1446, 1380, 1135, 827, 750, 690. HRMS (El) m/z calcd. for C,8H2 ,N02S [M]+ = 315.1293; 
found 315.1303.
tert- Butyl hex-5-en-2-yl(tosyl)carbamate 172
BocTsN
173 172
5-Hexen-2-ol 173 (1.00 g, 9.99 mmol, 1.0 eq.) was treated with TV-(fert-butoxycarbonyl)- 
jp-toluenesulfonamide (2.70 g, 10.1 mmol, 1.01 eq.) according to general method A using work up 
2. The crude product was purified by flash column chromatography (eluting the silica gel with 
30% ethyl acetate in hexanes) to give the title compound 172 as a clear oil (2.63 g, Yield: 75%). 
Compound reported in the literature but not spectroscopic data given. 28 1 JH NMR (400 MHz / 
CDC13) 3 7.81 (d, 2H, J=  7.6 Hz, 2 x Ts CH), 7.31 (d, 2H, J  = 7.6 Hz, 2 x Ts CH), 5.91 - 5.79 
(m, 1H, CH), 5.10-4.97 (m, 2H, CH2), 4.64-4.54 (m, 1H, CHN), 2.45 (s, 3H, Ts CH3),
2.14 - 2.03 (m, 2H, CH2), 1.86 - 1.75 (m, 2H, CH2), 1.46 (d, 3H, J  = 6 . 6  Hz, CH3), 1.37 (s, 9H, 
Boc C(CH3)3). 13C NMR (400 MHz / CDC13) 3 150.8 (Cq), 143.8 (Cq), 137.9 (Cq), 137.8 (CH),
129.2 (2 x Ts CH), 127.8 (2 x Ts CH), 115.1 (CH2), 84.0 (Cq), 55.0 (CH), 34.2 (CH2), 31.2 (CH2),
28.0 (Boc C(CH3)3), 21.7 (Ts CH3), 19.7 (CH3). IR (neat) u/cm'1: 2978, 1729, 1641, 1598, 1462, 
1380, 1145, 1100, 828. HRMS (El) m/z calcd. for Ci4 Hi9N 02S [M-C4H8]+= 297.1035; found 
297.1039.
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(2£,5l?)-2,5-Dimethyl-l-tosylpyrrolidme (cis) 174a & (2iS',55)-2,5-dimethyl-l-tosylpyrrolidine 
(trans) 174b
The sulfonamide 172 (100 mg, 0.28 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml) and 
cooled 0 °C, to which was added TfOH (0.20 ml, 0.14 mmol, 0.5 eq.). The resultant solution was
and the two layers separated. The aqueous layer was extracted with dichloromethane (3 x 10 ml), 
dried the combined organic layers over K 2 C O 3  and evaporated to give pyrrolidines 174 as a clear 
oil (71 mg, Yield: 99%). Cis : trans 1.0 : 3.0
The sulfonamide 172 (100 mg, 0.28 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml) and 
cooled 0 °C, to which was added TfOH (0.20 ml, 0.14 mmol, 0.5 eq.). The resultant solution was 
heated to 40. °C for 12 hours. The reaction mixture was quenched with saturated aqueous K 2 C O 3  
and the two layers separated. The aqueous layer was extracted with dichloromethane (3 x 1 0  ml), 
dried the combined organic layers over K 2 C O 3  and evaporated to give pyrrolidines 174 as a clear 
oil (63 mg, Yield: 8 8 %). Cis : trans 1.0 : 3.0
The sulfonamide 172 (100 mg, 0.28 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml) and 
cooled 0 °C, to which was added concentrated sulfuric acid (2 drops). The resultant solution was 
heated to 40 °C for 12 hours. The reaction mixture was quenched with saturated aqueous K 2 C O 3  
and the two layers separated. The aqueous layer was extracted with dichloromethane (3 x 1 0  ml), 
dried the combined organic layers over K 2 C O 3  and evaporated to give pyrrolidines 174 as a clear 
oil (63 mg, Yield: 8 8 %). Cis : trans 1.0 :1.0
See Table 2.1 on p. 31 for more details. All data obtained was in accordance with that previously 
reported in the literature. 2 8 2  All samples show identical spectroscopic and analytical data:
m.p.: 99 - 102 °C. JH NMR (500 MHz / CDC13) trans isomer: 5 7.67 (d, 2H, J=  8.3 Hz, 2 x Ts
J -  6.4 Hz, 2 x CHi). 13C NMR (500 MHz / C D C I 3 )  trans isomer: d 142.6 (Q), 139.8 (Q), 129.4
B ocTsN
172
T s
174a
T s
174b
heated to 40 °C for 12 hours. The reaction mixture was quenched with saturated aqueous K 2 C O 3
CH), 7.19 (d , 2H. J=  8.3 Hz, 2 x Ts CH), 4.03 - 3.91 (m, 2H, 2 x CHN), 2.34 (s, 3H, Ts CH3), 
2.18 - 2.04 (m, 2H, C/6 ), 1.46 -1.41 (m, 2H, CHi), 1.12 (d, 6 H, J=  6.4 Hz, 2 x C/6 ); cis isomer: 
<5 7.65 (d , 2H, J  = 8.0 Hz, 2  x Ts CH), 7.23 (d , 2H, J  = 8.0 Hz, 2  * Ts CH), 3.64 - 3.57 (m, 2H, 
2  x CHN), 2.35 (s, 3H, Ts C/6 ), 1.54 -1.47 (m, 2H, C/6 ), 1.46 -1.41 (m, 2H, C/6 ), 1.27 (d , 6 H,
(2 x Ts CH), 127.0 (2 x Ts CH), 56.2 (2 x CHN), 31.2 (2 x CH2), 23.7 (2 x CH3), 21.3 (Ts CH3); 
cis isomer: <5 143.1 (C„), 135.3 (Cq), 129.6 (2 x Ts CH), 127.5 (2 x Ts CH), 57.6 (2 x CHN), 32.0
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(2 x CH2), 21.49 (2 x CH3), 21.45 (Ts CH3). IR (neat) u/cm'1: 2972, 1599, 1462, 1380, 1145, 828. 
HRMS (El) m/z calcd. for Ci3HnNS0 2  [M] = 253.1137; found 253.1141.
Preparation of methyl esters 180 126
R 1 R1 a  R 1 = H
A  -------------► A  b R 1 = Me
H2N C 0 2H H2N C 0 2Me R i _  /-R
1 7 9  1 8 0
The amino acid 179 (1.0 eq.) was suspended in methanol (1 ml mmol' 1 of amino acid) and cooled 
to 0 °C. Thionyl chloride (1.5 eq.) was added dropwise and the reaction mixture was allowed to 
warm to room temperature overnight. The solvent was evaporated to give the amino acid methyl 
ester 180. All data obtained was in accordance with that previously reported in the literature. 126
(R1 = H) Methyl 2-aminoacetate 180a
Glycine 179a (4.00 g, 53.0 mmol, 1.0 eq.) gave the title compound 180a as a white solid (4.75 g, 
Yield: 100%). !H NMR (400 MHz / CD3 OD) 3 3.78 (s, Gtf2N), 3.68 (s, 3H, CH3).
(R1 = Me) Methyl 2-aminopropanoate 180b
Alanine 179b (4.00 g, 44.9 mml, 1.0 eq.) gave the title compound 180b as a clear oil (4.09 g, 
Yield: 100%). !H NMR (400 MHz / CD3 OD) 3 4.06 (q, 1H, J=  7.3 Hz, CH) 3.68 (s, 3H, CH3)
1.41 (d, 3H, J=  7.3 Hz, CH3).
(R1 = i-Pr) Methyl 2-amino-3-methylbutanoate 180c
Valine 179c (4.00 g, 34.2 mmol, 1.0 eq.) gave the title compound 180c as a clear oil (4.48 g, 
Yield: 100%). JH NMR (400 MHz / CD3 OD) 3 3.89 (d, 1H, J=  4.7 Hz, C£/N), 3.70 (s, 3H, CH3), 
2.25 - 2.16 (m, 1H, CH), 0.89 (d, 6 H, J=  6.7 Hz, 2 x CH3).
Preparation of imines 181126
R 1 R1 R 1 = H
A   A  R 1 = Me
H2N C 0 2Me / = N  C 0 2Me p i  _  /-_pr
1 8 0  Ph 181
Amino acid methyl ester 180 (1.0 eq.) was dissolved in dichloromethane (1 ml mmol' 1 of methyl 
ester); MgSC>4 (0.6 g g' 1 of methyl ester) and triethylamine (2.0 eq.) are added and the resultant 
suspension is treated with benzaldehyde (0.95 eq.) and stirred for 30 hours. The suspension was
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filtered and the solvent evaporated under reduced pressure. The residue was partitioned between 
water (30 ml) and ether (30 ml), the two layers were separated and the aqueous layer was further 
extracted with diethyl ether (2 x 30 ml). The combined organic layers were washed with brine 
(30 ml), dried over MgS0 4  and the solvent evaporated to give the imine 181. All data obtained was 
in accordance with that previously reported in the literature. 126
(R1 = H) (£)-Methyl 2-(benzylideneamino)acetate 181a
Methyl ester 180a (4.75 g, 53.0 mmol, 1.0 eq.) gave the title compound 181a as a colourless oil 
(5.83 g, Yield: 62%). lU NMR (500 MHz / CDC13) S 8.26 (br. s, 1H, CHN), 7.79 - 7.72 (m, 2H, 
2 x Ar CH), 7.43 - 7.38 (m, 3H, 3 x Ar CH), 4.39 (s, 2H, CH2N), 3.75 (s, 3H, CH3).
(R1 = Me) (£)-Methyl 2-(benzylideneamino)propanoate 181b
Methyl ester 180b (4.08 g, 44.9 mmol, 1.0 eq.) gave the title compound 181a as a colourless oil 
(5.66 g, Yield: 65%). ]H NMR (400 MHz / CDC13) S 8.29 (br. s, 1H, CHN), 7.79 - 7.76, (m, 2H, 
2 x Ar CH), 7.43 - 7.37 (m, 3H, 3 x Ar CH), 4.15 (q, 1H, J=  6.9 Hz, CH), 3.72 (s, 3H, CH3), 1.52 
(d, 3H, / =  6.9 Hz, CH3).
(R1 = *-Pr) (fi)-Methyl 2-(benzylideneamino)-3-methylbutanoate 181c
Methyl ester 180a (4.474 g, 34.2 mmol, 1.0 eq.) gave the title compound 181a as a colourless oil 
(3.19 g, Yield: 43%). !H NMR (400 MHz / CDC13) S 8.24 (br. s, 1H, CHN), 7.81 - 7.77 (m, 2H, 
2 x Ar CH), 7.44 - 7.40 (m, 3H, 3 x Ar CH), 4.01 (d, 1H, J=  7.3 Hz, CH), 3.74 (s, 3H, CH3), 
2.44 - 2.35 (m, 1H, CH), 0.97 (d, 3H, J=  6 . 8  Hz, CH3), 0.94 (d, 3H, J=  6 . 8  Hz, CH3).
Cinnamyl Derivatives 182119,126
R 1 r,— y  R1
'K n * *  "  Ph^  A"C° 2Mef=N C02Me
Ph'
/=N
PK
181 182a R1 = Ph, R = H
182b R1 = Ph, R = Me 
182c R1 = Ph, R = /-Pr
Lithium diisopropylamine was prepared by the dropwise addition of w-BuLi in hexanes (2.5 M 
solution in hexanes, 1 . 2  eq.) to a solution of diisopropylamine ( 1 . 2  eq.) in tetrahydrofuran 
(2 ml mmol' 1 of diidopropylamine) at 0 °C. After 30 minutes the solution was cooled to -78 °C. A 
solution of the 7V-(benzlidine)amino ester 181 (1.0 eq.) in tetrahydrofuran (2 ml mmol'1) was added 
dropwise via a syringe, and the resulting deep red solution was stirred for 30 minutes at -78 °C.
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An solution of cinnamyl bromide (1.1 eq.) in tetrahydrofuran (1 ml mmol'1) was added dropwise 
and the resulting solution stirred at -78 °C. After 1 hour the now orange solution was allowed to 
warm to room temperature, stirred for 1 hour, quenched with saturated aqueous ammonium 
chloride (4 ml mmol'1) and diluted with ether (3 x 4 ml mmol'1). The combined organic solutions 
were dried, filtered and evaporated to give the crude imines 182, which were characterised by 
proton NMR only.
(R1 = H) (£)-Methyl 2-((H)-benzylideneamino)-5-phenylpent-4-enoate 182a
(H)-Methyl 2-(benzylideneamino)acetate 181a (3.02 g, 17.1 mmol, 1.0 eq.) gave the title 
compound 182a as an orange oil (5.01 g, Yield: 100%). All data obtained was in accordance with 
that previously reported in the literature. 3 0  !H NMR (400 MHz / CDCI3) d 8.24 (s, 1H, CHN),
7.82 - 7.13 (m, 10H, 10 x Ar CH), 6.48 (dt, 1H, J=  15.8, 6.4 Hz, CH), 6.43 (d, 1H, J=  15.8 Hz, 
CH), 4.06 (t, 1H, J = 6.5 Hz, CHN), 3.75 (s, 3H, CH3), 2.97 - 2.73 (m, 2H, CH2).
(R1 = Me) (E)-Methyl 2-((/s)-benzylideneamino)-2-methyl-5-phenylpent-4-enoate 182b
(£)-Methyl 2-(benzylideneamino)propanoate 181b (1.12 g, 5.86 mmol, 1.0 eq.) gave the title 
compund 182b as an orange oil (900 mg, Yield: 50%). All data obtained was in accordance with 
that previously reported in the literature. 3 0  !H NMR (400 MHz / CDCI3) S 8.16 (s, 1H, CHN),
7.82 - 7.11 (m, 10H, 10 x Ar CH), 6.47 (dt, 1H, J=  15.8, 7.5 Hz, CH), 6.43 (d, 1H, J=  15.8 Hz, 
CH), 3.64 (s, 3H, CH3), 2.73 (d, 2H, J=  7.5 Hz, CH2), 1.45 (s, 3H, CH3).
(R1 = i-Pr) (H)-Methyl 2-((H)-benzylideneamino)-2-isopropyl-5-phenylpent-4-enoate 182c
(H)-Methyl 2-(benzylideneamino)-3-methylbutanoate 181c (2.97 g, 13.6 mmol, 1.0 eq.) gave the 
title compound 182c as an orange oil (2.50 g, Yield: 55%). JH NMR (400 MHz / C D C I 3 )  S 8.26 
(s, 1H, CHN), 7.71 - 7.15 (m, 10H, 10 x Ar CH), 6.41 (dt, 1H, J=  15.4, 7.3 Hz, CH), 6.3 (d, 1H, 
J=  15.4 Hz, CH), 3.74 (s, 3H, CH3), 2.84-2.73 (m, 2H, CH2), 2.48-2.34 (m, 1H, CH), 1.04 
(d, 6 H, J = l . \  Hz, 2 x CH?).
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Crotyl Derivatives 183119'126
Me— "  J — C02Me
/ = N 
Ph
183a R 1 = H 
183b R 1 = M e 
183c R 1 = i-Pr
Lithium diisopropylamine was prepared by the dropwise addition of «-BuLi in hexanes (2.5 M 
solution in hexanes, 1 . 2  eq.) to a solution of diisopropylamine (1 . 2  eq.) in tetrahydrofuran 
(2 ml mmol' 1 of diidopropylamine) at 0 °C. After 30 minutes the solution was cooled to -78 °C. A 
solution of the 7V-(benzlidine)amino ester 181 (1.0 eq.) in tetrahydrofuran (2 ml mmol'1) was added 
dropwise via a syringe, and the resulting deep red solution was stirred for 30 minutes at -78 °C. A 
solution of crotyl bromide ( 1 . 1  eq.) in tetrahydrofuran ( 1  ml mmol'1) was added dropwise and the 
resulting solution stirred at -78 °C. After 1 hour the now orange solution was allowed to warm to 
room temperature, stirred for 1 hour, quenched with saturated aqueous ammonium chloride 
(4 ml mmol'1) and diluted with ether (3 x 4 ml mmol'1). The combined organic solutions were 
dried, filtered and evaporated to give the crude imines 183, which were characterised by proton 
NMR only.
(R1 = H) (2s)-Methyl 2-((£)-benzylideneamino)hex-4-enoate 183a
(2s)-Methyl 2-(benzylideneamino)acetate 181a (5.83 g, 32.0 mmol, 1.0 eq.) gave the title 
compound 183a as an orange oil (6 . 8 8  g, Yield: 90%). All data obtained was in accordance with 
that previously reported in the literature. 3 0  lH NMR (400 MHz / CDC13) 3 8.16 (s, 1H, CHN), 7.69 
(dd, 2H, J=  7.6, 1.8 Hz, 2 x Ar CH), 136 - 7.30 (m, 3H, 3 x Ar CH), 5.53 - 5.37 (m, 1H, CH),
5.34 - 5.23 (m, 1H, CH), 3.92 (t, 1H, J  = 5.9 Hz, CHN), 3.66 (s, 3H, CH3), 2.69 - 2.40 (m, 2H, 
CH2), 1.55 (d, 3H, 7=7.1 Hz, CH3).
(R1 = Me) (£)-Methyl 2-((/s)-benzylideneamino)-2-methylhex-4-enoate 183b
(£)-Methyl 2 -(benzylideneamino)propanoate 181b (5.66 g, 29.6 mmol, 1.0 eq.) gave the title 
compouns 183b as an orange oil (4.68 g, Yield: 65%). All data obtained was in accordance with 
that previously reported in the literature. 3 0  ]H NMR (400 MHz / C D C I 3 )  3 8.23 (s, 1H, CHN), 
7.71 - 7.66 (m, 2H, 2 x Ar CH), 7.36 - 7.30 (m, 3H, 3 x Ar CH), 5.55 - 5.40 (m, 1H, CH),
5.36 - 5.19 (m, 1H, CH), 3.65 (s, 3H, CH3), 2.65 - 2.45 (m, 2H, CH2), 1.57 (d, 3H, 7=  6.3 Hz, 
CH3), 1.39 (s, 3H, CH).
Ph
R1
C 0 2MeA
181
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(R1 = /-Pr) (£)-Methyl 2-((£)-benzylideneamino)-2-isopropylhex-4-enoate 183c
(£)-Methyl 2-(benzylideneamino)-3-methylbutanoate 181c (3.19 g, 14.6 mmol, 1.0 eq.) gave the 
title compound 183c as an orange oil (1.93 g, Yield: 49%). lH NMR (400 MHz / CDC13) S 8.24 
(br. s, 1H, CHN), 7.82 - 7.76 (m, 2H, 2 x Ar CH), 7.44 - 7.40 (m, 3H, 3 x Ar CH), 5.55 - 5.40 
(m, 1H, CH), 5.36 - 5.19 (m, 1H, CH), 3.74 (s, 3H, CH3), 2.65 - 2.45 (m, 2H, CH2), 2.44 - 2.35 
(m, 1H, CH), 1.57 (d, 3H, J=  6.3 Hz, CH3), 0.97 (d, 3H, J  = 6 . 8  Hz, CH3), 0.94 (d, 3H,J =  6 . 8  
Hz, CH3).
Preparation of homoallylic sulfonamides of cinammyl derivatives 184*19,126
Ph— $  y - C 0 2Me ► p h — /  y ~ C 0 2Me
/ = N  TsHN
Ph
182a R1 = H 184a R1 = H
182b R1 = M e 184bR1 = M e
182c R1 = i-P r  184cR1=/-Pr
The crude imine 182 (1.0 eq.) was dissolved in ether ( 8  ml mmol'1) and 1 M hydrochloric acid 
( 8  ml mmol'1) was added slowly. The resulting mixture was then stirred vigorously for 2 hours. 
The organic layer was separated and the aqueous layer extracted with diethyl ether 
(2 x 4  ml mmol'1); these organic solutions were discarded. The aqueous layer was adjusted to pH 9 
with 2 M aqueous sodium hydroxide and the resulting solution extracted with dichloromethane 
(3 x 4  ml mmol'1). The combined organic extracts were dried over Na2 SC>4 and evaporated to yield 
the corresponding amine, assigned by proton NMR. The amine (1.0 eq.) was then immediately 
dissolved in dichloromethane (5 ml mmol'1) at -78 °C and treated with tosyl chloride (1.2 eq.), 
triethylamine (1.2 eq.) and a few crystals of DMAP. The resulting mixture was stirred overnight at 
room temperature, quenched by addition of 2 M hydrochloric acid (4 ml mmol'1) and the organic 
phase separated. The aqueous phase was further extracted with dichloromethane 
(2 x 4  ml mmol'1). The combined organic solutions were washed with brine, dried over Na2 SC>4 , 
filtered and evaporated. The residue was purified by recrystallisation from ethyl acetate / hexanes 
to give the sulfonamide 184.
(R1 = H) (Zs)-Methyl 2-(4-methylphenylsulfonamido)-5-phenylpent-4-enoate 184a
182a (3.99 g, 13.6 mmol, 1.0 eq.) gave the title compound 184a as a white solid (300 mg
Yield: 8.5%). All data obtained was in accordance with that previously reported in the
literature. 3 0 ,2 8 3  m.p.: 8 8  - 92 °C. !H NMR (500 MHz / CDC13) S 7.76 - 7.63 (m, 2H, 2 x Ts CH),
7.22 - 7.16 (m, 7H, 5 x Ar CH & 2 x Ts CH), 6.32 (d, 1H, J=  15.7 Hz, CH), 5.94 (app. ddd, 1H,
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J= 15.7, 7.9, 7.9 Hz, CH), 5.24 (s, 1H, NH), 4.03 (ddd, 1 H, J  = 7.9, 5.8, 5.8 Hz, CHN), 3.57 
(s, 3H, CH), 2.67 - 2.54 (m, 2H, CH2), 2.32 (s, 3H, Ts CH,). ,3C NMR (500 MHz / CDC13) S
171.4 (C9), 143.0 (Cq), 136.8 (C9), 136.6 (C9), 134.6 (Ar CH), 129.7 (2 x Ts CH), 128.5 (2 x Ar 
CH), 127.7 (CH), 127.27 (2 x Ts CH), 126.3 (2 x Ar CH), 122.6 (CH), 55.5 (CHN), 52.6 (CH3),
36.9 (CH2), 21.5 (Ts CH3). IR (nujol) u/cm'1: 3279, 1744, 1596, 1458, 1326, 1212, 1158, 1091, 
968, 905, 857, 817, 744, 690, 665. HRMS (El) m/z calcd. for Ci9H2 iN04S [M+l] = 360.1270, 
found 360.1261.
(R1 = Me) (£)-Methyl 2-methyl-2-(4-methylphenylsulfonamido)-5-phenylpent-4-enoate 184b 
182b (2.09 g, 6.82 mmol, 1.0 eq.) gave the sulfonamide 184b as a white solid (700 mg 
Yield: 27.5%). All data obtained was in accordance with that previously reported in the 
literature. 3 0  m.p.: 130 - 133 °C. *H NMR (500 MHz / CDC13) S 7.71 - 7.70 (m, 2H, 2 x Ts CH)
7.22 - 7.16 (m, 7H, 5 x Ar CH  & 2 x Ts CH), 6.36 (d, 1H, J=  15.8 Hz, CH), 5.91 (td, 1H, J=  7.5,
15.8 Hz, CH), 5.35 (s, 1H, Ntf), 3.63 (s, 3H, CH3), 2.60 (dd, 1H,J =  7.5, 15.1 Hz, CHAHB), 2.55 
(dd, 1H, J=  7.5, 15.1 Hz, CHAHB), 2.32 (s, 3H, Ts CH3), 1.43 (s, 3H, CH3). 13C NMR (500 MHz / 
CDC13): 173.5 (C9), 143.3 (Cq), 139.5 (Cq), 136.8 {Cq), 134.8 (Ar CH), 129.5 (2 x Ts CH), 128.5 
(2 x Ar CH), 127.6 (CH), 127.11 (2 x Ts CH), 126.3 (2 x Ar CH), 122.7 (CH), 62.5 ( Q ,  52.8 
(CH3), 43.0 (CH2), 22.6 (CH3), 21.5 (Ts CH3). IR (nujol): 3297, 1724, 1339, 1261, 1220, 1157, 
1122, 1091, 973, 849, 820, 747, 696, 673, 656. HRMS (El) m/z calcd. for C2oH2 3N0 4S 
[M+l] = 374.1462, found 374.1425
(R1 i-Pr) (JE)-Methyl 2-isopropyl-2-(4-methylphenylsulfonamido)-5-phenylpent-4-enoate 184c 
182c (2.48 g, 7.39 mmol, 1.0 eq.) gave the sulfonamide 184c as a white solid (2.00 g, 
Yield: 67.4%). m.p: 146 - 150 °C. 'H NMR (500 MHz / CDC13) S 7.83 - 7.82 (m, 2H, 2 x Ts CH),
7.34 - 7.16 (m, 7H, 5 * Ar CH & 2 * Ts CH), 6.46 (dt, 1H, J=  15.9, 7.7 Hz, CH), 6.34 (d, 1H, 
J=  15.9 Hz, CH), 5.52 (s, 1H, NH), 3.74 (s, 3H, CH), 3.06 (m, 2 H, CH), 2.40 - 2.38 (m, 4H, Ts 
C H  & CH), 1.05 (d, 3H,J =  6.9 Hz, CH ), 0.89 (d, 3H, J=  6.9 Hz, CH). 13C NMR (500 MHz / 
CDC13) 3 172.4 (C9), 143.1 (C9), 140.0 (Cy, 137.1 (C9), 133.5 (Ar CH), 129.5 (2 x Ts CH), 128.4 
(2 x Ar CH), 127.2 (CH), 126.9 (2 x Ts CH), 126.1 (2xA r CH), 124.3 (CH), 71.0 (C9), 52.6 
(CH3), 36.5 (CH2), 34.8 (CH), 21.4 (Ts CH3), 17.7 (CH3), 17.4 (CH3). IR (nujol): 3282, 1708, 
1596, 1457, 1325, 1261, 1154, 1094, 1006, 969, 910, 855, 813, 747, 693, 6 6 6 . HRMS (El) m/z 
calcd. for C2 2 H2 7N 04S [M+l] = 402.1739, found 402.1730.
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Preparation of homoallylic sulfonamides of cinammyl derivatives 185 119,126
Ph
C 0 2Me Ms 3 0 2Me
TsHN
183a R1 = H 
183b R1 = Me 
183c R1 = i-Pr
185a R1 = H 
185b R1 = Me
185c R1 = i-Pr
The crude imine 183 (1.0 eq.) was dissolved in ether ( 8  ml mm ol') and 1 M hydrochloric acid 
( 8  ml mmol’1) was added slowly. The resulting mixture was then stirred vigorously for 2 hours.
The organic layer was separated and the aqueous layer extracted with diethyl ether
with 2 M aqueous sodium hydroxide and the resulting solution extracted with dichloromethane
the c6 rresponding amine, assigned by proton NMR. The amine (1.0 eq.) was then immediately
triethylamine (1.2 eq.) and a few crystals of 4-dimethylaminopyridine (DMAP). The resulting 
mixture was stirred overnight at room temperature, quenched by addition of 2 M hydrochloric acid
dried over Na2 SC>4 , filtered and evaporated. The residue was purified by flash column 
chromatography (eluting silica gel with 40% ethyl acetate in hexanes) to give the sulfonamides 
185.
(R1 = H) (2s)-Methyl 2-(4-methylphenylsulfonamido)hex-4-enoate 185a 
183a (6 . 8 8  g, 29.7 mmol, 1.0 eq.) gave the sulfonamide 185a as a white solid (3.63 g, Yield: 41%). 
All data obtained was in accordance with that previously reported in the literature. 3 0  !H NMR 
(400 MHz / CDCI3) d 7.72 (d, 2H, J=  8.2 Hz, 2 x Ts CH), 7.29 (d, 2H, J=  8.2 Hz, 2 x Ts CH), 
5.65 - 5.44 (m, 1H, CH), 5.29 - 5.08 (m, 1H, CH), 4.04 - 3.95 (m, 1H, CHN), 3.52 (s, 3H, CH3),
2.42 (s, 3H, Ts CH3), 2.41-2.36 (m, 2H, CH2), 1.62 (d, 3H, J  = 6.4 Hz, CH3), 13CNMR 
(400 MHz / CDCI3) S 171.4 (Q ), 142.0 (Q.), 136.8 (Cq), 129.7 (2 x Ts CH), 127.3 (CH), 127.2 
(2 x Ts CH), 123.4 (CH), 55.5 (CHN), 52.6 (CH3), 36.9 (CH2), 21.5 (Ts CH3), 18.5 (CH3).
(R1 = Me) (fs)-Methyl 2-methyl-2-(4-methylphenylsulfonamido)hex-4-enoate 185b 
183b (4.68 g, 19.1 mmol, 1.0 eq.) gave the sulfonamide 185b as a beige solid (1.30 g, 
Yield: 22%). All data obtained was in accordance with that previously reported in the literature. 3 0  
JH NMR (400 MHz / CDCI3) S 7.75 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.28 (d, 2H, J=  8.3 Hz,
(2 x 4 ml mmol'1); these organic solutions were discarded. The aqueous layer was adjusted to pH 9
(3 x 4 ml mmol'1). The combined organic extracts were dried over Na2 SC>4 and evaporated to yield
dissolved in dichloromethane (5 ml mmol'1) at -78 °C and treated with tosyl chloride (1.2 eq.),
(4 ml mmol'1) and the organic phase separated. The aqueous phase was further extracted with 
dichloromethane (2 x 4 ml mmol*1). The combined organic solutions were washed with brine,
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2 x Ts CH), 5.55 - 5.46 (m, 1H, CH), 5.26 - 5.17 (m, 1H, CH), 3.64 (s, 3H, CH,), 2.51 - 2.44 
(m, 1H, CHaHb), 2.39 - 2.34 (m, 1H, CHaHb), 2.41 (s, 3H, Ts CH,), 2.05 (d, 3H, J  = 6.5 Hz, CH,), 
1.40 (s, 3H, CH,). 13C NMR (400 MHz / CDC13) 3 173.4 (C„), 142.3 (C,), 138.6 (C,), 131.7 (CH),
129.7 (2 x Ts CH), 127.2 (2 x Ts CH), 123.6 (CH), 62.5 ( Q ,  53.2 (CH3), 43.6 (CH2), 22.4 (CH3),
21.5 (Ts CH3), 18.5 (CH3).
(R1 /-Pr) (£)-Methyl 2-isopropyl-2-(4-methylphenylsulfonaniido)hex-4-enoate 185c 
183c (1.93 g, 7.07 mmol, 1.0 eq.) gave the sulfonamide 185c as a beige solid (815 mg, 
Yield: 34%). 'H NMR (400 MHz / CDC13) 3 7.71 - 7.70 (m, 2H, 2 x Ts CH) 7.22 - 7.16 (m, 2H, 
2 x Ts CH), 6.36 (dq, 1H, J=  15.8, 7.2 Hz, CH), 5.91 (dt, 1H, J  = 15.8, 7.5 Hz, CH), 3.63 (s, 3H, 
CH,), 2.76 - 2.53 (m, 2H, CH2), 2.32 (s, 3H, Ts CH,), 1.43 (s, 3H, CH,), 2.40 - 2.38 (m, 4H, Ts 
CH, & CH), 1.05 (d, 3H,J =  6.9 Hz, CH,), 0.89 (d, 3H, J=  6.9 Hz, CH,). 13C NMR (400 MHz / 
CDC13) 3 172.6 (C,), 142.8 (Q ), 137.5 (C,), 131.5 (CH), 129.7 (2 x Ts CH), 127.3 (2 x Ts CH),
124.1 (CH), 69.5 (Cg), 52.4 (CH3), 37.4 (CH2), 35.1 (CH), 21.6 (Ts CH3), 17.7 (CH3), 17.4 (CH3). 
HRMS (El) m/z calcd. for CnH^NC^S [M+H]+ = 340.1538; found 340.1536.
Cyclisations of cinnamyl derivatives 1 7 7 30'119
TsHN Vs
184a R1 = H 177a R1 = H
184b R1 = Me 177b R1 = Me
184c R1 = /'-Pr 177c R1 = i-Pr
See Table 2.2 on p.36 form more details.
The sulphonamide 184 (100 mg, 1.0 eq.) was dissolved in dichloromethane (10 ml), cooled to 0 °C 
and triflic acid (0.5 eq.) was added. The reaction was allowed to warm to room temperature and 
stirred for 1 hour after which a sample (ca. 3 ml) was taken, which was quenched with saturated 
aqueous K2 CO3 . The two phases were separated and the aqueous layer was extracted with 
dichloromethane (3 x 1 0  ml). The combined organic layers were dried over K2 CO3 , filtered and 
evaporated. The remaining reaction mixture was allowed to stir at room temperature overnight, 
quenched with saturated aqueous K2 CO3 . The two phases were separated and the aqueous layer 
was extracted with dichloromethane (3 x 10 ml). The combined organic layers were dried over 
K2 CO3 , filtered and evaporated to give the title compound 111.
The sulphonamide 184 (100 mg, 1.0 eq.) was dissolved in dichloromethane (10 ml), cooled to 0 °C
and triflic acid (1.0 eq.) was added. The reaction was allowed to warm to room temperature and
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stirred for 1 hour after which a sample (ca. 3 ml) was taken, which was quenched with saturated 
aqueous K 2 C O 3 .  The two phases were separated and the aqueous layer was extracted with 
dichloromethane (3 x 10 ml). The combined organic layers were dried over K 2 C O 3 ,  filtered and 
evaporated. The remaining reaction mixture was allowed to stir at room temperature overnight, 
quenched with saturated aqueous K 2 C O 3 .  The two phases were separated and the aqueous layer 
was extracted with dichloromethane (3 x 10 ml). The combined organic layers were dried over 
K 2 C O 3 ,  filtered and evaporated the title compound 177.
The sulphonamide 184 (100 mg, 1.0 eq.) was dissolved in dichloromethane (10 ml), cooled to 0 °C 
and triflic acid (2.0 eq.) was added. The reaction was allowed to warm to room temperature and 
stirred for 1 hour after which a sample (ca. 3 ml) was taken, which was quenched with saturated 
aqueous K 2 C O 3 .  The two phases were separated and the aqueous layer was extracted with 
dichloromethane (3 x 10 ml). The combined organic layers were dried over K 2 C O 3 ,  filtered and 
evaporated. The remaining reaction mixture was allowed to stir at room temperature overnight, 
quenched with saturated aqueous K 2 C O 3 .  The two phases were separated and the aqueous layer 
was extracted with dichloromethane (3 x 10 ml). The combined organic layers were dried over 
K 2 C O 3 ,  filtered and evaporated the title compound 177.
The sulphonamide 184 (100 mg, 1.0 eq.) was dissolved in dichloromethane (10 ml), cooled to 0 °C 
and triflic acid (5.0 eq.) was added. The reaction was allowed to warm to room temperature and 
stirred for 1 hour after which a sample (ca. 3 ml) was taken, which was quenched with saturated 
aqueous K 2 C O 3 .  The two phases were separated and the aqueous layer was extracted with 
dichloromethane (3x10  ml). The combined organic layers were dried over K 2 C O 3 ,  filtered and 
evaporated. The remaining reaction mixture was allowed to stir at room temperature overnight, 
quenched with saturated aqueous K 2 C O 3 .  The two phases were separated and the aqueous layer 
was extracted with dichloromethane (3 x 1 0  ml). The combined organic layers were dried over 
K 2 C O 3 ,  filtered and evaporated the title compound 177.
(R1 = H) (2R S, 5RS) and (2R S, 5SR)-Methyl 5-phenyl-l-tosylpyrrolidine-2-carboxylate 177a
All data obtained was in accordance with that previously reported in the literature. 3 0  All samples 
showed identical spectroscopic and analytical data of inseperable diastereoisomers: *H NMR 
(500 MHz / C D C I 3 )  maior isomer: S 7.36 (d 2H, J=  8.3 Hz, 2 x Ts CH), 7.10 - 7.09 (m, 1H, 
2 x Ar CH), 6.96 - 6.94 (m, 3H, 3 x Ar CH), 6.85 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 4.85 (d, 1H, 
J=  8.3 Hz, CH), 3.82 (s, 3H, CH3), 2.52 - 2.24 (m, 2H, CH2), 2.16 (s, 3H, Ts CH3), 1.83 - 1.67 
(m, 2H, CH2), 1.77 (s, 3H, CH3); minor isomer: S 7.12 - 6.79 (m, 9H, 4 x Ts CH & 5 x Ar CH),
5.22 (dd, 1H, J=  2.6, 9.1 Hz, CH), 3.72 (s, 3H, CH3), 2.57-2.46 (m, 1H, CHAHB), 2.13-2.04 
(m,2H, CH2), 1.66 - 1.57 (m, 1H, CHaHb), 2.21 (s, 3H, Ts CH3), 1.80 (s, 3H, CH3). I3C NMR
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(500 MHz / CDC13) <5172.8 (C„), 143.4 (C9), 141.2 (C9), 129.3 (2 x Ts CH), 128.2 (Ar CH), 127.8 
(2 x Ar CH), 127.2 (2 x Ts CH), 127.0 (2 x Ar CH), 62.0 (CH), 61.9 (CH), 52.4 (C02 CH3), 38.9 
(CH2 ), 29.5 (CH2), 21.5 (Ts CH3) (due to ratio between isomers, minor isomer was not visible in 
13C spectrum). IR (nujol) u/cm'1: 1261, 1095, 800. HRMS (El) m/z calcd. for C19H2 2NO4 S [M+H]+ 
= 360.1270, found 360.1266.
(R1 = Me) (2R S , 5R S )  and (2R S ,  55,R)-Methyl 2-methyl-5-phenyl-l-tosylpyrrolidine-2- 
carboxylate 177b
All data obtained was in accordance with that previously reported in the literature. 3 0  All samples 
showed identical spectroscopic and analytical data of inseperable diastereoisomers: !H NMR 
(500 MHz / CDCI3 ) major isomer: S 7.36 (d, 2H, J=  8.2 Hz, 2 x Ts CH), 7.11 - 7.09 (m, 1H, 
2 x Ar CH), 6.94 - 6.93 (m, 3H, 3 x Ar CH), 6.85 (d, 2H, J=  8.2 Hz, 2 x Ts CH), 4.85 (d, 1H, 
J=  8.3 Hz, CH), 3.82 (s, 3H, CH3), 2.52 - 2.24 (m, 2H, CHi), 1.83 - 1.67 (m, 2H, CHi), 2.16 (s, 
3H, Ts CH3), 1.77 (s, 3H, CH3); minor isomer: S 7.12 - 6.79 (m, 9H, 4 x Ts Ctf & 5 x Ar CH),
5.22 (dd, J=  2.6, 9.1 Hz, CH), 3.72 (s, 3H, CH3), 2.57 - 2.46 (m, 1H, CHAHB), 2.13 - 2.04 (m, 2H, 
CH2), 1.66 - 1.57 (m, 1H, CHA/7B), 2.21 (s, 3H, Ts CH3), 1.80 (s, 3H, C/C,). 13C NMR (CDC13 / 
500 MHz, ppm) maior isomer: S 175.4 (C9), 142.8 (C9), 142.2 (C9), 139.2 (C9), 129.1 (2 x Ts 
CH), 128.6 (2 x Ts CH), 127.5 (2 x Ar CH), 127.3 (2 x Ar CH), 126.9 (Ar CH), 70.4 (C9), 65.9 
(CH), 53.1 (CH3), 39.0 (CH2), 33.4 (CH2), 24.6 (CH3), 21.8 (CH3); minor isomer: S 175.1 (C9),
143.3 (C9), 142.4 (C9), 137.3 (C9), 129.0 (2 x Ts CH), 128.6 (2 x Ts CH), 128.3 (2 x Ar CH),
127.4 (2 x Ar CH), 127.0 (Ar CH), 71.3 (C9), 63.5 (CH), 53.2 (CH3), 37.9 (CH2), 34.6 (CH2), 24.6 
(CH3), 23.3 (CH3). IR (neat): 2951, 1740, 1598, 1495, 1454, 1379, 1336, 1271, 1154, 1090, 1065, 
996,916,876, 815,757,733, 702, 6 6 8 . HRMS (El) m/z calcd. for C2 oH23N0 4S [M+l] = 374.1426, 
found 374.1412.
(R* = i-Pr) (2R S , 5R S )  and (2R S ,  5 .S7 f)-Methyl 2-isopropyl-5-phenyl-l-tosyIpyrrolidine-2- 
carboxylate 177c
All samples showed identical spectroscopic and analytical data: 'H NMR (500 MHz / CDC13) 
maior isomer: S 7.25 - 7.16 (m, 5H, 5 x Ar CH), 7.08 - 6.94 (m, 4H, 4 x Ar CH), 5.14 (app. dd, 
1 H ,J=  5.2,9.2 Hz, CH), 3.75 (s, 3H, C/7,), 3.06 - 2.98 (m, 1H, CH), 2.68 - 2.63 (m, 1H, C/7cHD),
2.24 - 2.21 (m, 1H, CT/HbC), 2.21 (s, 3H, Ts C/7,), 2.05 - 2.00 (m, 1H, CBaHbC), 1.89 - 1.84 (m, 
1H, CHc/foCH), 1.15 (d, 3H, J  = 6 . 6  Hz, CH3), 0.92 (d, 3H, 7  = 6 . 6  Hz, C/7,); minor isomer: 3
7.25 - 7.16 (m, 5H,5 x Ar CH), 7.08 - 6.94 (m, 4H, 4 x CH), 4.96 (t, 1H, 7 =  7.3 Hz, CH, minor),
3.77 (s, 3H, CH3), 3.37 - 3.32 (m, 1H, CH), 2.51 - 2.47 (m, 1H, C/74 HBC), 2.36 - 2.33 (m, 1H,
CZ/cHdCH), 2.20 (s, 3H, Ts CH3), 2.17 - 2.12 (m, 1H, CHA/7„C), 1.99 - 1.94 (m, 1H, CHc/70 CH),
1.17 (d, 3H, J  = 6 . 8  Hz, C/7,, minor), 0.94 (d, 3H, J  = 6 . 8  Hz, C/7,, minor). 13C NMR (500 MHz /
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CDC13) major & minor isomers: 8 173.4 (C?), 141.6 (C,), 141.5 (C„), 136.9 (C,), 127.6 ( 2  x Ts 
CH), 127.3 (2 x Ar CH) 126.9 (2 x Ts CH), 126.6 (2 x Ar CH), 126.4 (Ar CH.), 65.5 (C,), 51.0 
(CH3), 32.6 (CH2), 30.7 (CH), 29.2 (CH2), 20.4 (CH3), 19.2 (CH3), 17.8 (CH3). IR (nujol): 1748, 
1597, 1463, 1377, 1347, 1242, 1152, 1089, 1043, 1002, 819, 762, 722, 702, 677. HRMS (El) m/z 
calculated for C2 2H2 7NC>4 S [M+l] = 402.1739, found 402.1739.
Cyclisations for isomer ratio determination for crotyl derivatives 178
CC^Me
TsTsHN
185a R1 = H 
185b R1 = Me 
185c R1 = #-Pr
178a R1 = H 
178b R1 = Me 
178c R1 = /-Pr
See Table 2.4 on p.38 for further details.
The sulphonamide 185 (100 mg, 1.0 eq.) was dissolved in dichloromethane (10 ml), cooled to 0 °C 
and triflic acid (0.5 eq.) was added. The reaction was allowed to warm to room temperature; 
samples {ca. 3 ml) were taken after for 1 hour, 2 hours and 3 hours, which were quenched with 
saturated aqueous K 2 C O 3 .  The two phases were separated and the aqueous layer was extracted 
with dichloromethane (3 x 1 0  ml). The combined organic layers were dried over K 2 C O 3 ,  filtered 
and evaporated. The remaining reaction mixture was allowed to stir at room temperature 
overnight, quenched with saturated aqueous K 2 C O 3 .  The two phases were separated and the 
aqueous layer was extracted with dichloromethane (3x10  ml). The combined organic layers were 
dried over K 2 C O 3 ,  filtered and evaporated to give the title compound 178.
The sulphonamide 184 (100 mg, 1.0 eq.) was dissolved in dichloromethane (10 ml), cooled to 0 °C 
and triflic acid (0.5 eq.) was added. The reaction was allowed to warm to room temperature; 
samples {ca. 3 ml) were taken after for 1 hour, 2 hours and 3 hours, which were quenched with 
saturated aqueous K 2 C O 3 .  The two phases were separated and the aqueous layer was extracted 
with dichloromethane (3 x 1 0  ml). The combined organic layers were dried over K 2 C O 3 ,  filtered 
and evaporated. The remaining reaction mixture was allowed to stir at room temperature 
overnight, quenched with saturated aqueous K 2 C O 3 .  The two phases were separated and the 
aqueous layer was extracted with dichloromethane (3x10  ml). The combined organic layers were 
dried over K 2 C O 3 ,  filtered and evaporated to give the title compound 178.
The sulphonamide 184 (100 mg, 1.0 eq.) was dissolved in dichloromethane (10 ml), cooled to 0 °C 
and triflic acid (0.5 eq.) was added. The reaction was allowed to warm to room temperature;
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samples (ca. 3 ml) were taken after for 1 hour, 2 hours and 3 hours, which were quenched with 
saturated aqueous K 2 C O 3 .  The two phases were separated and the aqueous layer was extracted 
with dichloromethane (3 x 1 0  ml). The combined organic layers were dried over K 2 C O 3 ,  filtered 
and evaporated. The remaining reaction mixture was allowed to stir at room temperature 
overnight, quenched with saturated aqueous K 2 C O 3 .  The two phases were separated and the 
aqueous layer was extracted with dichloromethane (3 x 10 ml). The combined organic layers were 
dried over K 2 C O 3 ,  filtered and evaporated to give the title compound 178.
The sulphonamide 185 (100 mg, 1.0 eq.) was dissolved in dichloromethane (10 ml), cooled to 0 °C 
and triflic acid (0.5 eq.) was added. The reaction was allowed to warm to room temperature; 
samples (ca. 3 ml) were taken after for 1 hour, 2 hours and 3 hours, which were quenched with 
saturated aqueous K 2 C O 3 .  The two phases were separated and the aqueous layer was extracted 
with dichloromethane (3 x 1 0  ml). The combined organic layers were dried over K 2 C O 3 ,  filtered 
and evaporated. The remaining reaction mixture was allowed to stir at room temperature 
overnight, quenched with saturated aqueous K 2 C O 3 .  The two phases were separated and the 
aqueous layer was extracted with dichloromethane (3 x 1 0  ml). The combined organic layers were 
dried over K 2 C O 3 ,  filtered and evaporated to give the title compound 178.
(R1 = H) (2RS, 5R S )  and (2R S , 5<57?)-Methyl 5-methyl-l-tosylpyrrolidme-2-carboxylate 178a
All data obtained was in accordance with that previously reported in the literature. All samples 
showed identical spectroscopic and analytical data of inseperable diastereoisomers: 1H NMR 
(400 MHz / C D C I 3 )  major isomer: 3 7.68 (d, 2H, J=  8.2 Hz, 2 x Ts CH), 7.17 (d, 2H, J=  8.2 Hz, 
2 x Ts CH), 4.30 (dd, 1H, J=  7.8, 2.3 Hz, CH), 3.79 -  3.76 (m, 1H, CH), 3.72 (s, 3H, CH3), 2.35 
(s, 3H, Ts CH3), 2.35 -  1.34 (m, 4H, 2 x CH2), 1.26 (d, 3H, J=  6.5 Hz, CH3); minor isomer: 3 7.72 
(d, 2H, J=  8.2 Hz, 2 x Ts CH), 7.12 (d, 2H, J=  8.2 Hz, 2 x Ts CH), 4.39 (dd, 1H, J=  7.4, 2.8 Hz, 
CH), 4.07-4.05 (m, 1H, CH), 3.68 (s, 3H, CH3), 2.34 (s, 3H, Ts CH3), 2.27-1.31 (m, 4H, 
2 x CH2). 13C NMR (400 MHz / C D C I 3 )  major isomer: 3 174.4 (Cq), 148.7 (Cq), 142.6 (Cq), 128.8 
(2 x Ts CH), 127.0 (2 x Ts CH), 66.5 (CH), 58.2 (CH), 52.7 (CH3), 38.6 (CH2), 31.2 (CH2), 24.3 
(CH3), 21.9 (CH3); minor isomer: 3 174.8 (Cq), 148.9 (Q), 142.8 (Cq), 128.6 (2 x Ts CH), 127.3 
(2 x Ts CH), 68.4 (CH), 57.6 (CH), 52.8 (CH3), 38.3 (CH2), 31.5 (CH2), 23.9 (CH3), 21.7 (CH3).
(R1 =  Me) (2R S ,  5R S )  and (2R S ,  55R)-Methyl 2,5-dimethyl-l-tosylpyrrolidine-2-carboxylate 
178b
All data obtained was in accordance with that previously reported in the literature. 3 0  All samples 
showed identical spectroscopic and analytical data of inseperable diastereoisomers: ]H NMR (400 
MHz / C D C I 3 )  major isomer: 3 7.69 (d, 2H, J=  8.2 Hz, 2 x Ts CH), 7.12 (d, 2H, J — 8.2 Hz, 
2 x Ts CH), 3.87 - 3.86 (m, 1H, CH), 3.74 (s, 3H, CH3), 2.34 (s, 3H, Ts CH3), 2.32 - 1.39 (m, 4H,
2 x Cf/2), 1-52 (s, 3H, CH,),  1.15 (d, 3H, J -  6.5 Hz, C7 /?); minor isomer: 8 7.72 (d, 2H, 
J= 8.2 Hz, 2 * Ts CH), 7.10 (d, 2H, J=  8.2 Hz, 2 x j s CH), 4.07 - 4.06 (m, 1H, CH), 3.66 (s, 3H, 
CHS), 2.34 (s, 3H, Ts CH3), 2.21-1.27 (m, 4H, 2  x CH2), 1.70 (s, 3H, CH3), 1.03 (d, 3H, 
J= 6.5 Hz, CH}). 13C NMR (400 MHz / CDC13) major isomer: 8 174.6 (C9), 149.2 (C„), 143.9 
(C9), 129.8 (2 x Ts CH), 127.9 ( 2  x Ts CH), 67.4 (CH), 57.8 (CH), 52.9 (CH3), 39.1 (CH2), 32.0 
(CH2), 27.3 (CH3), 22.2 (CH3), 21.8 (Ts CH3); minor isomer: 8 175.2 (C9), 149.2 (C9), 143.6 (C9),
129.7 (2 x Ts CH), 127.3 (2 x Ts CH), 70.4 (CH), 57.9 (CH), 52.8 (CH3), 38.3 (CH2), 32.0 (CH2),
27.3 (CH3), 22.2 (CH3), 21 . 8  (Ts CH3).
tert- Butyl (4-methylcyclohex-3-enyl)methyl(tosyl)carbamate 193
OH ______ ^  ^ j j ^ J ^ ^ N T s B o c
1 9 2  1 9 3
4-Methylenecyclohexyl methanol 192 (500 mg, 3.96 mmol, 1.0 eq.) was reacted with N-(tert- 
butoxycarbonyl)-p-toluenesulfonamide (1.09 g, 4.00 mmol, 1.01 eq.) according to general 
procedure A using work up 2. The crude product was purified by flash column chromatography 
(eluting silica gel with dichloromethane) to give the title compound 193 as a white solid (940 mg, 
Yield 63%). m.p.: 99 -101 °C. ‘H NMR (400 MHz / CDC13) 8 7.77 (d, 2H, J=  8.4 Hz, 2 x Ts 
CH), 7.30 (d, 2H, J  = 8.4 Hz, 2  x Ts CH), 5.37 (app. br. s, 1H, CH), 3.79 - 3.76 (m, 2H, Ci/2N),
2.43 (s, 3H, Ts CH3), 2 .16-1.72 (m, 7H, 3 x CH2 & CH), 1.65 (s, 3H, CH3), 1.32 (s, 9H, Boc 
C(CH3h). 13C NMR (400 MHz / CDC13) 8 151.2 (C9), 144.0 (Cq), 137.5 (C,), 134.0 (C?), 129.2 
(2 x Ts CH), 127.8 (2 x Ts CH), 119.6 (CH), 84.1 (Cq), 52.5 (CH2N), 34.3 (CH), 29.7 (CH2), 29.3 
(CH2), 27.9 (Boc C(CHsh), 26.7 (CH2), 23.5 (CH3), 21.6 (Ts CH3). IR (neat) D/cm'1: 3020, 2923, 
1728, 1598, 1459, 1380, 1138, 1100, 839. HRMS (ES) m/z calcd. for C2 2 H3 2N2 0 4NaS 
[M+MeCNNaf = 443.1980; found 443.1999.
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l-methyl-2-tosyl-2-azabicyclo [2.2.2] octane 194
NTsBoc
193 194
The sulfonamide 193 (100 mg 0.26 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added triflic acid (0.20 ml, 0.13 mmol, 0.5 eq.) and stirred at 20 °C for 48 hours. The 
reaction was quenched by the addition of saturated aqueous K2 CO3 (15 ml) and the two layers 
were separated. The aqueous layer was extracted with dichloromethane (2 * 30 ml), the combined 
organic layers dried over K2 CO3 and evaporated to give the title compound 194 as a colourless oil 
(70 mg Yield: 96%). 'H NMR (400 MHz / CDC13) <5 7.65 (d, 2H, J  = 8.3 Hz, 2 x Ts CH), 7.21 
(d, 2H, J  = 8.3 Hz, 2 x Ts CH), 2.75 (app. d, 2H, J  = 6.4 Hz, 2 x GftN), 2.34 (s, 3H, Ts CH,), 
1.98 -1.90 (m, 1H, CH), 1.84 - 1.77 (m, 1H, Cf^H B), 1.69 - 1.57 (m, 2H, CHj) 1.52 (s, 3H, CH}), 
1.50-1.44 (m, 3H, CH2 & CHAHB), 1.33-1.24 (m, 2 H, CH2), 1.18-1.07 (m, 1 H, C%HB), 
0.95 - 0.75 (m, 1H, CHaHb). i3C NMR (500 MHz / CDC13) S 144.6 (C,), 134.1 (C„), 129.7 (2 x Ts 
CH), 127.1 (2 x Ts CH), 52.7 (C,), 48.5 (CH2N), 34.6 (CH), 33.6 (CH2), 31.0 (CH2), 29.3 (CH2),
25.9 (CH2), 24.7 (CH3), 21.5 (Ts CH3). IR (neat) u/cm’1: 2928, 1710, 1598, 1459, 1380, 1138, 839. 
HRMS (APCI) m/z calcd. for C,5H2 2N 02S [M+H]+ = 280.1371; found 280.1380.
4-(Trimethylsilyloxy)cyclohexanecarbaldehyde 197132
H
197196
MeaSiO
2-Trimethylsilyloxy-1,3-butadiene 195 (2.50 g, 17.6 mmol, 1.0 eq.) was mixed with acrolein 196 
(2.40 ml, 35.2 mmol, 2.0 eq.), hydroquinone (0.2 g, 1.76 mmol, 0.1 eq.) and dry toluene (70 ml). 
The resulting solution was heated at 110 °C for 24 hours. The solvent and any unreacted starting 
materials were evaporated and the residue distilled by Kugelrohr at 67 - 70 °C (1.2 mm) to give 
the title compound 197 as an orange oil (2.75 g, Yield: 79%). All data obtained was in accordance 
with that previously reported in the literature. 13 2 NMR (400 MHz / C D C I 3 )  S 9.46 (br. s, 1H, 
CH), 6.46 (br. s, 1H, CH), 2.32 -1.51 (m, 7H, 3 x CH2 & CH), 0.05 (s, 9H, Si(CH3)2). 13C NMR 
(400 MHz / CDClj) 8 202.4 (CHO), 149.6 (C,), 116.2 (CH), 47.3 (CH), 39.5 (CH2), 29.5 
(2 x CH2), 1.09 (Si(CH3)3).
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4-(Hydroxymethyl)cyclohexanone 198132
o
MeaSiO
H
O
OH
197 198
4-(Trimethylsilyloxy)cyclohexanecarbaldehyde 197 (4.00 g, 2 0 . 2  mmol, 1.0 eq.) was dissolved in 
tetrahydrofuran (20 ml) and added dropwise to a suspension of LiAlfLi (420 mg, 11,1 mmol, 
0.55 eq.) in tetrahydrofuran (40 ml) at -78 °C over 30 minutes. The suspension was allowed to 
warm to room temperature over 2 hours; the solution was then cooled to 0 °C and water (12 ml), 
15% NaOH(aq) and water (30 ml) were added sequentially. The solution was dried over MgSC>4 and 
evaporated to give a viscous orange oil. This oil was dissolved in methanol (50 ml), a few drops of 
2 M HC1 and were added and the resulting suspension stirred at 20 °C for 30 minutes. The 
methanol was evaporated and the residue dissolved in diethyl ether (30 ml), dried over MgSC>4 and 
evaporated to give the title compound 198 as a clear oil (1.54 g, Yield: 60%). All data obtained 
was in accordance with that previously reported in the literature. 132 *H NMR (400 MHz / C D C I 3 )  3
3.51 (d, 2H, .7=6.4 Hz, CH20), 2.52 (br. s, 1H, Otf), 2.40- 1.84 (m, 7H 3 x CH2 & CH), 
1.44 - 1.34 (m, 2H, CHi). 13C NMR (400 MHz / C D C I 3 )  3 202.4 (Cq), 47.3 (CH2 0), 39.8 (CH),
39.5 (2 x CH2), 25.5 (2 x CH2). HRMS (El) m/z calcd. for C7Hi2 0 2  [M]+= 128.0837; found 
128.0837.
(4-Oxocyclohexyl)methyl methanesulfonate 202133
4-(Hydroxymethyl)cyclohexanone 198 (500 mg, 3.90 mmol, 1.0 eq.) and triethylamine (0.82 ml,
5 . 8 6  ml, 1 . 5  eq.) were stirred in dichloromethane ( 2 0  ml), to which was added mesyl chloride 
(0.36 ml, 4.68 mmol, 1.2 eq.) slowly and stirred at 20 °C for 30 minutes. The solution was then 
washed with water (2 x 30 ml), 1 M HC1 (30 ml), water (30 ml), brine (30 ml), dried over Na2 S0 4  
and evaporated to give the title compound 202 as a clear oil (769 mg, Yield: 96%). *H NMR 
(400 MHz / CDCI3) 3 4.09 (d, 2H, J=  6.5 Hz, CH20), 2.97 (s, 3H, Ms CH3), 2.42 - 2.06 (m, 9H, 
4 x CH2 & CH). 13C NMR (400 MHz / CDC13) 3 210.3 (C?), 72.6 (CH2 0), 39.9 (2 x CH2), 37.5
O
198 202
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(Ms CH3), 35.9 (CH), 28.7 (2 x CH2). HRMS (El) m/z calcd. for C8Hi4 0 4S [M]+= 206.0613; 
found 206.0612.
terf-Butyl 5-methyl-2-(prop-l-en-2-yl)hex-4-enyl(tosyl)carbamate 213
OH NTsBoc
212 213
Lavandulol 212 (500 mg, 3.24 mmol, 1.0 eq.) was treated with Y-(fert-butoxycarbonyl)- 
p-toluenesulfonamide (890 mg, 3.27 mmol, 1.01 eq.) according to general method A using work 
up 2. The crude product was purified by flash column chromatography (eluting silica gel with 
dichloromethane) to give the title compound 213 as a clear oil (509 mg, Yield: 41%). !H NMR 
(400 MHz / CDC13) S 7.80 (d, 2H, J  = 8.3 Hz, 2 x Ts CH), 7.36 (d, 2H, J=  8.3 Hz, 2 x Ts CH),
5.12 - 5.05 (m, 1H, CH), 4.85 (s, 1H, C7^HB), 4.79 (s, 1H, CKAHB), 4.11 - 3.79 (m, 2H, Ctf2N), 
3.61 - 3.48 (m, 1H, CH), 2.46 (s, 3H, Ts CH3), 2.39 - 2.27 (m, 1H, CT^Hf), 2.13 - 1.99 (m, 1H, 
CHeHf ), 1.72 (s, 3H, CH3), 1.40 (s, 3H, CH,), 1.34 (s, 3H, C/7,), 1.22 (s, 9H, Boc C(CH3)i). 13C 
NMR (400 MHz / CDC13) <S 151.1 (Cq), 144.6 (Cq), 143.9 (Cq), 137.6 (Cq), 132.5 (2 * Ts CH),
131.2 (Cq), 129.1 (2 x Ts CH), 123.1 (CH), 114.2 (CH2), 84.0 (Cq), 49.7 (CH2N), 47.7 (CH), 27.8 
(Boc C(CH3)3), 26.4 (CH2), 25.8 (CH3), 21.6 (Ts CH3), 19.7 (CH3), 18.8 (CH3). IR (neat) n/cm'1: 
2979, 1732, 1645, 1598, 1459, 1380, 1138, 1100, 965, 839. HRMS (ES) m/z calcd. for 
C24 H36N2 0 4 NaS [M+MeCNNa]+ = 471.2293; found 471.2270.
((liy,27?)-2-Methyl-5-(propan-2-ylidene)cyclopentyl)methanol 215
215a 215
(15,2i?)-2-Methyl-5-(propan-2-ylidene)cyclopentanecarboxylic acid 215a (1.00 g, 5.95 mmol,
1 . 0  eq.) in dry diethyl ether (15 ml) was added dropwise to a suspension of lithium aluminium 
hydride (300 mg, 7.74 mmol, 1.3 eq.) in dry diethyl ether (40 ml) at 0 °C. The suspension was 
stirred at room temperature for 1.5 hours; the reaction was cooled to 0 °C and aqueous 2 M NaOH
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was added dropwise until a white precipitate had formed. The suspension was filtered and washed 
with diethyl ether (30 ml), the filtrate was dried over MgS04  and evaporated to give alcohol 215 
as a clear oil (916 mg, Yield: 100%). All data obtained was in accordance with that previously 
reported in the literature. 2 8 4  'H (400 MHz / CDC13) S 3.46 - 3.37 (m, 2H, CH20), 2.33 (br. s, 1H, 
OH), 2.28-2.21 (m, 1H, CH), 2.11 -1.98 (m, 2H, CH2), 1.86- 1.74 (m, 1H, CH), 1..65 (s, 3H, 
CHs), 1.56 (s, 3H, CHs), 1.25 -1.14 (m, 2H, CH2) 0.88 (d, 3H, J=  7.0 Hz, CHi).
tert-Butyl ((l/?,27?)-2-meth\i-5-(propan-2-ylidene)cyclopent\i)iiiethyI(tosyl)carbamate 216
NTsBoc
, /
216
Alcohol 215 (916 mg, 5.95 mmol, 1.0 eq.) was treated with according to general method A using 
work up 1 to give the title compound 216 as a clear oil (376 mg, Yield: 15%). *H NMR (400 MHz 
/ CDCI3) S 7.76 (d, 2H, J=  8.4 Hz, 2  x Ts CH), 7.23 (d, 2H, J=  8.4 Hz, 2 x Ts CH), 3.90 -  3.57 
(m, 3H, CH2N & CH), 2.73-2.69 (m, 1H, CHAHB), 2.39-2.35 (m, 1H, CHaHb\  1.79-1.67 
(m, 3H, CH2 & CH), 1.63 (s, 3H, CH3), 1.63 (s, 3H, CH3), 1.33 (s, 9H, Boc C(CH3)3), 1.23 (s, 3H, 
CH3). 13C NMR (400 MHz / CDC13) S 157.6 (Cq), 142.3 (Q), 140.1 (Cq), 137.2 (Cq), 129.7 (2 x Ts 
CH), 127.3 (2 x Ts CH), 123.3 (Cq), 84.6 (Cq), 44.7 (CH), 41.9 (CH2N), 32.8 (CH), 29.5 
( 2  x CH2), 28.6 (Boc C(CH3)3), 21.5 (Ts CH3), 19.7 ( 2  x CH3), 18.1 (CH3). HRMS (ES) m/z calcd. 
for C2 2H37N2 0 4  [M+NH/] = 425.2474; found 425.2480.
Preparation of anhydrous cerium (III) chloride from cerium (III) chloride heptahydrate 
(CeCl3.7H20 )
A 250 ml two-necked flask, round bottomed flask was equipped with a glass stopper and three- 
way stopcock, the flask is connected to a trap that is cooled to -78 °C and attached to a vacuum 
pump. The flask is charged with powdered cerium (III) chloride heptahydrate (CeCl3 .7 H2 0 ) 
(1.38 g, 3.70 mmol) and evacuated to 0.1 -0.2 mm. After gradual warming to 90 °C over 30 
minutes with an oil bath, the flask is heated at 90- 100 °C for 2 hours with intermittent shaking. 
The system is filled with dry N2  and cooled to room temperature. The solid is transferred to a 
mortar and quickly pulverised with a pestle. The resulting white powder and magnetic stirring bar 
are placed in the original flask. Gradual wanning to 90 °C at 0.1 -0.2 mm over 30 minutes,
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followed by evacuating at 90 - 100 °C for 1.5 hours with intermittent shaking, gives cerium (III) 
chloride monohydrate (CeCls.EkO). The cerium (El) chloride monohydrate is gradually warmed to 
140 °C over 30 minutes under reduced pressure (0.1 -0.2 mm) without stirring. Heating at 
140 - 150 °C at 0.1 - 0.2 mm for 2 hours with gentle stirring affords a fine, white powder of 
anhydrous cerium (III) chloride. While the flask is still hot, the area that was not immersed in the 
oil bath was heated with a heat gun in order to remove the last traces o water. After introduction of 
nitrogen gas into the flask, the resulting anhydrous cerium (III) chloride was cooled to room 
temperature. One of the glass stoppers is replaced by a rubber septum under a stream of dry 
nitrogen.
(Zs)-l-Allylidene-2,3-dihydro-lH-indene and 3-allyl-lH-indene 224
o
223 224a 224b
CeCU (3.70 g, 15 mmol, 1.5 eq.) was suspended in tetrahydrofuran (30 ml) and stirred overnight. 
The suspension was cooled to 0 °C and indanone 223 (1.32 g, 10 mmol, 1.0 eq.) in tetrahydrofuran 
(10 ml) was added and stirred at 20 °C for 1 hour. Allylmagnesium grignard (10 ml, 20 mmol,
2.0 eq.) was added, resulting in an orange colour. After 30 minutes the suspension was cooled to 
0 °C, triethylamine (10.0 ml, 72 mmol, 7.2 eq.) and methanesulfonyl chloride (1.60 ml, 20 mmol,
2.0 eq.) were added sequentially and the suspension was warmed to 20 °C over 1 hour. Water 
(10 ml) and concentrated HC1 (10 ml) were added, and stirred for 30 minutes. The yellow mixture 
was extracted with diethyl ether (3 x 30 ml) and the combined organic phases were washed with 
saturated aqueous NaHCC>3 (2 x 30 ml) and brine (30 ml). The organic phase was then dried over 
MgSC>4 and evaporated to afford the title compounds 224 as a brown oil (1.55 g, Yield: 99%). All 
data obtained was in accordance with that previously reported in the literature. 2 8 5 *H NMR (400 
MHz / CDC13) (major = 224b, minor = 224a) S 7.69 (dd, 1H, J=  0.5, 7.2 Hz, Ar CH, major), 7.52 
(dt, 1H, J=  1.1, 7.4 Hz, Ar CH, major), 7.44 - 7.10 (m, 6 H, 2 x Ar CH, major & 4 x Ar CH, 
minor), 6.59 - 6.23 (m, 2H, 2 x CH, minor), 6.18 - 6.16 (m, 1H, CH, major), 6.03 - 5.91 (m, 1H, 
CH, major), 5.20 (dd, 1H, J=  16.0, 1.7 Hz, CHaHb, minor) 5.11 (dd, 1H, J=  17.2, 1.6 Hz, CHAHB, 
major), 5.06 (dd, 1H, J=  10.1, 1.7 Hz, CHa#s, minor), 5.04 (dd, 1H, J=  10.1, 1.6 Hz, CHaHb, 
major), 3.70-3.65 (m, 2 H, CH2, major), 3.11 -3.05 (m, 2H, CH2, minor), 2.65-2.60 (m, 2H, 
CH2, minor), 1.80 - 1.75 (m, 2H CH2, major). IR (neat) u/cm'1: 3020,2931, 1711, 1608, 1459, 750. 
LRMS (APCI) 174.09 (M+NH4 , 100%).
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(E)~3-(2,3-Dihydro-lH-inden-l-ylidene)propan-l-ol and 3-(lH-inden-3-yl)propan-l-ol 225
OH OH
224a 224b 225a 225b
9-BBN (21.0 ml, 10.3 mmol, 2.0 eq.) was added to 224 (800 mg 5.12 mmol, 1.0 eq.) and heated to 
80 °C for 1 hour. The reaction mixture was then cooled to room temperature and carefully treated 
with 5 M NaOH (5 ml) followed by 30 wt. % hydrogen peroxide in water (5 ml) and heated at 
60 °C for 1 hour. The reaction was cooled to room temperature and the aqueous layer was 
saturated with K 2 C O 3 ;  the organic layer was separated, dried over MgSC>4 and evaporated to give 
crude 225, which was used in the next step without further purification.
(E)-tert-Butyl 3-(2,3-dihydro-lH-inden-l-ylidene)propyl(tosyl)carbamate and tert-butyl 3- 
(lH-inden-3-yl)propyl(tosyl)carbamate 226
NTsBoc
225a 225b 226a 226b
Crude alcohol 225 (2.29 g, 13.2 mmol, 1.0 eq.) was treated with jV-(tert-butoxycarbonyl)- 
p-toluenesulfonamide (3.60 g, 13.3 mmol, 1.01 eq.) according to general procedure A, using work 
up 2. The crude product was purified by flash column chromatography (eluting silica gel with 
2 0  - 40 % ethyl acetate in hexanes followed dichloromethane) to give the sulfonamides 226 as an 
orange oil (588 mg, Yield: 11%). *H NMR (400 MHz / CDCI3) (major = 226b, minor = 226a) 
d 7.85 (d, 4H, J=  8.3 Hz, 4 x Ts CH, major and minor), 7.73 - 7.65 (m, 2H, Ar. CH, major and 
minor), 7.60 - 7.56 (m, 2H, Ar. CH, major and minor), 7.48 (m, 2H, Ar. CH, major and minor), 
7.31-7.10 (m, 6 H, Ar. CH, major; Ar CH, minor; 2 x Ts CH, major; 2 x Ts CH, minor), 
5.70 - 5.56 (m, 1H, CH minor isomer), 4.60 (t, 1H, J=  4.6 Hz, CH major isomer), 3.15 - 3.12 (m, 
1H, CHaRq, major and minor), 2.70-2.67 (m, 1H, CHAHB, major and minor), 2.43 (s, 3H, Ts 
CH3, major and minor), 2.21-2.12 (m, 2H, CH2, major and minor), 1.82 - 1.80 (m, 2H, CH2, 
major and minor), 1.68 - 1.47 (m, 2H, CH2, major and minor), 1.38 (s, 9H, Boc C(CH3)3, major 
and minor). 13C NMR (400 MHz / CDC13) (only the major isomer was visible) S 155.2 (Cq), 150.7 
(Q), 143.9 (Cq), 137.8 (Q), 137.1 (Cq), 134.6 (Ar CH), 133.6 (Cq), 129.4 (2 x Ts CH), 127.7 
(2 x Ts CH), 127.3 (Ar CH), 126.7 (Ar CH), 126.2 (CH), 123.7 (Ar CH), 84.0 (Cq), 36.2 (CH2N),
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34.3 ( 2  x CH2), 28.0 (Boc C(CH3)3), 25.8 (CH2), 21.6 (Ts CH3). HRMS (ES) m/z calc, for 
C19H2 2NO2 S [M+H]+ = 328.1371; found 328.1371.
3-(3-Chloropropyl)-lH-mdene 235
2 3 4  235
Indene 234 (1.00 g, 8.61 mmol, 1.0 eq.) was dissolved in tetrahydrofuran (50 ml) and cooled to 
0 °C, 2.5. M w-BuLi in hexanes (3.5 mmol, 8.69 mmol, 1.01 eq.) was added dropwise and the 
mixture was stirred for 30 minutes. The reaction mixture was then cooled to -78 °C, 1-chloro-
3-iodopropane 233 (2.30 ml, 21.5 mmol, 2.5 eq.) was added and the reaction mixture was allowed 
to warm to room temperature overnight. The reaction was quenched by the addition of saturated 
aqueous NH4 CI and extracted with diethyl ether (3 x 30 ml). The combined organic layers were 
washed with brine (2 x 30 ml), dried over MgSC>4 and evaporated. The residue was purified by 
flash column chromatography (eluting silica gel with 40% ethyl acetate in hexanes) to give the title 
compound 235 as an orange oil (1.25 g, Yield: 75%). *H NMR (500 MHz / CDCI3 ) S 7.41 - 7.12 
(m, 4H, 4 x Ar CH), 6.26 - 6.24 (m, 1H, CH), 3.64 (t, 2H, J=  6.1 Hz, CH2C\), 3.33 (d, 2H, 
J=  6.5 Hz, CH2), 2.25-2.19 (m, 2H, CH2), 2.19-2.13 (m, 2H, CH2). 13C NMR (400 MHz / 
CDCI3) S 145.1 (Cg), 144.5 (Cq), 142.8 (Cq), 128.7 (Ar CH), 126.1 (Ar CH), 124.7 (Ar CH), 123.9 
(Ar CH), 118.9 (CH), 44.8 (CH2 C1), 37.8 (CH2), 35.4 (CH2), 31.8 (CH2). IR (neat) u/cm'1: 3068, 
2923, 1712, 1602, 1459, 750, 700. HRMS (El) m/z calcd. for Ci2H13C1 (Cl35) [M]+= 192.0706; 
found 192.0705.
2-(3-(lH-Inden-3-yl)propyl)isoindolme-l,3-dione 236
The chloride 235 (796 mg, 4.13 mmol, 1.0 eq.) was dissolved in A,vV-dimethylformamide (50 ml), 
treated with phthalimide potassium salt (1.50 g, 8.25 mmol, 2.0 eq.) and heated to 90 °C for 
2 hours. The reaction mixture was cooled to room temperature, water (30 ml) was added and the
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aqueous layer extracted with diethyl ether (3 x 30 ml). The combined organic layers were washed 
with water (3 x 30 ml), brine (30 ml), dried over MgSC>4 and evaporated to give the title compound 
236 as orange oil (1.23 g, Yield: 98%). All data obtained was in accordance with that previously 
reported in the literature. 2 8 6  'H NMR (500 MHz / CDCI3) 8 7.77 -  7.64 (m, 4H, 4 x Ar CH),
7.35 - 7.09 (m, 4H, 4 x Ar CH), 6.23 - 6.21 (m, 1H, CH), 3.75 (t, 2H, J=  7.2 Hz, CftN), 3.23 
(d, 2H, J=  1.9 Hz, CHi), 2.55 (app. dt, 2H, 7 =  8.0, 1.7 Hz, CHi), 2.08 - 2.01 (m, 2H, CH2). I3C 
NMR (500 MHz / CDC13) 8 168.5 (2 x Cq), 145.1 (Cq), 144.4 (C„), 143.1 (C,), 134.0 (2 x Ar CH),
132.3 (2 x Cg), 128.3 (Ar CH), 126.1 (Ar CH), 124.6 (Ar CH), 123.8 (Ar CH), 123.2 (2«A r CH),
118.9 (CH), 38.0 (CH2N), 37.8 (CH2), 26.7 (CH2), 25.1 (CH2). IR (neat) u/cm'1: 3063,2939, 1712, 
1612,1459,750. HRMS (Cl) m/z calcd. for C2 0 H |8NO2  [M+H]+ = 304.1338; found 304.1336.
V-(3-(lH-Inden-3-yl)propyI)-4-me(hylbenzenesi]lfonamide 237
NHTs
The phthalimide 236 (1.23 g, 4.06 mmol, 1.0 eq.) was treated according to general method B to 
give the sulfonamide 237 as a viscous orange oil (584 mg, Yield: 44%). All data obtained was in 
accordance with that previously reported in the literature.2 8 7  'H NMR (400 MHz / CDCI3) 8 7.55 
(d, 2H,J =  8.3 Hz, 2 x Ts CH), 7.28 (br. d, 1H, J=  7.3 Hz, Ar. CH), 7.36 - 7.00 (m, 5H, 3 x Ar. 
CH & 2 x Ts CH), 5.70 - 5.56 (m, 1H, CH), 3.15 - 3.12 (m, 1H, CHAHB), 2.70 - 2.67 (m, 1H, 
CUaHb), 2.43 (s, 3H, Ts CH}), 2.21 - 2.12 (m, 2H, CH2), 1.82 - 1.80 (m, 2H, CH2), 1.68 -1.47 
(m, 2H, CH2). 13C NMR (400 MHz / CDCI3 ) 8 143.9 (2 x C„), 137.8 (Cq), 137.1 (C,), 133.4 (C,),
134.6 (Ar CH), 129.4 (2 x Ts CH), 127.7 (2 x Ts CH), 127.3 (Ar CH), 126.7 (Ar CH), 123.7 (Ar 
CH), 60.0 (CH), 36.2 (CH2N), 34.3 (2 x CH2), 25.8 (CH2), 21.6 (Ts CH>). IR (neat) u/cm'1: 3280, 
3064, 2926, 1712, 1598, 1459, 1380, 1139, 854, 750. HRMS (APCI) m/z calcd. for CI9 H2 2N0 2S 
[M+H]+ = 328.1371; found 328.1359.
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(2i)-2-(4-PhenyIbut-3-enyloxy)isoindoline-l,3-dione 263
£)-Phenylbut-3-en-1 -ol 157 (1.36 g, 9.22 mmol, 1.0 eq.) was treated with rV-hydroxyphthalimide 
(1.52 g, 9.31 mmol, 1.01 eq.) according to general procedure A using work up 2. The crude 
product purified by flash column chromatography (eluting silica gel with 40% ethyl acetate in 
hexanes) to give the title compound 263 as a yellow solid (535 mg, Yield: 20%). m.p.: 74 - 76 °C. 
*H NMR (400 MHz / C D C I 3 )  S 7.76 (app. d d , 2H, J=  7.7, 1.3 Hz, 2 x Ar CH), 7.67 (app. d d , 2H, 
J=  7.7, 1.3 Hz, 2 x Ar CH), 7.32 - 7.11 (m, 5H, 5 x Ar CH), 6.49 (d , 1H, J=  15.8 Hz, CH), 6.21 
(td , 1H, J=  6 .8 , 15.8 Hz, CH), 4.27 ( t ,  2H, J  = 6 . 8  Hz, CH2O ), 2.70 - 2.63 (m, 2H, CH2). 13C 
(400 MHz / C D C I 3 )  <5 163.7 (2 x c q), 140.3 (2 x Cq), 137.2 (C,), 134.5 (2 x Ar CH), 132.7 (Ar 
CH), 128.5 (2 x Ar CH), 127.3 (CH), 126.2 (2 x Ar CH), 124.7 (CH), 123.6 (2 x Ar CH), 77.4 
(CH20), 31.9 (CH2). HRMS (APCI) m/z calcd. for Ci8H16N 0 3 [M+H]+ = 294.1130; found 
294.1133.
(E)-4-MethyWV-(4-phenylbut-3-enyloxy)benzenesulfonamide 264
NHTs
The phthalimide 263 (535 mg, 1.83 mmol, 1.0 eq.) was treated according to general method B and 
the crude product was purified by flash column chromatography (eluting silica gel with 
dichloromethane) to give the sulfonamide 264 as a yellow solid (462 mg, Yield: 62%). !H NMR 
(400 MHz / CDC13) S 7.77 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.38 - 7.18 (m, 7H, 5 x Ar CH & 2 x Ts 
CH), 6.42 (d, 1H, J = 15.8 Hz, CH), 6.16 (td, 1H, J  = 6.9, 15.8 Hz, CH), 4.13 (t, 2H, J  = 6.9 Hz, 
CH20), 2.54 - 2.49 (m, 2H, CH3), 2.39 (s, 3H, Ts CH,). 13C NMR (400 MHz / CDCI3) <5 139.9 
(Cq), 137.2 (C,), 133.4 (C,), 132.2 (CH), 129.7 (2 x Ts CH), 129.7 (2 x Ts CH), 128.7 (2 x Ar 
CH), 128.6 (2 x Ar CH), 127.3 (CH), 126.1 (Ar CH), 76.3 (CH20), 29.9 (CH2), 21.7 (Ts CH3). 
HRMS (APCI) m/z calcd. for Ci7H2 0NO3S [M+H]+ = 318.1164; found 318.1170.
153
3-Phenyl-2-tosylmorpholine 265
NHTs
264 265
The sulfonamide 264 (100 mg, 0.27 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.20 ml, 0.14 mmol, 0.5 eq.) and the resulting solution stirred at room 
temperature for 24 hours. The reaction was quenched with saturated aqueous K 2 C O 3  and the two 
layers separated. The aqueous layer was extracted with dichloromethane (3 * 10 ml), the combined 
organic layers dried over K 2 C O 3  and evaporated to give the title compound 265 as a white solid 
(70 mg, Yield: 70%). m.p.: 92 - 95 °C. *H NMR (400 MHz / CDCI3 ) <5 7.62 (d, 2H, J  = 8.3 Hz, 
2 x Ts C H ) ,  7.33 - 7.20 (m, 7H, 5 x Ar C H  & 2 x Ts C H ) ,  4.89 (t, 1 H, J  = 4.9 Hz,CHN),
4.39 - 4.31 (m, 1H, CH^HbO), 4.10 - 4.03 (m, 1H, CHaHbO), 2.41 (s, 3H, Ts C H i ) ,  2.27 - 2.19 (m, 
1H, CHcHd), 2.06- 1.98 (m, 1H, CHcH D ) ,  1.65- 1.53 (m, 2H, C H 2 ) .  13C NMR (400 MHz / 
CDCI3) S 144.1 ( C g ) ,  139.3 ( C g ) ,  133.6 ( C q ) ,  129.2 (2 x Ts CH), 128.8 (2 x Ar CH), 128.1 (2 x Ar 
CH), 127.6 (2 x Ts CH), 127.2 (Ar CH), 71.4 (CH2 0), 59.7 (CHN), 30.0 (CH2), 21.7 (Ts CH3),
20.8 (CH2). IR (neat) u/cm'1: 2954, 1598, 1462, 1139, 1100, 825, 750, 690. HRMS (APCI) m/z 
calcd. forCi7H2oN03S [M+H]+ = 318.1164; found 318.1171.
(2s)-2-(Pent-3-enyloxy)isoindoline-l,3-dione 266
o
(£)-Pent-3-en-l-ol 153 (1.19 g, 13.79 mmol, 1.0 eq.) was treated with Y-hydroxyphthalimide 
(2.30 g, 13.93 mmol, 1.01 eq.) according to general method A using work up 2. The crude product 
was purified by flash column chromatography (eluting silica gel with dichloromethane) to give the 
title compound 266 as a clear oil (1.29 g, Yield: 41%). *H NMR (400 MHz / CDCI3) 3 7.77 (app. 
dd, 2H, J=  7.7, 1.3 Hz, 2 x Ar CH), 7.66 (app. dd, 2H, J  = 7.7, 1.3 Hz, 2 x Ar CH), 5.49 - 5.59 
(m, 1H, CH), 5.37 - 5.44 (m, 1H, CH), 4.14 (t, 2H,J =  7.0 Hz, CH2O), 2.40 - 2.46 (m, 2H, CH2), 
1.59 (d, 3H, J=  6.3 Hz, CH3). LRMS (ES) 232.09 (M+H+, 8 6 %), 288 (M+NH4+, 59%).
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(£)-4-MethyWV-(pent-3-enyloxy)benzenesulfonamide 267
266
(£)-2-(Pent-3-enyloxy)isoindoline-l,3-dione 266 (1.29 g, 5.56 mmol, 1.0 eq.) was treated 
according to general method B and the crude product was purified by flash column 
chromatography (eluting silica gel with dichloromethane) to give the sulfonamide 267 as a yellow 
solid (716 mg, Yield: 51%). !H NMR (400 MHz / CDCI3) S 7.80 (d, 2H, J=  8.3 Hz, 2 x Ts CH),
7.35 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 5.63 - 5.48 (m, 1H, CH), 5.42 - 5.33 (m, 1H, CH), 4.15 - 4.10 
(m, 2H, CH2O), 2.46 (s, 3H, Ts C/6 ), 2.34 - 2.26 (m, 2H, CH2), 1.70 (d, 3H, J=  6.2 Hz, C/6 ). 13C 
NMR (400 MHz / CDCI3) 6 144.7 (C,), 133.3 (C„), 131.5 (CH), 130.41 (CH), 129.9 (2 x Ts CH),
127.9 (2 x Ts CH), 66.9 (CH2 0), 31.2 (CH2), 21.7 (Ts CH3), 14.7 (CH3). HRMS (ES) m/z calcd. 
for Ci2Hi8N03S [M+H]+ = 256.1007; found 256.1019.
3-Ethyl-2-tosylisoxazolidine 269
NHTs
267 269
The sulfonamide 267 (50 mg 0.19 mmol, 1.0 eq.) was dissolved in dichloromethane (5 ml), to 
which was added triflic acid (0.15 ml, 0.09 mmol, 0.5 eq.). The resulting solution was stirred at 
0 °C for 24 hours and then quenched with saturated aqueous K2 CO3 (15 ml). The two layers were 
separated, the aqueous layer was extracted with dichloromethane (2x15  ml), the combined 
organic layers dried over K2 CO3 and evaporated to give the title compound 269 as an orange oil 
(32 mg Yield: 64%). 'H NMR (400 MHz / CDC13) <5 7.75 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 121 
(d, 2H, J=  8.3 Hz, 2  x Ts CH), 4.13 - 3.87 (m, 2H, CH20), 2.38 (s, 3H, Ts C/6 ), 2.31 - 2.23 
(m, 1H, CHH), 1.92 -1.84 (m, 2H, CH2), 1.69 - 1.60 (m, 2H, C/6 ), 1.14 (t, 3H, 7=  7.4 Hz, C/6 ). 
13C NMR (400 MHz / CDCI3 ) S 142.6 (C,), 139.8 (C,), 129.4 (2 x Ts CH), 127.1 (2 x Ts CH),
69.9 (CH2 0), 6 6 . 8  (CHN), 34.5 (CH2), 28.8 (CH2), 21.6 (Ts CH3), 10.9 (CH3). IR (neat) u/cm'1: 
2965, 1597, 1459, 1380, 1138, 1100, 839. HRMS (ES) m/z calcd. for Ci2H18N 03S 
[M+H]+ = 256.1007; found 256.1009.
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2-((4-Methylcyclohex-3-enyl)methoxy)isoindoIine-l,3-dione 270
OH
270192
4-Methyl-cyclohex-3-enyl)-methanol 192 (500 mg, 3.97 mmol, 1.0 eq.) was treated with 
iV-hydroxyphthalimide (650 mg, 4.01 mmol, 1.01 eq.) according to general procedure A using 
work up 1 to give the title compound 270 as a clear oil (1.08 g, Yield: 100%). ]H NMR (400 MHz 
/ CDCls) S 7.60 (app. dd, 2H, J=  7.7, 1.3 Hz, 2 x Ar CH), 7.47 (app. dd, 2H, J=  7.7, 1.3 Hz,
2 x Ar CH), 5.40 - 5.35 (m, 1H, CH), 3.70 - 3.65 (d, 2H, J=  6.5 Hz, CH2O), 2.21 -1.91 (m, 3H,
3 x Ci^He), 1.81-1.76 (m, 1H, CH), 1.65 (s, 3H, CH3), 1.43 - 1.32 (m, 3H, 3 x CUAHB). 13C 
NMR (400 MHz / CDC13) S 161.0 (2 x Cq), 134.4 (3 x Cq), 132.2 (2 x Ar CH), 128.5 (2 x Ar CH),
123.5 (CH), 82.9 (CH2 0), 32.5 (CH), 29.0 (CH2), 28.1 (CH2), 25.5 (CH2), 21.9 (CH3). IR (neat) 
u/cm’1: 3020, 2980,1733,1458, 1380, 1100, 964, 750.
4-Methyl-Ar-((4-methylcyclohex-3-enyl)methoxy)benzenesulfonamide 271
270
q ^NHTs
271
2-((4-Methylcyclohex-3-enyl)methoxy)isoindoline-l,3-dione 270 (1.08 g, 3.97 mmol, 1.0 eq.) was 
treated according to general procedure B and the crude product purified by flash column 
chromatography to give the sulfonamide 271 as a white solid (749 mg, Yield: 64%). 
m.p: 119 -124 °C. ‘H NMR (400 MHz / CDC13) S 7.67 (d, 2H, J=  8.4 Hz, 2 x Ts CH), 7.20 
(d, 2H, J=  8.4 Hz, 2 x Ts CH), 5.36 - 5.32 (m, 1H, CH), 4.11 - 3.97 (m, 2H, CH2O) 2.42 (s, 3H, 
Ts CHi), 2.10-1.71 (m, 4H, 2 x CH2), 1.65 (s, 3H, CH3), 1.36 - 1.23 (m, 3H, CH2 & CH). IR 
(neat) n/cm'1: 3060, 2956, 1597, 1459, 1380, 1100, 964, 839. HRMS (ES) calcd. for C15H2 0NO3 S 
[M-H]+ = 294.1164; found 294.1151.
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2-tosyl-3-oxa-2-azabicyclo [3.2.2] nonane 272
NHTs
271 272
The sulfonamide 271 (50 mg 0.17 mmol, 1.0 eq.) was dissolved in dichloromethane (5 ml), to 
which was added TfOH (0.13 ml, 0.09 mmol, 0.5 eq.) and the resulting solution stirred at 0 °C for 
24 hours. The reaction was quenched with saturated aqueous K2 CO3 and the two layers separated. 
The aqueous layer was extracted with dichloromethane (3x10  ml), the combined organic layers 
dried over K2 CO3 and evaporated to give the title compound 272 as an orange oil (43 mg 
Yield: 8 6 %). 'H NMR (400 MHz / CDC13) S 7.59 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.12 (d, 2H, 
J=  8.3 Hz, 2 x Ts CH), 4.04 - 3.74 (m, 2H, CH20), 2.33 (s, 3H, Ts CH3), 2.00 - 0.70 (m, 9H, 
4 x CH2 & CH), 1.55 (s, 3H, CH3). 13C NMR (400 MHz / CDC13) <5134.0 (C,), 132.8 (C,), 129.4 
(2 x Ts CH), 127.3 (2 x Ts CH), 73.4 (CH2 0), 54.1 (C,), 36.7 (CH), 32.8 (2 * CH2), 23.6 
(2 x CH2), 21.8 (CH3), 21.5 (Ts CH3). IR (neat) u/cm"1: 2925, 1597, 1469, 1380, 1148, 1100, 845. 
HRMS (El) m/z calcd. for Ci8Hi7N 0 3S [M]+ = 295.1208; found 295.1217.
2-(3-Methylcyclohex-2-enyloxy)isoindoline-l,3-dione 274a
274a273a
3-Methyl-2-cyclohexen-1 -ol 273a (500 mg, 4.46 mmol, 1.0 eq.) was treated with
N-hydroxyphthalimide (735 mg, 4.5 mmol, 1.01 eq.) according to general method A using work 
up 2 and purified the crude product by flash column chromatography (eluting silica gel with 40% 
ethyl acetate in hexanes) to give the title compound 274a as a white solid (606 mg, Yield: 53%). 
m.p: 105 - 107 °C. JH NMR (400 MHz / CDC13) S 7.78 (app. dd, 2H, J  = 7.71.3 Hz, 2 x Ar CH), 
7.68 (app. dd, 2H, J = 7.7, 1 . 3  Hz, 2 x Ar CH), 5.60 (s, 1H, CH), 4.70 - 4.65 (m, 1H, CHO), 1.66 
(s, 3H, CH3), 1.65 - 1.56 (m, 6 H, 3 x CH2). HRMS (ES) m/z calcd. for C15H19N2 O3 
[M+NKUf = 275.1396; found 275.1399.
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4-Methyk/V-(3-methylcyclohex-2-enyloxy)benzenesulfonamide x275a
274a
NHTs
275a
The phthalimide 274a (606 mg, 2.36 mmol, 1.0 eq.) was treated according to general procedure B 
and the cmde product was purified by flash column chromatography (eluting silica gel with 
dichloromethane) to give the sulfonamide 275a as a yellow oil (414 mg, Yield: 65%). lH NMR 
(400 MHz / CDC13) S 7.82 (d, 2U ,J=  8.3 Hz, 2 x Ts CH), 7.34 (d, 2H, J=  8.3 Hz, 2  x Ts CH),
5.51 -447 (m, 1H, CH), 4.51-4.45 (m, 1H, CHO), 2.44 (s, 3H, Ts CH3), 1.93 - 1.86 (m, 3H, 
3 x CHaRb), 1.68 (s, 3H, CH3), 1.67 - 1.52 (m, 3H, 3 x CHaHb). 13C NMR (400 MHz / CDCI3) d
143.6 (Cq), 140.7 (Cq), 136.4 (Cq), 129.6 (2 x Ts CH), 129.4 (2 x Ts CH), 125.6 (CH), 77.0 (CH2),
36.6 (CH), 30.6 (2 x CH2), 23.4 (CH3), 21.8 (CH3). HRMS (ES) m/z calcd. for Ci4 H2 0NO3S 
[M+H]+ = 282.1164; found 282.1154.
(l/?,5£)-l-Methyl-7-tosyl-6-oxa-7-azabicyclo [3.2.1] octane 276a
TsN O
276a
The sulfonamide 275a (100 mg 0.36 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.26 ml, 0.18 mmol, 0.5 eq.) and the resulting solution stirred at 0 °C for 
24 hours. The reaction was quenched with saturated aqueous K 2CC>3 and the two layers separated. 
The aqueous layer was extracted with dichloromethane ( 3  x 10 ml), the combined organic layers 
dried over K 2C C >3 and concentrated to give the title compound 276a a yellow oil (86 mg 
Yield: 8 6 %). 'H NMR (400 MHz / C D C I 3 )  3 7.76 (d, 2H, J=  8.3 Hz, 2 x Ts C H ) ,  7.28 (d, 2H, 
J=  8.3 Hz, 2 x Ts C H ) ,  4.39 - 4.30 (m, 1 H, C H O ) ,  2.39 (s, 3H, Ts C H 3 ) ,  2.21 -1.84 (m, 2H, C H 2 ) ,
1.67 - 1.52 (m, 2H, C H 2 ) ,  1.35 - 1.21 (m, 2H, C H 2 ) ,  1.13 (s, 3H, C H i ) ,  0.96 - 0.90 (m, 2H, C H 2 ) .  
13C NMR (400 MHz / C D C I 3 )  3 144.9 (C,), 132.4 ( C q ) ,  129.6 (2 x Ts CH), 129.4 (2 x Ts CH),
85.9 ( C g ) ,  60.4 (CHO), 42.7 (CH2), 36.7 (CH2), 30.6 (CH2), 23.4 (CH3), 21.8 (CH3), 18.8 (CH2). 
IR (neat) o/cm'1: 2930, 1710, 1597, 1449, 1380, 1138, 1100, 839. HRMS (El) m/z calcd. for 
C14H2oNS0 3  [M+H]+ = 282.1164 observed [M+H+] = 282.1171.
NHTs
275a
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2-(3,5,5-Trimethylcyclohex-2-enyloxy)isoindolme-l ,3-dione 274b
.OH
273b 274b
3,5,5-trimethyl-2-cyclohexen-l-ol 273b (0.60 ml, 3.57 mmol, 1.0 eq.) was treated with 
iV-hydroxyphthalimide (0.588 g, 3.60 mmol, 1.01 eq.) according to general procedure A using 
work up 2 and purified the crude product by flash column chromatography (eluting silica gel with 
40% ethyl acetate in hexanes) to give the title compound 274b as a white solid (504 mg, 
Yield: 54%). m.p.: 91 - 94 °C. 'H NMR (400 MHz / CDC13) <5 7.78 (app. dd, 2H, J=  7.7, 1.3 Hz, 
2 x  Ar C H ) ,  7.68 (app. dd, 2H, J  = 7.7, 1.3 Hz, 2 x  Ar C H ) ,  5.63 - 5.58 (m, 1H, C H ) ,  4.75 - 4.67 
(m, 1H, C H O ) ,  1.66 (s, 3H, C H 3 ) ,  1.65 - 1.56 (m, 4H, 2 x CH i ) ,  0.99 (s, 3H, CH i ) ,  0.82 (s, 3H, 
CH i ) .  13C NMR (400 MHz / CDC13) <5 160.1 (2 x C q ) ,  140.0 (2 x C g ) ,  134.4 (2 x Ar CH), 129.0 
( C g ) ,  123.5 (2 x Ar CH), 118.1 (CH), 84.1 (CHO), 44.2 (CH2), 40.1 (CH2), 31.2 ( C g ) ,  30.8 (CH3),
26.5 (CH3), 23.8 (CH3). HRMS (ES) m/z calcd. for C3 4 H4 2N3 0 6  [ ( 2  x M)+NH4 +]+ = 588.3074; 
found 588.3062.
4 -Methyl-7V-(3 ,5 ,5 -trimethylcyclohex-2 -enyloxy)benzenesulfonamide 275b
NHTs
275b274b
The phthalimide 274b (488 mg 1.71 mmol, 1.0 eq.) was treated according to general procedure B 
and the crude product was purified by flash column chromatography (eluting silica gel with 
dichloromethane) to give the sulfonamide 275b as an orange oil (526 mg, Yield: 90%). *H NMR 
(400 MHz / CDC13) S  7.82 (d, 2H, J =  8.3 Hz, 2 x Ts C H ) ,  7.34 (d, 2H, J =  8.3 Hz, 2 x Ts C H ) ,  
5.54-5.48 (m, 1H, C H ) ,  4.74-4.69 (m, 1H, C H O ) ,  2.44 (s, 3H, Ts C H 3 ) ,  1.68 (s, 3H, C H 3 ) ,
1.67 -1.52 (m, 4H, 2 x CH2), 0.99 (s, 3H, C H 3 ) ,  0.82 (s, 3H, C H 3 ) .  13C NMR (400 MHz / CDC13) 
<5 149.5 ( C q ) ,  143.7 ( C g ) ,  136.7 ( C g ) ,  129.3 (2 x Ts CH), 127.6 (2 x Ts CH), 123.1 (CH), 77.0 
(CH), 46.7 (CH2), 43.4 (CH2), 31.8 (C,), 29.4 (2 x CH3), 27.5 (CH3), 21.4 (CH3). IR (neat) u/cm'1: 
3054, 2961, 1712, 1598, 1449, 1380, 1138, 1100, 839. LRMS (ES) 308 (M-H+, 8 6 %), 294 
(M-CH3 , 73%).
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(l/?,5S)-l,3,3-Trimethyl-7-tosyl-6-oxa-7-azabicyclo[3.2.1]octane 276b
NHTs
TsN-
275b 276b
The sulfonamide 275b (100 mg 0.32 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.26 ml, 0.16 mmol, 0.5 eq.) and the resulting solution stirred at 0 °C for 
24 hours. The reaction was quenched with saturated aqueous K2 CO3 and the two layers separated. 
The aqueous layer was extracted with dichloromethane (3x10  ml), the combined organic layers 
dried over K2 CO3 and concentrated to give the title compound 276b a yellow oil (90 mg 
Yield: 90%). 'H NMR (400 MHz / CDCI3 ) 8 7.76 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.28 (d, 2H, 
7=  8.3 Hz, 2 x Ts CH), 4.40 - 4.36 (m, 1H, CHO), 2.39 (s, 3H, Ts CH3), 2 . 2 1  -1.84 (m, 2H, CH2),
1.67 -1.52 (m, 2H, CH2), 1.15 (s, 3H, CH3), 1.03 (s, 6 H, 2 x CH3), 0.96 - 0.90 (m, 2H, CH2). 13C 
NMR (400 MHz / CDCI3) <5 144.9 (Q ), 132.4 (C?), 129.6 (2 x Ts CH), 129.4 (2 x Ts CH), 85.9 
(Cq), 60.4 (CHO), 48.2 (C,), 42.7 (CH2), 36.7 (CH2), 33.5 (2 x CH3), 30.6 (CH2), 23.4 (CH3), 21.8 
(CH3). IR (neat) u/cm'1: 2930, 1710, 1597, 1449, 1380, 1138, 1100, 839. HRMS (El) m/z calcd. 
for CisHmNOsS [M+H]+ = 310.1432; found 310.1438.
7-Methyl-3-methyleneoct-6-en-l-ol 283288
281 282 283
TMEDA (9.10 ml, 0.604 mmol, 2.6 eq.) and diethyl ether (50 ml) were stirred together and cooled
to 0 °C. To this was then added 1.6M «-BuLi in hexanes (31.0 ml, 0.51 mmol, 2.2 eq.) and the
resulting pale yellow solution was stirred at room temperature for 1 hour. The solution was then
cooled to 0 °C and 3 -methyl-3-buten-l-ol 282 (2.40 ml, 0.232 mmol, 1.0 eq.) was added dropwise
and the solution turned to an intense yellow colour. The reaction mixture was then stirred at room
temperature for 6  hours to give the desired dianion as a yellow slurry. The slurry was the cooled to
-78 °C and 3 ,3 -dimethylallyl bromide 281 (3.20 ml, 0.279 mmol, 1.2 eq.) in ether ( 6  ml) was
added slowly. The reaction was then allowed to warm to room temperature slowly over 16 hours.
Stirred at room temperature for another further 3 hours; the reaction was then quenched by the
careful addition of saturated aqueous N H 4 C I  (20 ml). The resulting layers were then separated and
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the aqueous layer was extracted with ether (3 x 30 ml), the combined organic layers were dried 
over MgSC>4 and concentrated in vacuo. 1 g of the 3.587 g of the crude product was purified by 
flash column chromatography (eluting silica gel with dichloromethane) to give the title compound 
283 as a clear oil (348 mg, Yield: 97%). All data obtained were in accordance with those 
previously reported in the literature. 2 8 8  NMR (400 MHz / CDCI3) 8 5.13 - 5.05 (m, 1H, CH),
4.86 (br. s, 1H, CH), 4.82 (br. s, 1H, CH), 3.69 (t, 2H, J=  6.3 Hz, CH2), 2.29 (t, 2H, J=  6.3 Hz, 
CH2), 2.15 - 2.00 (m, 4H, 2 x CH2), 1.67 (s, 3H, CH3), 1.59 (s, 3H, CH3y 13C (400 MHz / CDC13)
145.9 (Cq), 132.0 ( Q ,  123.8 (CH), 111.8 (CH2), 60.3 (CH2), 39.3 (CH2), 35.7 (CH2), 26.3 (CH3),
27.5 (CH3), 17.8 (CH3). LRMS m/z (APCI) 137.1 (M+ + H, 100%).
2-(7-Methyl-3-methyleneoct-6-enyloxy)isomdoline-l,3-dione 284
2 8 4
7-Methyl-3-methyleneoct-6-en-l-ol 283 (348 mg, 2.259 mmol, 1.0 eq.) was treated with 
A-hydroxyphthalamide (372 mg, 2.282 mmol, 1.01 eq.) according to general method F. The crude 
product 284 was not purified before use in the next step.
4-Methyl-N-(7-methyl-3-methyleneoct-6-enyloxy)benzenesulfonamide 285289
2 8 4  0  285
Crude phthalimide 284 (1.05 g, 3.512 mmol, 1.0 eq.) was treated according to general method F 
and the crude product was purified by flash column chromatography (eluting silica gel with 
dichloromethane) to give the sulfonamide 285 as a clear oil (340 mg Yield: 30%). !H NMR
(400 MHz / CDCI3 ) 3 7.81 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.34 (d, 2H, J=  8.3 Hz, 2 x Ts CH),
7.12 (br, s, 1H, NH), 5.08 (br. t, 1H, J=  6.7 Hz, CH), 4.80 (br. s, 1H, CH), 4.76 (m, 1H, CH), 4.10
(t, 2H, J=  6 . 8  Hz, CH2O), 2.45 (s, 3H, Ts CH3), 2.33 (t, 2H, J=  6 . 8  Hz, CH2), 2.13 - 1.99 (m, 4H, 
2 x CHi), 1.68 (s, 3H, CH3), 1.60 (s, 3H, CH3). 13C NMR (400 MHz / CDC13) 8 145.5 (Cq), 144.8
(Cq), 133.6 (1Cq), 131.8 (Q), 129.7 (2 x Ts CH), 128.6 (2 x Ts CH), 123.8 (CH2), 111.1 (CH), 75.6
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(CH2), 36.0 (CH2), 34.6 (CH2), 26.3 (CH3), 25.7 (CH3), 21.7 (Ts CH3), 17.7 (CH2). HRMS (El) 
m/z calcd. for Ci7 H2 6N0 3S [M + H]+ = 324.1633; found 324.1636.
6,6-Dimethyl-l-tosyl-2-oxa-l-azaspiro[4.5]decane 286
N H Ts
2 8 5  286
The sulfonamide 285 (100 mg 0.31 mmol, 1 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.31 ml, 0.15 mmol, 0.5 eq.) and the resulting solution stirred at 0 °C for 
1 hour. The reaction was quenched with saturated aqueous K2 C0 3 and the two layers separated. 
The aqueous layer was extracted with dichloromethane (3x10  ml), the combined organic layers 
dried over K2 C 0 3 and evaporated. The crude product was purified by flash column 
chromatography (eluting silica gel with dichloromethane) to give the title compound 286 as a 
yellow oil (70 mg Yield: 70%). 'H NMR (500 MHz / CDC13) 8 7.83 (2H, d, J  = 8.3 Hz, 2 x Ts 
CH), 7.32 (2H, d ,J  = 8.5 Hz, 2 x Ts CH), 4.23 - 4.11 (m, 2H, CH2O), 2.47 (ddd, 1H, 7=  11.8,9.4, 
6.2 Hz, C/TfHs), 2.43 (s, 3H, Ts CH3), 2.21 (ddd, 1H, J  = 11.8, 9.4, 5.9 Hz, CHaHb), 2.17 - 2.09 
(m, 1H, C//cHd), 2.01 (d, 1H, J=  13.4 Hz, CHEHF), 1.97 -  1.88 (1H, m, CRcHd), 1.77 (app. dddd, 
1 H, J =  13.7, 7.9, 3.6, 0.9 Hz, CffGHH), 1.57-1.51 (m, 1H, CHqHh), 1-49 (d, 1H, J  = 13.4, 
CHeHf), 1.40- 1.29 (m, 2H, CH2), 1.07 (s, 3H, CH3), 0.93 (s, 3H, CH3). 13C NMR (500MHz / 
CDC13) <5 144.2 (Cq), 136.0 (C„), 129.3 (2 x Ts CH), 128.6 (2 x Ts CH), 71.2 (CH2 0), 69.5 (C„), 
47.1(CH2), 40.7 (CH2), 38.7 (CH2), 33.8 (CH2), 31.4 (C,), 21.7 (Ts CH3), 21.6 (2 x CH3) 20.0 
(CH2). IR (neat) u/cm'1: 2952, 1598, 1455, 1327, 1156, 1089, 814, 670. HRMS (El) m/z calcd. for 
Ci7H25N 03S [M]+ = 323.1555; found 323.1552.
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3-(4-methylcyclohex-3-enyl)but-3-en-l-ol 288147
HO
28 7 288
A mixture of (R)-limonene 287 (25.0 g, 183.5 mmol, 1.0 eq.), paraformaldehyde (2.65 g,
88.1 mmol, 0.48 eq.) and dichloromethane (200ml) were stirred at 0 °C for 10 minutes. Then 
fuming stannic chloride (0 . 1 0  ml, 2 2 2 . 6  mmol, 1 . 2  eq.) was added dropwise, forming a 
heterogeneous orange solution. This solution was stirred at 20 °C for 3 days, after which the 
solution had turned a tan colour. Under vigorous stirring, dilute aqueous NaOH (20 ml) was added. 
The two phases were separated and the aqueous phase was further extracted with ether (3 x 30 ml), 
the combined organics were dried over Na2 SC>4 and evaporated. The resulting oil was filtered 
through silica with petroleum ether to remove any residual starting materials, followed by 
methanol to give the title compound 288 as a clear oil (3.70 g, Yield: 12%). All data obtained was 
in accordance with that previously reported in the literature. 2 9 0  ]H NMR (400 MHz / CDCI3) S
Alcohol 288 (500 mg, 3.01 mmol, 1.0 eq.) was treated with A-hydroxyphthalimide (495 mg,
3.04 mmol, 1.01 eq.) according to general procedure A using work up 1 to give the title compound 
289 as a yellow solid (576 mg, Yield: 62%). NMR (400 MHz / CDCI3) S 7.85 (app. dd, 2H,
5.43 - 5.37 (m, 1H, CH), 5.17 - 4.98 (m, 2H, CH2), 3.48 (t, 2H, J=  7.0 Hz, CH2O), 2.40 - 2.32 
(m, 1H, CH), 2.15-1.87 (m, 4H, 2 x CH2), 1.83 - 1.76 (m, 2H, CH2), 1.73 (s, 3H, CH3),
1.52 -1.41 (m, 2H, CH2).
2-(3-(4-Methylcyclohex-3-enyl)but-3-enyloxy)isoindolme-l,3-dione 289
2 8 8 289
J=  7.7, 1.3 Hz, 2 x Ar CH), 7.76 (app. dd, 2H, J  = 7.7, 1.3 Hz, 2 x Ar CH), 5.41 - 5.35 (m, 1H, 
CH), 4.98 -4.96 (m, 2H, CH2), 3.59 (t, 2H, J=  7.3 Hz, CH20), 2.19 -  1.80 (m, 7H, 3 * CH2 & 
CH), 1.65 (s, 3H, CH3), 1.54 - 1.41 (m, 2H, GHi). IR (neat) u/cm'1: 2962, 2921, 1786, 1730, 1641, 
1449, 1380, 1138, 1100, 839. LRMS (ES) 310.14 (M-H+, 54%).
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4-MethyWV-(3-(4-methylcyclohex-3-enyl)but-3-enyloxy)benzenesulfonamide 290
290
The phthalimide 289 (576 mg, 1.85 mmol, 1.0 eq.) was treated according to general procedure B 
and the crude product was purified by flash column chromatography (eluting silica with 
dichloromethane) to give the title compound 290 as a yellow solid (218 mg, Yield: 24%). 
m.p.: 74 - 76 °C. 'H NMR (400 MHz / CDCI3) <5 7.74 (d, 2H, J  = 8.3 Hz, 2 * Ts C H ) ,  121 (d, 2H, 
J=  8.3 Hz, 2 x Ts C H ) ,  5.33 - 5.29 (m, 1H, C H ) ,  4.76 -  4.74 (m, 1H, CJ^HB), 4.70 - 4.68 (m, 1H, 
C ftH B), 4.04 (t, 2H, J=  7.0 Hz, C H 2 O), 2.38 (s, 3H, Ts C H 3 ) ,  2.28 (t, 2H, J  =  7.0 Hz, C H 2 ) ,
2.09 -  1.60 (m, 7H, 3 x C H 2  &  C H ) ,  1.58 (s, 3H, C H 3 ) .  13C NMR (400 MHz / CDC13) S 150.0 ( C q ) ,
133.8 (C?), 133.6 (C,), 129.8 ( C q ) ,  129.7 (2 x Ts CH), 128.6 (2 x Ts CH), 120.5 (CH), 109.4 
(CH2), 76.1 (CH2), 39.7 (CH), 33.2 (CH2), 31.2 (CH2), 30.6 (CH2), 28.1 (CH2), 23.5 (CH3), 21.7 
(Ts CH3). IR (neat) u/cm'1: 3222, 3069, 2921, 1641, 1597, 1449, 1380, 1138, 1100, 839. HRMS 
(ES) m/z calcd. for Ci8H2 6 N 03S [M+H]+ = 336.1633; found 336.1629.
4-Methyl-2?-tosylspiro[bicyclo[2.2.2]octane-2,3’-isoxazolidine] 291
2 9 0  291
The sulfonamide 290 (201 mg, 0.59 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), 
cooled to 0 °C and triflic acid (0.40 ml, 0.29 mmol, 0.5 eq.) was added. The resulting solution was 
stirred at 0 °C for 1 hour, after which the reaction was quenched with saturated aqueous K 2 C O 3 ,  
the two layers were separated, the aqueous layer extracted with dichloromethane (2 x 1 0  ml), the 
combined organics dried over K 2 C O 3  and evaporated to give the title compound 291 as a yellow 
oil (174 mg, Yield: 87%).*H NMR (400 MHz / CDC13) S 7.76 (d, 2H, J=  8.4 Hz, 2 x Ts CH), 7.25 
(d, 2H, J=  8.4 Hz, 2 x Ts CH), 4.39 - 4.13 (m, 2H, CH2O), 2.36 (s, 3H, Ts CH3), 1.73 - 0.84 
(m, 15H, 6  x CH2 & CH), 0.75 (GEfc). 13C NMR (400 MHz / CDC13) S 143.3 (Cq), 130.4 (Cq),
129.4 ( 2  x Ts CH), 128.7 (2 x Ts CH), 69.4 (CH2 0), 62.7 ( Q ,  42.1 (CH2), 31.8 (CH2), 31.7
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(CH2), 31.6 (CH2), 30.8 (CH), 27.9 (CH3), 23.4 (CH2), 23.1 (CH2), 21.6 (Ts CH3), 20.4 (Q). IR 
(neat) v/cm'1: 2959, 1597, 1449, 1380, 1138, 1100, 839. HRMS calcd. for C18H26N 03S 
[M+H]+ = 336.1633; found 336.1635.
fcrf-Butyl 2-nitrophenyIsulfonylcarbamate291
B0 C2 O (1.78 g, 8.17 mmol, 1.1 eq.) was added in one portion to a stirred solution of 
2-nitrobenzenesulfonamide (1.49 g, 7.38 mmol, 1.0 eq.), triethylamine (1.14 ml, 8.17 mmol,
1.1 eq.) and DMAP (92 mg mmol, eq.) in dichloromethane (20 ml) under nitrogen. After 2 hours 
the solvent was removed under vacuum, and the residue dissolved in ethyl acetate (60 ml), washed 
with 1 M HC1 (50 ml), water (50 ml), brine (50 ml) and dried over MgSC>4 . The solvent was 
removed under reduced pressure and the crude product was recrystallised from ethyl acetate / 
petrol to give the title compound as a white solid (982 mg, Yield: 44%). All data obtained was in 
accordance with that previously reported in the literature. 291 *H NMR (400 MHz / CDCI3) 3
(s, 9H, Boc C(CH3)3). 13C NMR (400 MHz / CDC13) 3 148.5 (Q), 135.6 (2 x Q), 134.7 (Ns CH),
133.3 (Ns CH), 132.5 (Ns CH), 125.1 (Ns CH), 84.9 (Q), 27.9 (Boc C(CH3)3). HRMS (El) m/z 
calcd. for C6H6N2 S0 4  [M-Boc]+ = 202.0048; found 202.0049.
8.39 - 8.365 (m, 1H, Ns CH), 7.91 - 7.88 (m, 1H, Ns CH), 7.84 - 7.80 (m, 2H, 2 x Ns CH), 1.45
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A^-(2-Bromobenzyl)-4-methylbenzenesulfonamide 366
C C " — -  C C " ‘
364 366
2-Bromobenzylamine 364 (2.00 g, 10.8 mmol, 1.0 eq.) was treated according to general procedure 
C and the crude product was purified by column chromatography (eluting silica gel with 40% 
ethyl acetate in hexanes) to give the sulfonamide 366 as a white crystalline solid (3.17 g, 
Yield: 87%). All data obtained was in accordance with that previously reported in the literature. 2 9 2  
m.p.: 78 - 80 °C. 'H NMR (400 MHz / CDC13) S 7.73 (d, 2H, J=  8.0, 2 * Ts CH), 7.48 (dd, 1H, 
J = 8.0 Hz, Ar CH), 7.33 (d, 1H, J  = 8.0 Hz, Ar CH), 7.28 (d, 2H, J=  8.0 Hz, 2 x Ts CH), 7.24 
(d, 1H, J  = 8.0 Hz, Ar CH), 4.90 (app. t, 1H, J  = 6.5 Hz, NH), 4.26 (app. d, 2H, J=  6.5 Hz, 
CH2K), 2.43 (s, 3H, Ts CH3). ,3C NMR (400 MHz / CDCI3) 8 143.5 (Cq), 137.0 (C9), 135.5 (C„),
132.8 (Ar CH), 130.6 (Ar CH), 129.7 (2 x Ts CH), 129.6 (Ar CH), 127.7 (Ar CH), 127.1 (2 x Ts 
CH), 123.5 (Cq), 47.5 (CH2N), 21.6 (Ts CH3). IR (neat), v  / cm 1: 3290, 1441, 1328, 1158, 1093, 
1026, 814, 750. HRMS (ES) m/z calcd. for Ci4 H |6 BrN02S [M+H]+ = 341.9908 (Br81) and 
339.9929 (Br79); found 341.9982 (Br81) and 339.9998 (Br79).
ferf-Butyl 2-bromophenethyl(tosyl)carbamate 368a
-  cc
368 368a
2-Bromophenylethanol 368 (2.20 ml, 16.2 mmol, 1.0 eq.) was treated with N-{tert- 
butoxycarbonyl)-/?-toluenesulfonamide (4.50 g, 16.14 mmol, 1.01 eq.) according to general 
procedure A using work up 2. The crude product was purified by column chromatography (eluting 
silica gel with 40% ethyl acetate in hexanes) to give the title compound 368a as a colourless oil 
(6.89 g, Yield: 94%). ■h NMR (500 MHz / CDC13) 8 7.77 (d, 2H, J =  8.3 Hz, 2 x Ts C H ) ,
7.57 - 7.54 (m, 1H, Ar C H ) ,  7.34 - 7.32 (m, 1H, Ar C H ) ,  7.29 (d, 2H, J =  8.3 Hz, 2 x Ts C H ) ,
7.25 - 7.23 (m, 1H, Ar C H ) ,  7.14 - 7.11 (m, 1H, Ar C H ) ,  4,09 (t, 2H, J =  1A  Hz, C H 2N ) ,  3.21 
(t, 2H, J =  7.4 Hz, C H 2 ) ,  2.44 (s, 3H, Ts C H 3 ) ,  1.29 (s, 9H, Boc C(CH 3 ) 3 ) .  13C NMR (500 MHZ / 
CDCI3) 8 150.9 ( C f ) ,  144.2 ( C g ) ,  137.8 ( C g ) ,  137.2 ( C q ) ,  132.9 (Ar CH), 131.6 (Ar C H ) ,  129.2 
(2 x Ts CH), 128.3 (Ar CH), 128.1 (2 x Ts CH), 127.7 (Ar C H ) ,  84.2 (Boc C,(CH3)3), 46.7 
(CH2N), 36.9 (CH2), 27.8 (Boc C(CH3)3), 21.6 (Ts C H / ) .  IR (neat), n /c m '1: 2932, 1728, 1448,
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1247, 815, 753, 539. HRMS (ES) m/z calcd. for C2 oH28BrN2 0 4 S [M+NR|]+= 471.0953 (Br79); 
found 471.0956 (Br79).
iV-<2-Bromophenetliyl)-4-methylbenzenesulfonamide 367120
NTsBoc
-  cc
368a 367
Trifluoroacetic acid (3.00 ml, 40.4 mmol, 5.0 eq.) was added dropwise to the forgoing sulfonamide 
368a (3.61 g, 7.94 mmol, 1.0 eq.) in dichloromethane (20 ml) and stirred at room temperature for 
2 hours. Water (20 ml) was then added and the organic layer washed with water (2 x 20 ml), dried 
over Na2 SC>4 and evaporated to give the sulfonamide 367 as a white solid (2.79 g, Yield: 99%). All 
data obtained was in accordance with that previously reported in the literature. 2 9 3  m.p.: 62 - 63 °C. 
!H NMR (400 MHz / CDC13) 5 7.63 (d, 2H, / =  8.3 Hz, 2 x Ts CH), 7.43 -  7.391 (m, 1H, Ar CH), 
7.20 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.14 -  7.01 (m, 3H, 3 x ArCH), 4.38 (app. br. s, 1H, NH),
3.16 (t, 2H, J=  7.1 Hz, CH2N), 2.84 (t, 2H, J=  7.1 Hz, CH2), 2.34 (s, 3H, Ts CH3). 13C NMR (400 
MHz / CDCI3) 3 143.5 (Q ), 132.2 (Q), 131.8 (Q), 133.1 (Ar CH), 131.2 (Ar CH), 129.8 (2 x Ts 
CH), 128.7 (Ar CH), 127.6 (Ar CH), 126.1 (2 x Ts CH), 124.4 (Q), 42.6 (CH2N), 36.3 (CH2), 21.5 
(Ts CHs). JR (neat), 0  / cm’1: 3062, 2932, 1448, 815, 753, 539. HRMS (ES) m/z calcd. for 
C15Hi6BrN02S [M f = 354.0163 (Br79); found 354.0176 (Br79).
(/s)-4-Methyl-7V-(2-styrylbenzyl)benzenesulfonamide 362a
CC™— NHTs
362a
Br
366
By the general procedure D, reaction between A-(2-bromobenzyl)-4-methylbenzenesulfonamide 
366 (100 mg 0.294 mmol, 1.0 eq.) and toms-2 -phenylvinylboronic acid 369a (57 mg, 0.384 mmol,
1.3 eq.) to give the title compound 362a as a brown oil (107 mg, Yield: 99%). *H NMR (400 MHz 
/  C D C I 3 )  3 7.69 (d, 2H, J  — 8.2 Hz, 2 x Ts CH), 7.55 - 7.53 (m, 1H, Ar CH), 7.42 - 7.37 (m, 1H, 
Ar CH), 7.32 - 7.07 (m, 10H, 7 x Ar CH & 2 x Ts CH 8c CH), 6.91 (d, 1H, J=  16.1 Hz, CH), 4.40 
(app. t, 1H, J = 5.7 Hz, NH), 4.16 (app. d, 2H, J=  5.7 Hz, CH2N), 2.37 (s, 3H, Ts CH3). 13C NMR
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(400 M H z  /  C D C I 3 )  <5 143.5 (2 x C?), 137.0 (2 x C,), 132.5 (C?), 132.0 (Ar C H ) ,  129.9 (Ar C H ) ,
129.8 (2 x Ts C H ) ,  128.9 (Ar C H ) ,  128.8 (2 x Ar C H ) ,  128.1 (Ar C H ) ,  127.9 (Ar C H ) ,  127.2 
(2 x Ts CH), 126.8 (2 x Ar C H ) ,  126.2 ( C H ) ,  124.5 ( C H ) ,  45.5 (CH2N), 21.9 ( C H 3) .  IR (neat), u / 
cm'1: 3290, 1598, 1327, 1158, 1092, 1042, 963, 815, 761, 691. H R M S  (APCI) m/z calculated for 
C 2 2 H 2 2 N O 2 S  [ M + H ] +  = 364.1371, found 364.1389.
(£)-N-(2-(4-Chlorostyryl)benzyl)-4-methyIbenzenesulfonamide 362b
3 6 6
Reaction according to general procedure D, between 7V-(2-bromobenzyl)-4- 
methylbenzenesulfonamide 366 (100 mg 0.294 mmol, 1.0 eq.) and trans-2-(4-
chlorophenyl)vinylboronic acid 369b (70 mg, 0.384 mmol, 1.3 eq.) gave the title compound 362b 
as a brown oil (116 mg, Yield: 99%). *H NMR (500 MHz / CDC13) <5 7.69 (d, 2H, J=  8.3 Hz, 
2 x Ts CH), 7.54 - 7.52 (m, 1H, Ar CH), 7.41 - 7.05 (m, 10H, 2 x Ts CH, 7 x Ar CH & CH), 6.89 
(d, 1H, J=  16.3 Hz, CH), 4.39 (app. t, 1H,J =  5.9 Hz, NH), 4.15 (app. d, 2H,J =  5.9 Hz, Ctf2N), 
2.37 (s, 3H, Ts CHi). I3C NMR (500 MHz / CDC13) d 139.7 (Q), 134.6 (2 x Cq), 133.6 (C,), 133.0 
(C,), 132.6 (C,), 132.0 (Ar CH), 130.5 (Ar CH), 129.8 (2 * Ts CH), 128.8 (Ar CH), 128.7 (2 x Ar 
CH), 128.0 (Ar CH), 127.3 (2 x Ts CH), 127.3 (Ar CH), 126.8 (CH), 125.4 (Ar CH), 124.6 (CH), 
45.6 (CH2N), 21.6 (Ts CH3). IR (neat), u / cm'1: 3277, 3026, 2921, 1597, 1448, 815, 753, 658. 
HRMS (El) m/z calcd. for C2 2 H2 0 ClNO2S [M]+ = 397.0903 (Cl35); found 397.0906 (Cl35).
NHTs
(£)-Ar-(2-(4-Fluorostyryl)benzyl)-4-methylbenzenesulfonamide 362c
CC""
3 6 6
NHTs
3 6 2 c
By general procedure D, reaction between 7V-(2-bromobenzyl)-4-methylbenzenesulfonamide 366 
(100 mg 0.294 mmol, 1.0 eq.) and fra«s-2-(4-fluorophenyl)vinylboronic acid 369c (64 mg, 0.384 
mmol, 1.3 eq.) gave the sulfonamide 362c as a dark brown oil (111 mg, Yield: 99%). NMR
(400 MHz / CDCI3) <5 7.64 (d, 2H, J  = 8.3 Hz, 2 x Ts CH), 7.55 -  7.48 (m, 1H, Ar CH), 7.39 
(d, 2H, J  = 8.3 Hz, 2 x Ts CH), 7.27 -  7.11 (m, 6 H, 6  x Ar CH), 7.08 -  6 . 8 6  (m, 3H, Ax CH & 
2 x CH), 4.16 (app. d, 2H, J  = 6 . 6  Hz, CH2N), 2.34 (s, 3H, Ts CH}). 13C NMR (400 MHz / CDCI3) 
5 162.3 (C,), 134.3 (2 x Cq), 133.7 (Cq), 133.0 (Cq), 132.6 (Cq), 132.2 (Ar CH), 130.5 (Ar CH),
129.7 (2 x Ts CH), 128.5 (Ar CH), 128.3 (2 x CH), 127.6 (Ar CH), 127.3 (Ar CH), 127.2 (Ar CH),
126.8 (CH), 125.4 (Ar CH), 124.6 (CH), 45.6 (CH2N), 21.6 (Ts CH3). IR (neat), u / cm'1: 3280, 
3026, 2922, 1598, 1448, 1074, 815, 750, 706. HRMS (APCI) m/z calcd. for C2 2 H 21FNO2 S 
[M+H]+ = 382.1277; found 382.1268.
(Ts)-4-MethyWV-(2-(4-(trifluoromethyl)styryl)benzyl)benzenesulfonamide 362d
cc
3 6 6
Reaction according to general procedure D between 7V-(2-bromobenzyl)-4- 
methylbenzenesulfonamide 366 (100 mg 0.294 mmol, 1.0 eq.) and trans-2-[4-
(fluoromethyl)phenyl]vinylboronic acid 369d (83 mg, 0.384 mmol, 1.3 eq.), gave the product 
362d as a dark brown oil (121 mg, Yield: 95%). NMR (500 MHz / CDCI3) S I .70 (d, 2H, 
J=  8.3 Hz, 2 x Ts CH), 7.58 - 7.47 (m, 6 H, 2 x Ts CH & 4 x Ar CH), 7.39 - 7.08 (m, 5H, 4 x Ar 
CH & CH), 6.95 (d, 2H, J=  16.1 Hz, CH), 4.41 (app. t, 1H, J=  6.0 Hz, NT/), 4.16 (app. d, 2H, 
J  = 6.0 Hz, CH2N), 2.37 (s, 3H, Ts CH}). 13C NMR (500 MHz / CDCI3) <5145.2 (Cq), 144.5 (C,),
142.5 (Cq), 135.8 (C„), 135.6 (2 x Ar CH), 129.6 (Cq), 129.4 (Cq), 128.9 (2 x Ts CH), 128.7 
(2 x CH), 126.0 (2 x Ts CH), 125.7 (2 x ArCH), 125.5 (C,), 125.6 (2xAr  CH), 123.7 (2xAr 
CH), 45.5 (CH2N), 21.6 (Ts CH3). IR (neat), u / cm'1: 3274, 3028, 2928, 1614, 1598, 1448, 1274,
815,750. HRMS (El) m/z calcd. for C2 3 H2 0 F3NO2 S [M4-] =431.1167; found 431.1169.
NHTs
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(£)-4-Methyl-Ar-(2-(4-methylstyryl)benzyl)benzenesulfonamide 362e
C C “
3 6 6
By general procedure D, reaction between Ar-(2-bromobenzyl)-4-methylbenzenesulfonamide 366 
(100 mg 0.294 mmol, 1.0 eq.) and fr<ms-2-(4-methylphenyl)vinylboronic acid 369e (62 mg, 
0.384 mmol, 1.3 eq.), gave the sulfonamide 362e as dark yellow oil (106 mg, Yield: 96%). 
'HNMR (400 MHz / CDC13) <5 7.64 (d, 2H, J  = 8.3 Hz, 2 x Ts CH), 7.39 (d, 2H, J  = 8.3 Hz, 
2 x Ts CH), 7.30 -  7.11 (m, 6 H, 6  x Ar CH), 7.10 -  7.02 (m, 3H, 2 x Ar CH & CH), 6.95 (d, 1H, 
J=  15.8 Hz, CH), 4.16 (app. d, 2H, J  = 6 . 6  Hz, CH2H), 2.34 (s, 6 H, 2 x Ar CH3). I3C NMR 
(400 MHz / CDCI3) <5146.5 (Cq), 136.9 (2 x Cq), 135.5 (3 x Cq), 132.8 (2 x Ar CH), 130.5 (2 x Ar 
CH), 129.8 (2 x Ar CH), 129.7 (2 x Ts CH), 129.6 (2 x Ar CH), 127.8 (CH), 127.2 (2 x Ts CH),
123.5 (CH), 41.5 (CH2N), 21.6 (2 x Ar CH3). IR (neat), i» / cm'1: 3289, 3021, 2921, 1598, 1512, 
1448,1274, 815, 750. HRMS (El) m/z calcd. for C2 3 H2 3NO2 S [M]+ = 377.1450; found 377.1438.
(/i)-7V-(2-(2-CyclohexylvinyI)benzyl)-4-methylbenzenesulfonamide 362f
or
3 6 6
Reacted according to general procedure D between JV-(2-bromobenzyl)-4- 
methylbenzenesulfonamide 366 (100 mg 0.294 mmol, 1.0 eq.) and 2-cyclohexylvinylboronic acid 
369f (59 mg, 0.384 mmol, 1.3 eq.) to give the sulfonamide 362f as a light brown oil (78 mg, 
Yield: 72%). 1H NMR (500 MHz / CDC13) <5 7.69 (d, 2H, J  = 8.3 Hz, 2 x Ts CH), 7.33 - 7.30 
(m, 1H, Ar CH), 7.25 (d, 2H, J  = 8.3 Hz, 2 x Ts CH), 7.17 - 7.14 (m, 1H, Ar CH), 7.07 -  7.01 
(m, 2H, 2 x Ar CH), 6.23 (d, 1H, J=  15.7 Hz, CH), 5.94 (dd, 1H, J=  15.7, 7.1 Hz, CH), 4.08 (app. 
d, 2H, J=  5.8 Hz, C//2N), 2.38 (s, 3H, Ts CH3), 1.99 - 1.92 (m, 1H, CH), 1.74 -  1.60 (m, 5H, 
5 x CH), 1.29 - 1.00 (m, 5H, 5 x CH). 13C NMR (500 MHz / CDCI3) S 143.5 (2 x Cq), 140.6 (Ar 
CH), 137.0 (Q ), 132.2 (C„), 129.7 (2 x Ts CH), 129.6 (Ar CH), 128.6 (Ar CH), 127.3 (2 x Ts 
CH), 127.1 (Ar CH), 126.4 (CH), 123.4 (CH), 45.5 (CH2N), 41.4 (CH), 32.9 (2 x CH2), 26.1
NHTs
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(3 x CH2), 21.6 (Ts CH3). IR (neat), o / cm'1: 3271, 2924,2851,1704,1598,1448, 1274, 815,750. 
HRMS (El) m/z calcd. for C2 2 H2 7NO2 S [M]+ = 369.1763; found 369.1762.
jV-(2-Cyclohexenylbenzyl)-4-methylbeiizeiiesulfoiiamide 362g
cc™
3 6 6
By general procedure D, reaction between A-(2-bromobenzyl)-4-methylbenzenesulfonamide 366 
(100 mg 0.294 mmol, 1.0 eq.) and 1-cyclohexen-l-yl boronic acid pinacol ester 369g (80 mg, 
0.384 mmol, 1.3 eq.) gave the sulfonamide 362g as a light brown oil (94 mg, Yield: 93%). 
'HNMR (500 MHz / CDC13) S 7.68 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.24 (d, 2H, J=  8.3 Hz, 
2 x Ts CH), 7 .16- 7.07 (m, 4H, 4 x A r  CH), 1.02-6.99 (m, 1H, CH), 4.01 (app. d, 2H, 
J=  5.9 Hz, CftN ), 2.37 (s, 3H, Ts CH}), 1.98- 1.95 (m,4H, 2  x CH2), 1.57-1.51 (m, 4H, 
2 x CH2). 13C NMR (500 MHz / CDCb) <5 144.5 (Cq), 143.5 {Cq), 137.5 (C„), 136.8 (C?), 132.9 
(Q), 129.7 (2 x Ts CH), 129.2 (Ar CH), 128.8 (Ar CH), 127.9 (Ar CH), 127.2 (2 x Ts CH), 127.0 
(Ar CH), 126.9 (CH), 45.2 (CH2 N), 30.8 (CH2), 25.4 (CH2), 22.9 (CH2), 21.9 (CH2), 21.6 (Ts 
CH3). IR (neat), o / cm'1: 3279, 3026, 1498, 1448, 1274, 990, 815, 750. HRMS (ES) m/z calcd. for 
C2 0H25NO2 S [M+H]+ = 342.1528; found 342.1520.
NHTs
(is)-4-MethyWV-(2-(pent-l-enyl)benzyl)benzenesulfonamide 362h
r j ^ ^ j ^ ^ N H T s _______^  | j ^ ^ ^ N H T s
3 6 6
Reaction according to general procedure D, between Y-(2-bromobenzyl)-4- 
methylbenzenesulfonamide 366 (100 mg 0.294 mmol, 1.0 eq.) and 1-penten-l-ylboronic acid 
pinacol ester 369h (75 mg, 0.382 mmol, 1.3 eq.) to gave the sulfonamide 362h as a brown oil 
( 6 8  mg, Yield: 70%). *H NMR (400 MHz / CDC13) S 7.69 (d, 2H, J  = 8.3 Hz, 2 * Ts CH),
7.34 - 7.31 (m, 1H, Ar CH), 7.24 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.18 - 7.00 (m, 3H, 3 x Ar CH),
6.31 -6.28 (m, 1H, CH), 6.04 - 5.95 (m, 1H, CH), 4.05 (app. d, 2H, J=  5.9 Hz, CH2N), 2.37 
(s, 3H, Ts CH3), 2.06 - 1.98 (m, 2H, CH2), 1.43 - 1.35 (m, 2H, CH2) , 0.86 (t, 3H, J=  7.3 Hz,
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CH}). 13C NMR (400 MHz / CDC13) <5143.8 (C„), 137.2 (2 x C,), 134.8 (Ar CH), 132.1 (Cq), 
129.9 (2 x Ts CH), 129.6 (CH), 128.5 (Ar CH), 127.3 (2 x Ts CH), 127.1 (CH), 126.3 (Ar CH),
125.8 (Ar CH), 45.5 (CH2N), 30.7 (CH2), 22.6 (Ts CH3), 21.5 (CH2), 13.9 (CH3). IR (neat), 0  / 
cm'1: 3029, 1648, 1598, 1441, 1328, 1158, 1093, 1026, 814, 750. HRMS (El) m/z calcd. for 
Ci9H2 3N02S [M]+ = 329.1450; found 329.1449.
(2s)-4-Methyl-./V-(2-styrylphenethyl)benzenesulfonamide 360a
cc
3 6 7
By general procedure D, reaction between iV-(2-bromophenethyl)-4-methylbenzenesulfonamide 
367 (100 mg, 0.282 mmol, 1.0 eq.) and Jra«s-2 -phenylvinylboronic acid 369a (55 mg, 
0.367 mmol, 1.3 eq.) gave the sulfonamide 360a as a brown oil (106 mg, Yield: 99%). *H NMR 
(500 MHz / CDCls) S 7.53 (d, 2H, J=  8.0 Hz, 2 x Ts CH), 7.41 (d, 2H, J=  8.0 Hz, 2 x Ts CH), 
7.35 -  6.96 (m, 10H, 9 x Ar CH  & CH), 6.84 (d, 1H, J  = 16.2 Hz, CH), 3.82 (t, 2H, J  = 8.4 Hz, 
CH2N), 2.79 ( t ,  2H, J  = 8.4 Hz, CH2), 2.26 (s, 3H, Ts CHi). 13C NMR (500 MHz / CDC13) S 137.5 
(2 x Cq), 136.5 (2 x C?), 135.4 (C„), 129.7 (2 x Ts CH), 128.8 (2 x Ar CH), 127.9 (2 x Ts CH),
127.3 (2xAr  CH), 127.1 (2x  ArCH), 126.7 (2xAr  CH), 126.4 (Ar CH), 126.3 (CH), 125.4 
(CH), 43.5 (CH2N), 33.9 (CH2), 21.6 (Ts CH3). IR (neat), v  / cm'1: 3286, 3028,2922, 1598, 1448,
1274,990,815,750. HRMS (El) m/z calcd. for C2 3 H2 3N 02S [M]+ = 377.1450; found 377.1450.
NHTs
(£>Y-(2-(4-Chlorostyryl)phenethyl)-4-methylbenzenesulfonamide 360b
.NHTs NHTs
3 6 0 b
Br 
3 6 7
Reaction according to general procedure D between 7V-(2-bromophenethyl)-4- 
methylbenzenesulfonamide 367 (100 mg, 0.282 mmol, 1.0 eq.) and trans-2-
(4 -chlorophenyl)vinylboronic acid 369b (67 mg, 0.367 mmol, 1.3 eq.) gave the sulfonamide 360b 
as an orange oil ( 6 6  mg, Yield: 85%). *H NMR (400 MHz / CDCI3) S 7.56 (d, 2H, J  — 8.3 Hz,
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2 x Ts CH), 7.37 (d, 2H, J=  8.3 Hz, 2 * Ts CH), 7.29 - 7.26 (m, 2H, 2 x Ar CH), 7.23 -  7.10 (m, 
6 H, 5 x Ar CH &  CH), 7.05 - 7.03 (m, 1H, Ar C/7), 6.82 (d, 1H, J  = 16.1 Hz, CH), 3.84 (t, 2H, 
J= 8.3 Hz, CH2H), 2.84 (t, 2H, J  = 8.3 Hz, CH2), 2.35 (s, 3H, Ts CH3). I3C NMR (400 MHz / 
CDClj) S 138.4 (Q), 137.8 (C?), 137.3 (C„), 135.5 (2 x c,), 134.9 (Cq), 129.3 (2 x Ts CH), 128.6 
(2 x Ar CH), 127.9 (2 x Ar CH), 127.7 (2 x Ts CH), 126.9 (2 x Ar CH), 126.4 (Ar CH), 125.8 
(CH), 125.7 (Ar CH), 125.2 (CH), 43.5 (CH2N), 33.4 (CH2), 21.3 (Ts, CH3). IR (neat), n / cm'1: 
3285, 3064, 2924, 1703, 1598, 1448, 1274, 990, 815, 750, 657. HRMS (El) m/z calcd for 
C2 3H2 3C1N02S [M+H]+ = 412.1138 (Cl35); found 412.1136 (Cl35).
(£)-A7-(2-(4-Fluorostyryl)phenethyl)-4-methylbenzenesulfonamide 360c
oc
3 6 7
By general procedure D, reaction between A-(2-bromophenethyl)-4-methylbenzenesulfonamide 
367 (100 mg, 0.282 mmol, 1.0 eq.) and fra«s-2-(4-fluorophenyl)vinylboronic acid 369c (60 mg, 
0.367 mmol, 1.3 eq.) gave the sulfonamide 360c as an orange oil (44 mg, Yield: 60%). NMR 
(400 MHz / CDC13) S 1.66 -  7.54 (m, 4H, 2 x Ar CH & 2 x Ts CH), 7.51 - 7.48 (m, 1H, Ar CH),
7.44 -  7.39 (m, 2H, 2 x Ar CH), 1.23 -  7.07 (m, 3H, Ar CH & 2 x Ts CH), 7.04 -  6.97 (m, 3H, 
2 x Ar CH & CH), 6.84 (d, 1H, J  = 16.1 Hz, CH), 3.84 (t, 2H, J=  8.5 Hz, C/ftN), 2.82 (t, 2H, 
/ =  8.5 Hz, CH2), 2.35 (s, 3H, Ts CH3). I3C NMR (400 MHz / CDC13) 5 138.6 (Q), 137.8 (Cq),
137.5 ( C , ) ,  135.5 (2 x C , ) ,  134.9 ( C „ ) ,  129.5 (2 x Ts C H ) ,  128.6 (2 x Ar C H ) ,  127.8 (2«Ar  C H ) ,
127.8 (2 x Ts C H ) ,  127.0 (2 x Ar C H ) ,  126.4 (Ar C H ) ,  125.8 ( C H ) ,  125.7 (Ar C H ) ,  125.2 ( C H ) ,
43.5 ( C H 2N ) ,  33.4 ( C H 2) ,  21.3 (Ts, C H 3) .  IR (neat), u / cm'1: 3283,2924,1718, 1598,1508,1448, 
1274, 1074, 990, 815, 750. H R M S  (El) m/z calcd for C 23H 22F N 0 2 S  [M]+ = 395.1355; found 
395.1354.
NHTs
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(£)-4-Methyl-7V-(2-(4-(trifluoromethyl)styryl)phenethyl)benzenesulfonamide 360d
NHTs NHTs
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Reaction according to general procedure D between 7V-(2-bromophenethyl)-4- 
methylbenzenesulfonamide 367 (100 mg, 0.282 mmol, 1.0 eq.) and trans-2-
[4-(trifluoromethyl)phenyl]vinylboronic acid 369d (80 mg, 0.367 mmol, 1.3 eq.) gave the 
sulfonamide 360d as a brown oil (125 mg, Yield: 99%). NMR (500 MHz / CDC13) S 7.62 - 7.49 
(m, 5H, 3 x Ar C H  & 2 x  Ts C H ), 7.23 -  7.09 (m, 5H, 3 x  Ar C H  & 2 x Ts C H ) ,  7.06 -  6.87 
(m, 4H, 2 x Ar C H  & 2 x C H ) ,  3.84 (t, 2H, J  = 8.4 Hz, C H 2N), 2.82 (t, 2H,J =  8.4 Hz, C H 2 ) ,  2.29 
(s, 3H, Ts CH 3 ) .  13C NMR (500 MHz / CDC13) S 143.5 (C9), 140.9 ( C q ) ,  140.5 ( C q ) ,  137.7 ( C q ) ,
135.7 (Q), 130.3 ( C q ) ,  129.7 (2 x Ts CH), 128.5 (Ar CH), 128.1 (Ar CH), 127.7 (Ar CH), 127.5 
(Ar CH), 127.3 (2 x Ts CH), 126.8 (2 x Ar CH), 126.6 (Ar CH), 126.3 (CH), 125.7 (Ar CH), 125.1 
(CH), 123.7 { C q ) ,  43.8 (CH2N), 34.1 (CH2), 21.6 (Ts CH3). IR (neat), o / cm’1: 3283, 3065, 2926, 
1613, 1599, 1448, 1274, 815, 750. HRMS (El) m/z calcd. for C2 4 H2 2 F3N 02S [M]+ = 445.1323; 
found 445.1329.
(E)-4-Methyl-7V-(2-(4-methylstyryl)phenethyl)benzenesulfonamide 360e
By general procedure D, reaction between 7V-(2-bromophenethyl)-4-methylbenzenesulfonamide 
367 (100 mg, 0.282 mmol, 1.0 eq.) and /ra«s-2-(4-methylphenyl)vinylboronic acid 369e (60 mg, 
0.367 mmol, 1.3 eq.) to give the sulfonamide 360e as a brown oil (109 mg, Yield: 99%). JH NMR 
(500 MHz / CDC13) S 7.65 -  7.55 (m, 4H, 2 x Ar CH & 2 x Ts CH), 7.45 - 7.42 (m, 2H, 2 x Ar
(Ar CH), 129.7 (2 x Ts CH), 129.4 (2 x Ar CH), 128.6 (2 x Ar CH), 127.7 (2 x Ts CH), 127.4
NHTsNHTs
CH), 7.23 - 7.21 (m, 2H, Ar CH & CH), 7.17 -  6.99 (m, 6 H, 3 x Ar CH, 2 x Ts CH & CH), 3.84 
(t, 2H, J=  8.4 Hz, CH2N), 2.82 (t, 2H, .7=8.4 Hz, CH2), 2.35 (s, 6 H, 2 x Ar CH3). 13CNMR 
(500 MHz / CDClj) 5 143.4 (C„), 137.2 (2 x Q ), 137.0 (2 x C?), 135.3 (C,), 133.1 (Ar CH), 131.2
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(CH), 127.1 (2 x Ar CH), 127.0 (CH), 42.5 (CH2N), 36.4 (CH2), 21.6 (Ar CH3), 21.5 (Ar CH3). IR 
(neat) D /c m '1: 3286,2922,1598, 1513,1448,1274, 815,750. LRMS (El) 274.09 (M-C9H9 , 68%).
NHTs
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(£)-7V-(2-(2-Cyclohexylvinyl)phenethyl)-4-methylbenzenesulfonamide 360f
^N H T s
Br
367
Reaction according to general procedure D between 7V-(2-bromophenethyl)-4- 
methylbenzenesulfonamide 367 (100 mg, 0.282 mmol, 1.0 eq.) and 2-cyclohexyl vinyl boronic 
acid 369f (57 mg, 0.367mmol, 1.3 eq.) gave the sulfonamide 360f as a yellow oil (73 mg, 
Yield: 69%). 'H NMR (500 MHz /  CDC13) <5 7.59 (d, 2H, J  =  8.3 Hz, 2 x Ts C H ) ,  7.31 - 7.28 
(m, 1H, Ar C H ) ,  7.19 (d, 2H, J =  8.3 Hz, 2 x Ts C H ) ,  7.17 -  6.98 (m, 2H, 2 x Ar C H ) ,  6.95 - 6.93 
(m, 1H, Ar C H ) ,  6.37 (br. d, 1H, J =  15.7 Hz, C H ) ,  5.89 (dd, 1H, J =  15.7, 7.1 Hz, C H ) ,  3.08 
(t, 2H, J =  7.0 Hz, CH2N), 2.77 (t, 2H, J =  7.0 Hz, C H 2 ) ,  2.34 (s, 3H, Ts C H } ) ,  2.07 -  1.97 (m, 1H, 
C H ) ,  1.74 - 1.57 (m, 5H, 5 x C H ) ,  1.30 -  1.00 (m, 5H, 5 x C H ) .  I3C NMR (500 MHz /  CDC13) S
138.4 (2 x C q ) ,  137.6 ( C q ) ,  137.2 (C,), 129.4 (2 x Ts CH), 128.5 (Ar CH), 127.9 (2 x Ts CH),
127.7 (Ar CH), 126.8 (Ar CH), 126.5 (CH), 125.8 (Ar CH), 123.8 (CH), 43.6 (CH2N), 38.4 (CH),
33.7 (2 x CH2), 33.2 (CH2), 26.4 (2 x CH2), 25.3 (CH2), 21.3 (Ts CH3). IR (neat) d / cm'1: 3283, 
2924, 2850, 1707, 1598, 1448, 1274, 815, 750. HRMS (El) m/z calcd. for C2 3 H3 0NO2S 
[M+H]+ = 384.1997; found 384.1993.
7V-(2-Cyclohexenylphenethyl)-4-methylbenzenesulfonamide 360g
.NHTs ^NHTs
Br
367 360g
By general procedure D, reaction between 7V-(2-bromophenethyl)-4-methylbenzenesulfonamide
367 (100 mg, 0.282 mmol, 1.0 eq.) and 1 -cyclohexen-ylboronic acid pinacol ester 369g (76 mg,
0.367 mmol, 1.3 eq.) gave the sulfonamide 360g as a yellow oil (94 mg, Yield: 94%). *H NMR
(500 MHz / CDC13) S 7.60 (d, 2H, J=  8.3 Hz, 2 x Ts, CH), 7.32 - 7.29 (m, 2H, 2 x Ar CH), 7.15
(d, 2H, J=  8.3 Hz, 2  x Ts CH), 7.13 -  7.04 (m, 1H, Ar CH), 7.02 -  6.95 (m, 1H, Ar CH), 6.90
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(app. t, 1H; J =  7.5 Hz, C H ) ,  3.85 (t, 2H, 7 =  8.4 Hz, C H 2N), 2.82 (t, 2H, J =  8.4 Hz, CH 2 ) ,  2.30 
(s, 3H, Ts C H 3 ) ,  2.04 -  1.98 (m, 4H, 2 x C H 2 ) ,  1.64 -  1.54 (m, 4H, 2 x C H 2 ) .  13C NMR (500 MHz 
/ CDCI3) <5 143.0 ( C q ) ,  138.2 (2 x C,), 131.7 ( C q ) ,  129.6 (2 x Ts CH), 129.1 (Ar CH), 127.4 (2 x Ts 
CH), 127.1 (Ar CH), 127.0 (C,), 125.1 (Ar CH), 123.7 (ArCH) 115.0 (CH), 43.9 (CH2N), 33.1 
(CH2), 30.9 (CH2), 25.3 (CH2), 23.0 (CH2), 22.0 (CH2), 21.5 (Ts CH3). IR (neat) o / cm'1: 3292, 
2926,1598, 1448, 1274, 815, 750. HRMS (El) m/z calcd. for C2 iH2 5N 02S [M]+ = 355.1606; found 
355.1612.
(E)-4-Methyl-7V-(2-(pent-l-enyl)phenethyl)benzenesulfonamide 360h
cc
367
Reaction according to general procedure D between iV-(2-bromophenethyl)-4- 
methylbenzenesulfonamide 367 (100 mg, mmol, 1.0 eq) and penten-l-yl boronic acid 369h 
(40 mg, 0.367 mmol, 1.3 eq.) gave the sulfonamide 360h as a brown oil (83 mg, Yield: 97%). 
'HNMR (500 MHz / CDCI3 ) S 7.60 (d, 2H, J=  8.3 Hz, 2 x Ts C H ) ,  7.15 (d, 2H, J=  8.3 Hz, 
2 x Ts C H ) ,  7.14 -  6.87 (m, 4H, 4 x Ar C H ) ,  6.43 - 4.380 (m, 1H, C H ) ,  5.95 (d, 1H, 7=  15.5 Hz, 
C H ) ,  3.84 (t, 2H, 7 =  8.4 Hz, C H 2N), 2.82 (t, 2H, 7 = 8.4 Hz, C H 2 ) ,  2.30 (s,3H, Ts C/6 ), 
2.12-2.03 (m, 2H, C H 2 ) ,  1.43- 1.34 (m,2H, C H 2 ) ,  0.88-0.82 (m, 3H, C/6 ). 13C NMR (500 
MHz / CDC13) S 142.0 ( C q ) ,  137.2 ( C q ) ,  137.0 ( C q ) ,  133.8 (Ar CH), 133.1 (C,), 129.7 (2 x Ts CH),
127.7 (Ar CH), 127.3 (2 x Ts CH), 126.8 (Ar CH), 126.5 (Ar CH), 125.1 (CH), 123.7 (CH), 43.5 
(CH2N), 35.3 (CH2), 33.4 (CH2), 27.9 (CH2), 21.6 (Ts CH3), 13.8 (CH3). IR (neat) v / cm 1: 3291, 
3028, 2957, 2926, 1598, 1448, 1274, 815, 750. HRMS (El) m/z calcd. for C2 0H2 5NO2S 
[M]+ = 343.1606; found 343.1600.
NHTs
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l-Benzyl-2-tosylisoindoline 363a
NHTs
362a
NTs
The sulfonamide 362a (20 mg, 0.055 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.10 ml, 0.028 mmol, 0.5 eq.). The resulting solution was heated to 40 °C 
for 2 hours, then cooled to room temperature and quenched with saturated aqueous K2 CO3 . The 
quenched solution was then separated and the aqueous layer was extracted with dichloromethane 
(3 x 10 ml). The combined organic solutions were dried over K2 CO3 and evaporated to give the 
isoindole 363a as a yellow oil (19.5 mg, Yield: 98%).
The sulfonamide 362a (102 mg, 0.28 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added concentrated sulfuric acid (2 drops). The resulting suspension was stirred at 
20 °C for 48 hours and quenched with saturated aqueous K2 CO3 . The quenched solution was then 
separated and the aqueous layer was extracted with dichloromethane (3 x 10 ml). The combined 
organic layers were dried over K2 CO3 and evaporated to give the isoindole 363a as a yellow oil 
(94 mg, Yield: 92%).
The two samples showed identical spectroscopic and analytical data: *H NMR (400 MHz / CDCI3) 
d 7.66 (d, 2H, J=  8.2 Hz, 2 x Ts CH), 7.54 - 7.52 (md, 2H, 2 x Ar CH), 131 - 7.35 (m, 2H, 2 x Ar 
CH), 121 -124  (m, 2H, 2 x Ar CH), 7.21 -  7.14 (m, 3H, 3 x Ar CH), 7.10 -  7.00 (m, 1H, Ar 
CH), 6.95-6.84 (m, 1H, Ar CH), 5.28 (t, 1H, .7=6.4 Hz, CHN), 4.53 (d, 1H, J=  15.9 Hz, 
CT^HbN), 4.12 (d, 1H, J=  15.9 Hz, CUaHbN), 2.95 (d, 2H, .7= 6.4 Hz, CH2), 225 (s, 3H, Ts 
CH3). 13C NMR (400 MHz / CDC13) 3 143.2 (C9), 139.8 (C9), 137.0 (C9), 132.9 (C9), 132.6 (C9),
129.8 (2 x Ts CH), 129.5 (2 x Ar CH), 128.8 (Ar CH), 128.1 (Ar CH), 127.8 (Ar CH), 127.1 
(2 x Ts CH), 126.9 (Ar CH), 126.5 (Ar CH), 125.9 (Ar CH), 124.6 (Ar CH), 54.7 (CHN), 45.6 
(CH2N), 32.3 (CH2), 21.6 (Ts CH3). IR (neat) u / cm"1: 3278, 3059 3029, 2917, 2848, 1599, 1448,
1274,815,750. HRMS (APCI) m/z calcd. for C2 2H2 2N 02S [M+H]+ = 364.1371; found 364.1386.
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fl-(4-Chlorobenzyl)-2-tosylisoindoline 363b
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The sulfonamide 362b (95 mg, 0.238 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.20 ml, 0.119 mmol, 0.5 eq.). The resulting solution was heated to 40 °C 
for 24 hours, then cooled to room temperature and quenched with saturated aqueous K2 CO3 . The 
quenched solution was then separated and the aqueous layer was extracted with dichloromethane 
( 3 x 1 0  ml). The combined organic layers were dried over K2 CO3 and evaporated to give the 
isoindole 363b as a yellow oil (77 mg, Yield: 81%).
The sulfonamide 362b (106 mg, 0.267 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), 
to which was added concentrated sulfuric acid (2 drops). The resulting suspension was stirred at 
40 °C for 48 hours, then cooled to room temperature and quenched with saturated aqueous K2 CO3 . 
The quenched solution was then separated and the aqueous layer was extracted with 
dichloromethane (3x10 ml). The combined organic layers were dried over K2 CO3 and evaporated 
to give the isoindole 363b as a yellow oil (74 mg, Yield: 70%).
The two samples showed identical spectroscopic and analytical data: *H NMR (400 MHz / CDCI3) 
5 7.75-7.52 (m, 4H, 2 x Ts C H  & 2 x Ar C H ) ,  7.35-6.88 (m, 8 H, 2 x Ts C H  & 6  x Ar C H ) ,
5.31 (d, 1H, J =  15.4 Hz, C i^H BN), 4.59 (d, 1H, J =  15.4 Hz, CHAtfsN), 4.11 (t, 1H, J =  6.2 Hz, 
CHN), 2.98 (app. br. s, 2H, C H 2 ) ,  2.28 (s, 3H, Ts C H 3 ) .  13C NMR (400 MHz / CDCI3) <5 143.2 
( C q ) ,  139.8 ( C q ) ,  137.0 ( C q ) ,  132.6 ( C q ) ,  132.4 ( C q ) ,  132.2 ( C q ) ,  129.6 (Ar CH), 129.5 (2 x Ts CH),
128.6 (Ar CH), 128.5 (Ar CH), 128.4 (Ar CH), 127.4 (Ar CH), 127.2 (Ar CH), 127.1 (2 x Ts CH),
126.5 (Ar CH), 125.9 (Ar CH), 54.7 (CHN), 44.0 (CH2N), 32.3 (CH2), 21.6 (Ts CH3). IR o / cm'1: 
3277, 3062 3028, 2923, 2855, 1598, 1448, 1274, 815, 750, 658. HRMS (APCI) m/z calcd. for 
C2 2H2 iC1NQ2S [M+H]+ = 398.0982 (Cl35); found 398.0983 (Cl35).
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l-(4-Fluorobenzyl)-2-tosylisoindoline 363c
NHTs
362c
NTs
363c
The sulfonamide 362c (97 mg, 0.255 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.20 ml, 0.127 mmol, 0.5 eq.). The resulting solution was heated to 40 °C 
for 24 hours, then cooled to room temperature and quenched with saturated aqueous K2CO3. The 
quenched solution was then separated and the aqueous layer was extracted with dichloromethane 
(3 x 10 ml). The combined organic layers were dried over K2CO3 and evaporated to give the 
isoindole 363c as a brown oil (81 mg, Yield: 84%).
The sulfonamide 362c (115 mg, 0.302 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), 
to which was added concentrated sulfuric acid (2 drops). The resulting suspension was stirred at 
40 °C for 24 hours, then cooled to room temperature and quenched with saturated aqueous K2CO3. 
The quenched solution was then separated and the aqueous layer was extracted with 
dichloromethane (3x10  ml). The combined organic layers were dried over K2CO3 and evaporated 
to give the isoindole 363c as a brown oil (84 mg, Yield: 73%).
The two samples showed identical spectroscopic and analytical data: NMR (500 MHz / CDCI3)
3 7.57 (d, 2H, J=  8.2, 2 x Ts CH), 7.33 - 7.30 (m, 2H, 2 x Ar CH), 7.20 - 7.17 (m, 2H, 2 x Ar 
CH), 7.11 (d, 2H, J=  8.2 Hz, 2 x Ts CH), 7.10 - 6.94 (m, 2H, 2 x Ar CH), 6.90 - 6.84 (m, 1H, Ar 
CH), 6.75-6.72 (m, 1H, Ar CH), 5.22 (t, 1H, J=6.4Hz,  CHN), 4.98 (d, 1H, J=  16.1 Hz, 
C^HbN), 4.08 (d, 2H, J=  16.1 Hz, C /^H BN), 3.97 (d, 2H, J=6.4Hz,  CH2), 2.26 (s, 3H, 
Ts CH3). I3C NMR (500 MHz / CDC13) <5143.5 (2 x Cq), 137.0 (Cq), 135.6 (2 x Cq), 132.8 
(Ar CH), 132.4 (Cq), 130.5 (Ar CH), 129.7 (2 x Ts CH), 129.5 (2 x Ar CH), 127.7 (2 x Ar CH),
127.1 (2 x Ts CH), 126.5 (Ar CH), 115.2 (Ar CH), 70.2 (CHN), 54.2 (CH2N), 32.6 (CH2), 21.5 
(Ts CH3). IR \) / cm'1: 3278, 3059 3029, 2917, 2848, 1599, 1448, 1274, 815, 750, 706. HRMS 
(APCI) m/z calcd. for C2 2H2 iFN02S [M+H]+ = 382.1277; found 382.1268.
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2-Tosyl-l-(4-(trifluoromethyl)benzyl)isomdoline 363d
NHTs
The sulfonamide 362d (132 mg, 0.305 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), 
to which was added TfOH (0.20 ml, 0.153 mmol, 0.5 eq.). The resulting solution was heated to 
40 °C for 24 hours, then cooled to room temperature and quenched with saturated aqueous K2CO3. 
The quenched solution was then separated and the aqueous layer was extracted with 
dichloromethane (3x10  ml). The combined organic layers were dried over K2CO3 and evaporated 
to give the isoindole 363d as a yellow oil (93 mg, Yield: 71%).
The sulfonamide 362d (100 mg, 0.265 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), 
to which was added concentrated sulfuric acid (2 drops). The resulting suspension was stirred at 
40 °C for 24 hours, then cooled to room temperature and quenched with saturated aqueous K2CO3. 
The quenched solution was then separated and the aqueous layer was extracted with 
dichloromethane (3x10 ml). The combined organic layers were dried over K2CO3 and evaporated 
to give the isoindole 363d as a yellow oil (67 mg, Yield: 67%).
The two samples showed identical spectroscopic and analytical data: *H NMR (500 MHz / CDCI3) 
d 7.32-7.28 (m, 4H, 2 x Ts CH  & 2 x Ar CH), 7.01-6.94 (m, 6 H, 2 x Ts CH & 4 x Ar CH),
6.86-6.73 (m, 1H, Ar CH), 6 .16-6.13  (m, 1H, ArCH), 5.20 (t, 1H, .7=6.5 Hz, CHN), 4.98 
(d, 1H, J=  16.1 Hz, C77^HbN), 4.11 (d, 1H, J=  16.1 Hz, CH^HbN), 3.65 (d, 2H, J= 6.5 Hz, 
CH2), 2.19 (s, 3H, Ts CH3). 13C NMR (500 MHz / CDC13) S 143.3 (Q), 141.7 (2 x Cq), 135.5 
(Cq), 135.2 (Cq), 133.6 (Cq), 130.2 (2 x Ar CH), 129.5 (2 x Ts CH), 128.9 (Ar CH), 127.1 (Ar 
CH), 127.0 (2 x Ts CH), 126.2 (2 x Ar CH), 125.1 (Ar CH), 125.0 (Ar CH), 123.9 (Q), 70.7 
(CHN), 52.6 (CH2N), 33.5 (CH2), 21.4 (Ts CH3). IR (neat), u / cm'1: 3357, 3261, 3063, 2924, 
1615, 1599, 1448, 1274, 815, 750. HRMS (El) m/z calcd. for C2 3 H2 0 F3NO2S [M+] = 431.1167; 
found 431.1168.
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l-(4-Methylbenzyl)-2-tosylisoindoline 363e
NHTs
362e
NTs
The sulfonamide 362e (78 mg, 0.207 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.20 ml, 0.103 mmol, 0.5 eq.). The resulting solution was heated to 40 °C 
for 24 hours, then cooled to room temperature and quenched with saturated aqueous K2CO3. The 
quenched solution was then separated and the aqueous layer was extracted with dichloromethane 
(3 x 10 ml). The combined organic layers were dried over K2CO3 and evaporated to give the 
isoindole 363e as a brown oil (67 mg, Yield: 8 6 %).
The sulfonamide 362e (100 mg, 0.265 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), 
to which was added concentrated sulfuric acid (2 drops). The resulting suspension was stirred at 
40 °C for 24 hours, then cooled to room temperature and quenched with saturated aqueous K2CO3. 
The quenched solution was then separated and the aqueous layer was extracted with 
dichloromethane (3x10  ml). The combined organic layers were dried over K2C03 and evaporated 
to give the isoindole 363e as a brown oil (67 mg, Yield: 67%).
The two samples showed identical spectroscopic and analytical data: *H NMR (500 MHz / CDCI3) 
d 7.64 (d, 2H, J=  8.4 Hz, 2 x Ts CH), 7.38 - 7.35 (m, 2H, 2 x Ar CH), 7.25 - 7.23 (m, 2H, 2 x Ar 
CH), 7.17 (d, 2H, J=  8.4 Hz, 2 x Ts CH), 7.14 -  7.10 (m, 2H, 2 x Ar CH), 7.09 - 7.02 (m, 2H, 
2 x Ar CH), 5.27 (t, 1H, .7=6.5 Hz, C7/N), 4.62 (d, 1H, J=  15.9, C7^HBN), 4.27 (d, 1H, 
J=  15.9 Hz, C/^HbN), 2.96 (d, 2H, 7=6.5  Hz, CH2), 2.33 (s, 6 H, 2 x Ar CH3). 13C NMR 
(500 MHz / CDCI3) 5 143.5 (Q ), 140.5 (C9), 137.1 (C,), 135.1 (2 * C,), 132.0 (Q), 132.8 (2 x Ar 
CH), 130.5 (2 x Ar CH), 129.7 (2 x Ts CH), 129.5 (2 x Ar CH), 127.7 (2 x Ar CH), 127.2 (2 x Ts 
CH), 77.3 (CHN), 49.0 (CH2N), 30.0 (CH2), 21.5 (2 x Ar CH3). IR (neat), u / cm'1: 329, 3054, 
3023, 2922, 2864, 1598, 1512, 1448, 1274, 815, 750. HRMS (El) m/z calcd. for C2 3 H2 3 N 02S 
[M]+ = 377.1450; found 377.1448.
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| l-(Cyclohexylmethyl)-2-tosylisoindoline 363f
NHTs
362f
NTs
363f
The sulfonamide 362f (90 mg, 0.250 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.20 ml, 0.125 mmol, 0.5 eq.). The resulting solution was heated to 40 °C 
for 2 hours, then cooled to room temperature and quenched with saturated aqueous K2 CO3 . The 
quenched solution was then separated and the aqueous layer was extracted with dichloromethane 
(3 x 10 ml). The combined organic layers were dried over K2 CO3 and evaporated to give the 
isoindole 363f as a brown oil (84 mg, Yield: 93%).
The sulfonamide 362f (64 mg, 0.265 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added concentrated sulfuric acid (2 drops). The resulting suspension was stirred at 
40 °C for 4 hours, then cooled to room temperature and quenched with saturated aqueous K2 CO3 . 
The quenched solution was then separated and the aqueous layer was extracted with 
dichloromethane (3x10  ml). The combined organic layers were dried over K2CO3 and evaporated 
to give the isoindole 363f as a brown oil (64 mg, Yield: 100%).
The two samples showed identical spectroscopic and analytical data: *H NMR (400 MHz / CDCI3) 
S 7.52 (d, 2H, J=  7.8 Hz, 2 x Ts CH), 7.20 -  6.89 (m, 6 H, 4 x Ar CH & 2 x Ts CH), 4.85 (app. br. 
s, 1H, CHN), 4.53 (d, 1H, J=  14.8 Hz, CH^HBN), 4.47 (d, 1H, J=  14.8 Hz, CHAHsN), 2.87 
(dd,2H, J=  10.3, 2.8 Hz, CH2) 2.18 (s, 3H, Ts CH3), 1.74- 1.40 (m, 7H, CH & 3 x CH2), 
1.13 - 0.76 (m, 4H, 2 x C H 2) .  I3 C  N M R  (400 M H z  /  C D C I 3 )  <5143.4 (C?), 141.2 (C,), 136.8 (C„),
134.9 (Q), 129.6 (2 x Ts C H ) ,  127.5 (Ar C H ) ,  127.5 (Ar CH), 127.4 (Ar C H ) ,  127.3 (2 x Ts CH),
122.6 (Ar CH), 64.4 ( C H N ) ,  53.5 ( C H 2N ) ,  44.8 (CH2), 33.7 (CH), 33.9 ( C H 2) ,  33.5 (CH2), 26.5 
( C H 2) ,  26.2 (2 x C H 2) ,  21.5 (Ts C H 3) .  IR (neat) n / cm'1: 3031, 2922, 2850, 1707, 1598, 1448, 
1274, 815,750. H R M S  (ES) m/z calcd. for C 22H 28N 0 2 S  [M+H]+ = 370.1841; found 370.1843.
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2’-Tosylspiro[cyclohexane-l,l’-isoindoline] 363g
NHTs
NTs
362g 363g
The sulfonamide 362g (97 mg, 0.283 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.20 ml, 0.142 mmol, 0.5 eq.). The resulting solution was stirred at 0 °C 
for 6  hours and then quenched with saturated aqueous K 2 C O 3 .  The quenched solution was then 
separated and the aqueous layer was extracted with dichloromethane (3 x1 0  ml). The combined 
organic layers were dried over K 2 C O 3  and evaporated to give the isoindole 363g as a yellow oil 
( 6 8  mg, Yield: 70%).
The sulfonamide 362g (82 mg, 0.240 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added concentrated sulfuric acid (2 drops). The resulting suspension was stirred at 0 °C 
for 24 hours and quenched with saturated aqueous K 2 C O 3 .  The quenched solution was then 
separated and the aqueous layer was extracted with dichloromethane ( 3x 1 0  ml). The combined 
organic layers were dried over K 2 C O 3  and evaporated to give the isoindole 363g as a brown oil 
(64 mg, Yield: 78%).
The two samples showed identical spectroscopic and analytical data: *H NMR (400 MHz / CDCI3) 
d 7.72 (d, 2H, J=  8.2 Hz, 2 x Ts CH), 7.57 - 7.54 (m, 1H, Ar CH), 7.21 -  7.15 (m, 4H, 2 x Ar CH 
& 2 x Ts CH), 7.10 - 7.07 (m, 1H, Ar CH), 4.53 (app. s, 2H, CH2N), 2.74 - 2.71 (m, 2H, CH2),
2.32 (s, 3H, Ts CH3), 1.82 -  1.67 (m, 8 H, 4 x CH2). 13C NMR (400 MHz / CDC13) <5 145.8 (Cq),
142.9 (C9), 138.6 (C9), 134.3 (C„), 129.4 (2 x Ts CH), 127.4 (Ar CH), 127.2 (2 x Ts CH), 127.0 
(Ar CH), 124.0 (Ar CH), 122.5 (Ar CH), 74.4 (C9), 52.9 (CH2N), 36.4 (2 x CH2), 24.4 (2 x CH2),
22.8 (CH2), 21.6 (Ts CH3). IR (neat), u / cm'1: 3045, 2927, 2879, 1728, 1598, 1498, 1448, 1274, 
990, 815,750. HRMS (El) m/z calcd. for C2 0 H2 4NO2S [M+H]+ = 342.1528; found 342.1528.
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l-Butyl-2-tosylisoindoline 363h
NHTs
362h
NTs
363h
The sulfonamide 362h ( 6 6  mg, 0.185 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.13 ml, 0.093 mmol, 0.5 eq.). The resulting solution was heated to 40 °C 
for 3 hours, then cooled to room temperature and quenched with saturated aqueous K2 CO3 . The 
quenched solution was then separated and the aqueous layer was extracted with dichloromethane 
(3 x 10 ml). The combined organic layers were dried over K2 CO3 and evaporated to give the 
isoindole 363h as a brown oil ( 6 6  mg, Yield: 100%).
The sulfonamide 362h (28 mg, 0.085 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added concentrated sulfuric acid (2 drops). The resulting suspension was heated to 
40 °C for 3 hours, then cooled to room temperature and quenched with saturated aqueous K2 CO3 . 
The quenched solution was then separated and the aqueous layer was extracted with 
dichloromethane (3x10  ml). The combined organic layers were dried over K2 CO3 and evaporated 
to give the isoindole 363h as a brown oil (27 mg, Yield: 98%).
The two samples showed identical spectroscopic and analytical data: NMR (500 MHz / CDCI3)
S 7.26 (d, 2H, J  = 8.1 Hz, 2 x Ts CH), 7.14 (d, 2H, J=  8.1 Hz, 2 x Ts CH), 7.12 - 7.09 (m, 2H, 
2 x Ar CH), 7.04 -  6.97 (m, 2H, 2 x Ar CH), 4.92 (app. br. s, 1H, CHN), 4.58 (d, 1H, J=  14.8 Hz, 
O ^ H bN), 4.51 (d, 1H, J=  14.8 Hz, CHA/W ) ,  2.26 (s, 3H, Ts CH3), 2.10-2.02 (m, 1H, 
C#cHd), 1.80-1.73 (m, 1H, CUcHD), 1.32-1.11 (m, 3H, CH2 & CHEHF), 0.91-0.81 (m, 1H, 
CHb/Z/t), 0.73 (t, 3H, J  = 7.3 Hz, CH3). I3C NMR (500 MHz / CDC13) S 143.3 (C?), 140.2 (C,),
135.9 (C,), 135.1 (C?), 129.7 (2 x Ts CH), 127.6 (Ar CH), 127.5 (Ar CH), 127.3 (2 x Ts CH),
122.4 (Ar CH), 122.3 (Ar CH), 66.1 (CHN), 54.1 (CH2N), 33.1 (CH2), 25.5 (CH2), 22.7 (CH2),
21.5 (Ts CH3), 14.0 (CH3). IR u / cm'1: 3281, 3054,2957,2871,1728, 1597,1448,1274, 815, 750. 
HRMS (APCI) m/z calcd. for Ci9H2 4N 02S [M+H]+ = 330.1528; found 330.1523.
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l-Benzyl-2-tosyl-l,2,3,4-tetrahydroisoquinoline 361a
NHTs
360a
NTs
361a
The sulfonamide 360a (22 mg, 0.058 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.10 ml, 0.029 mmol, 0.5 eq.). The resulting solution mixture was stirred 
at 0 °C for 24 hours and then quenched with saturated aqueous K2 CO3 . The quenched solution was 
then separated and the aqueous layer was extracted with dichloromethane ( 3 x 1 0  ml). The 
combined organic layers were dried over K2 CO3 and evaporated to give the isoquinoline 361a as a 
yellow oil (22 mg, Yield: 100%).
The sulfonamide 360a (97 mg, 0.257 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added concentrated sulfuric acid (2 drops). The resulting suspension was stirred at 
20 °C for 48 hours and then quenched with saturated aqueous K2 CO3 . The quenched solution was 
then separated and the aqueous layer was extracted with dichloromethane (3x10 ml). The 
combined organic layers were dried over K2 CO3 and evaporated to give the isoquinoline 361a as a 
brown oil (96 mg, Yield: 99%).
The two samples showed identical spectroscopic and analytical data: *H NMR (400 MHz / CDCI3) 
d 7.37 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.13 -  6.85 (m, 10H, 2 x Ts CH Sc 8  x Ar CH), 6.75 - 6.71 
(m, 1H, Ar CH), 5.12 (t, 1H, J=  6 . 6  Hz, CHN), 3.48 -  3.42 (m 1H, GfifcHsN), 3.36 - 3.28 (m, 1H, 
CUAHBN), 3.07-3.02 (m, 2 H, CH2), 2 .64-2.55 (m, 1 H, CtfcHD), 2.42-2.34 (m, 1 H, CUcHd),- 
2.23 (s, 3H, Ts CH3). I3C NMR (400 MHz / CDCI3) S 143.0 (Cq), 137.7 (Cq), 136.9 (Cq), 135.6 
(Cq), 133.5 (Cq), 129.9 (2 x Ar CH), 129.5 (2 x Ts CH), 128.7 (Ar CH), 128.3 (2 x Ar CH), 127.3 
(ArCH), 127.2 (2 x Ts CH), 126.9 (Ar CH), 126.6 (Ar CH), 125.0 (Ar CH), 57.9 (CHN), 44.5 
(CH2N), 40.0 (CH2), 27.2 (CH2), 21.5 (Ts CH3). IR (neat), v  / cm'1: 3290, 3060, 3027,2925,2874, 
1652, 1598, 1448, 1274, 990, 815, 750. HRMS (ES) m/z calcd. for C2 3 H24N 02S 
[M+H]+ = 378.1528; found 378.1539.
185
l-(4-Chlorobenzyl)-2-tosyl-l,2,3,4-tetrahydroisoquinoline 361b
NHTs
Cl Cl
The sulfonamide 360b (52 mg, 0.126 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was then added TfOH (0.10 ml, 0.063 mmol, 0.5 eq.). The resulting solution was heated to 
40 °C for 48 hours, then cooled to room temperature and quenched with saturated aqueous K2 CO3 . 
The quenched solution was then separated and the aqueous layer was extracted with 
dichloromethane (3x10  ml). The combined organic layers were dried over K2 CO3 and evaporated 
to give the isoquinoline 361b as a brown oil (44 mg, Yield: 87%). NMR (400 MHz / CDCI3) 
81.65 -7.55 (m, 3H, 2 x Ts CH  & Ar CH), 7.39 (d, 2H, .7=8.3 Hz, 2 x Ts CH), 7.16-6.99 
(m, 4H, 4 x Ar CH), 6.93 -  6.75 (m, 3H, 3 x Ar CH), 5.07 (t, 1H, J= 6.6 Hz, CHN), 3.53 -  3.47 
(m, 1H, CT^HbN),, 3.37 -  3.30 (m, 1H, CHA775 N), 3.09 - 3.00 (m, 2H, CH2), 2.93 - 2.78 (m, 2H, 
CH2), 2.28 (s, 2H, Ts CH3). 13C NMR (400 MHz / CDC13) 8 144.1 (Cq), 143.2 (2 x Cq), 138.0 (Cq),
136.0 (Cy, 134.8 (Cy, 131.2 (Ar CH), 129.7 (Ar CH), 129.5 (2 x Ts CH), 128.8 (Ar CH), 128.3 
(Ar CH), 127.2 (Ar CH), 127.1 (2 x Ts CH), 127.0 (Ar CH), 126.1 (Ar CH), 125.1 (Ar CH), 57.9 
(CHN), 43.9 (CH2N), 40.1 (CH2), 28.9 (CH2), 21.5 (Ts CH). IR (neat), 0  / cm'1: 3062, 3028, 2925, 
2874, 1916, 1694, 1598, 1448, 815, 753, 658. HRMS (El) m/z calcd for C2 3H2 3 CINO2 S 
[M+H]+ = 412.1138 (Cl35); found 412.1135 (Cl35).
l-(4-Fluorobenzyl)-2-tosyl-l,2,3,4-tetrahydroisoquinolme 361c
The sulfonamide 360c (42 mg, 0.106 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.10 ml, 0.051 mmol, 0.5 eq.). The resulting solution was heated to 40 °C 
for 48 hours, then cooled to room temperature and quenched with saturated aqueous K2 C03. The 
quenched solution was then separated and the aqueous layer was extracted with dichloromethane 
(3 x 10 ml). The combined organic layers were dried over K2 C0 3 and evaporated to give the 
isoquinoline 361c as a brown oil (30 mg, Yield: 72%). *H NMR (400 MHz / CDC13) 81.64 (d, 2H,
NHTs
186
J= 8.3 Hz, 2 x Ts CH), 7.42 (d, 2H, 7 = 8 . 3  Hz, 2  x Ts CH), 7.25 - 7.21 (m, 2H, 2 x Ar CH),
7.16 -  6.99 (m, 3H, 3 x Ar CH), 6.91 -  6.76 (m, 3H, 3 x Ar CH), 4.33 (t, 1H, J=  6.3 Hz, CHN), 
3.89 - 3.82 (m, 2H, CH2N), 3.20 -  3.14 (m, 2H, CH2), 3.05 (d, 2H, J=  6.3 Hz, CH2), 2.35 (s, 3H, 
Ts CH,). 13C NMR (400 MHz / CDC13) <5 174.5 (Cq), 143.5 (2 x Cq), 138.4 (Cq), 137.1 (Cq), 133.7 
(C,), 133.1 (Ar CH), 131.2 (Ar CH), 129.7 (2 x Ts CH), 129.3 (Ar CH), 128.6 (Ar CH), 127.7 (Ar 
CH), 127.1 (2 x Ts CH), 126.0 (Ar CH), 115.2 (Ar CH), 114.9 (Ar CH), 58.1 (CHN), 42.6 
(CH2N), 36.4 (CH2), 27.4 (CH2), 21.6 (Ts CH3). IR (neat), u / cm'1: 3063,2926,2874,1599, 1509, 
1448, 1274,1074, 990, 815, 750. HRMS (APCI) m/z calcd. for C2 2H2 iFN02S [M+H]+ = 382.1277; 
found 382.1268.
2-Tosyl-l-(4-(trifluoromethyl)benzyl)-l,2,3,4-tetrahydroisoquinolme 361 d
NHTs
360d
NTs
361d
The sulfonamide 360d (47 mg, 0.106 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.10 ml, 0.053 mmol, 0.5 eq.). The resulting solution was heated to 40 °C 
for 48 hours, then cooled to room temperature and quenched with saturated aqueous K2 CO3 . The 
quenched solution was then separated and the aqueous layer was extracted with dichloromethane 
( 3 x 1 0  ml). The combined organic layers were dried over K2 CO3 and evaporated to give the 
isoquinoline 361d as a brown oil (35 mg, Yield: 75%).
The sulfonamide 360d (116 mg, 0.261 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), 
to which was added concentrated sulfuric acid (2 drops). The resulting suspension was heated to 
40 °C for 48 hours, then cooled to room temperature and quenched with saturated aqueous K2 CO3 . 
The quenched solution was then separated and the aqueous layer was extracted with 
dichloromethane (3 x 1 0  ml). The combined organic layers were dried over K2 CO3 and evaporated 
to give the isoquinoline 361 d as a brown oil (65 mg, Yield: 56%).
The two samples showed identical spectroscopic and analytical data: JH NMR (400 MHz / CDCI3)
S 7.32 -  7.28 (m, 4H, 2 x Ts CH  & 2 x Ar CH), 7.01 -  6.94 (m, 6 H, 2 * Ts CH & 4 x Ar CH),
6.86-6.73 (m, 1H, Ar CH), 6.76-6.73 (m, 1H, Ar CH), 5.05 (t, 1H, 7=6.6 Hz, CHN),
3.46-3.43 (m, 1H, C ^ H BN), 3.31-3.24 (m, 1H, CRAHBN), 3.05 (d, 2H, J=  6 . 6  Hz, CH2),
2.60-2.57 (m, 1H, CHcHD), 2 .37-2.24 (m, 1 H, CHcHD), 2.19 (s, 3H, Ts CH,). 13C NMR
(400 MHz / CDC13) 3 143.3 (2 x Cq), 141.7 (2 x Cq), 135.5 (Cq), 135.2 (Q), 133.6 (Cq), 130.2
187
(2 x Ar CH), 129.5 (2 x Ts CH), 128.9 (Ar CH), 127.1 (Ar CH), 127.0 (2 x Ts CH), 126.2 (2 x Ar 
CH), 125.1 (Ar CH), 125.0 (Ar CH), 57.7 (CHN), 44.3 (CH2N), 40.1 (CH2), 27.3 (CH2), 21.4 (Ts 
CH3). IR (neat), u / cm'1: 3063, 2931, 2874, 1617, 1599, 1555, 1448, 1274, 815, 750. HRMS (El) 
m/z calcd. for C2 4H2 2 F3N 02S [M]+ = 445.1323; found 445.1312.
l-(4-Methylbenzyl)-2-tosyl-l,2,3,4-tetrahydroisoquinolme 361e
NHTs
360e
NTs
361 e
The sulfonamide 360e (52 mg, 0.133 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added TfOH (0.10 ml, 0.066 mmol, 0.5 eq.). The resulting solution was heated to 40 °C 
for 24 hours, then cooled to room temperature and quenched with saturated aqueous K2 C03. The 
quenched solution was then separated and the aqueous layer was extracted with dichloromethane 
( 3 x 1 0  ml). The combined organic layers were dried over K2 C0 3 and evaporated to give the 
isoquinoline 361e as a brown oil (28 mg, Yield: 54%).
The sulfonamide 360e (121 mg, 0.309 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), 
to which was then added concentrated sulfuric acid (2 drops). The resulting suspension was heated 
to 40 °C for 48 hours, then cooled to room temperature and quenched with saturated aqueous 
K2 C03. The quenched solution was then separated and the aqueous layer was extracted with 
dichloromethane (3x10  ml). The combined organic layers were dried over K2 C0 3 and evaporated 
to give the isoquinoline 361e as a brown oil (97 mg, Yield: 80%).
The two samples showed identical spectroscopic and analytical data: !H NMR (400 MHz / CDC13) 
S 1M  (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.45 - 7.42 (m, 4H, 4 x Ar CH), 7.21 (d, 2H, J=  8.3 Hz, 
2 x Ts CH), 7.12 -  6.99 (m, 4H, 4 x Ar CH), 5.06 (t, 1H, J=  6.3 Hz, CHN), 3.42 - 3.37 (m, 2H, 
CH2N), 3.29-3.14 (m, 2H, CH2), 3.01 (d, 2H, .7=6.4 Hz, CH2), 2.35 (s, 6 H, 2 x Ar CH3),
2.34 - 2.21 (m, 2H, CH2). 13C NMR (400 MHz / CDC13) S 143.4 (2 x Cq), 137.2 (2 x Cq), 136.9 
(Cq), 133.0 (Cq), 131.2 (2 x Ar CH), 129.7 (2 x Ts CH), 128.6 (2 x Ar CH), 127.7 (2 x Ar CH),
127.1 (2 x Ts CH), 124.4 (2 x Ar CH), 77.3 (CHN), 42.5 (CH2N), 36.4 (2 x CH2), 21.6 (2 x Ar 
CH3). IR (neat) u / cm'1: 3051, 3020, 2922, 2867, 1598, 1512, 1448, 1274, 815, 750. HRMS (El) 
calcd. for C2 4H2 6N 02S [M+H]+ = 392.1684; found 392.1689.
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l-(Cyclohexylmethyl)-2-tosyl-l,2,3,4-tetrahydroisoquinoUne 361f
NHTs
The sulfonamide 360f (39 mg, 0.102 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was then added TfOH (0.10 ml, 0.059 mmol, 0.5 eq.). The resulting solution was heated to 
40 °C for 24 hours, then cooled to room temperature and quenched with saturated aqueous K2 CO3 . 
The quenched solution was then separated and the aqueous layer was extracted with 
dichloromethane (3x10 ml). The combined organic layers were dried over K2 CO3 and evaporated 
to give the isoquinoline 361f as a brown oil (35 mg, Yield: 90%). *H NMR (500 MHz / CDCI3) 
3 7.51 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.06 - 6.90 (m, 5H, 2 x Ts CH & 3 x Ar CH), 6.79 - 6.76 
(m, 1H, Ar CH), 4.98 (t, 1H, J=  6.9 Hz, CHN), 3.85 -  3.79 (m, 2 H, CTftN), 3 . 4 4  -  3 . 3 5  (m, 2 H, 
CH2), 2.25 (s, 3H, Ts CH3), 1.72 - 0.78 (m, 13H, CH-&6* CH2). 13C NMR (500 MHz / CDC13) 3
137.6 (2 x Cq), 137.4 (Q ), 134.0 (Cq), 129.2 (2 x Ts CH), 127.9 (2 x Ts CH), 127.7 (2 x Ar CH),
126.4 (Ar CH), 15.9 (Ar CH), 57.6 (CHN), 48.6 (CH2N), 38.4 (CH2), 33.9 (2 x CH2), 31.3 (CH),
25.8 (2 x CH2), 25.2 ( 2  x CH2), 21.3 (Ts CH3). IR (neat) u / cm'1: 3061, 3024, 2922, 2850, 1699, 
1598, 1448, 1274, 815, 750. HRMS (El) m/z calcd. for C2 3 H3 0NO2 S [M+H]+= 384.1997; found 
384.1980.
2,-Tosyl-3\4,-dihydro-2,H-spiro[cyclohexane-l,r-isoquinolme] 361g
The sulfonamide 360g (40 mg, 0.115 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was then added TfOH (0.10 ml, 0.058 mmol, 0.5 eq.). The resulting solution was stirred at 
0 °C for 24 hours and then quenched with saturated aqueous K2 C03. The quenched solution was 
then separated and the aqueous layer was extracted with dichloromethane (3 x 10 ml). The
brown oil (33 mg, Yield: 83%).
The sulfonamide 360g (90 mg, 0.253 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was added concentrated sulfuric acid (2 drops). The resulting suspension was stirred at 20
NHTs
combined organic layers were dried over K 2 C O 3  and evaporated to give the isoquinoline 361g as a
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°C for 24 hours and then quenched with saturated aqueous K2 CO3 . The quenched solution was 
then separated and the aqueous layer was extracted with dichloromethane (3 x 10 ml). The 
combined organic layers were dried over K2 CO3 and evaporated to give the isoquinoline 360g as a 
brown oil (73 mg, Yield: 81%).
The two samples showed identical spectroscopic and analytical data: l¥L NMR (400 MHz / CDC13) 
5 7.63 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.23 -  6.99 (m, 6 H, 2 x Ts CH & 4 x Ar CH), 3.17 (app. dd, 
2H, J=  13.6, 7.0 Hz, CH2N), 2.61 - 2.85 (m, 2H, CH2), 2.35 (s, 3H, Ts CH3), 1.80 -  1.09 (m, 10H, 
5 x CH2). I3C NMR (400 MHz / CDClj) <5 142.0 (C„), 140.0 (C,), 134.0 (C„), 131.8 (C„), 129.6 
(2 x Ts CH), 129.4 (Ar CH), 127.3 (2 x Ts CH), 126.9 (Ar CH), 126.7 (Ar CH), 126.5 (Ar CH),
50.0 (C?), 44.0 (CH2N), 33.1 (CH2), 30.9 (CH2), 26.4 (CH2), 25.3 (CH2), 23.1 (CH2), 22.0 (CH2),
21.5 (Ts CH3). IR (neat) u / cm'1: 3063, 3028, 2926, 2857, 1598, 1448, 1274, 815, 750. HRMS 
(El) m/z cald. for C2 ,H2 5N 02S [M]+ = 355.1606; found 355.1601.
l-Butyl-2-tosyl-l,2,3,4-tetrahydroisoquinoline 361h
361h S
The sulfonamide 360h (54 mg, 0.157 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was then added TfOH (0.10 ml, 0.079 mmol, 0.5 eq.). The resulting solution was stirred at 
0 °C for 24 hours and then quenched with saturated aqueous K 2 C O 3 .  The quenched solution was 
then separated and the aqueous layer was extracted with dichloromethane (3 x 10 ml). The 
combined organic layers were dried over K 2 C O 3  and evaporated to give the isoquinoline 361h as a 
brown oil (50 mg, Yield: 92%).
The sulfonamide 360h (72 mg, 0.209 mmol, 1.0 eq.) was dissolved in dichloromethane (10 ml), to 
which was then added concentrated sulfuric (2 drops). The resulting suspension was heated to 
40 °C for 24 hours, then cooled to room temperature and quenched with saturated aqueous K 2 C O 3 .  
The quenched solution was then separated and the aqueous layer was extracted with 
dichloromethane (3x10  ml). The combined organic layers were dried over K 2 C 0 3 and evaporated 
to give the isoquinoline 361h as brown oil (64 mg, Yield: 89%).
The two samples showed identical spectroscopic and analytical data: *H NMR (400 MHz / CDC13) 
6 7.51 (d, 2H, J=  8.1 Hz, 2 x Ts CH), 7.07 -  6.94 (m, 5H, 3 x Ar CH & 2 x Ts CH), 6.82 - 6.79 
(m, 1H, Ar CH), 4.88 (t, 1H, J — 6.5 Hz, CHN), 3.81 - 3.77 (m, 1H, C/T^HbN), 3.43 -  3.35 (m, 1H,
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NHTs
CHaAbN), 2.46 -  2.41 (m, 2H, CH2), 2.24 (s, 3H, Ts CH,), 1.78 -  1.58 (m, 2H, CH2), 1.44 -  1.16 
(m, 4H, 2 x CH2), 0.82 (t, 3H, J=  7.1 Hz, CH,). 13C NMR (400 MHz / CDCU) <5 142.9 (Cq), 137.9 
(C,), 137.0 (C„), 132.6 (C,), 129.3 (2 x Ts CH), 128.9 (Ar CH), 127.0 (2 x Ts CH), 126.9 (Ar 
CH), 126.5 (Ar CH), 126.0 (Ar CH), 56.8 (CHN), 38.7 (CH2N), 37.5 (CH2), 28.6 (CH2), 26.2 
(CH2), 22.5 (CH2), 21.5 (Ts CH3), 14.1 (CH3). IR (neat) u / cm'1: 3063, 3025, 2955, 2930, 1598, 
1448, 1274, 815, 750. HRMS (ES) m/z calcd. for C2 0 H2 6NO2S [M+H]+= 344.1684; found 
344.1694.
2-MethyI-l-tosylpiperidine 474294
H Ts
465 474
2-Methylpiperidine 465 (2.40 ml, 20.2 mmol, 1.0 eq.) was treated according to general procedure 
C to give the title compound 474 as a white solid (4.57 g, Yield: 90%). All data obtained was in 
accordance with that previously reported in the literature. 2 9 4  m.p.: 56 - 58 °C. ]H NMR (400 MHz / 
CDCI3) S 7.63 (d, 2H, J  = 8.2 Hz, 2 x Ts CH), 7.20 (d, 2H, J  = 8.2 Hz, 2 x Ts CH), 4.16 (app. 
pent, 1H, J  = 6.9 Hz, CHN), 3.66 - 3.59 (m, 1H, G ^ H BN), 2.93 - 2.87 (m, 1H, CH a^N ), 2.34 
(s, 3H, Ts CH,), 1.60 -1.21 (m, 6 H, 3 x CH2), 0.99 (d, 3H, J=  6.9 Hz, CH,). 13C NMR (400 MHz 
/ CDC13) S 142.8 (Q), 138.3 (Cq), 129.7 (2 x Ts CH), 126.9 (2 x Ts CH), 48.5 (CHN), 40.5 
(CH2N), 30.4 (CH2), 25.2 (CH2), 21.6 (Ts CH3), 18.3 (CH2), 15.4 (CH3). IR(neat) u/cm'1: 2939, 
1597,1263, 1037,995. HRMS (El) m/z calcd. for C |3H 19N 02S [M]+ = 253.1137; found: 253.1133.
2-Ethyl-l-tosylpyrrolidine 475295
474 475
2-Methyl-1-tosylpiperidine 474 (100 mg, 0.39 mmol, 1.0 eq.) was dissolved in dichloromethane 
( 1 0  ml) and to this concentrated sulfuric acid ( 2  drops) was added and the reaction mixture stirred 
at 40 °C under nitrogen for 72 hours. The reaction was allowed to cool and was then quenched 
with saturated aqueous K 2 C O 3  (10 ml). The quenched solution was then separated and the aqueous
f-I
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K2CO3 and evaporated to give a white solid (72 mg, Yield: 72%). 9% pyrrolidine 475. 
(11.24:1 ratio)
2-Methyl-1-tosylpiperidine 474 (100 mg, 0.39 mmol, 1.0 eq.) was dissolved in Toluene (10 ml) 
and to this TfOH (0.30 ml, 0.197 mmol, 0.5 eq.) was added and the reaction mixture stirred at 
110 °C under nitrogen for 72 hours. The reaction was allowed to cool and was then quenched with 
saturated aqueous K2 CO3 (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K2CO3 and evaporated to give a white solid ( 6 6  mg, Yield: 6 6 %). 5% pyrrolidine 475. (19 :
1 ratio)
2-Methyl-1-tosylpiperidine 474 (100 mg, 0.39 mmol, 1.0 eq.) was dissolved in Toluene (10 ml) 
and to this concentrated sulfuric acid ( 6  drops) was added and the reaction mixture stirred at 
110 °C under nitrogen for 24 hours. The reaction was allowed to cool and was then quenched with 
saturated aqueous K2 CO3 (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K2CO3 and evaporated to give a white solid (72 mg, Yield: 72%). 21% pyrrolidine 475. 
(4.62:1.0 ratio)
2-Methyl-1-tosylpiperidine 474 (100 mg, 0.39 mmol, 1.0 eq.) was dissolved in Toluene (10 ml) 
and to this concentrated sulfuric acid ( 6  drops) was added and the reaction mixture stirred at 40 °C 
under nitrogen for 72 hours. The reaction was allowed to cool and was then quenched with 
saturated aqueous K 2 C O 3  (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K 2 C O 3  and evaporated to give a white solid (21 mg, Yield: 21%). 6 % pyrrolidine 475. 
(15.98:1 ratio)
See Table 4.3, p. 101 for further details. All data obtained was in accordance with that previously 
reported in the literature. 2 9 5  The four samples showed identical spectroscopic and analytical data: 
m.p.: 49-51 °C. *H NMR (400 MHz / CDC13) piperidine: S 7.61 (d, 2H, J=  8.2 Hz, 2 x Ts CH), 
7.18 (d, 2H, J=  8.2 Hz, 2 x Ts CH), 4.17 -  4.11 (m, 1H, CHN), 3.63 -  3.57 (m, 1H, CT^HbN), 
2.90-2.85 (m, 1H, CHA//sN), 2.32 (s, 3H, Ts CH3), 1.55-1.24 (m, 6 H, 3 x CH2), 0.97 (d, 3H, 
J=  6.9 Hz, CH$); pyrrolidine : 3 7.72 (d, 2H, J — 8.2 Hz, 2 x Ts CH), 7.08 (d, 2H, J — 8.2 Hz,
2 x Ts CH), 3 .49-3.43 (m, 1H, CHN), 3.33 -3.27 (m, 1H, C/^HBN), 3.20-3.16 (m, 1H, 
CHa#sN),2.33 ( s, 3H, Ts CH3, minor), 1.82 -  1.63 (m, 2H, CH2), 1.55 -  1.24 (m, 4H, 2 x CH2), 
0.82 (t, 3H, J=  7.1 Hz, CH3). JR (neat) u/cm'1: 2939, 2866,1598,1038, 996.
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3-Methyl-l-tosylpiperidine 476296
466 476
3-Methylpiperidine 466 (2.00 g, 20.2 mmol, 1.0 eq.) was treated according to general procedure C 
to give the title compound 476 as a white solid (4.27 g, Yield: 84%). All data obtained was in 
accordance with that previously reported in the literature. 2 9 6  m.p.: 104 - 107 °C. !H NMR 
(400 MHz / CDC13) S 7.57 (d, 2H, J  = 8.3 Hz, 2 x Ts CH), 7.25 (d, 2H, J=  8.3 Hz, 2 x Ts CH),
3.58 - 3.36 (m, 4H, 2 x Ctf2 N), 2.37 (s, 3H, Ts CH3), 1.74-1.51 (m, 5H, 2 x CH2 & CH), 0.80 (d, 
3H, J  = 6.5 Hz, CH3). IR (neat) u/cm'1: 2939, 1597, 1263, 1037, 995. HRMS (El) m/z calcd. for 
C13H19NO2 S [M]+ = 253.1137; found: 253.1134.
2-Phenylpiperidine 46929 7
480
A mixture of 2-phenylpiperidine 480 (4.60 ml, 32 mmol, 1.0 eq.) concentrated HC1 (4 ml) and 
ethanol ( 2 0  ml) with PtC>2 (300 mg, 1.3 mmol, 0.04 eq.) was placed in a Paar apparatus and 
subjected to catalytic hydrogenation at a pressure of 1 atmosphere at room temperature for 
24 hours. The catalyst was removed by filtration through a plug of celite and washed with EtOH 
(100 ml). The solvent was evaporated to dryness. The solid residue was treated with 2M NaOH 
(30 ml) and the free base extracted with diethyl ether (3 x 30 ml). The ether extracts were 
combined and dried over MgSC>4 and evaporated to give the title compound 469 as a white solid 
(4.04 g, Yield: 78%). All data obtained was in accordance with that previously reported in the 
literature.297 m.p.: 105 - 108 °C. 'H NMR (400 MHz / CDC13) S 7.40 - 7.23 (m, 5H, 5 x Ar CH), 
3.61 (dd, 1H, J  = 7.9, 2.5 Hz, CHN), 3.25 - 3.19 (m, 1H, CH*HBN), 2.82 (td, 1H, J=  11.5, 2.5, 
CH aH sN ), 1.98 - 1.65 (m, 5H, 2 x CH2 & NH), 1.60 - 1.46 (m, 2H, CH2). I3C NMR (500 MHz / 
CDClj) 5 145.6 (C,), 128.4 (2 x Ar CH), 127.1 (Ar CH), 126.7 (2 x Ar CH), 62.4 (CHN), 47.8 
(CH2N), 35.0 (CH2), 26.0 (CH2), 25.5 (CH2). IR neat u/cm'1: 3026, 2932,2851, 2787, 1602, 1106, 
996,698. HRMS (El) m/z calcd. for Cn Hi5N [M]+ = 161.1204; found: 161.1200.
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2-Phenyl-l-tosylpiperidine 460298
469 460
3-Methylpiperidine 469 (4.04 g, 25.1 mmol, 1.0 eq.) was treated according to general procedure C 
to give the title compound 460 as a white solid (7.11 g, Yield: 90%). All data obtained was in 
accordance with that previously reported in the literature. 2 9 8  m.p.: 109 - 112 °C. JH NMR 
(500 MHz / CDCI3) <5 7.76 (d, 2H, J=  8.3 Hz, 2  x Ts CH), 7.35 - 7.28 (m, 6 H, 2 x Ts CH & 4 x Ar 
CH), 7.26 - 7.22 (m, 1H, Ar CH), 3.84 (d, 1H, J=  13 Hz, CtfN), 3.04 - 2.98 (m, 1H, , Ci^HBN),
2.44 (s, 3H, Ts CH3), 2.26-2.21 (m, 1H, CHA/^N ), 1.67-1.62 (m, 1 H, CtfcHD), 1.47-1.43 
(m, 1H, CHcHd), 1.42- 1.36 (m, 2H, CH2), 1.33 - 1.24 (m, 2H, CH2). 13C NMR (500 MHz / 
CDCI3) S 142.9 (Q), 138.9 (Q ), 138.7 (Q), 129.7 (2 x Ts CH), 128.6 (2 x Ar CH), 127.05 (2 x Ts 
CH), 127.0 (2 x Ar CH), 126.8 (Ar CH), 55.3 (CHN), 41.9 (CH2N), 27.2 (CH2), 24.3 (CH2), 21.6 
(Ts CH3), 18.9 (CH2). IR neat u/cm'1: 2939, 2866, 1598, 1106, 996, 698. HRMS (APCI) m/z calcd. 
for Ci8H2 2N 02S [M+H]+ = 316.1371; found: 316.1363.
2-Benzyl-l-tosylpyrrolidine 481299
460 481
2-Phenyl-1-tosylpiperidine 460 (100 mg, 0.317 mmol, 1.0 eq.) was dissolved in toluene (10 ml) 
and, stirred under nitrogen. TfOH (0.20 ml, 0.159 mmol, 0.5 eq.) was added to the solution and 
stirred at 110 °C for 72 hours. The reaction was allowed to cool and quenched by the addition of 
saturated aqueous K2 C 0 3 (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K2 C0 3 and evaporated to give a yellow oil (80 mg, Yield: 80%).
2-Phenyl-1-tosylpiperidine 460 (100 mg, 0.317 mmol, 1.0 eq.) was dissolved in toluene (10 ml) 
and stirred under nitrogen.. Concentrated H2 SC>4 (2 drops) was added to the solution and stirred at 
110 °C for 72 hours. The reaction was allowed to cool and quenched by the addition of saturated 
aqueous K2 C 0 3 (10 ml). The quenched solution was then separated and the aqueous layer was
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washed with dichloromethane (3 x 10 ml). The combined organic layers were dried over solid 
K2CO3 and evaporated to give a yellow oil (80 mg, Yield: 80%).
Both samples showed decomposition of the piperidine and no isolation of the desired pyrrolidine 
481. This was shown by comparison with literature spectroscopic data for 2-benzyl-1- 
tosylpyrrolidine. 2 9 9
2-Cyclohexylpiperidine 470 2 6 5  3 0 0
470
A mixture of 2-phenylpiperidine 480 (4.60 ml, 32 mmol, 1.0 eq.) concentrated HC1 (4 ml) and 
ethanol (20 ml) with PtC>2 (0.3 g, 1.3 mmol, 0.04 eq.) was placed in a Paar apparatus and subjected 
to catalytic hydrogenation at a pressure of 2 to 3 atmospheres at room temperature for 48 hours. 
The catalyst was removed by filtration through a plug of celite and washed with ethanol (100 ml). 
The solvent was evaporated to dryness. The solid residue was treated with 2 M NaOH (30 ml) and 
the free base extracted with diethyl ether (3 x 30 ml). The ether extracts were combined, dried 
over MgSC>4 and evaporated to give the title compound 470 as a yellow oil (4.358 g, Yield: 81%). 
All data obtained was in accordance with that previously reported in the literature. 3 0 0  !H NMR 
(500 MHz / CDCI3) S 3.08 (app. dq, 1H, J=  11.7, 2.3 Hz, CHN), 2.62-2.57 (m, 1H, C H ^ N ),
2.23-2.16 (m, 1H, CHAtfsN), 1.83 - 1.55 (m, 8 H, 4 x CH2\  1.43 - 1.25 (m, 2H, CH2), 1.24 - 1.05 
(m, 5H, 2 XCH2 & CH), 1.02 - 0.92 (m, 2H, CH2). I3C NMR (500 MHz / CDC13) <5 62.0 (CHN),
47.6 (CH2N), 43.5 (CH), 29.7 (CH2), 29.4 (CH2), 29.3 (CH2), 26.8 (CH2), 26.7 (CH2), 26.5 (CH2),
26.4 (CH2), 25.2 (CH2). IR neat u/cm'1: 2927, 2852, 1629, 1106, 996. HRMS (El) m/z calcd. for 
CnH21N [M]+ = 167.1674; found: 167.1677.
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2-Cyclohexyl-l-tosylpiperidine 484
470 484
2-Cyclohexylpiperidine 470 ( 1 . 0 0  g, 5.99 mmol, 1 . 0  eq.) was treated according to general 
procedure C to give the title compound 484 as a clear oil (1.71 g, Yield: 89%). 'H NMR (500 MHz 
/ CDC13) <5 7.73 (d, 2H, J  = 8.3 Hz, 2 x Ts CH), 7.27 (d, 2H, J  = 8.3 Hz, 2 x Ts CH), 3.80-3.77 
(m, 1H, C/^HbN), 3 .69-3.61 (m, 1H, CHN), 3.00-2.94 (m, 1H, CHA/^N ), 2.42 (s, 3H, Ts 
CHi), 1.85 - 1.08 (m, 17H, 8  x CH2 and CH). 13C NMR (500 MHz / CDCI3) <5 142.5 (C,), 139.5 
(C?), 129.7 (2 x Ts CH), 127.0 (2 x Ts CH), 58.6 (CHN), 41.5 (CH2N), 34.8 (CH), 30.5 (CH2),
30.0 (CH2), 26.4 (CH2), 26.3 (CH2), 26.2 (CH2), 24.4 (2 x CH2), 23.9 (CH2), 21.4 (Ts CH3), 18.6 
(CH2). IR (neat) u/cm'1: 2929, 2852, 1716, 1598, 1106, 996. HRMS (APCI) m/z calcd. for 
Ci8H2 8N 02S [M+H]+ = 322.1841; found: 322.1845.
2-(Cyclohexylmethyl)-l-tosylpyrrolidine 485
485
Ts
484
2-Cyclohexyl- 1-tosylpiperidine 484 (100 mg, 0.312 mmol, 1.0 eq.) was dissolved in toluene 
(10 ml) and stirred under nitrogen. TfOH (0.20 ml, 0.156 mmol, 0.5 eq.) was added to the solution 
and stirred at 110 °C for 24 hours. The reaction was allowed to cool and quenched by the addition 
of saturated aqueous K 2 C O 3  (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K 2 C O 3  and evaporated to give a yellow oil (31 mg, Yield: 31%). 32% pyrrolidine 485. 
(2.41:1.0 ratio)
2-Cyclohexyl-1-tosylpiperidine 484 (100 mg, 0.312 mmol, 1.0 eq.) was dissolved in toluene 
(10 ml) and stirred under nitrogen. TfOH (0.20 ml, 0.156 mmol, 0.5 eq.) was added to the solution 
and stirred at 110 °C for 72 hours. The reaction was allowed to cool and quenched by the addition 
of saturated aqueous K 2 C O 3  (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10 ml). The combined organic layers were dried over
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solid K2 CO3 and evaporated to give a yellow oil (73 mg, Yield: 73%). 48% pyrrolidine 485. 
(1 .1 0 : 1 . 0  ratio)
2-Cyclohexyl-1-tosylpiperidine 484 ( 1 0 0  mg, 0.312 mmol, 1 . 0  eq.) was dissolved in toluene 
(10 ml) and stirred under nitrogen. Concentrated sulfuric acid ( 2  drops) was added to the solution 
and stirred at 110 °C for 72 hours. The reaction was allowed to cool and quenched by the addition 
of saturated aqueous K2 CO3 (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K2CO3 and evaporated to give a yellow oil (56 mg, Yield: 56%). 23% pyrrolidine 485. 
(3.29:1.0 ratio)
See Table 4.6, p. 106 for further deatils. The three samples showed identical spectroscopic and 
analytical data: JH NMR (500 MHz / CDC13) piperidine: S 7.65 (d, 2H, J=  8.4 Hz, 2 x Ts CH), 
7.20 (d, 2H, J=  8.4 Hz, 2 x Ts CH), 3.73 -  3.68 (m, 1H, CHN), , 3.57 -  3.54 (m, 1H, C/^HBN), 
2.92 - 2.85 (m, 1H, CHAH5 N), 2.34 (s, 3H, Ts CH3), 1.79 -  1.76 (m, 1H, CH), 1.72 - 1.65 (m, 6 H, 
3 x CHi), 1.64 -  1.06 (m, 10H, 5 x CH2); pyrrolidine: S 7.73 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.23 
(d, 2H, J=  8.3 Hz, 2 x Ts CH), 3.64 -  3.58 (m, 1H, CHN), 3.34 -  3.30 (m, 1H, C ^ H BN), 3.14 -  
3.10 (m, 1H, CHa/^N), 2.35 (s, 3H, Ts CH3), 1.72 - 1.65 (m, 7H, 3 x CH2&CH), 1.64 -  1.06 (m, 
10H, 5 x CH2). 13NMR (500 MHz / CDC13) piperidine: d 142.6 (Cq), 139.5 (Cq), 129.5 (2 x Ts 
CH), 127.0 (2 x Ts CH), 58.3 (CHN), 41.1 (CH2 N), 34.9 (CH), 30.3 (CH2), 30.0 (2 x CH2), 26.4 
(CH2), 26.3 (CH2), 26.2 (CH2), 24.4 (CH2), 23.9 (CH2), 21.5 (Ts CH3), pyrrolidine: 6 143.1 (Cq), 
139.1 (Cq), 129.6 (2 x Ts CH), 127.5 (2 x Ts CH), 58.4 (CHN), 48.7 (CH2N), 35.0 (CH), 34.1 
(CH2), 32.7 (CH2), 31.1 (2 x CH2), 30.3 26.6 (CH2), 24.0 (CH2), 21.7 (Ts CH3), 18.6 (2 x CH2). IR 
(neat) u/cm’1: 2926, 2853, 1598, 1106, 996.
2-Benzyl-l-tosylpiperidine 4612
471 461
2-Benzylpiperidine 471 (200 mg, 1.14 mmol, 1.0 eq.) was treated according to general procedure 
C to give the title compound 461 as a colourless solid (346 mg, Yield: 92%). All data obtained was 
in accordance with that previously reported in the literature. 2  m.p.: 78-81 °C. H NMR (400 MHz 
/ CDC13) S 7.54 (d, 2H, J  = 8.3 Hz, 2 x Ts CH), 7.23 - 7.13 (m, 6 H, 2 x Ts CH & 4 x Ar CH), 
7.09 - 7.06 (m, 1H, Ar CH), 4.22 (app. t, 1H, J=  6 .8 , CHN), 3.74 - 3.67 (m, 1H, Ci^HBN),
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I 3.04-2.97 (m, 1H, CHA77gN), 2.76 (app. q, 2H,J =  6.8 Hz, Cff2), 2.32 (s, 3H, Ts CH}), 1.61 - 
I 1.54 (m, 4H, 2 x CH2), 1.40 - 1.27 (m, 2H, CH2). 13C NMR (500 MHz / CDC13) <5 142.8 (C,), 
J 138.7 (C„), 138.5 (C„), 129.6 ( 2 « A r  CH), 129.2 (2 x Ts CH), 128.5 (2 x Ar CH), 127.0 (2 x Ts 
|  CH), 126.4 (Ar CH), 54.3 (CHN), 40.9 (CH2N), 35.7 (CH2), 26.0 (CH2), 24.9 (CH2), 21.5 (Ts 
! CH3), 18.3 (CH2). IR neat u/cm'1: 2940, 2864, 1598, 1108, 996, 698. HRMS (APCI) m/z calc, for 
Ci9H2 4N 02S [M+H]+ = 330.1528; found: 330.1522.
2-Phenethvl-l-tosylpyrrolidine 486301
T s  
461
2-Benzyl-1-tosylpiperidine 461 (100 mg, 0.304 mmol, 1.0 eq.) was dissolved in toluene (10 ml) 
and stirred under nitrogen. Concentrated sulfuric acid (2 drops) was added to the solution and 
stirred at 110 °C for 24 hours. The reaction was allowed to cool and quenched by the addition of 
saturated aqueous K2 CO3 (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K2CO3 and evaporated to give a yellow oil (85 mg, Yield: 85%). 27% pyrrolidine 486. 
(2.71: 1 ratio)
2-Benzyl-1-tosylpiperidine 461 (100 mg, 0.304 mmol, 1.0 eq.) was dissolved in toluene (10 ml) 
and stirred under nitrogen. TfOH (0.20 ml, 0.152 mmol, 0.5 eq.) was added to the solution and 
stirred at 110 °C for 72 hours. The reaction was allowed to cool and quenched by the addition of 
saturated aqueous K2 CO3 (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K2 CO3 and evaporated to give a yellow oil (61 mg, Yield: 61%). 43.7% pyrrolidine 486. 
(1.29: 1 ratio)
2-Benzyl-1-tosylpiperidine 461 (100 mg, 0.304 mmol, 1.0 eq.) was dissolved in toluene (10 ml) 
and stirred under nitrogen. TfOH (0.40 ml, 0.304 mmol, 1.0 eq.) was added to the solution and 
stirred at 110 °C for 24 hours. The reaction was allowed to cool and quenched by the addition of 
saturated aqueous K 2 C O 3  (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10 ml). The combined organic layers were dried over
T s
486
198
|  solid K2 CO3 and evaporated to give a yellow oil (80 mg, Yield: 80%). 30% pyrrolidine 486. 
| (2.43:1 ratio)
1 2-Benzyl-1-tosylpiperidine 461 ( 1 0 0  mg, 0.304 mmol, 1 . 0  eq.) was dissolved in toluene ( 1 0  ml)
| and stirred under nitrogen. TfOH (0.90 ml, 0.608 mmol, 2.0 eq.) was added to the solution and 
[■ stirred at 110 °C for 24 hours. The reaction was allowed to cool and quenched by the addition of 
I saturated aqueous K 2 C O 3  (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K 2 C O 3  and evaporated to give a yellow oil (83 mg, Yield: 83%). 57% pyrrolidine 486. (1 : 
1.33 ratio)
See Table 4.7, p. 107 for further details. All samples show identical spectroscopic and analytical 
data: All data obtained was in accordance with that previously reported in the literature. 301 *H 
NMR (500 MHz / CDC13) piperidine: 3 7.52 (d, 2H, J=  8.4 Hz, 2 x Ts CH), 7.22 -  7.15 (m, 3H, 
3 x Ar CH), 7.14 -  7.10 (m, 2H, 2 x Ar GH), 7.05 (d, 2H, J=  8.4 Hz, 2 x Ts CH), 4.22 - 4.16 
(m, 1H, CHN), 3 .73-3 .66  (m, 1H, C /^H BN), 3.04-2.97 (m, 1H, CH a^N ), 2.73 (q, 2H, 
7=  6 . 8  Hz, CH2), 2.29 (s, 3H, Ts CH3), 1.62 -  1.43 (m, 4H, 2 x CH2) , 1.39 - 1.25 (m, 2H, CH2),; 
pyrrolidine: S 7.22 -  7.15 (m, 5H, 2 x Ts CH3 x Ar CH), 7.14 -  7.10 (m, 4H, 2 x Ts CH Sc 2 x Ar 
CH), 3.00-2.90 (m, 1H, CflN), 2 .69-2.63 (m, 1H, C ^ H BN), 2.60-2.56 (m, 1 H, CHAtf5 N), 
2.50-2.39 (m,2H, CH2), 2.28 (s, 3H, Ts CH3), 1.69 (app. br. s, 2H, CH2), 1.39-1.25 
(m,2H, CH2), 1.24 - 0.97 (m, 2H, CH2). 13C NMR (500 MHz / CDC13) piperidine: S 142.8 (Cq),
138.7 (Cq), 138.6 (Cq), 129.6 (2xArCH),  129.2 (2 x Ts CH), 128.5 (2xArCH),  127.0 
(2 x Ts CH), 126.4 (Ar CH), 54.4 (CHN), 40.9 (CH2N), 35.8 (CH2), 26.0 (CH2), 24.9 (CH2), 21.4 
(Ts CH3), 18.3 (CH2); pyrrolidine: S 139.3 (Q ), 139.1 (Cq), 138.7 (Cq), 129.9 (2 x Ar CH), 129.3 
(2 x Ts CH), 128.4 (2 x Ar CH), 127.6 (2 x Ts CH), 126.2 (Ar CH), 58.3 (CHN), 47.2 (CH2N),
44.0 (CH2), 33.0 (CH2), 26.2 (CH2), 24.9 (CH2), 21.5 (Ts CH3). IR (neat) u/cm'1: 2938, 2861, 
1598,1108, 996, 698.
(2£,6R)-2,6-Dimethyl-l-tosylpiperidine 487302
467 487
2,6-Dimethylpiperidine 467 (2.00 g, 17.7 mmol, 1.0 eq.) was treated according to general 
procedure C and the crude product was purified using column chromatography (eluting silica gel
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Is with 30% ethyl acetate in hexanes) to give the title compound 487 as a white solid (1.50 g, 
Yield: 32%). All data obtained was in accordance with that previously reported in the literature. 30 2  
i m.p: 63 - 65 °C. *H NMR (400 MHz / CDCI3 ) <5 7.63 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.20 (d, 2H, 
|  J= 8-3 Hz, 2 x Ts CH), 4.11 (app. p, 2H, J=  7.1 Hz, 2 x CHN), 2.34 (s, 3H, Ts CH,), 1.73 -1.61 
\ (m, 2H, CH2), 1.40- 1.29 (m, 4H, 2 x CH2), 1.27 (d, 6 H, 7 =  7.1 Hz, 2 x CH3). 13C NMR 
; (400 MHz / CDC13) S 142.6 (C„), 139.0 (C?), 129.6 (2 x Ts CH), 126.7 (2 x Ts CH), 47.9 
[ (2 x CHN), 29.6 ( 2  x c/fc), 22.4 (CH2), 21.5 (Ts C//3), 13.4 ( 2  x CiT,). IR (neat) Wcm'1: 3026, 
2924, 1599, 1265, 1108, 996. HRMS (El) m/z calcd. for C|4 H2 |N 02S [M]+ = 367.1293; found: 
367.1284.
I
(2iy,5/f)-2-Ethyl-5-methyl-l-tosylpyrrolidine 488a & (2 i?,5 /?)-2 -ethyl-5 -methyl-l-
tosylpyrrolidine 488b
4 8 7  4 8 8 a  4 8 8 b
2.6-Dimethyl-1-tosylpiperidine 487 (100 mg, 0.374 mmol, 1.0 eq.) was dissolved in toluene 
(10 ml) and stirred under nitrogen. Concentrated sulfuric acid (2 drops) was added to the solution 
and stirred at 110 °C for 24 hours. The reaction was allowed to cool and quenched by the addition 
of saturated aqueous K2 CO3 (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K2 CO3 and evaporated to give a yellow oil (77 mg, Yield: 77%). 487: 1 (28%); 488a: 1.83 
(50%); 488b: 0.81 (22%)
2.6-Dimethyl-1-tosylpiperidine 487 (100 mg, 0.374 mmol, 1.0 eq.) was dissolved in toluene 
(10 ml) and stirred under nitrogen. Concentrated sulfuric acid (2 drops) was added to the solution 
and stirred at 110 °C for 3 hours. The reaction was allowed to cool and quenched by the addition 
of saturated aqueous K2CO3 (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K2CO3 and evaporated to give a yellow oil (78 mg, Yield: 78%). 487: 1 (46%); 488a: 0.61 
(28%); 488b: 0.58 (26%)
2.6-Dimethyl-1-tosylpiperidine 487 (100 mg, 0.374 mmol, 1.0 eq.) was dissolved in toluene
(10 ml) and stirred under nitrogen. Concentrated sulfuric acid (2 drops) was added to the solution
and stirred at 110 °C for 24 hours. The reaction was allowed to cool and quenched by the addition
of saturated aqueous K2CO3 (10 ml). The quenched solution was then separated and the aqueous
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layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K2 CO3 and evaporated to give a yellow oil (77 mg, Yield: 7 7 %). 487: 1  (23%); 488a: 2.46 
(54%); 488b: 1(23%)
2.6-Dimethyl-1-tosylpiperidine 487 ( 1 0 0  mg, 0.374 mmol, 1.0 eq.) was dissolved in toluene 
(10 ml) and stirred under nitrogen. Concentrated sulfuric acid ( 2  drops) was added to the solution 
and stirred at 110 °C for 72 hours. The reaction was allowed to cool and quenched by the addition 
of saturated aqueous K2 CO3 (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K2CO3 and evaporated to give a yellow oil (59 mg, Yield: 59%). 487: 1 (43%); 488a: 1 
(43%); 488b: 0.43 (14%)
2.6-Dimethyl-1-tosylpiperidine 487 (100 mg, 0.374 mmol, 1.0 eq.) was dissolved in toluene 
(10 ml) and stirred under nitrogen. TfOH (0.20 ml, 0.187 mmol, 0.5 eq.) was added to the solution 
and stirred at 110 °C for 72 hours. The reaction was allowed to cool and quenched by the addition 
of saturated aqueous K2 CO3 (10 ml). The quenched solution was then separated and the aqueous 
layer was washed with dichloromethane (3x10  ml). The combined organic layers were dried over 
solid K2 CO3 and evaporated to give a yellow oil (69 mg, Yield: 69%). 487: 4 (62%); 488a: 0.25 
(15%); 488b: 0.37 (23%)
See Table 4.8, p. 108 for further details. All samples show identical spectroscopic and analytical 
data: *H NMR (400 MHz / CDC13) piperidine: S 7.61 (d, 2H, J=  8.2 Hz, 2 x Ts CH), 7.17 (d, 2H, 
J=  8.2 Hz, 2 x Ts CH), 4.09 (app. p, 2H, J=  7.1 Hz, 2 x CHN), 2.32 (s, 3H, Ts CH3), 1.70 -  1.57 
(m, 2H, CH2), 1.40 - 1.29 (M, 2H, 2 x CH2), 1.24 (d, 6 H, J=  7.1 Hz, 2 x CH3); cis pyrrolidine 
488a: 3 7.83 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.08 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 3.62 - 3.57 (m, 
1H, CHN), 3.45 - 3.39 (m, 1H, CHN), 2.32 (s, 3H, Ts CH3)„ 2.02 -  1.72 (m, 2H, CH2), 1.51 -  1.28 
(m, 4H, 2  x CHi), 1.09 (d, 3H, J=  6.4 Hz, CH3). 0.83 (t, 3H, J=  7.5 Hz, CH3); trans pyrrolidine 
488b: 5 7.71 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.32 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 3.96 - 3.89 (m, 
1H, CHN), 3.69 - 3.63 (m, 1H, CHN), 2.29 (s, 3H, Ts CH3), 2.02 -  1.72 (m, 2H, CH2), 1.51 -  1.28 
(m, 4H, 2 x CH2), 1.09 (d, 3H, J=  6.4 Hz, CH3), 0.71 (t, 3H, J=  7.4 Hz, CH3). IR (neat) u/cm*1: 
2968,1599, 1265, 1108,996.
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1-Tosylpiperidine 489303
< ? - o
H T s
4 6 4  4 8 9
Piperidine 464 (1.20 ml, 11.8 mmol, 1.0 eq.) was treated according to general procedure C to give 
1-tosylpiperidine 489 as a colourless solid (2.61 g, Yield: 92%). All data obtained was in 
accordance with that previously reported in the literature. 3 0 4  m.p.: 89 - 92 °C. ‘H NMR (400 MHz / 
CDC13) 3 7.57 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 7.25 (d, 2H, J=  8.3 Hz, 2 x Ts CH), 2.89 (app. t, 
4H, J=  5.8 Hz, 2 x Ci^N), 2.37 (s, 3H, Ts CH3), 1.60 -  1.55 (m, 4H, 2 x CH2), 1.37 -  1.30 (m, 
2H, CH2). 13C NMR (400 MHz / CDC13) <5143.3 (Cq), 133.2 (Q), 129.5 (2 x Ts CH), 127.8 
(2 x Ts CH), 47.0 (2 x CH2N), 25.1 (2 x CH2), 23.5 (CH2), 21.6 (Ts CH3). IR (neat) u/cm'1: 3056, 
2938, 2925, 1596, 1154, 994. HRMS (APCI) m/z calcd. for Ci2 Hi8N 02S [M+H]+= 240.1058; 
found: 240.1059.
(£)-6-Methylhept-5-en-2-one oxime 4432 6 1
4 4 2  44 3
6-Methylhept-5-en-2-one 442 (2.90 ml, 1.98 mmol, 1.0 eq.) was suspended in ethanol (30 ml), to 
this suspension was then added hydroxylamine hydrochloride salt (2.60 g, 3.96 mmol, 2.0 eq.) and 
sodium acetate (small spatula). The suspension was heated to reflux for 2 hours. Once the reaction 
had cooled, the ethanol was evaporated off and the residue was partitioned between water (30 ml) 
and diethyl ether (30 ml). The aqueous layer was then extracted with ether (3 x 30 ml) and the 
combined organic fractions were dried over MgS0 4  and concentrate in vacuo. The oil was purified 
by column chromatography (eluting silica gel with 2 0 % ethyl actetate in hexanes) to give the title 
compound 443 as a clear oil (1.66 g, Yield: 60%). All data obtained was in accordance with that 
previously reported in the literature. 3 0 5  2H NMR (400 MHz / CDCI3) 3 5.07 — 5.01 (m, 1H, CH),
2.24-2.21 (m, 4H, 2 x CH2), 1.91 (s, 3H, CH3), 1.70 (s, 3H, CH3), 1.63 (s, 3H, CH3). 13C NMR 
(400 MHz / CDCI3) 3 158.7 (Cq), 132.7 (Cq), 123.12 (CH), 35.9 (CH2), 25.7 (CH3), 24.9 (CH2),
17.7 (CH3), 13.4 (CH3). IR (neat) u/cm'1: 3246, 2924, 1736, 1262. HRMS (APCI) m/z calcd. for 
C8Hi6NO [M+H]+ = 142.1232; found: 142.1230.
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|  6-MethyIhept-5-en-2-amine 444262
4 4 3  4 4 4
II
[■ Oxime 443 (430 mg, 3.02 mmol, 1.0 eq.) dissolved in tetrahydrofuran (20 ml) and added dropwise 
to a suspension of LiAlTLj (0.41 g, 10.9 mmol, 3.6 eq.) in tetrahydrofuran (40 ml) at 20 °C. The 
suspension was then heated to reflux for 3 hours and the subsequently cooled to 20 °C. When 
cooled, water (4 ml), 15% NaOH (4 ml) and water (4 ml) were added sequentially and the reaction 
then stirred for a further hour. The reaction mixture was filtered and washed with tetrahydrofuran 
(40 ml), dried over MgSC>4 and concentrated to give the title compound 444 as a clear oil. 
(383 mg, Yield: 100%). All data obtained was in accordance with that previously reported in the 
literature. 3 0 6  ‘H NMR (400 MHz / CDC13) S 4.99 - 4.93 (m, 1H, CH), 2.75 (app. sext, 1H, 
J=  6.3 Hz, CHN), 1.91 - 1.79 (m, 2H, CHj), 1.54 (s, 3H, CH3), 1.47 (s, 3H, CH,), 1.29-1.18 
(m, 2H, CH2), 0.93 (d, 3H, J=  6.3 Hz, CH3). ,3C NMR (400 MHz / CDC13) S 131.8 (C9), 124.0 
(CH), 46.8 (CHN), 39.5 (CH2), 25.7 (CH3), 24.9 (CH3), 23.3 (CH2), 17.7 (CH3). IR (neat) u/cm'1: 
3472,2925,1649, 1262.
4-Methyk/V-(6-methylhept-5-en-2-yl)benzenesulfonamide 445
NHTs
4 4 4  4 4 5
6-Methylhept-5-en-2-amine 444 (141 mg, 1.11 mmol, 1.0 eq.) was treated according to general 
procedure C and the crude product was purified using column chromatography (eluting silica gel 
with 40% ethyl acetate in hexanes) to give the title compound 445 as a yellow oil (155 mg, 
Yield: 50%). %). All data obtained was in accordance with that previously reported in the 
literature. 3 0 7  NMR (400 MHz / CDCI3) 3 7.69 (d, 2H, J  — 8.3 Hz, 2 x Ts CH), 7.23 (d, 2H, 
J=  8.3 Hz, 2 x Ts CH), 4.87 - 4.82 (m, 1H, CH), 3.28 - 3.24 (m, 1H, CHN), 2.36 (s, 3H, Ts CH3), 
1.90-1.71 (m, 2H, CH2), 1.57 (s, 3H, CH3), 1.45 (s, 3H, CH3), 1.40 - 1.30 (m, 2H, CH2), 0.97 (d, 
3H, J  — 6 . 6  Hz, CH3). 13C NMR (400 MHz / CDC13) 3 143.2 (Cg), 138.2 (Cq), 132.4 (Cq), 129.7 
(2 x Ts CH), 127.1 (2 x Ts CH), 123.2 (CH), 49.8 (CHN), 37.5 (CH2), 25.7 (CH3), 24.2 (CH3), 
21.8 (CH2), 21.5 (Ts CH3), 17.7 (CH3). IR(neat) u/cm'1: 3279, 2924, 1918, 1598, 1262. HRMS 
(APCI) m/z calcd. for Ci5H2 4N 02S [M+H]+ = 282.1528; found: 282.1530.
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I  N-(6-methylhept-5-en-2-yI)methanesulfonamide 490
1
NHMs
| 6-Methylhept-5-en-2-amine 444 (383 mg, 3.02 mmol, 1.0 eq.) was dissolved in dichloromethane 
 ^ (30 ml) and cooled to —78 °C under N2 . To this was then added triethylamine (0.43 ml, 3.05 mmol, 
1-01 eq.), DMAP (4 crystal) and MsCl (0.23 ml, 17.7 mmol, 1.0 eq.). The reaction mixture was 
? allowed to warm to room temperature over 16 hours. The mixture was washed with waterI
(3 x 30 ml), 2 M HC1 (2 x 30 ml) and 2 M NaOH (2 x 30 ml), then dried over Na2 S0 4  and 
i concentrated. Purified using column chromatography (eluting silica gel with 40% ethyl acetate in 
hexanes) to give the title compound 490 as a clear oil (305 mg, Yield: 49%). 'H NMR (400 MHz / 
CDCI3) S 5.04 - 5.00 (m, 1H, CH), 3.46 - 3.38 (m, 1H, C//N), 2.90 (s, 3H, Ms CH3), 2.05 -1.95 
(m, 2H, CH2), 1.62 (s, 3H, CH3), 1.54 (s, 3H, CH3), 1.47 -  1.42 (m, 2H, CH2), 1.18 (d, 3H, 7=  6.5 
Hz, CH}). I3C NMR (400 MHz / CDCI3 ) S 137.7 (C9), 123.1 (CH), 50.1 (CHN), 44.2 (Ms CH3),
37.7 (CTfe), 25.7 (CH3), 24.4 (CH3), 22.4 (CH2), 17.8 (CH3). IR (neat) u/cm-1: 3291, 2926, 1673, 
1262. HRMS (El) m/z calcd. for C9 H 19NO2 S [M]+ = 205.1137; found: 205.1138.
Methyl 6-methylhept-5-en-2-ylcarbamate 500308
NHC02Me
444 500
Methyl chloroformate (0.75 ml, 9.64 mmol, 1.1 eq.) was added to a suspension of 6-methylhept-5-
en-2-amine 444 (1.11 g, 8.77 mmol, 1.0 eq.) and NaHC03 (2.20 g, 26.3 mmol, 2.0 eq.) in a 50/50
mixture of tetrahydrofuran and water (60 ml). The mixture was stirred at room temperature over
night and then diluted with water (50 ml) and washed with diethyl ether (30 ml). The aqueous
layer was acidified with 2 M HC1 and washed with ethyl acetate (3 * 30 ml). The combined
organic layers were washed with water (30 ml), dried over MgS04  and concentrates to a viscous
oil. This was purified by column chromatography (eluting silica gel with 0 - 40% ethyl acetate in
hexanes) to give the title compound 500 as a clear oil (0.469 g, Yield: 29%). *H NMR (500 MHz /
CDC13) 3 7.20 (s, 1H, NH), 5.08 - 4.95 (m, 1H, CH), 4.41 (app. s, 1H, CHN), 3.59 (s, 3H, CH3),
1.99 - 1.94 (m, 2 H, CH2), 1.61 (s, 3H, CH3), 1.52 (s, 3H, CH3), 1.39 - 1.35 (m, 2 H, CH2), 1.06
(d, 3H, J  = 6 . 6  Hz, CH3). 13C NMR (400 MHz / CDC13) 3 156.5 (Cq), 132.1 (Cq), 123.6 (CH),
51.8 (CH3), 46.9 (CHN), 37.2 (CH2), 25.7 (CH3), 24.6 (CH3), 21.9 (CH2), 17.7 (CH3). IR (neat)
204
u/cm'1: 3329, 2967, 1699, 1538, 1262. HRMS (APCI) m/z calculated for C10H2 0NO2 [M+H]+ = 
186.1494; found: 186.1491.
Methyl 2,2,6-trimethylpiperidine-l-carboxylate 501
NHC02Me
^  N ^  
C 02Me
500 501
Methyl 6-methylhept-5-en-2-ylcarbamate 500 (50 mg, 0.27 mmol, 1.0 eq.) was dissolved in 
dichloromethane (10 ml) and cooled to 0 °C under nitrogen. Concentrated sulfuric acid (2 drops) 
was added and the reaction stirred for 1 hour. The reaction mixture was quenched with saturated 
aqueous K2 CO3 (10 ml). The quenched solution was then separated and the aqueous layer was 
washed with dichloromethane (3 x 10 ml). The combined organic layers were dried over K2 CO3 
and concentrated in vacuo to give the title compound 501 as a clear oil (36 mg, Yield: 72%). 
‘HNMR (400 MHz / CDC13) S 4.14 (app. dp, 1H, .7=7.0, 2.2 Hz, CT/N), 3.49 (s, 3H, C/7,), 
1.65 -1.48 (m, 4H, 2 x CH2), 1.43 -  1.36 (m, 2H, C/7?), 1.29 (s, 3H, CHi), 1 . 2 0  (s, 3H, C/fj), 1.02 
(d, 3H, J=  7.0 Hz, C/7,). 13C NMR (400 MHz / CDCI3) <5156.9 (C,), 54.3 ( Q ,  51.8 (CH3), 48.3 
(CHN), 39.1 (CH2), 29.6 (CH3), 28.3 (CH2), 27.7 (CH3), 21.8 (CH3), 14.7 (CH2). IR (neat) u/cm'1: 
3328, 2965, 1699, 1538, 1262. HRMS (El) m/z calcd. for Ci0 H19NO2 [M]+ = 185.1416; found: 
185.1411.
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Appendix
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Table 1. Crystal data and structure refinement for dwk0901.
Identification code 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions
Volume
Z
Density (calculated)
Absorption coefficient 
F(000)
Crystal size
Theta range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to theta = 27.46° 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F^
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter 
Extinction coefficient 
Largest diff. peak and hole
dwk0901
Ci3 H1 9 N 0 2 S
253.35
150(2) K
0.71073 A
Orthorhombic
P212121
a = 6.2975(2) A a=90°.
b =  11.1070(3) A p= 90°.
c=  18.1443(5) A y = 90°.
1269.13(6) A3 
4
1.326 Mg/m3  
0.245 m n r 1 
544
0.30 x 0.30 x 0.30 mm3  
2.24 to 27.46°.
-8 <=h<=8 , -14<=k<=14, -23<=1<=23 
2863
2863 [R(int) = 0.0000]
98.3 %
0.9301 and 0.9301 
Full-matrix least-squares on F^ 
2863 /0 /  158 
1.049
R1 = 0.0327, wR2 = 0.0786 
R1 = 0.0348, wR2 = 0.0803 
0.07(7)
0.159(10)
0.213 and -0.317 e.A“3
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Table 2. Atomic coordinates ( x 10^) and equivalent isotropic displacement parameters (A^x 1(P) for wk0901. U(eq) 
is defined as one third of the trace of the orthogonalized UH tensor.
X y z U(eq)
C(l) 5856(3) 2754(2) 6489(1) 26(1)
C(2) 7415(3) 3770(2) 6661(1) 30(1)
C(3) 9597(3) 3244(2) 6472(1) 27(1)
C(4) 9472(3) 1949(2) 6769(1) 2 2 ( 1 )
C(7) 7342(2) -285(2) 5783(1) 2 2 ( 1 )
C(8 ) 9402(3) -742(2) 5754(1) 24(1)
C(9) 10151(3) - 1 2 2 2 (2 ) 5096(1) 26(1)
C(10) 8894(3) -1267(1) 4466(1) 24(1)
C(ll) 6828(3) -803(2) 4510(1) 25(1)
C(12) 6059(2) -308(2) 5158(1) 23(1)
C(13) 5134(3) 2760(2) 5687(1) 32(1)
C(14) 10234(3) 1847(2) 7559(1) 31(1)
C(15) 9696(4) -1830(2) 3764(1) 33(1)
N(5) 7153(2) 1678(1) 6694(1) 2 2 (1 )
0 ( 1 ) 4066(2) 341(1) 6567(1) 28(1)
0 (2 ) 7316(2) -386(1) 7194(1) 30(1)
S(6 ) 6344(1) 309(1) 6620(1) 2 1 ( 1 )
2 2 1
Table 3. Bond lengths [A] and angles [°] for dwk0901.
C(l)-N(5)
C(l)-C(13)
C(l)-C(2)
C(2)-C(3)
C(3)-C(4)
C(4)-N(5)
C(4)-C(14)
C(7)-C(12)
C(7)-C(8)
C(7)-S(6)
C(8)-C(9)
C(9)-C(10)
C(10)-C(ll)
C(10)-C(15)
C(ll)-C(12)
N(5)-S(6)
0(1)-S(6)
0(2)-S(6)
N(5)-C(l)-C(13)
N(5)-C(l)-C(2)
C(13)-C(l)-C(2)
C(l)-C(2)-C(3)
C(2)-C(3)-C(4)
N(5)-C(4)-C(14)
N(5)-C(4)-C(3)
C(14)-C(4)-C(3)
C(12)-C(7)-C(8)
C(12)-C(7)-S(6)
C(8)-C(7)-S(6)
C(9)-C(8)-C(7)
C(8)-C(9)-C(10)
C(9)-C(10)-C(l 1)
C(9)-C(10)-C(15)
C(ll)-C(10)-C(15)
C(12)-C(ll)-C(10)
C(ll)-C(12)-C(7)
C(l)-N(5)-C(4)
1.494(2)
1.524(2)
1.528(2)
1.532(3)
1.537(2)
1.497(2)
1.516(2)
1.392(2)
1.394(2)
1.7720(16)
1.390(2)
1.391(2)
1.402(2)
1.506(2)
1.386(2)
1.6098(14)
1.4379(12)
1.4333(13)
113.78(14)
100.85(13)
112.56(15)
104.43(14)
103.40(14)
112.32(14)
101.90(13)
112.68(14)
120.19(15)
119.91(12)
119.89(13)
119.22(15)
121.72(16)
117.97(16)
121.21(17)
120.80(16)
121.21(15)
119.69(15)
113.26(13)
2 2 2
C(l)-N(5)-S(6) 124.19(11)
C(4)-N(5)-S(6) 120.42(11)
0(2)-S(6)-0(l) 119.22(8)
0(2)-S(6)-N(5) 108.25(8)
0(1)-S(6)-N(5) 107.32(8)
0(2>S(6)-C(7) 105.72(8)
0(1)-S(6)-C(7) 107.81(8)
N(5>S(6)-C(7) 108.10(8)
Symmetry transformations used to generate equivalent atoms:
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Table 4. Anisotropic displacement parameters (A^x 10^) for dwk0901. The anisotropic displacement factor 
exponent takes the form: -2n^[ h^a*^U ^ + ... + 2 h k a* b* ]
UH U22 U33 U23 Ul3 U12
C(l) 24(1) 23(1) 30(1) -1(1) 1(1) 4(1)
C(2) 34(1) 21(1) 36(1) -2(1) -2(1) 2(1)
C(3) 29(1) 25(1) 26(1) 3(1) -2(1) -5(1)
C(4) 18(1) 24(1) 22(1) 0(1) 0(1) 0(1)
C(7) 23(1) 17(1) 25(1) 1(1) -1(1) 1(1)
C(8) 24(1) 22(1) 28(1) 3(1) -4(1) 1(1)
C(9) 22(1) 21(1) 35(1) KD 2(1) 0(1)
C(10) 28(1) 16(1) 28(1) 0(1) 3(1) -2(1)
C(ll) 29(1) 22(1) 26(1) -1(1) -5(1) -1(1)
C(12) 21(1) 19(1) 28(1) 0(1) -2(1) 0(1)
C(13) 32(1) 31(1) 34(1) 4(1) -9(1) 4(1)
C(14) 28(1) 38(1) 27(1) 4(1) -6(1) -5(1)
C(15) 37(1) 30(1) 31(1) -3(1) 6(1) 4(1)
N(5) 19(1) 20(1) 26(1) 1(1) -2(1) 2(1)
0 (1) 20(1) 31(1) 32(1) 0(1) 4(1) -4(1)
0 (2) 36(1) 27(1) 26(1) 7(1) -2(1) 0(1)
S(6) 21(1) 21(1) 22(1) 2(1) 1(1) -1(1)
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[Table 5. Hydrogen coordinates ( x 10^) and isotropic displacement parameters (A^x 10^) for dwk0901.
X y z U(eq)
H(l) 4594 2814 6822 31
H(2A) 7342 3998 7188 36
H(2B) 7110 4488 6357 36
H(3A) 10747 3701 6717 32
H(3B) 9843 3249 5933 32
H(4) 10313 1398 6446 26
H(8) 10283 -726 6179 29
H(9) 11559 -1527 5075 31
H(ll) 5939 -827 4087 31
H(12) 4662 13 5177 27
H(13A) 6375 2690 5364 49
H(13B) 4386 3514 5582 49
H(13C) 4178 2078 5601 49
H(14A) 9467 2427 7867 47
H(14B) 11760 2018 7581 47
H(14C) 9970 1030 7740 47
H(15A) 11238 -1937 3796 49
H(15B) 9358 -1305 3347 49
H(15C) 9015 -2615 3694 49
■ . i
y
